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The most exciting phrase to hear in Science, the one that heralds 
new discoveries, is not “Eureka!” but “That’s funny…” 
- Isaac Asimov






The blood-CNS barriers form a highly selective biological firewall; regulating the 
passage of solutes between the blood and cerebral microenvironment. This thesis 
modelled the blood-CNS barriers in vivo to determine the transport of nutrients, 
metabolic products and drugs across these barriers, and was split into two main parts: 
 
1. L-arginine and ADMA transport - Circulating levels of the cationic amino 
acid L-arginine and its endogenously produced homologue asymmetric 
dimethylarginine (ADMA) are in delicately poised equilibrium. Dysregulation of 
this balance has well-documented implications in cardiovascular disease and also 
more recently conditions of the brain, as ADMA is a potent inhibitor of nitric 
oxide synthase (NOS) enzymes, including the endothelial (eNOS) and neuronal 
(nNOS) isoforms. Until now it has been postulated that ADMA competes for 
transport across membranes via the same cationic transport system as L-arginine 
(system y+), however this hypothesis has surprisingly never been tested. 
 
The major contributors to transport of both amino acids were investigated to 
determine how their respective intracellular and extracellular concentrations affect 
transport across the blood-CNS barriers. These data also have strong relevance to other 
research areas due to the widespread influence of NO in physiological pathways in 
health and disease. 
 
At the time of writing, this study represents the first true characterisation of ADMA 
transport across any physiological membrane in vivo and reveals a likely mechanism for 
explaining ‘the L-arginine paradox’ – the clinical observation that NO-deficient patients 
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respond well to oral supplementation with L-arginine even though [arginine]plasma is 
easily sufficient to saturate eNOS. 
 
2. ‘NanoHAT’ - Efflux transporters expressed at the blood-CNS barriers remain one 
of the biggest hurdles for the efficient delivery of therapeutic agents to the brain. 
The anti-trypanosomal drug pentamidine was shown previously by our group to be 
a substrate for efflux from the blood-CNS barriers and does not ordinarily 
accumulate to pharmacologically relevant levels in the brain. Pluronic® co-
polymers are known biological response modifiers that are approved for use in 
humans and have generated a great deal of interest due to their ability to inhibit 
efflux transporters and spontaneously form micelles in solution. In this study, a co-
formulation of pentamidine and Pluronic® P85 was evaluated as a potential future 
treatment for CNS-stage Human African Trypanosomiasis, using a combination of 
in silico, in vitro, and in vivo methodologies.  
 
Combining our group’s knowledge and expertise in blood-brain barrier research 
with colleagues in Molecular Biophysics and Materials & Molecular Modelling has 
resulted in the creation of a ‘mini formulation-development pathway’ that can be 
utilised to optimise and develop formulations in the future. 
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Glossary 
ABC ATP-binding cassette 
(superfamily of transporters) 
AMT Adsorptive-mediated 
transcytosis 
ADMA Asymmetric dimethylarginine 
ARAMI L-arginine in acute myocardial 
infarction (a human clinical 
study) 
atm Atmosphere (measure of 
atmospheric pressure) 
ATP Adenosine-5'-triphosphate 
BAATs Broad-scope amino acid 
transporters 
CAATs Cationic amino acid transporters 
BBB Blood-brain barrier 
BCECs Brain capillary endothelial cells 
BCH 2-aminobicyclo-(2, 2, 1)-heptane-
2-carboxylic acid – specific 
inhibitor of system L and system 
B0,+ transport 
BCRP Breast cancer-resistance protein 
BCSFB Blood-cerebrospinal fluid barrier 
CAAs Cationic amino acids 
CaM Calmodulin 
CaMKII Calmodulin kinase II 
CAT Cationic amino acid transporter 
cDNA Complementary 
deoxyribonucleic acid 
cGMP 3’,5’-cyclic guanosine 
monophosphate 
CHARMM Chemistry at HARvard 
Macromolecular Mechanics (a 
group of force fields used in 
molecular dynamics simulations) 
CMC Critical micelle concentration 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CVO Circumventricular organ 
DDAH NG,NG-dimethylarginine 
dimethylaminohydrolase 
FAD Flavin adenine dinucleotide 
FMD Flavin adenine mononucleotide 
GABA γ-aminobutyric acid 
GLUT Glucose transporter 
GTP Guanosine triphosphate 
H4B Tetrahydrobiopterin 
hCMEC-D3 Human Cerebral Microvascular 
Endothelial Cell line (human in 
vitro model of the BBB) 
hnRNP Heterogenous nuclear 
ribonuclear protein 
ISF Interstitial fluid 
Kin Unidirectional transfer constant 
Km Half-saturation constant 
LAMMPS Large-scale Atomic/Molecular 
Massively Parallel Simulator 
(molecular dynamics simulations 
software) 
L-NMMA NG-monomethyl-L-arginine 
LOX-1 Lectin-like oxidised low-density 
lipoprotein receptor-1 
MCT Monocarboxylate transporter 
MDR Multidrug resistance 
MRI Magnetic resonance imaging 
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mRNA Messenger ribonucleic acid 
MRP Multidrug resistance-related 
protein 
NADPH Reduced nicotinamide adenine 
dinucleotide phosphate 
Nagg Aggregation number (of micelle) 
NBD Nucleotide binding domain (sub-
domain of P-glycoprotein) 
NF-κB Nuclear factor kappa B 
NMDA N-methyl-D-aspartate 
NO Nitric oxide 
NOS Nitric oxide synthase (of which 
there are endothelial, inducible 
and neuronal subtypes) 
OAT Organic anion transporter 
OATP Organic anion-transporting 
polypeptides 
(ox-)LDL (Oxidised) low density 
lipoprotein 
P Partition coefficient 
P-gp P-glycoprotein 
PKC Protein kinase C 
PKG Protein kinase G 
PRMT Protein arginine 
methyltransferase 
RMT Receptor-mediated trsanscytosis 
SBP Substrate-binding pocket (sub-
domain of P-glycoprotein) 
SDMA Symmetric dimethylarginine 
sGC Soluble guanylate cyclase 
SLC Solute carrier (superfamily of 
transporters) 
TEER Trans-endothelial electrical 
resistance  
TJs Tight junctions 
Vi Initial volume of distribution 
Vmax Maximal rate of transport 
ZO Zonula occludens, (of which 
there are -1, -2 and -3 isotypes), 
scaffold proteins found in tight 
junctional complexes 
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1  
General Introduction 
The central nervous system (CNS) represents the most significant development in the 
course of metazoan evolution. The abundance and diversity of animals that possess a 
CNS in some shape or form is testament to the evolutionary advantage that the CNS, 
and its ability to efficiently process information, confers. High fidelity neuronal 
signalling is enabled, in part, by the maintenance of a stable microenvironment in the 
immediate surroundings of the CNS. A high degree of homeostatic regulation of this 
microenvironment, and its separation from the highly variable and potentially 
neurotoxic contents of the blood, is brought about by the barriers of the CNS. 
1.1 The barriers of the CNS 
The barriers of the CNS can be thought of as a 'biological firewall' for the brain – 
tightly controlling movement of molecules and cells (both self and foreign) between the 
blood and compartments of the CNS. The barrier interfaces involved in this process 
are: 
i. The blood-brain barrier – Separates the brain interstitial fluid (ISF) from 
blood. 
ii. The blood-cerebrospinal fluid barrier – Separates the cerebrospinal fluid 
(CSF) from the choroid plexus ISF. 
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The main roles of these barriers are to prevent the free, unregulated movement of 
molecules between the brain fluids and blood, to provide specific transport routes for 
ions and essential nutrients required by the CNS, as well as the removal of metabolic 
waste products. The adult brain has very little potential for repair and regeneration, 
and thus protection from neurotoxic substances both in the blood and from metabolism 
is crucial. Both barriers display specific morphological features that contribute to these 
processes, and are described below. 
1.1.1 The blood-brain barrier (BBB) 
Evidence that a barrier may exist between the blood and the brain was first observed 
in 1885, when Ehrlich intravenously injected Trypan Blue and other intravital dyes 
into peripheral veins and arteries. Ehrlich found that the brain and other CNS tissues 
were poorly stained, while other organs were heavily stained ((Ehrlich, 1885), as cited 
in (Bradbury, 1993)). However, at this time, both Ehrlich and others incorrectly 
inferred from these data that internal organs merely had varying affinities for the 
different dyes. The concept of a barrier was not hypothesised until several years later, 
when it was observed by a student of Ehrlich that injecting Trypan Blue dye into the 
CSF resulted in only the brain being stained ((Goldman, 1913), as cited in (Bradbury, 
1993)). 
The crude light microscopy techniques of the time proved insufficient to identify the 
precise location of the blood-brain barrier (BBB). It was not until the development of 
scanning electron microscopes several decades later that light was shed onto the precise 
morphology of the cerebral vasculature and its associated molecular and cellular 
components. 
1.1.1.1 Characteristics and components of the BBB 
There are many features (either cellular or otherwise), at the blood-brain interface that 
could conceivably contribute to a ‘barrier-like’ phenotype - a basal lamina that is made 
up of type IV collagen, laminin and fibronectin, with pericytes embedded within its 
structure; astrocyte processes that intimately surround the basal lamina; and brain 
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capillary endothelial cells (Figure 1-1). This multi-faceted nature of the so-called 
'neurovascular unit' initially led to a debate surrounding the precise location of the 
BBB. It was initially and correctly proposed to be at the brain capillary endothelium 
(Reese & Karnovsky, 1967), while other hypotheses suggested that the BBB-phenotype 
was due to astrocyte processes surrounding brain capillaries (Pappenheimer, 1970). 
This was definitively settled upon by demonstration of the low ion-conductance of 
brain capillary endothelium (Crone & Olesen, 1982), which has a net resistance of 
approximately 1900 Ω·cm2 (compared to resistance as low as 1-2 Ω·cm2 in some 
peripheral capillaries). 
Important anatomical features that help distinguish brain capillary endothelial cells 
(BCECs) from endothelial cells found elsewhere in the body are outlined here, and 
detailed in the sections that follow: 
A. Presence of complex tight junctions 
B. Adherens junctions 
C. Lack of fenestrations 
D. Minimal pinocytotic activity 
E. High mitochondrial content 
F. Enzyme activity 
Sections that follow these relate to the additional cellular and non-cellular components 
of the neurovascular unit shown in Figure 1-1: 
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Figure 1-1: The neurovascular unit. The neurovascular unit is composed of several cell 
types in close association, working together to maintain optimal brain function. Cerebral 
endothelial cells, the building blocks of the BBB, form tight junctions that restrict the 
paracellular pathway. Pericytes partially envelop the endothelial cells and share a common 
basal lamina with them. Astroglial end-feet ensheath the microvessel wall; astrocytes are 
important in barrier induction and provide links to neurons. Microglia are CNS resident 
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1.1.1.1A Presence of complex tight junctions 
The low ion-conductance of the brain capillary endothelium relative to endothelia 
elsewhere in the body is predominantly due to the presence of tight junctions (TJs) 
between adjacent BCECs (Romero et al., 2003). In addition to limiting paracellular 
permeability to ions and other polar compounds, a secondary function of TJs is to 
separate the membranes of brain capillary endothelial cells into the brain (abluminal) 
and blood (luminal) sides (van Meer & Simons, 1986); facilitating the spatial 
segregation of functionally distinct lipids (Tewes & Galla, 2001) and proteins (Betz & 
Goldstein, 1978; Betz et al., 1980) (including transporters). TJs are intricate structures 
that span the intercellular space between BCECs, and are formed by a complex of 
transmembrane proteins and cytoplasmic accessory proteins that both cluster the 
transmembrane proteins and serve as a platform for interacting signalling and scaffold 
proteins (Figure 1-2). TJs are found throughout the whole of the paracellular cleft in 
BCECs. 
The transmembrane components of TJs include the proteins occludin, claudins and 
junctional adhesion molecules (JAMs).  
Occludin is a 60-65 kDa protein with four transmembrane domains, two extracellular 
loops and three cytoplasmic domains (two of which are the N- and C-terminal domains 
(Furuse et al., 1993). It is the extracellular loops that confer the occluding function of 
occludin, and particularly the second loop that determines the trans-endothelial 
electrical resistance (TEER) (Feldman et al., 2005). The C-terminal domain consists of 
150 amino acids, and associates with the scaffold proteins zonula occludens (ZO)-1, ZO-
2 and ZO-3 for anchoring to the actin cytoskeleton (Fanning et al., 1998), and 
regulatory proteins such as protein kinase C (Andreeva et al., 2006). Occludin contains 
many phosphorylation sites on the hydroxyl groups of serine and threonine residues, 
with phosphorylation or dephosphorylation of these sites regulating the association of 
occludin with ZO proteins and consequently its membrane localisation (Andreeva et al., 
2001; Kale et al., 2003). The N-terminal domain of occludin also has an integral role in 
the assembly of TJs, as its deletion in BCEC monolayers grown in vitro results in low 
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TEER values and increased paracellular permeability to small polar molecules 
(Bamforth et al., 1999). 
 
Figure 1-2: Simplified schematic representation of the tight junctional complex 
found between the majority of brain capillary endothelial cells. Transmembrane 
proteins occludin, claudins and JAMs span the intercellular cleft between adjacent 
endothelial cells. Scaffold ZO and cingulin proteins are closely associated and facilitate 
anchoring to the actin cytoskeleton and myosin, while additional regulatory proteins such 
as protein kinase C (PKC), 7H6 and AF6 are involved in the regulation of TJ assembly. 
Claudins are another essential structural component of TJs, and a multi-gene family of 
2024 kDa transmembrane proteins, of which 24 have been identified in mammals 
(Furuse et al., 1998). Sequence and structural homology within the claudin family is 
highly conserved; with four transmembrane domains, two extracellular loops and two 
cytoplasmic domains (a long C-terminal sequence, and short N-terminal sequence) 
(Heiskala et al., 2001). It is thought that the baseline seal of TJs arises from claudins, 
which is then augmented by occludin, since overexpression of claudins in fibroblasts 
results in TJ-like strands, and occludin only localizes to the TJ if claudin is also present 
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claudins also binds ZO proteins (as shown in Figure 1-2). The extracellular loops of 
claudins from neighbouring cells can interact either via homophilic (Piontek et al., 
2008) or heterophilic (Furuse et al., 1999) interactions within a single TJ. It is the 
extracellular loops that determine the charge and size selectivity for paracellular 
permeability, and it is thought that differences in the claudin content between the BBB 
and BCSFB could explain why TEER values for the BBB are typically significantly 
higher than those observed for the BCSFB (Matter & Balda, 2003; Van Itallie & 
Anderson, 2004). It is generally accepted that claudins 3, 5, and 12 are present at the 
BBB; while there is some evidence that claudin 1 may also be present (Morcos et al., 
2001; Nitta et al., 2003; Wolburg et al., 2003). It should be noted that while TJ strands 
can be formed without occludin (Balda et al., 1996; Saitou et al., 1998), the absence of 
claudin-5 at the BBB in double knockout (-/-) mice results in a size-selective increase 
in paracellular permeability to molecules with a molecular weight of less than 800 Da 
(Nitta et al., 2003). The identity of claudins present in TJs at the BCSFB will be 
discussed in section 1.1.2.1 - The choroid plexuses.  
JAMs belong to the immunoglobulin superfamily and have a single transmembrane 
domain, a single extracellular domain, extracellular N-terminal domain and cytoplasmic 
C-terminal domain (Bazzoni & Dejana, 2004) (Figure 1-2). JAMs form homophilic 
and heterophilic interactions with other JAMs on neighbouring cells to form dimers 
(Bazzoni et al., 2000). The C-terminal domain of JAMs typically associates with ZO-1, 
cingulin, junction-associated protein (AF6), tight-junction-associated protein antigen 
(7H6) and other scaffold proteins (Itoh et al., 2001), while also containing residues that 
are phosphorylated by protein kinase C (Suzuki et al., 2002). It is thought that 
phosphorylation of JAMs may be involved in the recruitment of ZO proteins and 
occludin into TJ complexes (Bazzoni & Dejana, 2004), while scaffold proteins such as 
cingulin promote binding to the actin cytoskeleton, which can also bind directly to both 
claudin and occludin (Huber et al., 2001). 
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1.1.1.1B Adherens junctions 
Adherens junctions at the BBB, like TJs, are formed between adjacent endothelial 
cells. In contrast to TJs however, adherens junctions are formed through associations 
between cadherins and catenins; transmembrane proteins which in turn bind actin 
(Vestweber, 2008). Adherens junctions form a paracellular ‘zipper-like’ structure along 
the cell border (Dejana, 2004), and in the case of endothelial cells typically contain 
vascular endothelial (VE)-cadherin (Bazzoni et al., 2000). Adherens junctions are not 
unique to endothelial cells, but appear to have a critical function in the assembly of 
TJs and function of BCECs. Binding of VE-cadherin in adherens junctional complexes 
has been shown to result in the modulation of TJs by both inhibiting FoxO1 activity (a 
repressor of claudin-5 transcription) and by sequestering β-catenin (a stabiliser of 
FoxO1 activity) (Taddei et al., 2008). Furthermore, β-catenin has been shown to 
directly control claudin gene expression – a process that is dependent on the Wnt 
signalling pathway (Liebner et al., 2008). 
1.1.1.1C Lack of fenestrations 
Fenestrations are ultramicroscopic pores in the plasma membranes of endothelial cells 
that facilitate the rapid but non-specific exchange of molecules between blood vessels 
and surrounding tissues. Fenestrations are present in highly permeable tissues such as 
the glomerulus (Deen et al., 2001). However, fenestrations are very scarcely found in 
BCECs – no doubt an adaptation to prevent the non-specific transcellular movement of 
polar molecules between the blood and brain, as was demonstrated with the molecule, 
α-aminoisobutyric acid (Fenstermacher et al., 1988). 
1.1.1.1D Minimal pinocytotic activity 
Pinocytosis is a form of endocytosis, whereby extracellular fluid (and any contents) is 
taken up by the cell in a non-specific manner following membrane invagination. Since 
un-regulated, non-specific uptake of solutes is undesirable at the BBB, it is easy to 
imagine that pinocytic activity at the BBB is low. Indeed, this has been demonstrated 
by a number of different studies (Brightman & Reese, 1969; Sedlakova et al., 1999). 
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However, it should be noted that increased pinocytic activity is frequently observed at 
the BBB in pathological conditions (Tuomanen et al., 1985; Kondo & Suzuki, 1993). 
1.1.1.1E High mitochondrial content 
Endothelial cells of the BBB have been found to contain a significantly higher density 
of mitochondria relative to other endothelial cells elsewhere in the body (Oldendorf & 
Brown, 1975), or indeed non-BBB endothelia in the brain (Fenstermacher et al., 1988). 
It has been proposed that this confers a large capacity for work, since this greater 
density of mitochondria can be expected to have a higher output of ATP production 
(Oldendorf et al., 1977). Indeed, BCECs are highly metabolically active (see section 
1.1.1.1F - Enzyme systems below), and also express a large number of transport 
systems, some of which require energy either directly (primary active transport) or 
indirectly (secondary active transport); making use of ion gradients that are maintained 
by energy-requiring ion pumps (see section 1.2 - Transport across the BBB). 
1.1.1.1F Enzyme systems 
In addition to serving as a physical barrier (as described above in sections A-D), the 
BBB also serves as a metabolic (enzymatic) barrier. This is an important consideration 
in the design of CNS drugs, since metabolism often leads to pharmacological 
inactivation, and ultimately elimination from the circulation. While drug metabolism 
primarily falls under the remit of the hepatic and renal systems, it is known to also 
occur at the level of the BBB (el-Bacha & Minn, 1999). Extracellular (ecto-) enzymes 
such as peptidases and nucleotidases that respectively metabolise peptides and ATP 
have been described at the BBB (el-Bacha & Minn, 1999). Furthermore, both phase I 
enzymes (e.g. cytochrome P450-1A and -2B) and phase II enzymes (e.g. glutathione S-
transferase and UDP-glucouronosyltransferase) have been identified at the BBB in both 
rodents and humans (Strazielle & Ghersi-Egea, 2005). 
1.1.1.1G Basal lamina and basement membrane 
BCECs are completely encompassed by a basal lamina – a perivascular extracellular 
matrix excreted by BCECs typically between 40-50 nm thick. The basal lamina is 
predominantly made up of collagen IV, heparin sulphate, laminin, fibronectin, tenascin 
1. GENERAL INTRODUCTION 
- 40 - 
and proteoglycans secreted by endothelial cells (Farkas & Luiten, 2001). The basal 
lamina is a constituent of the basement membrane, which is composed of two layers; 
one separating pericytes from endothelial cells, while the other compartmentalises 
pericytes from astrocyte endfeet in the neurovascular unit (Figure 1-1). The basement 
membrane is regulated and maintained by pericytes (Kose et al., 2007). 
1.1.1.1H Astrocytes 
Astrocytes are star-shaped glial cells, with multiple cytoplasmic fibrils predominantly 
made up of glial acidic fibrillary protein (Walz, 2000). Two distinct types of astrocytes 
are typically found in the CNS: 
i. Type-1 – Protoplasmic astrocytes, mainly located in grey matter, with fewer 
cytoplasmic filaments, which are not stained by the A2B5 antibody (Black et 
al., 1993) 
ii. Type-2 – Fibrous astrocytes, mainly located in white matter, with numerous 
cytoplasmic filaments, which are positively stained by the A2B5 antibody 
(Black et al., 1993) 
As was alluded to earlier, astrocytes are intimately associated with BCECs; so much so 
that it was initially astrocytic end-feet that were proposed to be directly responsible for 
the 'physical barrier' element of the BBB phenotype (De Robertis & Gerschenfeld, 
1961). This hypothesis was later discounted on the observation that horseradish 
peroxidase did not penetrate the luminal walls of the brain microvasculature when 
injected i.v., but could diffuse through the 20 nm gaps between astrocyte end-feet to 
reach the abluminal surface of the endothelium if injected directly into the brain 
(Brightman & Reese, 1969). Several discoveries since these early experiments lead to 
the re-examination of the role of astrocytes in the induction and maintenance of the 
BBB. 
Astrocytes are the most abundant cell of the human brain, and do not initiate or 
propagate action potentials along their processes, despite expressing potassium and 
sodium channels (Nedergaard et al., 2003; Seifert et al., 2006). Astrocytes do, however, 
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exhibit an inducible increase in the intracellular concentration of Ca2+ ions, which is 
thought to be of functional significance in astrocyte-astrocyte and astrocyte-neuron 
communication (Cornell-Bell et al., 1990; Charles et al., 1991). 
One of the earliest astrocytic functions to be described was the homeostatic 
maintenance of CNS ion concentrations – particularly K+ (Kuffler et al., 1966). 
Astrocytic processes are also involved in neurotransmitter homeostasis; clearing 
neurotransmitters from the synaptic space via specific transporters for glutamate, γ-
aminobutyric acid (GABA) and glycine. It is believed that these neurotransmitters are 
first converted into precursors by enzymes in the astrocytes, before recycling back into 
the synaptic space for uptake and reconversion by neurons (Seifert et al., 2006). 
Astrocytes are also known to provide metabolic support for surrounding cells - storing 
glycogen granules particularly in regions of high synaptic density (Phelps, 1972). These 
glycogen stores have been shown to be necessary and sufficient to sustain neurons in 
hypoglycaemic conditions; a process that is modulated by glutamate (Brown & 
Ransom, 2007). Other studies have shown that astrocytic glycogen can be broken down 
into lactate and transferred to neuronal synapses or axons (Voutsinos-Porche et al., 
2003; Brown et al., 2004; Brown & Ransom, 2007). 
Astrocytes also have an integral role in the developing brain, as molecular boundaries 
formed by astrocytes are required to guide the growth of developing neuronal axons 
and neuroblasts (Powell & Geller, 1999). There is also accumulating evidence that 
astrocytes are required for the maturation of the neuronal synapse during 
synaptogenesis, a role mediated via the release of extracellular signalling molecules such 
as thrombospondin (Christopherson et al., 2005; Barres, 2008). More recently, 
astrocytes have been implicated in the regulation of breathing via the release of ATP in 
response to physiological decreases in pH (Gourine et al., 2010). 
Astrocytes are more recently implicated in the regulation of cerebral blood flow at a 
local level. In making such a large number of contacts with cerebral blood vessels, 
astrocytes are ideally positioned to directly influence the perivascular milieu; releasing 
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known regulators of vascular tone, such as prostaglandins, nitric oxide, and arachidonic 
acid (Gordon et al., 2007). It has also been proposed that astrocytes are responsible for 
regional changes in cerebral blood flow due to synaptic activity – indeed, astrocytes 
have been directly implicated in changes in blood flow in the visual cortex following 
visual stimulation, as detected by fMRI (Schummers et al., 2008; Wolf & Kirchhoff, 
2008). 
In context of the astrocytic influence on BBB development, there is strong in vitro 
evidence to suggest that astrocytes are involved in the induction of the BBB phenotype 
(Beck et al., 1984; Abbott et al., 2006; Savidge et al., 2007). Conversely, there are some 
aspects of the BBB that become functional during CNS development in vivo before the 
appearance of astrocytes (Haseloff et al., 2005), and embryonic neural progenitor cells 
induce BBB properties in BCECs (Weidenfeller et al., 2007). 
1.1.1.1I Pericytes 
Pericytes were first described almost 150 years ago (Diaz-Flores et al., 2009), but their 
functions are only just beginning to become clearer. Pericytes are found within the 
basal lamina, often in close association to BCECs (Figure 1-1), and are attached to 
extracellular matrix proteins of the basal lamina via integrins (Stratman et al., 2009). 
Pericytes are morphologically distinct from BCECs by virtue of their nuclei – pericytes 
have a circular nucleus, while endothelial cells have an elongated nucleus (Dore-Duffy 
& Cleary, 2011). Pericytes can also form gap junctions with endothelial cells, created 
by the mutual expression of connexin-43 (CX43) in the plasma membranes, facilitating 
the intercellular transfer of nutrients, metabolites, secondary messengers and ions 
(Bobbie et al., 2010). 
An integral role for pericytes in BBB development has recently come to light, where it 
was demonstrated that BBB formation early in embryonic development coincides with 
the recruitment of pericytes, before the differentiation of astrocytes from progenitor 
cells (previously thought to be responsible for induction of the BBB phenotype) 
(Daneman et al., 2010). Pericytes are now known to be crucial for the development of 
TJs, and the downregulation of transcytosis – two highly characteristic features of the 
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BBB (Daneman et al., 2010). The same study, which utilised pericyte-deficient mice, 
has revealed that pericytes are required for the downregulation of genes linked to 
increased vascular permeability that are ordinarily attenuated at the BBB, including as 
plasmalemma vesicle-associated protein (Plvap) and angiopoietin-2 (Angpt2) (Daneman 
et al., 2010). Other genes that appear to be downregulated by pericytes at the BBB 
during development include intercellular cell adhesion molecule 1 (Icam1), and 
activated leukocyte adhesion molecule (Alcam) – implying that pericytes also suppress 
the infiltration of immune cells into the CNS (the proinflammatory responses of which 
could stunt the development of the BBB) (Daneman et al., 2010). Interestingly, the 
development of other characteristic features of the BBB, such as the high expression of 
the glucose transporter, GLUT-1, appear unaffected by the absence of pericytes 
(Armulik et al., 2010). 
The involvement of pericytes in the maintenance of BBB integrity appears to continue 
through to adulthood and even the aging CNS (Bell et al., 2010). The loss of pericytes 
during adulthood results both in increased paracellular transport due to the breakdown 
of TJs, and also increased transendothelial fluid flow (Bell et al., 2010). Furthermore, 
the study also identified that the loss of pericytes in adult mice resulted in increased in 
the CNS-infiltration of blood-derived macrophages, and eventual complete loss of some 
cerebral capillaries, as is observed in the aging human brain (Bell et al., 2010). 
However, in contrast with the reported differences in gene expression during 
embryogenesis described above, a loss of pericytes does not appear to result in the 
upregulation of genes such as Icam1.  
Pericytes have long been hypothesised to be involved in the control of capillary blood 
flow - likely mediated by their stellate-shaped, finger-like processes that are wrapped 
around the capillary wall – however this has only recently been confirmed 
experimentally (Peppiatt et al., 2006; Bell et al., 2010). This process is likely regulated 
by contractility mediated by Ca2+ influx into the pericyte (Kamouchi et al., 2004), 
possibly stimulated by the binding of receptors to endothelin-1, vasopressin or 
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angiotensin II, which are all known to be expressed on the cell surface of pericytes 
(Diaz-Flores et al., 2009; Hamilton et al., 2010). 
1.1.1.1J Microglia 
The BBB is a major contributing factor in creating an "immunoprivileged" 
environment for the CNS, and while immune cells can transmigrate from the blood into 
the brain under certain conditions, the primary form of active immune defence in the 
CNS are the microglia. Microglia make up approximately 20% of the total glial cell 
population in the brain and serve as the resident macrophages (Lawson et al., 1992). 
Microglia survey the CNS for plaques, damaged cells and foreign bodies, all of which 
can be phagocytosed before presenting antigens to T-cells (Gehrmann et al., 1995). 
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1.1.2 The blood-cerebrospinal fluid barrier (BCSFB) 
The blood-cerebrospinal fluid barrier (BCSFB) separates the CSF from the choroid 
plexus ISF, and is made up of the choroid plexuses and arachnoid membrane, described 
in the following sections. 
1.1.2.1 The choroid plexuses 
There are four choroid plexuses in total – one in each of the lateral ventricles (I and 
II), one in the third ventricle (III) and one in the fourth (IV), just beneath the 
cerebellum. The implication of the choroid plexuses in some barrier function between 
the blood and CSF was first hypothesised almost 100 years ago, when Trypan Blue dye 
was found to stain the choroid plexuses when injected systemically, while the rest of 
the CNS remained unstained ((Goldman, 1913), as cited in (Bradbury, 1993)). 
1.1.2.1A Choroid plexus structure 
The barrier function of the choroid plexuses is secondary to the main function of 
secreting CSF, and this is reflected in the morphology of the choroid plexuses. At the 
macro level, the choroid plexuses are formed from invaginations of the pia mater – the 
innermost layer of the meninges, and are made up of several villous processes (Figure 
1-3). The choroid plexuses float within the CSF, and are attached to the ventricular 
ependyma by a stalk. The ependyma is a continuation of the epithelial layer of the 
choroid plexuses, formed by a single layer of modified cuboidal epithelial cells filled 
with mitochondria (Del Bigio, 1995), forming approximately 15% of the total 
cytoplasmic volume in primates (Cornford et al., 1997). Within each villus is a single 
capillary branched from either the anterior or posterior choroidal arteries, however, 
unlike capillaries of the BBB, endothelial cells of the choroid plexus capillaries are 
termed as being "leaky", since they are fenestrated, do not have any TJs, and thus do 
not contribute to the barrier function of the BCSFB. 
The apical (brain-facing) surface of choroid plexus epithelial cells are densely coated 
with microvilli, with very few kinocilia (Strazielle & Ghersi-Egea, 2000). This is a 
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distinguishing feature of epithelial cells from the ependymal cells, which have a large 
number of kinocilia, and very few microvilli (Scott et al., 1974). The surface area of the 
plasma membrane between the lateral walls of choroid plexus epithelial cells is 
increased by the presence of infoldings, which are particularly discernible at the 
basolateral (blood-facing) side of the epithelial cell layer (Keep & Jones, 1990). 
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Figure 1-3: Cross-section (top) and longitudinal (bottom) views of a single villus of 
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1.1.2.1B Barrier characteristics 
While choroid plexus epithelial cells are not as finely tuned to serving as a barrier as 
BCECs, they do display both structural and metabolic characteristics that confer 
barrier properties to the choroid plexus. As with BCECs, the primary anatomical 
adaptation preventing the paracellular diffusion of molecules between choroid plexus 
epithelial cells are TJs, which form a continuous fence at the choroid plexus 
(Brightman & Reese, 1969). However, in contrast to BCECs, TJs do not line the entire 
paracellular cleft of choroid plexus epithelium; and are located only between the apical 
(CSF-facing) side of the epithelial cells (Brightman & Reese, 1969). In structural terms, 
the components of TJs between choroid plexus epithelia are very similar to those 
already described between brain capillary endothelia (section 1.1.1.1A - Presence 
of complex tight junctions), with the most obvious differences being in the claudins. 
The most abundant claudin in choroid plexus epithelial cell TJs is claudin-3 (Wolburg 
et al., 2009), however claudins 1, 2 and 11 are also expressed to complete the full 
repertoire in mice (Wolburg et al., 2001). Thus far, only claudin-1 has been 
characterised at the apical side of the human choroid plexus (Anstrom et al., 2007). 
The difference in claudins may explain the lower TEER value for the choroid plexus 
epithelium, which has been recorded at approximately 24 Ω cm2 in vivo in the bull frog 
(Zeuthen & Wright, 1981). Measurement of choroid plexus TEER in vivo is technically 
difficult to achieve, however, measurements taken from cultured mouse choroid plexus 
epithelial cells estimate TEER values of between 150-200 Ω cm2 (Zheng & Zhao, 2002). 
The "leaky" description of choroid plexus endothelial cells can therefore also be applied 
to the epithelial cells, at least when comparing to BCECs, since paracellular 
permeability is significantly higher at the choroid plexus epithelium, as demonstrated 
by the ability of lanthanum ions to cross from the blood into the ventricular lumen, but 
not between BCECs (Bouldin & Krigman, 1975). TJs between choroid plexus epithelial 
cells do, however, appear to prevent paracellular flux, since large proteins such as 
horseradish peroxidase in the blood have been shown to permeate through the capillary 
walls, and fill the extracellular space of the choroid plexus stroma; diffusing up to, but 
not beyond the apical TJs (Reese et al., 1971). 
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The choroid plexuses, like the BBB, are also active as enzymatic barriers; containing 
enzymes that break down xenobiotics into less toxic or less pharmacologically-active 
products (Strazielle et al., 2004). Since drug metabolising enzymes are expressed at 
significantly higher levels in the choroid plexuses relative to the brain cortex, it has 
been hypothesised that the BCSFB may play a more prominent role in the 
detoxification of the CNS than the BBB (Ghersi-Egea et al., 1994). The rabbit, mouse 
and human choroid plexus epithelium has been shown to contain enzymes that 
metabolise monoamine neurotransmitters (monoamine oxidase and catechol-o-
methyltransferase) (Lindvall & Owman, 1980; Kalaria et al., 1988; Vitalis et al., 2002), 
in addition to other enzymes that are more implicitly associated with drug metabolism 
(i.e. cytochrome P-450, uridine-5'-diphosphoglucuronosyl transferase and glutathione-S-
transferases) (Cammer et al., 1989; Volk et al., 1991; Johnson et al., 1993; Ghersi-Egea 
et al., 1994; Philbert et al., 1995). 
1.1.2.1C CSF secretion 
CSF fills the ventricles of the brain, subarachnoid spaces, and around the spinal cord; 
serving to mechanically and immunologically protect the brain, as well as in the 
autoregulation of cerebral blood flow. CSF has slightly altered concentrations of Na+, 
K+, Cl- and Ca2+, but far lower protein levels relative to plasma, and was originally 
thought to merely be an ultrafiltrate of plasma. It is now clear that CSF is not an 
ultrafiltrate, and is in fact actively secreted by the choroid plexuses (Ernst et al., 1986; 
Speake et al., 2001). The total volume of CSF in humans is estimated at 140-150 mL, a 
volume that is completely replaced four times each day, placing total daily CSF 
production at approximately 600 mL (Wright, 1978). 
CSF secretion is facilitated by a polarised distribution of ion transporters in the apical 
and basolateral membranes of choroid plexus epithelial cells working in concert to bring 
about the net movement of ions across the epithelium. This creates an osmotic gradient 
favouring the movement of water into the cerebral ventricles; a process that is driven 
by the pump (Na+/K+)-ATPase, which is expressed in the membranes of the microvilli 
at the apical surface of the choroid plexus (Ernst et al., 1986). 
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Following secretion by the choroid plexuses, CSF circulates around the CNS, before 
being reabsorbed into the venous system via the superior saggital sinus (Figure 1-4). 
CSF from the lateral ventricles flows into the third ventricle, through the cerebral 
aqueduct and then into the fourth ventricle. From here, the fluid passes through 
median and lateral apertures (not shown in Figure 1-4), to the cisterna magna before 
circulating into the cerebral and spinal subarachnoid spaces. The flow of CSF is not 
continuous, but more pulsatile in nature. This is thought to ensure the one-way flow of 
CSF from the subarachnoid spaces into the venous sinuses, and is linked to arterial 
pulse pressure (Takizawa et al., 1986a; Takizawa et al., 1986b). 
 
 
Figure 1-4: Circulation of CSF. CSF (blue) is secreted by the choroid plexuses (which 
are located in the cerebral ventricles), before circulating through the ventricular cavities 
and entering the subarachnoid space. 
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1.1.2.2 The arachnoid membrane 
The arachnoid membrane lies beneath the dura mater and above the pia mater, 
collectively known as the meninges. The arachnoid membrane is the only member of 
the three meninges that contributes to the blood-CSF barrier, and contains TJs 
between the outermost arachnoid epithelial cells (closest to the dura mater) 
(Nabeshima et al., 1975). Early studies have demonstrated amino acid transport at the 
arachnoid membrane in both mammals (Wright et al., 1971; Lorenzo & Snodgrass, 
1972) and amphibia (Wright, 1974). However, its relatively low surface area compared 
to that of the choroid plexuses and BBB suggests that the overall contribution of the 
arachnoid membrane to the transport of amino acids into the brain is low. 
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1.1.3 The circumventricular organs (CVOs) 
Circumventricular organs (CVOs) are excluded from the BBB and are characterised by 
their extensive vasculature (Fry & Ferguson, 2007). The endothelium of CVOs closely 
resembles that of the choroid plexus, where the ‘leaky’ capillaries serve to aid their 
function – namely to either secrete substances (e.g. hormones (Macchi & Bruce, 2004)), 
or detecting chemical signals in the blood (e.g. area postrema detecting toxins in the 
blood to induce vomiting (Brizzee & Neal, 1954)). The choroid plexus is sometimes 
considered as a CVO due to its similarities in terms of vasculature and fenestrated 
capillaries, however this is debatable since the choroid plexus does not contain the 
neural tissues that CVOs do (Cottrell & Ferguson, 2004). CVOs include the area 
postrema, organum vasculosum of the lamina terminalis, subfornical organ, 
subcommissural organ, pituitary gland, median eminence and pineal gland, however, 
(due to the ease of locating these tissues) only the pineal and pituitary glands were 
studied for the purposes of this thesis. 
1.1.3.1 Pineal gland 
The morphology and location of the pineal gland varies greatly among mammals. The 
human pineal gland is located within 1-2 mm of the midline of the brain, and weighs 
between 100-180 mg (Macchi & Bruce, 2004), while the pineal gland in mice were 
typically found to weigh up to 300 µg (MF, personal observations). The pineal gland is 
highly vascularised and is supplied by branches of the posterior choroidal arteries 
derived from cerebral arteries in the posterior mesencephalon (Macchi & Bruce, 2004). 
Innervation of the pineal gland includes both the peripheral parasympathetic and 
sympathetic systems, as well as nerve fibres from the CNS (Wurtman & Axelrod, 
1965). 
The main function of the pineal gland is the secretion of the hormone melatonin in a 
circadian manner, in response to stimulation by the suprachiasmatic nuclei, which is 
regulated by light/dark cycles (Macchi & Bruce, 2004). A role for the pineal gland in 
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reproduction is also hypothesised, since pineal tumours can affect sexual development 
(Macchi & Bruce, 2004). 
1.1.3.2 Pituitary gland 
The pituitary gland can be divided into two lobes – the anterior lobe and posterior lobe 
(Steel & Polak, 1997). While technically not a part of the brain, the pituitary gland is 
connected to the hypothalamus via a stalk-like structure called the infundibular stem. 
Indeed, the posterior lobe of the pituitary gland develops from the hypothalamus itself, 
and is located just below the hypothalamus, in the sella turcica of the sphenoid bone at 
the base of the skull (Amar & Weiss, 2003). Collectively, the anterior and posterior 
lobes of the pituitary gland are involved in maintaining homeostasis and influencing the 
activity of other glands (Amar & Weiss, 2003) via the secretion of signalling molecules 
such as oxytocin and vasopressin produced by the hypothalamus (Steel & Polak, 1997). 
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1.2 Transport across the BBB 
Estimates of the total length of perfused cerebral vasculature in the adult human brain 
have been placed at approximately 600-700 km (Zlokovic, 2005). No single neuronal cell 
body is ever further than 15 µm from a capillary (Tsai et al., 2009). The total surface 
area formed by brain capillaries has been calculated to be approximately 100-150 cm2 
g-1, which when scaled up to a typical adult brain mass of 2 kg equates to 20-30 m2 
(Begley & Brightman, 2003). This constitutes a massive surface for the exchange of 
molecules between the blood and brain ISF. 
It was initially proposed that metabolites passively diffuse through the BBB by 
facilitative transport alone, and that the saturation of these transporters was 
responsible, in part, for the regulation of brain metabolism (Pardridge, 1983). It has 
since emerged that there are several routes by which a molecule can cross the BBB; 
summarised in Figure 1-5. 
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Figure 1-5: Simplified schematic diagram summarising possible routes of crossing 
the blood-brain barrier. Paracellular movement of hydrophilic molecules is typically 
blocked by tight junctions. Small lipophilic (lipid-soluble) molecules and some gases can 
diffuse across the plasma membranes of the capillary endothelial cells. Transport can be 
facilitated by transport proteins embedded in the plasma membrane that can be bi-
directional, uni-directional, symport or antiport in their transport activity, and with varying 
degrees of ion-dependence. Efflux transporters such as P-glycoprotein (P-gp) are also 
known to exist at the blood-brain barrier and are vital in contributing to the metabolic 
barrier phenotype. Transport across the blood-brain barrier can also be receptor-mediated 
(RMT) in the case of insulin or transferrin, or absorptive-mediated (AMT) through 
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1.2.1 Paracellular diffusion 
Paracellular diffusion relates to the movement of water-soluble molecules by passive 
diffusion through the intercellular space between cells, largely driven by 
electrochemical, hydrostatic and osmotic gradients. Low paracellular permeability of 
the BBB is predominantly maintained by TJs, which form a balance between the 
contractile forces generated at the endothelial cytoskeleton, and the adhesive forces 
between TJ proteins of neighbouring cells to exclude the passage of polar molecules 
through the BBB (Garcia & Schaphorst, 1995; van Hinsbergh & van Nieuw 
Amerongen, 2002). The increase in paracellular permeability at the BBB resulting from 
the breakdown of TJs is observed in a large number of CNS diseases (Hawkins & 
Davis, 2005). 
1.2.2 Transcellular diffusion 
Since the paracellular route from the blood into the brain is essentially blocked by TJs, 
any molecular traffic across the BBB is forced to go through the cell, via the so-called 
transcellular route. Any molecules utilising the transcellular route across the BBB are 
required to cross both the luminal and abluminal plasma membranes of BCECs, and 
thus passive transcellular diffusion is restricted to small lipophilic molecules (e.g. 
ethanol) and gases (e.g. O2 and CO2) (Abbott et al., 2006). 
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Figure 1-6: Examples of proteins involved in transport mechanisms at the BBB. The 
transport of many essential polar molecules such as amino acids and glucose is mediated 
by carrier-mediated transporters belonging to the solute carrier (SLC) transporter family. 
These transport mechanisms can either be facilitated (reliant on substrate concentration 
gradients) or secondarily active (utilising electrochemical/ion gradients), and can be bi-
directional, uni-directional (influx or efflux), or exchangers. Active efflux transporters 
utilise ATP hydrolysis to pump substrates out of the cell. Receptor-mediated transcytosis 
involves the binding of substrates that are typically large proteins, such as insulin, which 







e.g.  INS-R  Insulin receptor 
 TF-R  Transferrin receptor 
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 LEP-R  Leptin receptor 
 FCGRT  Fc fragment of IgG 
  receptor transporter 
 SCARB1  Scavenger  
  receptor B1 
Receptor-mediated 
transcytosis 
e.g.  GLUT-1  Glucose transporter 1 
 LAT-1  Large neutral amino acid 
  transporter 1 
 CAT-1  Cationic amino acid 
  transporter 1 
 MCT-1  Monocarboxylic acid 
  transporter 1 
 CNT-2  Concentrative nuceloside 
  transporter 2 
 CHTX  Choline transporter 
 NBTX  Nucelobase transporter 
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   acid transporter 
 TAUT  Taurine transporter 
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1.2.3 The solute carrier transporters 
The result of forming a restrictive barrier between the brain and blood is that many 
metabolites and nutrients required for normal neuronal function (e.g. glucose) do not 
permeate the BBB and therefore rely on selective transport systems (Figure 1-6). 
Transport proteins are expressed throughout the neurovascular unit, and are not 
restricted to BCECs or the choroid plexus epithelium. Since the primary focus of this 
thesis is transport displayed by these two cell types (and their contribution to BBB 
and BCSFB transport respectively), the reader is referred to reviews elsewhere for 
transporter expression in other parts of the neurovascular unit (Neuwelt et al., 2011). 
Nutrient transport at the BBB is mainly mediated by the solute carrier transporters 
(SLCs), which constitute a super-family of 46 different sub-groups, totalling over 380 
proteins in humans (Hoglund et al., 2011). SLC transporters can either be facilitated 
transport carrier proteins or secondary active transporters. Facilitated transport 
involves the movement of molecules or ions across the plasma membrane through 
specific membrane transporters, and is an energy-independent process only enabling the 
movement of substances down their concentration gradient. Secondary active 
transporters (sometimes referred to as co-transporters or counter-transporters) utilise 
the electrochemical ion gradients across the membrane to transport molecules in the 
same (symport or co-transport) or opposite (antiport or counter-transport) direction as 
the ion flux. This is distinct from primary active transport, as it does not involve the 
direct hydrolysis of ATP. 
As described in section 1.1.1.1A - Presence of complex tight junctions, the 
existence of TJs at the BBB creates two distinct membrane domains (luminal and 
abluminal); facilitating the spatial segregation of functionally distinct lipids (Tewes & 
Galla, 2001) and proteins, including transporters (Betz & Goldstein, 1978; Betz et al., 
1980). SLC transporters can have either a polarised expression (either luminal or 
abluminal), or be expressed on both membranes (Abbott, 2002; Abbott et al., 2010). 
The most highly expressed SLC transporter at the BBB is glucose transporter 1 
(GLUT-1, encoded by the SLC2A1 gene), no doubt reflecting the brain's requirement 
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for a constant supply of energy (Pardridge et al., 1990). Indeed, it has recently been 
shown that the expression of GLUT-1 is a crucial checkpoint in the development of the 
BBB in vivo (Zheng et al., 2010). GLUT-1 is expressed at both the luminal and 
abluminal membrane of BCECs, and has also been detected intracellularly (Harik et 
al., 1990; Farrell & Pardridge, 1991). It is thought that intracellular GLUT-1 may be 
mobilised to the membranes as a response to hypoglycaemia (Simpson et al., 1999). As 
with many of the SLC transporters, GLUT-1 displays a high-degree of substrate 
specificity, to the stereoisomeric level; transporting D-glucose, 2-deoxyglucose, 3-O-
methyl-glucose, galactose and mannose, but not L-glucose (Pardridge & Oldendorf, 
1975b). 
While the CNS has a high demand for glucose obtained via GLUT-1 from the systemic 
circulation, it appears that glial cells and neurons have differing preferences for their 
energy source. Glial cells appear to be almost totally dependent on glucose for ATP 
production, while neurons also metabolise lactate (Pellerin & Magistretti, 2003). It is 
thought that after being transported across the BBB by BCECs, glucose is broken 
down into lactate by astrocytes, and then released into the ISF before being taken up 
by surrounding neurons, the so-called “lactate shuttle hypothesis” (Pellerin & 
Magistretti, 2003). Neurons have previously been shown to be dependent on lactate for 
migration during development, since the inhibition of lactate transport in neonatal mice 
caused extensive disorganisation of the parietal cortex attributed to irregular cortical 
neuronal migration and neuronal cell death (Adle-Biassette et al., 2007). Lactate is 
transported by monocarboxylate transporters (MCTs); four of which have been 
detected in the brain (MCT-1, -2, -4 and -8) (Bergersen, 2007). In the process described 
above, the release of lactate by astrocytes into the ISF is mediated by MCT-4, and its 
uptake into neurons by MCT-2 (Bergersen, 2007). Transport of lactate across the BBB 
is mediated by MCT-1 (encoded by SLC6A1), which is expressed at both the luminal 
and abluminal membranes of BCECs (Bergersen et al., 2001). MCT-8 is also expressed 
in BCECs, where it mediates transport of thyroid hormones (Roberts et al., 2008b). 
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SLC transporters at the BBB that display broader substrate-specificities include the 
organic anion transporters (OATs) and organic anion-transporting polypeptides 
(OATPs). OATs belong to the SLC22 family of transporters, functioning as secondary 
active transporters for the movement of organic anions against chemical and ion 
gradients (VanWert et al., 2010). OATs such as OAT-3 have been identified as key 
transporters involved in the transport of pharmaceutical small molecules at the BBB, 
(VanWert et al., 2010). OATPs, are also secondary active transporters, but are 
sodium-independent, and typically transport large, amphipathic compounds such as bile 
salts, thyroid hormones and steroid conjugates (Russel et al., 2002). OATP1-A4 has 
been detected at both the luminal and abluminal membranes of the BBB in rats, and 
OATP1-A5 on mainly the abluminal membrane (Roberts et al., 2008b; Westholm et 
al., 2008). In humans OATP1-A2 and –B1 are both expressed at the luminal membrane 
of BCECs (Bronger et al., 2005). The thyroid hormone transporter, OATP1-C1 is also 
expressed at the human BBB, but its membrane localisation is still elusive (Eyal et al., 
2009). 
Amino acid transporters constitute a large proportion of SLCs expressed at the BBB. 
These will be discussed in greater detail in Chapter 2, with a particular focus on the 
transport of cationic amino acids across the BBB and BCSFB. 
1.2.4 The ATP-binding cassette family of transporters 
The ATP-binding cassette (ABC) family of transporters is made up of three sub-
families: 
i. Multidrug-resistance proteins (MDRs) – ABCB-1 to -11, including P-
glycoprotein (P-gp). 
ii. Multidrug resistance-related proteins (MRPs) – ABCC1-5. 
iii. Breast cancer-resistance proteins (BCRPs) – ABCG1-8. 
ABC transporters are multidomain integral membrane proteins that are found in all 
mammalian species (Jones & George, 2004). Substrates for the ABC transporters vary 
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from small ions to large peptides, but a common feature shared by ABC transporters is 
their utilisation of energy obtained through ATP hydrolysis to change the confirmation 
of their transmembrane domains; resulting in the transport of substrate typically 
against its concentration gradient (Begley, 2004). ABC transporters typically act as 
efflux pumps – removing substrate from cells – and thus their precise membrane 
localisation at the BBB is an important consideration when elucidating their function. 
1.2.4.1 P-glycoprotein 
One of the most important and best characterised of all ABC transporters is P-gp, 
which is mainly expressed at the luminal membrane of the BBB in both humans and 
rodents – efficiently removing a broad range of substrates that may have crossed the 
luminal membrane (Roberts et al., 2008a; Eyal et al., 2009). It has been shown that P-
gp substrates can be as small as 0.3 kDa and as large as 4 kDa (Ramachandra et al., 
1998; Lam et al., 2001), but most are hydrophobic and partition into the lipid bi-layer 
(Gottesman & Pastan, 1993; Gatlik-Landwojtowicz et al., 2006).  
P-gp, also known as MDR-1 (Figure 1-6) is encoded by the ABCB1 gene in humans, 
and abcb1a and abcb1b genes in mice (Cordon-Cardo et al., 1989; Begley, 2004). Both 
abcb1a and abcb1b share up to 87% sequence homology with human ABCB1 (Ng et al., 
1989), and the functional significance of the two rodent isoforms is unclear, since the 
single MDR-1 isoform in humans appears to fulfil the functions of the two rodent 
isoforms (Demeule et al., 2002). It should be noted that of the two rodent isoforms, 
only abcb1a is expressed in endothelial cells (Schinkel et al., 1997), while abcb1b 
appears to be localised to the brain parenchyma (Regina et al., 1998), with regional 
variation (Kwan et al., 2003; Karssen et al., 2004). Analysis of the mouse BBB 
transcriptome revealed that abcb1a mRNA was very highly expressed in the brain 
microvasculature (Linnet & Ejsing, 2008). P-gp has traditionally been recognised to be 
important for drug disposition and response (Silverman, 1999; Lin, 2004), and are a 
particularly difficult hurdle to overcome in the efficient delivery of drugs to the brain 
(Pardridge, 2005). However, more recent findings indicate that BCRPs may play a 
more significant role at the human BBB, while P-gp is more important at the murine 
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BBB (Uchida et al., 2011). This is discussed in greater detail in section 1.2.4.3 - 
Breast cancer-resistance proteins. 
1.2.4.1A Structure and function 
P-gp is a 170 kDa complex molecule, made up of 1280 amino acids in the human, and 
1276 amino acids in the mouse. It is made up of two similar halves that have 43% 
sequence homology with each other and are joined by a flexible linker region (Figure 
1-7) (Gottesman & Pastan, 1993). The protein contains a total of 12 hydrophobic 
transmembrane regions that span the membrane, and intracellular N- and C-termini 
(Higgins et al., 1997). Two nucleotide-binding domains (one for each half of the 
protein) confer the ability of P-gp to bind and hydrolyse ATP and contain highly 
conserved amino acid sequences – the Walker motifs. The sequence of the Walker 
motifs are highly specific and do not tolerate mutations without completely abolishing 
the ATP-hydrolysing capacity and thus the overall transport function of the protein 
(Muller et al., 1996). Similarly, mutations in the linker region between the two halves 
also result in a loss of transport activity (Currier et al., 1989). 
It has been inferred from photoaffinity probe-binding studies and site-specific mutation 
studies that the substrate-binding sites of P-gp are in close proximity to 
transmembrane regions V and VI, and XI and XII (Bruggemann et al., 1989; Schurr et 
al., 1989; Greenberger, 1993). However, a study that more recently observed that the 
substrate specificity and activity of P-gp can be changed by substituting specific amino 
acids in both transmembrane and intracellular regions outside these 4 domains – 
suggesting the relationship between the structure and function of P-gp is complex (Lin 
& Yamazaki, 2003). 
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Figure 1-7: Putative structure of P-gp, with 12 predicted transmembrane regions 
(red cylinders). Glycosylation sites on the extracellular loop between transmembrane 
regions I and II are represented by orange stars. The black dotted lines represent 
intramembrane binding sites (domains V and VI, and XI and XII). ATP binds to two 
intracellular nucleotide binding domains known as the Walker motifs. 
 
Two models have been proposed to describe the mechanism for substrate efflux from 
cells by P-gp – the 'hydrophobic vacuum cleaner' model and 'flippase' model (Shapiro 
& Ling, 1997; Aller et al., 2009; Colabufo et al., 2010). According to the 'hydrophobic 
vacuum cleaner' model, P-gp sucks in substrate from the plasma membrane and ejects 
it from the cell through the central pore. In the 'flippase' model, P-gp detects substrate 
in the inner leaflet of the plasma membrane, binds the substrate, and extrudes it from 
the cell by 'flipping' it orientation with respect to the phospholipids in the inner and 
outer leaflets of the plasma membrane. It has most recently been proposed that the 
reality for P-gp activity may be a combination of both models, shown in Figure 1-8 
(O'Brien et al., 2012). 
in 
out 





1. GENERAL INTRODUCTION 
- 64 - 
 
Figure 1-8: Hypothetical model of P-gp substrate transport. A). The default 
conformation of P-gp (primed to bind substrate) is shown. A large cavity of 
approximately 6000 Å3 constitutes the substrate-binding pocket (SBP), and is lined with 
hydrophobic and aromatic amino acid residues. Lipid-soluble substrates for P-gp partition 
into the inner leaflet of the plasma membrane, before passing through pores made up of 
transmembrane regions V &VI or XI & XII to reach the SBP. Once the SBP has been 
bound, two molecules of ATP bind to the nucleotide-binding domains (NBD). B). ATP 
binding causes a conformational change in the protein that brings the NBDs together, 
and facilitates the release of substrate out of the cell, or back into the outer leaflet. 
Adapted from (O'Brien et al., 2012). 
 
While there is no clear chemical characteristic that marks a molecule out as a P-gp 
substrate, they are typically compounds that are hydrophobic and or amphipathic in 
nature (Schinkel, 1999). It has become apparent that a large number of substrates are 
shared between P-gp and drug-metabolising enzymes expressed at the BBB, such as the 
cytochrome P450 enzymes CYP2D6 (Uhr et al., 2004) and CYP3A (Wacher et al., 
1995). Based on these observations a recent hypothesis has been proposed relating to a 
possible co-operation between P-gp and drug-metabolising enzymes – the 'drug 
transporter-metabolism alliance' hypothesis (Benet, 2009). It is thought that by 















1. GENERAL INTRODUCTION 
- 65 - 
creates a cycle where the molecules passively diffuse into the BCEC before being 
ejected by P-gp. On each cycle, a portion of the drug molecules may be broken down 
by drug-metabolising enzymes, while intact molecules are recycled back out of the cell 
by P-gp (Benet, 2009). 
1.2.4.2 Multi-drug resistance-related proteins 
The multidrug resistance-related protein (MRP) family is made up of 9 members, 
encoded by the genes ABCC1-9 in humans (Bernacki et al., 2008). Of these 9 members, 
MRP-4, -5, -8 and -9 have a similar overall structure to P-gp, with two distinct 
domains comprised of 6 transmembrane regions each (12 in total). As per P-gp, these 
MRPs have two NBDs (Chen & Tiwari, 2011). The remaining MRPs (MRP-1, -2, -3, -6 
and -7) have the same two overall domains, and a third domain made up of an 
additional 5 transmembrane regions (17 in total), although the function of this domain 
is unclear (Begley, 2004). 
MRPs typically transport organic anions and neutral organic compounds, and 
sometimes require co-factors such as glutathione to mediate their efflux activity (Deeley 
& Cole, 2006; Deeley et al., 2006). MRPs and P-gp have overlapping substrate 
specificity, and their activity is sometimes difficult to distinguish (Seelig et al., 2000), 
although it has been noted that MRPs tend to display a preference for organic anions 
or drugs that are conjugated to glutathione or glucuronate in the CNS (Minn et al., 
2002). 
The expression of MRPs in the context of the BBB is not as clearly defined as that for 
P-gp described in the previous section. Some authors have suggested that MRP-1 is 
present and active at the BBB in removing drugs from the brain (Sugiyama et al., 
2003), while others have detected no change in the efflux of the MRP-1 substrate 
fluorescein from the brain in MRP-1 knockout mice (Sun et al., 2001). Since MRP-1 
expression (usually apical) does not typically overlap with P-gp expression (usually 
basolateral) in polarised cells, it has been theorised that the same would be true at the 
BBB (Cisternino et al., 2003). For the same study it was deemed that abluminal 
expression of MRP-1 would result in transport of MRP-1 substrates into the CNS, as 
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MRP-1, like P-gp, is an efflux transporter (removing substrates from cells). In situ 
brain perfusion with several MRP-1 substrates failed to detect MRP-1 at the mouse 
BBB (Cisternino et al., 2003). In contrast to MRP-1, MRP-2, -4 and -5 have all been 
detected at the luminal membrane of BCECs (Eyal et al., 2009), while MRP-3 has only 
been detected in the capillaries supplying brain tumours (Calatozzolo et al., 2005). 
1.2.4.3 Breast cancer-resistance proteins 
The best-characterised transporter belonging to the breast cancer-resistance protein 
(BCRP) family is encoded by ABCG2, and was first discovered in a chemotherapy-
resistant breast cancer cells line (Schinkel & Jonker, 2003). However, there is no 
evidence to suggest that the expression of BCRP is specific to breast cancer cells, or 
indeed that BCRP plays a significant role in the development of chemotherapy-
resistance in breast cancer (Schinkel & Jonker, 2003). Unlike MRPs and P-gp, BCRP is 
made up of only one domain made up of six transmembrane regions and a single NBD; 
putatively functioning as a homodimer (Bernacki et al., 2008). 
BCRP expression has been detected mainly at the luminal surface of BCECs in pigs 
(Eisenblatter et al., 2003), mice (Cisternino et al., 2004), and humans (Cooray et al., 
2002). There was initially some debate surrounding the degree of expression of BCRP 
at the BBB, with some groups detecting greater levels of BCRP than P-gp 
(Eisenblatter et al., 2003), and others finding that the opposite is true (Dauchy et al., 
2008). In any case, BCRP expression in BCECs has been found to be three times 
higher in P-gp deficient mice, suggesting that BCRP compensates for a lack of P-gp at 
the BBB (Cisternino et al., 2004). Most recently, a comparison of transporter and 
receptor protein expression at the BBB found that BCRP is expressed at significantly 
higher levels than P-gp at human BBB, while the opposite is true at the murine BBB 
(Uchida et al., 2011). The implications of this difference in expression likely indicate a 
disparity in the relative contributions of the transporters to drug efflux from the brain 
between species. 
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1.2.5 Endocytosis 
Endocytosis is the process by which cells take up molecules by engulfing them, and in 
the context of endothelial cells, can be divided into three categories: 
i. Pinocytosis – Also known as fluid- or bulk-phase endocytosis, where 
extracellular fluid (and any contents) is taken up by the cell in a non-specific 
manner following membrane invagination (downregulated in BCECs, see 
section 1.1.1.1D - Minimal pinocytotic activity). 
ii. Adsorptive endocytosis – Initiated when solutes bind to the cell surface and 
are internalised following non-specific, electrostatic interactions. 
iii. Receptor-mediated endocytosis – Initiated where solutes bind to cognate 
receptors expressed in the plasma membrane via specific receptor-ligand 
interactions. 
Across these categories, there are two underlying mechanisms or types of vehicles – 
clathrin-coated pits and caveolae. Clathrin-coated pits are vesicles with a diameter of 
approximately 200 nm formed by coating of the plasma membrane with the electron-
dense protein, clathrin (Mousavi et al., 2004). The coating of clathrin on the plasma 
membrane is a vital step in the recruitment of a number of accessory proteins to the 
plasma membrane, and the formation of vesicles (Mousavi et al., 2004). The degree of 
plasma membrane coating with clathrin is high in BCECs, and particularly at the 
luminal membrane, implying that clathrin-dependent endocytosis particularly for the 
uptake of solutes in the blood, predominates at the BBB (Simionescu et al., 1988). The 
coating of plasma membrane with clathrin creates an anionic microenvironment, and 
thus it is thought that clathrin-coated pits are primarily responsible for adsorptive 
endocytosis following interaction with cationic moieties in solutes (Herve et al., 2008). 
Caveolae are a form of lipid raft, forming an omega- (Ω-) shaped invagination of the 
plasma membrane typically 50-100 nm in diameter (Anderson, 1998). The scaffolds for 
caveolae formation are created by caveolins, a family of three integral membrane 
proteins – caveolin-1, -2 and -3 (Scherer et al., 1996; Tang et al., 1996; Williams & 
Lisanti, 2004). It is thought that caveolae are comparatively much fewer in number 
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than clathrin-coated pits at the BBB (Herve et al., 2008), however this may be due to 
the fact that the size of caveolae make them difficult to detect by electron microscopy, 
particularly since BCECs in vivo are typically only 500 nm thick (from luminal to 
abluminal membranes) (Abbott et al., 2010). Despite this apparent low number of 
caveolae at the BBB, it is known that caveolae are a crucial component in the increase 
in BBB permeability in pro-inflammatory conditions due to internalisation of both 
claudin-5 and occludin (Kirkham & Parton, 2005; Stamatovic et al., 2009). It is 
thought that the mechanism underlying these changes in permeability may be through 
interactions between caveolin-1 and endothelial nitric oxide synthase (eNOS), since 
caveolin-1 deficient mice display increased eNOS activity (Drab et al., 2001) resulting 
in downregulation of ZO-1 (Song et al., 2007). 
1.2.6 Transcytosis 
Transcytosis is a form of vesicular transport that differs from endocytosis by virtue of 
the fact that during transcytosis vesicles are transported across the cell (from one polar 
side to the other). The underlying mechanisms of transcytosis initiation are identical to 
endocytosis, and thus it is hardly surprising that two kinds of transcytotic vesicles have 
been found to originate from the luminal membrane of BCECs: the caveolae and 
clathrin-coated pits (Herve et al., 2008). 
Transcytosis across the BBB via endocytotic/vesicular mechanisms is the main route 
by which macromolecules such as proteins can enter the CNS. Both specific and non-
specific transcytotic mechanisms exist at the BBB – termed receptor-mediated 
transcytosis (RMT) and adsorptive-mediated transcytosis (AMT), respectively. RMT 
involves the binding of macromolecular ligands to specific receptors expressed in the 
plasma membrane of BCECs, resulting in the initiation of endocytosis (Abbott et al., 
2010). After a complex is formed between the receptor and ligand a caveolus is formed 
that pinches off into a vesicle, internalising both the ligand and the receptors. Vesicles 
are then shuttled across to the opposite pole of the cell by the cytoskeleton, before 
releasing the contents via exocytosis. 
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In contrast, AMT is initiated by charge interactions of strongly cationic molecules with 
negatively charged cell surface binding sites, rather than any receptor-ligand 
interactions (Sauer et al., 2005). 
For both mechanisms, the transcytosis of intact protein or peptide requires the 
avoidance of the lysosomal compartment of the cell, which would result in degradation. 
Routing away from lysosomes appears to be a unique feature of the BBB endothelium, 
where there is a stronger requirement for the transcytosis of intact macromolecules 
(relative to peripheral endothelia) (Mukherjee et al., 1997; Nag & Begley, 2005). 
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1.3 Transport across the BCSFB 
As discussed in section 1.1.2 - The blood-cerebrospinal fluid barrier 
(BCSFB), the absence of TJs between endothelial cells, 'looser' TJs that exist 
between epithelial cells, and increased fenestrations result in a 'leaky' BCSFB relative 
to the BBB, with increased paracellular permeability. This considered, other transport 
mechanisms do still exist at the BCSFB, with any differences to the BBB detailed 
below. 
1.3.1 SLC transporters 
The concentration of glucose in the CSF is approximately half that of glucose in plasma 
– creating a concentration gradient that favours transport into the CSF. Glucose 
transport across the BCSFB was first demonstrated in the sheep choroid plexus, and 
found to be Na+-independent (Deane & Segal, 1985). GLUT-1 expression has been 
detected at both the apical and basolateral membranes of the choroid plexus epithelium 
in rats, mice and rabbits, with a much stronger presence in the basolateral membrane 
(Gerhart et al., 1989; Harik et al., 1990). Furthermore, the membrane of the choroid 
plexus endothelium is highly enriched with GLUT-1 (Cornford et al., 1998). Data 
pertaining to the expression of either GLUT-2 or GLUT-3 in the choroid plexus 
epithelium have proved inconclusive (Fields et al., 1999; Arluison et al., 2004). 
Hexokinase-1, the high-affinity enzyme responsible for the first step of glucose 
metabolism, is highly expressed in the choroid plexus epithelium (Fields et al., 1999). 
Therefore, it would appear that, while GLUT-1 expression at the BBB serves the 
purpose of providing the brain as a whole with its main source of energy, glucose 
transport at the choroid plexus is more in line with satisfying the metabolic needs of 
the choroid plexus itself. Interestingly, GLUT-1 does not appear to be expressed in the 
pineal gland (Argandona et al., 2005), but is expressed in the pituitary gland in rats, at 
least at the mRNA level (Koehler-Stec et al., 2000). 
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In terms of monocarboxylate transporters, the choroid plexus epithelium expresses 
MCT-8 at the apical surface, where it is thought it is mainly responsible for the 
transport of thyroid hormone (Roberts et al., 2008b). MCT-1 is also expressed, with a 
similar non-polarised distribution between the apical and basolateral membranes (as 
previously described for the BBB); but at significantly lower levels relative to BCECs 
(Leino et al., 1999). A third monocarboxylate transporter, MCT-3, is also expressed at 
the choroid plexus and is theorised to be involved in the regulation of lactate levels in 
CSF (Philp et al., 2001). 
The cellular localisation of OATP transporters in the choroid plexus epithelium has 
been determined by immunohistochemistry; revealing that OATP1-A4 is the most 
abundant OATP transporter at the BCSFB (Zhang et al., 2010) and is expressed in the 
basolateral membrane (Gao et al., 1999), while OATP1-A5 is expressed in the apical 
membrane (Kusuhara et al., 2003). OATP2-B1 and OATP1-C1 have also both been 
detected in the choroid plexus epithelium at the mRNA and protein levels (Choudhuri 
et al., 2003). While the precise cellular localisation of OATP2-B1 at the BCSFB is 
currently unknown, OATP1-C1 is known to be located mostly at the basolateral 
membrane, mediating thyroid hormone transport (Roberts et al., 2008b). 
OAT transporters are also present at the BCSFB, with OAT-1 and OAT-3 confirmed 
to be located apically at the choroid plexus epithelium, and OAT-2 is expressed as 
mRNA (Choudhuri et al., 2003). Meanwhile, OCT-1, -2 and -3 have also been detected 
at the mRNA with unknown cellular localisations (Choudhuri et al., 2003). 
Amino acid transporters are also expressed at the BCSFB, and will be detailed in 
chapter 2. 
1.3.2 ABC transporters 
There is some debate surrounding the expression of P-gp at the BCSFB. Some studies 
have detected P-gp in the human and rodent choroid plexus (Rao et al., 1999; Daood et 
al., 2008), while others have found that P-gp expression is low or even completely non-
existent (Nies et al., 2004; Gazzin et al., 2008). Where P-gp was detected, the 
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localisation of expression was placed at the apical (CSF-facing) side of the choroid 
plexus epithelium, and in sub-apical intracellular compartments (Rao et al., 1999). This 
implies that the direction of P-gp substrate transport favours transport back into the 
CSF, in contrast to the function of P-gp at the BBB as preventing blood-borne 
substrates from reaching the brain described in section 1.2.4.1 - P-glycoprotein. 
Similarly, BCRP is also present at the apical membrane of the choroid plexus 
epithelium in mice (Tachikawa et al., 2005). 
In further contrast to the BBB, the most abundant efflux transporter at the BCSFB is 
MRP-1 (encoded by ABCC1), found in the basolateral membrane of the choroid plexus 
epithelium (Rao et al., 1999). MRP-4 has also been detected at the basolateral 
membrane of the human choroid plexus epithelium (Nies et al., 2004), while MRP-5 
may also be present (at least at the transcriptional level) (Lee et al., 2004). 
1.3.3 Transcytosis 
Transcytosis across the BCSFB was initially hypothesised to be non-existent after the 
observation that the endocytosis of a number of tracers at the basolateral side robustly 
resulted in their degradation by lysosomes (van Deurs, 1980). This reaffirmed the 
observations that intraventricular injection of horseradish peroxidase (at the apical side 
of the rat choroid plexus) overwhelmingly led to its endocytic delivery to lysosomes 
(van Deurs et al., 1978). Since these early observations, receptor-mediated transcytosis 
of the peptide hormone leptin following formation of a complex with low-density 
lipoprotein receptor-related protein 2 (LRP2) has been detected through the choroid 
plexus epithelium (Dietrich et al., 2008). LRP2 is also putatively involved in the 
clearance of β-amyloid from the CSF, as Alzheimer's patients appear to have reduced 
levels of LRP2 at the choroid plexus (Alvira-Botero & Carro, 2010). These most recent 
studies appear to indicate the existence of bi-directional transcytotic mechanisms at the 
BCSFB. 
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2  
Cationic amino acid transport 
across the mouse blood-CNS 
barriers 
2.1 Introduction 
Despite making up only 2% of the body by mass, the human brain receives 15% of the 
cardiac output, 20% of total oxygen consumption, and 25% total glucose utilisation 
(Herculano-Houzel, 2011). In addition to obtaining the core components for cellular 
respiration from the blood, the brain also receives a supply of other compounds that are 
essential to basic anabolic and catabolic processes. 
Nucleic acids are the blueprints of life, and the amino acids that they encode are the 
basic building blocks from which life is built. Twenty-two of these so-called 
"proteinogenic" or protein-building amino acids exist, and of these, twenty are directly 
encoded by the genetic code – the "standard" amino acids (shown in Table 2-1). The 
standard amino acids can be further categorised broadly into those that can be 
synthesised de novo by an organism (non-essential), and those that cannot (essential). 
Amino acids that cannot be synthesised de novo must therefore be obtained from the 
organism's external surroundings - in the case of complex organisms such as humans, 
the diet. Essential amino acids are dissipated through the body via the circulatory 
2. ADMA & L-ARGININE 
- 74 - 
system. Indeed, even non-essential amino acids can be transported from the organ of 
their synthetic origin, to other parts of the body. As the primary interface regulating 
transport between the blood and brain, the BBB contains a broad variety of specific 
amino acid transporters with varying characteristics and substrate specificities 
(Pardridge, 1998). 
 
Table 2-1: The twenty "standard" amino acids. 
Characteristics  
Non-polar, small Glycine (Gly), Alanine (Ala) 
Non-polar, hydrophobic Valine (Val), Leucine (Leu), Isoleucine (Ile), 
Phenylalanine (Phe), Methionine (Met), Proline (Pro), 
Tryptophan (Trp) 
Polar, neutral Serine (Ser), Threonine (Thr), Tyrosine (Tyr), 
Cysteine (Cys), Asparagine (Asp), Glutamine (Gln) 
Polar, acidic Aspartic acid (Asp), Glutamate (Glu) 
Polar, basic Arginine (Arg), Histidine (His), Lysine (Lys) 
 
 
The classical perception of diet as being solely a means of obtaining energy and 
building material (such as amino acids) has been challenged over the past decade. 
Omega-3 fatty acids, for example, are known to have positive effects on cognition and 
learning, and form the basis for a plethora of over-the-counter dietary supplements 
after they were shown to be crucial in supporting cognitive process in humans (McCann 
& Ames, 2005) and maintaining synaptic plasticity in rodents (Wu et al., 2007). While 
the exact mechanisms underlying these processes are not yet clear, it is generally 
accepted that diet can affect behaviour and health (Gomez-Pinilla, 2008). 
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The transport of amino acids from blood to brain is an essential first step in several 
amino acid synthesis pathways. In the cases of serotonin, dopamine and other amino 
acid neurotransmitters synthesised from amino acid precursors, the rate-limiting 
enzymes responsible for their biosynthesis are generally not saturated by the 
intracellular concentrations for precursors typically attained in the brain (Pardridge, 
1998). The consequence of this is that the biosynthesis of amino acid neurotransmitters 
is proportional to the availability of the precursors to the brain, which is determined by 
the kinetics of their transport at the BBB (Pardridge, 1977). Furthermore, and based 
on the same principles, the synthesis of proteins in the brain is also limited by the 
kinetics of amino acid transport mechanisms at the BBB. 
A large number of different amino acid transport systems are known to exist at the 
BBB, with expression being polarised to either the luminal or abluminal membrane, or 
localised to both membranes of the brain capillary endothelial cells. Each transport 
system consists of at least one gene-product, with many systems containing several 
proteins. These transporters can be sufficient to transport their substrate, while others 
complex with other system members to function. All transport systems can be broadly 
categorised by their substrate specificity, transport rates, and sodium (Na+) or chloride 
(Cl-) ion dependence. Many dietary (essential) amino acids display rapid and saturable 
rates of brain uptake (Oldendorf, 1971); utilising a number of different transport 
systems that are broadly categorised as being either dependent or independent on Na+. 
This chapter will focus on the transport systems with known abilities to transport 
cationic amino acids, however more exhaustive reviews of all amino acid transport 
systems at the BBB have been published elsewhere (Hawkins et al., 2006). 
2.1.1 Cationic amino acids (CAAs) 
Among the 20 'standard' amino acids encoded by the genetic code, only three are 
classed as cationic, although only arginine and lysine are positively charged at pH 7.4. 
The structures for arginine, histidine and lysine are shown in Figure 2-1. 
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Figure 2-1: Three standard cationic amino acids and their structures. 
 
2.1.1.1 Cationic amino acid transporters 
Transport of some amino acids into the brain was shown to be a secondarily active 
process that is dependent on the Na+ concentration gradient generated by (Na+/K+)-
ATPase at the abluminal membrane (Vorbrodt, 1988). Indeed, brain capillary 
endothelial cells are known to have a high density of mitochondria than their 
counterparts in muscle tissue (Oldendorf & Brown, 1975) for generating the energy 
needed to drive active transport.  
All transporters known to transport amino acids belong to the solute carrier (SLC) 
superfamily – a major group of membrane transport proteins that also include other 
transporters responsible for the cellular uptake and efflux of nutrients, metabolites, 
drugs and neurotransmitters, as described in chapter 1 (Hediger et al., 2004). As 
much as 22% of Slc genes expressed at high levels in brain capillary endothelial cells 
are amino acid transporters (Dahlin et al., 2009). Within the SLC superfamily, the 
majority of amino acid transport at the blood-CNS barriers is thought to be mediated 
by the system L transporter LAT-1 (SLC7A5) expressed at both the abluminal and 
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(Duelli et al., 2000). System L is a bi-directional transport system specific to large, 
neutral amino acids and is inhibited by 2-aminobicyclo-(2, 2, 1)-heptane-2-carboxylic 
acid (BCH) (Smith & Stoll, 1998). However, with respect to transport of CAAs across 
mammalian cell membranes, two families of transporters in particular are of 
considerable importance (O'Kane et al., 2006):  
i. Broad-scope Amino Acid Transporter (BAAT) family, consisting of systems 
b0,+, y+L, and B0,+ 
ii. Cationic Amino Acid Transporter (CAAT) family, consisting of system y+ 
A putative third transport system, b+, has been shown to have the capacity to 
transport CAAs, but thus far has only been identified in mouse blastocysts, and 
remains an orphan transporter, with no encoding gene identified (Van Winkle & 
Campione, 1990). A summary of both the CAAT and BAAT family of transporters is 
shown in Table 2-2 and Table 2-3. 
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2.1.1.1A Broad-scope amino acid (BAAT) transporters 
Although broad-scope amino acid transporters are not prototypical cationic amino acid 
transporters, they do display varying abilities to transport cationic amino acids across 
the plasma membrane in a Na+-independent manner, except for system B0,+, which is 
dependent on Na+ for transporting both neutral and cationic amino acids. 
System b0,+ 
System b0,+, a Na+-independent transport system, is so-called because of its ability to 
transport both cationic and neutral amino acids (the 0 and + exponents were given to 
represent neutral and cationic amino acids, respectively). System b0,+ activity is best 
understood in the contexts of small intestine epithelium and renal proximal tubule, 
where it is mediated by two covalently-linked proteins, b0,+AT and rBAT (Slc7a9 and 
Slc3a1, respectively) (Wagner et al., 2001). Heterologous co-expression of these two 
proteins facilitates the high-affinity influx of extracellular cationic amino acids and L-
cysteine in exchange for intracellular neutral amino acids via an antiport mechanism 
(Busch et al., 1994; Chillaron et al., 1996; Pfeiffer et al., 1999a). Mutations in either 
b0,+AT and rBAT can disrupt the reabsorption of cationic amino acids and L-cysteine 
into the bloodstream, leading to cystinuria (Calonge et al., 1994; Chairoungdua et al., 
1999; Pfeiffer et al., 1999a). A recent study profiling the expression of Slc genes in the 
mouse brain revealed that rBAT is particularly highly expressed (Dahlin et al., 2009). 
Since system b0,+ activity requires heterodimerisation of rBAT with b0,+AT, the fact 
that these proteins were not found to be expressed at the mouse BBB at equal levels 
raises an interesting question that is yet to be explained. The expression of system b0,+ 
in the choroid plexus is currently unknown. 
System y+L 
System y+L is a high capacity transport system that transports cationic amino acids in 
a Na+-independent manner and neutral amino acids in a Na+-dependent manner (Deves 
et al., 1992). The system was so named because of these properties, as it resembles 
both system y+ and system L. System y+L activity is mediated by the proteins y+LAT1 
and y+LAT2, respectively encoded by Slc7a7 and Slc7a6, although both proteins 
associate with the almost constitutively expressed transmembrane protein 4F2hc, 
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encoded by Slc3a2 (Deves et al., 1992; Pfeiffer et al., 1999b). The functional distinction 
of system y+L from system y+ is made difficult by the facts that both have a similar 
high affinity for cationic amino acids, but also that no specific inhibitor of system y+L 
has been identified to date. Perhaps the only distinguishable difference between the two 
systems might be the ability of L-leucine (a neutral amino acid) to inhibit transport of 
L-lysine mediated by system y+L in the presence of Na+ - a phenomenon that is not 
observed with system y+ (Estevez et al., 1998; Rotmann et al., 2007). The y+LAT2 
protein in particular is found to be highly expressed at the mouse choroid plexus, 
relative to other amino acid transporters (Dahlin et al., 2009). 
System B0,+ 
System B0,+ (not to be confused with b0,+) was first discovered as displaying Na+-
dependent cationic, neutral and zwitterionic amino acid transport activity in mouse 
blastocysts after the observation that alanine transport was inhibited by arginine, 
lysine and BCH (Van Winkle et al., 1985). The broad substrate specificity of the 
transport system led to it being given the name B0,+. It should be noted that the 
inhibition of B0,+ by BCH is believed to be competitive due to the observation that 
inhibition of leucine uptake by B0+ generates a current (Sloan & Mager, 1999). 
Transporter cloning has revealed a protein that is 645 amino acids long (named 
ATB0,+), encoded by the Slc6a14 gene and sharing sequence homology with glycine and 
proline transporters (Sloan & Mager, 1999). Human ATB0,+ expression is greatest at 
the apical membrane of bronchial epithelial cells (Sloan & Mager, 1999) where it is 
believed to be involved in the transepithelial transport of arginine (Galietta et al., 
1998). In contrast, murine ATB0,+ expression appears to be highest in the colon (Sloan 
& Mager, 1999). ATB0,+ is believed to be the only cationic amino acid transporter with 
the ability to accumulate arginine against its concentration gradient (Deves & Boyd, 
1998). 
System B0,+ was initially proposed to be one of the mediators of large neutral amino 
acid efflux at the abluminal side of the blood-brain barrier (O'Kane & Hawkins, 2003), 
however this hypothesis was later changed after further studies demonstrated a lack of 
cross-competition between neutral and basic amino acids (which also excluded the 
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transport system, y+L) (O'Kane et al., 2004). In contrast to these findings, ATB0,+ had 
already been detected at the abluminal membrane of the bovine BBB in vitro (Sanchez 
del Pino et al., 1995), and this observation has been confirmed more recently (Czeredys 
et al., 2008). The exact contribution of B0,+ to amino acid transport at the blood-brain 
barrier is therefore far from clear cut. Even less is known about the expression of 
system B0,+ at the choroid plexus. 
2.1.1.1B Cationic amino acid (CAAT) transporters 
Na+-independent bi-directional facilitated transport of cationic amino acids across 
plasma membranes was first attributed to system y+ in cell culture (White, 1985), and 
was also later shown to be present at the rat BBB (Stoll et al., 1993). System y+ has an 
affinity for L-arginine, L-lysine and L-ornithine in the µmolar range (Stoll et al., 1993), 
but also has a low affinity for neutral amino acids in the presence of Na+ ions (White, 
1985). Transport by system y+ is sensitive to inhibition by L-homoarginine (Stoll et al., 
1993). The murine cationic amino acid transporter protein (CAT-1, encoded by Slc7a1) 
responsible for system y+ activity has been cloned and expressed in Xenopus oocytes 
(Kim et al., 1991), and has been found to share greater than 88% sequence homology 
with corresponding rat (Stoll et al., 1993) and human (Yoshimoto et al., 1992) genes. 
The putative structure of CAT-1 is depicted in Figure 2-2. 
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Figure 2-2: Putative structure of CAT-1, with 14 predicted transmembrane domains 
(red cylinders). Glycosylation sites on the extracellular loop between transmembrane 
domains III and IV are represented by orange stars (the number and precise position of 
these can vary between species). Green triangles represent residues that are critical for 
transport function. The black dotted line represents the region that determines differences 
in transport properties between different isoforms of CAT. 
 
Three additional CAT isoforms have now been characterised, and named CAT-2, CAT-
3 and CAT-4; encoded by the genes Slc7a2, Slc7a3 and Slc7a4, respectively. Human 
CAT-2 is found as two splice variants (hCAT-2A and -2B), and both have been shown 
to exhibit varying degrees of voltage-dependence when L-arginine transport was 
observed after transfection into Xenopus oocytes (Nawrath et al., 2000). CAT-3 
isolated from mouse and rat brains has also been shown to exhibit system y+ activity, 
however with differing substrate specificity compared to CAT-1, and also the ability to 
transport neutral amino acids in a Na+-independent manner (Hosokawa et al., 1997; Ito 
& Groudine, 1997). The final isoform identified to date, CAT-4, was isolated from 
human placenta and found to share approximately 40% sequence homology with other 
CAT proteins (Sperandeo et al., 1998). However, there is currently no evidence to 
suggest that CAT-4 exhibits system y+ activity (Wolf et al., 2002). Despite this 
apparent lack of transport activity, CAT-4 has been found to be expressed at the 
mouse blood-CSF barrier at particularly high levels relative to all other amino acid 
transporters (Dahlin et al., 2009). 
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CAT-1 has been shown to be localised at the plasma membrane of porcine aortic 
endothelial cells, and more specifically in caveolae-like clusters closely associated with 
the endothelial isoform of nitric oxide synthase, eNOS (McDonald et al., 1997). As a 
classical system y+ transporter, CAT-1 is bi-directional in its transport activity, 
however it is subject to strong stimulation by substrate at the opposite (trans-) side of 
the membrane (Kim et al., 1991). This spatial and functional localisation constitutes an 
elegant means by which extracellular L-arginine can be transported into the cell and 
utilised in the synthesis of NO, and indicates that CAT-1 has an integral part in this 
process. Indeed, CAT-1 knockout mice produce pups that, when homozygous for CAT-
1 deficiency, die very soon after birth (Perkins et al., 1997).  
CAT-1 mRNA is expressed at high levels in brain capillaries and choroid plexus (Stoll 
et al., 1993), and the protein is found at both the luminal and abluminal membranes of 
brain capillary endothelial cells (Takase-Yoden & Watanabe, 2001). The half-saturation 
constant, Km for arginine transport by system y+ in the absence of competitors has 
previously been shown to be 56 µM, and the maximal influx rate, Vmax 24 nmol/min/g 
using the rat in situ brain perfusion technique (Stoll et al., 1993). The apparent Km 
under normal physiological conditions (in the presence of other amino acids, Km(app)) 
has been calculated as 302 µM for arginine, and the rate of influx 6.7 nmol/min/g. This 
considered, a plasma concentration of over 100 µM would result in arginine being 
transported from plasma into the capillary endothelium, and then the brain as system 
y+ is expressed at both the luminal and abluminal membranes of the BBB (O'Kane et 
al., 2006). 
It was originally proposed that transport of cationic amino acids across the BBB was 
solely due to system y+ activity (O'Kane et al., 2006), however there is more recent 
evidence to suggest that this may not be the case. Investigations into the transporter 
transcriptome of whole mouse brains and a mouse brain capillary endothelial cell line 
has identified transporters for systems y+, y+L, and b0,+, but also system L (Dahlin et 
al., 2009; Lyck et al., 2009). One must however be weary of such data as whole-brain 
samples will of course contain a number of different cell types other than BCECs, and 
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cultured cell lines are also susceptible to culture-induced changes in gene expression. 
While system L does not seem to transport L-arginine (Tomi et al., 2005), it is a 
transport system that warrants investigation in respect to L-arginine as its expression 
does appear to be regulated at the transcriptional level by L-arginine deprivation 
(Padbury et al., 2004). 
2.1.1.2 L-arginine, nitric oxide and its role in the brain 
L-arginine is a semi-essential cationic amino acid that humans primarily obtain from 
the diet, although it can also be synthesised de novo in adults (Umbarger, 1978). L-
arginine is the immediate precursor of nitric oxide (NO), and is also involved in the 
synthesis of creatine (Humm et al., 1997) and growth hormone (Alba-Roth et al., 
1988). 
Nitric oxide (NO) is a gaseous signalling molecule that is now known to act on a wide 
range of mammalian biological systems - an attribute which no doubt contributed to it 
being named ‘Molecule of the Year’ in 1992 by the journal Science (Culotta & 
Koshland, 1992). NO is synthesised from L-arginine by one of a family of nitric oxide 
synthase (NOS) enzymes. Three isoforms of NOS have been characterised in humans 
(Forstermann et al., 1994); all of which have been classified according to the tissue or 
cell type of origin found when determining cDNA expression. Two of the isoforms - 
neuronal (nNOS) and endothelial (eNOS), have been found to be constitutively 
expressed, while the third isoform shown to be inducible (iNOS) (Majano et al., 2001). 
In contrast, the nomenclature of the genes that encode the isoforms (NOS1-3) reflects 
the order in which the human genes were cloned, i.e. nNOS, iNOS and eNOS 
respectively (Moncada et al., 1997).  
NOS enzymes are generally accepted to function as homodimers, catalysing the 
conversion of L-arginine to L-citrulline and NO in the presence of the co-substrates 
nicotinamide adenine dinucleotide phosphate (reduced form, NADPH), O2 and the co-
factors, flavins adenine dinucleotide (FAD) and mononucleotide (FMN) (Palacios et al., 
1989; Bredt & Snyder, 1990; Mayer et al., 1990). All three isoforms are known to 
require calmodulin (CaM) for efficient transfer of electrons between the oxygenase and 
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reductase domains of the NOS enzymes (Stuehr, 1997). However, a difference in the 
dependence on either CaM or Ca2+ provides an interesting insight into the regulation of 
NO production by the different isoforms. Both eNOS and nNOS have been shown to 
reversibly bind CaM in a Ca2+-dependent manner, whereas iNOS binds CaM with high 
avidity regardless of intracellular Ca2+ concentration (Nathan & Xie, 1994). Regulation 
of iNOS activity is thought to vary between cell types, however regulation has been 
shown to occur at the transcriptional level via transcription factors such as NF-κB 
(Kleinert et al., 2004). There is also evidence to suggest that iNOS activity is regulated 
by trafficking via calmodulin kinase II (CaMKII) in vascular smooth muscle cells (Jones 
et al., 2007), or that is not regulated at all e.g. in the case of pulmonary epithelia (Guo 
et al., 1995) and renal medulla (Morrissey et al., 1994). 
NO has been implicated in regulatory and mediatory roles in a variety of different 
physiological processes and pathological conditions involving the cardiovascular, 
nervous and immune systems. In the cardiovascular system, NO is known to promote 
smooth muscle relaxation; resulting in vasodilatation and increasing blood flow. A 
similar effect on smooth muscles in the gastrointestinal tract has also lead to 
suggestions that NO is involved in homeostasis of the gut (Lamarque et al., 1996). The 
effect of NO in smooth muscle was first shown to involve soluble guanylate cyclase 
(sGC) (Katsuki et al., 1977), which is known to initiate an intracellular signalling 
cascade through the catalytic conversion of guanosine triphosphate (GTP) to 3’,5’-
cyclic guanosine monophosphate (cGMP) (Arnold et al., 1977). An increase in 
intracellular cGMP results in the activation of protein kinase G (PKG) and 
consequently the phosphorylation of downstream proteins involved in the regulation of 
intracellular Ca2+; hyperpolarising smooth muscle cells via Ca2+-dependent potassium 
channels and promoting relaxation by increasing myosin phosphatase activity (Tanaka 
et al., 2006). It should be noted however, that NO-mediated signalling via the cGMP 
cascade is not restricted to smooth muscle relaxation alone, and has roles in the brain 
in neurotransmission and synaptic plasticity. 
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A significant role for NO in the brain was first described in neurotransmission when it 
was shown to be produced as the result of stimulation N-methyl-D-aspartate (NMDA) 
receptors by glutamate (Garthwaite et al., 1988), a known prerequisite for long term 
potentiation - a form of synaptic plasticity in the brain implicated in memory. Since 
then, NO has been implicated in the release of other neurotransmitters such as 
dopamine and serotonin in the rat medial pre-optic area (Lorrain & Hull, 1993) by a 
process that requires both sGC and cGMP (Kaehler et al., 1999). 
An additional role of NO in the brain is in the regulation of cerebral blood flow. This 
was first discovered via the cranial window method, whereby the competitive NOS 
inhibitor NG-monomethyl-L-arginine (L-NMMA) was topically applied to the basilar 
artery, which then constricted (Faraci, 1990). Since these early experiments, NO has 
been implicated in cerebral autoregulation (White et al., 2000), and the 
chemoregulation of cerebral blood flow in humans (Lavi et al., 2003). A very 
comprehensive review of the current understanding of the cornucopia of roles NO has in 
the regulation of cerebral blood flow has been recently published (Toda et al., 2009). 
However, it suffices to say that the role of NO in the brain is both complex and far 
reaching, and any disruption to the delicately balanced processes that control its 
production can be expected to have severe consequences in the brain, for example in 
ischaemic stroke (Terpolilli et al., 2012). 
One such molecule that is known to inhibit NO production is NG,NG-dimethyl-L-
arginine (asymmetric dimethylarginine or ADMA) – an endogenously occurring 
analogue of L-arginine. 
2.1.1.3 ADMA 
ADMA was first found to be a biologically significant inhibitor of nitric oxide 
production in 1992 (Vallance et al., 1992a; Vallance et al., 1992b). It is believed that 
the inhibition of NOS by ADMA stems from the inability of NOS to utilise ADMA as a 
substrate (Vallance et al., 1992a). Since these initial observations there has been an 
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explosion of interest in ADMA, as evidenced by the exponential increase in the number 
of publications relating to “asymmetric dimethylarginine” (Figure 2-3). 
 
 
Figure 2-3: Number of scientific publications (including reviews) per year relating to 
“asymmetric dimethylarginine” (PubMed searches, November 2012). 
 
The Ki (dissociation constant for inhibitor binding) for ADMA's inhibition of nNOS has 
been calculated to be 0.7 µM (Cardounel & Zweier, 2002) and the Ki of eNOS to be 0.9 
µM (Cardounel et al., 2007), however ADMA appears to have a preference for nNOS as 
demonstrated by the IC50 (half the maximal inhibitory concentration) for nNOS being 
almost 10-fold lower than that for eNOS (1.5µM vs 12 µM) (Tsikas et al., 2000). With 
these values taken into account, one may expect that the ADMA concentration is 
sufficient to tonically inhibit nNOS, however when considering that the Km of arginine 
for nNOS is as low as 2.4 µM (Cardounel & Zweier, 2002) the effects of arginine will 
predominate under normal, physiological conditions. 
However, much of the interest in ADMA surrounds its involvement in disease as an 
endogenous inhibitor of NOS. It has become apparent that abnormally high levels of 
ADMA circulating in plasma are often detected in a number of pathological conditions 
associated with cardiovascular or endothelial dysfunction. A summary of cardiovascular 
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control conditions is shown in Table 2-4. Table 2-5 shows a number of 
cerebrovascular diseases and others relating to the brain where altered ratios of 
arginine:ADMA are found. 
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2.1.1.3A ADMA synthesis from L-arginine 
Protein methylation is a common mechanism of post-translational modification utilised 
in the regulation of many different cellular processes in both prokaryotes and 
eukaryotes. Methylation of amino acids (specifically arginine, lysine and histidine) 
provides a useful means of expanding the functional repertoire of the cellular proteome. 
Arginine methylation is mediated by protein arginine methyltransferase (PRMT) 
enzymes, which specifically methylate the guanidino group of arginine residues 
incorporated into proteins (Rawal et al., 1995). PRMT activity was first characterised 
and attributed to ‘protein methylase I’ over 40 years ago (Paik & Kim, 1968). Two 
types of PRMT have been classified to date - type I and type II (Gary & Clarke, 1998). 
Both subtypes catalyse the formation of L-NMMA as the first step of methylation, 
however the second step of methylation is where the difference between PRMT 
subtypes is seen. Type I PRMT enzymes catalyse the formation of ADMA, whereas 
type II PRMT enzymes catalyse the formation of symmetric dimethylarginine (SDMA) 
(Gary & Clarke, 1998) (shown in Figure 2-4). Proteomic analysis of HeLa cells 
revealed that approximately 200 proteins contain putatively methylated arginine 
residues, preferentially in arginine-glycine rich sequences (Boisvert et al., 2003), and it 
has also been demonstrated that in some cases, arginine methylation is required as a 
signal for localisation within the nucleus of the cell (Smith et al., 2004). Interestingly, 
approximately 65% of all intracellular protein-incorporated ADMA is found in 
heterogenous nuclear ribonuclear proteins (hnRNPs), which are involved in the 
regulation of mRNA maturation (Boffa et al., 1977). 
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Figure 2-4: Arginine and its methylated derivatives. 
  
As direct methylation of free L-arginine is yet to be demonstrated (Vallance & Leiper, 
2004) cytosolic methylated arginine derivatives are believed to occur only through the 
proteolysis of proteins containing methylated arginine. Proteolysis is a complex and 
multi-step process, and thus the rate determining factor for plasma levels of ADMA are 
yet to be determined, although it has been suggested that there is a correlation 
between PRMT expression and the amount of ADMA produced (Boger et al., 2000b).  
The high expression and activity of type I PRMT enzymes in the lungs designate them 
as the major source of ADMA (4.23 µmol per gram of protein) in interstitial fluid and 
plasma (Bulau et al., 2007), however an early study in rat brains showed that the 
ADMA concentration is typically 1.10 µmol per gram of protein (similar to that found 
in the heart, and higher than that found in the liver), while separation of whole brain 
into nuclear, myelin and mitochondria-synaptosome fractions demonstrated the 
concentrations of free ADMA to be 2.12, 0.44 and 0.07 µmol per gram of dry weight, 
respectively (Nakajima et al., 1971). Soon after this initial data was published, the 
arginine concentration in rabbit brain was found to be almost 300-fold greater than 
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ADMA in rat brain slices revealed concentrations of approximately 95 and 5 µM, 
respectively (Cardounel & Zweier, 2002). 
2.1.1.3B ADMA clearance 
After the detection of substantial amounts of both SDMA and ADMA in human urine, 
it was generally accepted that free methylarginines were cleared from the body by renal 
excretion (Kakimoto & Akazawa, 1970). This notion was challenged when the amount 
of SDMA in rabbit urine was found to be 30-fold higher than that of ADMA, and it 
was proposed that some catabolic pathway must exist for both ADMA and also L-
NMMA (McDermott, 1976). Support for this theory came from studies involving radio-
labelled ADMA and SDMA in rat (Ogawa et al., 1987b), in which it was seen that 
radio-labelled methylarginine metabolites were present in tissue and plasma samples of 
rats that were injected with [14C]-ADMA, but not [14C]-SDMA. Further investigation 
revealed that more than 90% of all ADMA generated was metabolised as opposed to 
being excreted (Ogawa et al., 1987a), and the enzyme responsible was later purified 
and termed NG,NG-dimethylarginine dimethylaminohydrolase (DDAH) (Ogawa et al., 
1989). In humans, approximately 300 µmol of ADMA is produced each day, of which 
approximately 250 µmol (80%) is metabolised by DDAH (Achan et al., 2003).  
DDAH enzymes are highly conserved throughout evolution and have been identified in 
prokaryotes (Tran et al., 2000). Two isoforms (DDAH-1 & -2) exist in higher 
vertebrates and are thought to be the result of a gene duplication event that occurred 
some time before the evolution of bony fish (Tran et al., 2000). Both DDAH isoforms 
catalyse the conversion of ADMA to citrulline and dimethylamine, with a Michaelis 
affinity constant (Km) of approximately 180 µM (Ogawa et al., 1989). DDAH-mediated 
metabolism of ADMA is thought to occur via nucleophilic attack of the methylated 
guanidino group of ADMA by a cysteine residue (Cys-249) in the tertiary structure of 
the activated DDAH enzyme (Murray-Rust et al., 2001), although this is yet to be 
definitively shown. It is known however, that substitution of the cysteine residue for 
serine renders the DDAH enzyme inactive, and thus Cys-249 does have some critical 
role in DDAH function (Murray-Rust et al., 2001). As yet, no co-factors have been 
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conclusively identified, and it has been shown that Zn2+, Cu2+ and Cd2+ are inhibitory 
(Ogawa et al., 1989), although this may be species specific (Bogumil et al., 1998). 
Closer analysis of DDAH-2 has revealed many hallmarks of a ‘house-keeping’ gene 
within the promoter region (Jones et al., 2003), and although it is expressed 
constitutively, it does also appear to be subject to some form of regulation at the 
transcriptional level (Achan et al., 2002). 
DDAH enzymes were initially shown to co-localise with NOS enzymes in the rat (Tojo 
et al., 1997) and this was later confirmed in humans (Leiper et al., 1999). Studies on 
the pattern of expression of both DDAH-1 and -2 have shown that they are frequently 
associated respectively to nNOS and eNOS (Tran et al., 2000), although not exclusively 
confined to tissues expressing NOS. As a consequence, DDAH is able to indirectly 
activate NOS by clearing ADMA. However, in conditions of elevated levels of ADMA, 
it has been shown that the resulting inhibition of eNOS can result in the complete 
uncoupling of the enzyme, leading to a switch from NO production to the production of 
superoxide radicals (Boger et al., 2000a). The sulfhydryl group present on the cysteine 
residue in the active site of DDAH renders it extremely sensitive to oxidative stress 
(Murray-Rust et al., 2001), and as ADMA can itself induce oxidative stress, the 
DDAH-ADMA-NOS system can easily slip into a vicious cycle if ADMA levels are not 
tightly regulated. This is particularly important in inflammation and diabetes, where 
excessive NO produced by iNOS and oxidative stress can respectively result in the 
nitrosylation (Leiper et al., 2002) or oxidation (Lin et al., 2002) of the critical cysteine 
in DDAH, and ultimately the inactivation of the enzyme. 
At this stage it is unclear if ADMA has any biological significance in a regulatory role, 
or whether it is merely a by-product of product of normal protein turnover in the cell. 
However, it should be noted that ADMA is also subject to metabolic conversion to α-
keto valeric acid by the enzyme alanine:glyoxylate aminotransferase (Ogawa et al., 
1990), although the overall contribution of this route to overall ADMA metabolism is 
undetermined thus far. 
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2.1.1.4 The L-arginine paradox 
Prior to the discovery of ADMA, it was shown that dietary supplementation with L-
arginine was sufficient to alleviate endothelial dysfunctions caused by impaired nitric 
oxide synthesis associated with conditions such as hypercholestrolemia (Cooke et al., 
1991). In contrast, characterisation of the enzyme kinetics of nitric oxide synthesis 
showed that levels of endogenous L-arginine (the nitric oxide precursor) were already 
above the saturation threshold in these conditions (Schmidt et al., 1991). 
Quantification of the intracellular concentration of L-arginine revealed it to be 
approximately 0.3-0.8 mM in bovine endothelial cells (Gold et al., 1989), which is easily 
sufficient to saturate eNOS when considering the Km (substrate concentration that 
produces half-maximal velocity in the presence of an inhibitor) is approximately 2.9 µM 
(Bredt & Snyder, 1990). Plasma concentrations of L-arginine in both healthy humans 
and patients suffering from cardiovascular disease are typically between 45-100 µM 
(Boger & Bode-Boger, 2001), and slightly higher (140 µM) in mice (Hallemeesch et al., 
2004). Therefore, the observation that dietary (Bode-Boger et al., 1998) or intravenous 
(Drexler et al., 1991; Creager et al., 1992; Bode-Boger et al., 1996; Bode-Boger et al., 
1998) supplementation with L-arginine was sufficient to increase NO production in 
humans (healthy or otherwise), and in animal models of cardiovascular disease (Girerd 
et al., 1990; Rossitch et al., 1991) was somewhat puzzling at first. As such, this 
phenomenon became known as the ‘L-arginine paradox’.  
Plasma concentrations of ADMA are often measured at between 0.3-0.5 µM in healthy 
humans (Martens-Lobenhoffer et al., 2004), and can reach 3 µM in certain disease 
states (Cakir et al., 2005; Bode-Boger et al., 2007). It has been shown that ADMA 
produced by one cell (e.g. an endothelial cell) can inhibit nitric oxide synthesis in a 
neighbouring cell (e.g. a macrophage) (Fickling et al., 1999).  
Taking into consideration that ADMA appears to be able to exit and enter cells, 
exploring the L-arginine paradox with respect to ADMA and L-arginine transport is a 
sensible step to understanding the pathway for NO generation. The route by which 
ADMA crosses the cell membrane is yet to be formally identified, however it has been 
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shown that ADMA can be a substrate for transport by the y+ cationic amino acid 
transport system, albeit at concentrations that are far greater than those seen in 
physiological or even pathological conditions (Bogle et al., 1995). The archetypal 
system y+ transporter CAT-1 and eNOS are sub-cellularly located in close proximity to 
each other in caveolae in the plasma membrane (McDonald et al., 1997); ensuring that 
eNOS receives a plentiful supply of L-arginine in via CAT-1 transport. Indeed, L-
arginine transport by CAT-1 is a pre-requisite of NO production by the endothelium in 
vivo (Zani & Bohlen, 2005). 
Two possible explanations have been put forward to explain the L-arginine paradox: 
2.1.1.4A Competition hypothesis 
Pathological concentrations of ADMA in plasma could compete with L-arginine for 
transport into endothelial cells; thus reducing the intracellular bioavailability of L-
arginine for the synthesis of NO by eNOS. Increasing plasma concentrations of L-
arginine with dietary supplementation could then ‘tip’ transport mediated by system y+ 
back in favour of transporting L-arginine into the cell; as the proportion of ADMA 
present in plasma would be reduced, and the degree of competition for transport 
exerted by ADMA also reduced. Therefore, it is conceivable that increased competition 
for L-arginine transport into the cell with extracellular ADMA would result in NO 
deficiency, both due to reduced intracellular L-arginine, and due to the fact that 
extracellular ADMA would have a direct route for inhibiting eNOS via CAT-1. In this 
case NO deficiency could be alleviated with L-arginine supplementation, and reduced 
competition for L-arginine transport into the cell. A schematic representation of the 
competition hypothesis is shown in Figure 2-5. 
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Figure 2-5: The competition hypothesis to explain the L-arginine paradox. Left panel: 
Under physiological conditions, L-arginine is transported into the cell by the CAT-1 
transporter and converted to L-citrulline and nitric oxide (NO) by endothelial nitric oxide 
synthase (eNOS). Centre panel: Increases in extracellular ADMA observed under 
pathological conditions out-compete L-arginine for transport into the cell. Once inside the 
cell, ADMA inhibits eNOS, with the net result being a drop in NO production. Right 
panel: Following dietary supplementation with L-arginine, the concentration of 
extracellular L-arginine increases. This tips the balance of transport into the cell back into 
the favour of L-arginine ahead of ADMA, and restores NO production. 
 
2.1.1.4B Trans-stimulation hypothesis 
Since ADMA is produced intracellularly (see section 2.1.1.3A - ADMA synthesis 
from L-arginine), inhibition of NOS may be due directly to free ADMA released by 
the proteolysis of proteins containing methylated L-arginine residues. An alternative 
model to explain the L-arginine paradox has been proposed, stating that increasing 
plasma concentrations of L-arginine following dietary supplementation could promote 
efflux of intracellular ADMA from the cell via trans-stimulation of CAT-1 (Teerlink et 
al., 2009). The simultaneous removal of ADMA from the cell with increased influx of L-
arginine into the cell could conceivably simultaneously relieve inhibition of NOS by 
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CAT-2B is also known to have the capacity to transport ADMA (in addition to other 
methylarginines) and it has been shown that the presence of some methylarginines such 
as ADMA can inhibit L-arginine uptake into the brain (Closs et al., 1997). While CAT-
2B and CAT-3 are both expressed in the brain, have strong affinity for cationic amino 
acids, and also demonstrate trans-activation activity, they are both less sensitive to 
trans-stimulation relative to CAT-1 (Closs et al., 1997; Vekony et al., 2001). A 
schematic representation of the trans-stimulation hypothesis is shown in Figure 2-6. 
The facts that y+ transporters at the abluminal membrane would be directly subject to 
changes in ADMA production in the brain, and similarly luminal y+ transporters to 
ADMA in plasma, make ADMA and L-arginine transport an interesting subject for 
investigation in the context of the blood-CNS barriers. 
 
 
Figure 2-6: The trans-stimulation hypothesis to explain the L-arginine paradox. Left 
panel: Under physiological conditions, L-arginine is transported into the cell by the CAT-1 
transporter and converted to L-citrulline and nitric oxide (NO) by endothelial nitric oxide 
synthase (eNOS). Centre panel: Increases in intracellular ADMA observed under 
pathological conditions result from the proteolysis of proteins containing methylated 
arginine residues. Intracellular ADMA inhibits eNOS, with the net result being a drop in 
NO production. Right panel: Dietary supplementation with L-arginine trans-stimulates 
the CAT-1 transporter to increase the rate of removal of ADMA from the cell while 
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2.2 Aims 
The aims of this chapter of the thesis are to: 
i. Elucidate the transport mechanism(s) utilised by ADMA at the murine blood-
brain and blood-CSF barriers, and compare them to those used by L-arginine. 
ii. Determine the effects (if any) of ADMA on L-arginine transport at the murine 
blood-brain and blood-CSF barriers. 
iii. Determine the effects (if any) of L-arginine on ADMA transport at the murine 
blood-brain and blood-CSF barriers. 
iv. Investigate the aforementioned two hypotheses (competition and trans-
stimulation) to explain the L-arginine paradox in the context of the murine 
blood-brain and blood-CSF barriers. 
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2.3 Methods 
2.3.1 Blood-CNS barrier model & accessory methodologies 
2.3.1.1 Animals & anaesthesia 
All experiments requiring the use of animals were performed in accordance with the 
Animal (Scientific Procedures) Act, 1986. All animals used in procedures were adult 
male BALB/c mice (between 23 g and 25 g) sourced from Harlan Laboratories, Oxon, 
UK, unless otherwise stated. Free access to water and food was provided ad libitum. 
Domitor® (medetomidine hydrochloride) and Vetalar® (ketamine) were both purchased 
from Harlan Laboratories; Cambridge, UK. All animals were anaesthetised (2 mg/kg 
Domitor® and 150 mg/kg Vetalar® injected intraperitoneally), and a lack of self-
righting and paw-withdrawal reflexes (as surrogate indicators of consciousness) 
thoroughly checked prior to carrying out all procedures. Animals were heparinised with 
100 units heparin (in 0.9% m/v NaCl(aq), Harlan Laboratories; Oxon, UK), administered 
via the intraperitoneal route prior to surgery. 
2.3.1.2 In situ brain/choroid plexus perfusion 
The in situ brain/choroid plexus perfusion method is designed to directly infuse the 
brain with artificial plasma via a cannula placed in the heart. Artificial plasma is 
prepared to mimic the ionic composition of blood, and any solutes and transport 
inhibitors of interest can be added in known concentrations and delivered to the brain 
for defined periods of time. There are a number of advantages associated with using the 
in situ brain/choroid plexus perfusion technique over other methods (e.g. brain uptake 
index (BUI) method) to study blood-brain and blood-CSF barrier transport: 
i. Perfusions can be carried out over a long period of time (up to 30 minutes), 
allowing accurate measurements of brain uptake with respect to time for slowly 
permeating molecules, and the kinetics of transport calculated accordingly. 
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ii. The solute of interest is delivered to the CNS at a known concentration with a 
constant flow that does not vary with time. 
iii. The concentration of solutes, potential competitors, transport inhibitors and 
ions can easily be manipulated in the perfusate in order to measure saturable 
transport across the BBB and identify the transport systems involved. 
iv. The solute is exposed to the brain microcirculation before any peripheral organs 
involved in metabolism (e.g. liver, kidneys or lungs) and thus one can be 
confident that the compound is intact when interacting with transporters at the 
blood-brain and blood-CSF barriers. 
2.3.1.2A Surgical preparation 
The experimental procedure followed a previously outlined protocol (Sanderson et al., 
2007). Following anaesthesia and heparinisation of the mouse (as described in section 
2.3.1.1 - Animals & anaesthesia), a low transverse incision was made with scissors 
just above the pubic region, which was then extended up on both sides up to just under 
the forelimbs. This exposed the entire peritoneal cavity, enabling the movement of the 
liver to expose the diaphragm. An incision in the diaphragm was then made, and the 
ribcage also cut and held open with a haemostat. 
2.3.1.2B Experimental procedure 
The pericardium was then carefully cut, and the left ventricle of the heart cannulated 
with a 25G x 10mm butterfly-winged needle, before making an incision in the right 
atrium. The butterfly-winged needle was connected to a perfusion circuit as detailed in 
Figure 2-7. 
2.3.1.2C Perfusion circuit 
The artificial plasma was infused into the heart via this circuit and could thus enter the 
body and reach the vasculature of the head. The right atrium of the heart was 
sectioned to allow outflow of the artificial plasma. Thus, an open circuit is created and 
the artificial plasma only passes through the circulation once. 
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The artificial plasma was kept at physiological temperature (37 °C) and oxygenated by 
95% O2 / 5% CO2 gas being bubbled through the solution, before being pumped 
through the tubing circuit by means of a peristaltic pump. Radiolabelled and unlabelled 
test molecules, substrates and inhibitors were infused into the inflowing artificial 
plasma via the slow drive syringe pump. The speed of the peristaltic pump and syringe 
plunger pressure was fine-tuned to give a pre-determined and constant flow rate of 5 
mL/minute. On its route, the artificial plasma was passed through a bubble trap to 
ensure that any bubbles that could compromise the integrity of the blood-CNS 
interfaces were removed. 
 
 
Figure 2-7: Schematic representation of experimental setup for in situ brain/choroid 
plexus perfusion. The heart is drawn in isolation for simplicity, but in reality is still in situ 
and provides access to the vascular bed after cannulation of the left ventricle with a 25G 
x 10mm butterfly-winged needle (shown with orange wings). The oxygenated artificial 
plasma is passed through the system of tubing by a peristaltic pump at a flow rate of 5 
mL/minute, and bubbles removed by a bubble trap. The perfusate is then infused with the 
solute of interest, which is radiolabelled. After one full circulation of the entire circulatory 
system the perfusate exits the body via an incision made in the right atrium. 
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2.3.1.2D Composition of artificial plasma 
A full breakdown of the contents of artificial plasma is shown in Appendix 1. 
2.3.1.2E Radiolabelled solutes of interest 
Sucrose (non-metabolisable baseline) 
[14C]-sucrose (mol. wt., 342.3 g/mol; specific activity, 0.412 Ci/mmol; 99% 
radiochemical purity; Moravek Biochemicals, Brea, CA), was present in the artificial 
plasma for all perfusion experiments. First and foremost, it should be noted that the 
molecular weight of [14C]-sucrose is comparable to that of the other radiolabelled solutes 
of interest (e.g. [3H]-arginine = 174.2 g/mol, [3H]-ADMA = 276.7 g/mol). Thus, based 
on the molecular weight alone, it would not be un-reasonable to expect that the three 
compounds would have similar transport characteristics. However, molecular weight is 
only one determinant of a compound's transport characteristics, and indeed [14C]-
sucrose is frequently used as a measure of BBB permeability due to its poor penetrance 
through the brain microvasculature as a polar molecule with no specific transport 
system.  
In these experiments, [14C]-sucrose was used both as an internal control of blood-brain 
barrier integrity, but also as a quantitative measure of cerebrovascular space. All values 
for uptake of [3H]-arginine or [3H]-ADMA in brain regions were corrected for [14C]-
sucrose vascular space to normalise uptake and reduce regional discrepancies due to 
differences in vascularity. Thus, any regional differences in brain uptake of 
radiolabelled solutes of interests are likely to be due to differences in transporter 
expression, rather than due to differences in blood supply. 
By comparison to vascular space in brain regions, [14C]-sucrose distribution in the 
pineal and pituitary gland samples is also an indicator of vascular space but represents 
the ability of [14C]-sucrose to cross between capillary endothelial cells in the absence of 
tight junctions (paracellular permeability). By contrast, [14C]-sucrose distribution in 
choroid plexus samples represents the vascular space and extracellular space formed 
between choroid plexus capillary endothelium and epithelium (Sanderson et al., 2009). 
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Arginine 
[3H]-arginine (mol. wt., 174.2 g/mol; specific activity, 43 Ci/mmol; >97% radiochemical 
purity) was purchased from Amersham Radiochemicals, Buckinghamshire, UK. 
The inclusion of [3H]-arginine as a radiolabelled solute of interest in the artificial plasma 
thus facilitated the measurement of its penetration into the CNS after in situ 
brain/choroid plexus perfusion. 
ADMA 
[3H]-ADMA (mol. wt., 276.7 g/mol; specific activity, 8 Ci/mmol; 96.4% radiochemical 
purity) was synthesised and tritiated by Amersham Radiochemicals, Cardiff, UK. 
The inclusion of [3H]-ADMA as a radiolabelled solute of interest in the artificial plasma 
thus facilitated the measurement of its penetration into the CNS after in situ 
brain/choroid plexus perfusion. 
2.3.1.2F CNS sampling 
After the perfusion time had elapsed the butterfly-winged needle was removed, and a 
sample of the artificial plasma taken. A sample of CSF was then taken from the 
cisterna magna (a subarachnoid compartment where CSF accumulates, and most 
convenient site for CSF sampling from small animals) using a pre-prepared micro-
needle made from borosilicate glass capillaries, the animal decapitated and the brain 
removed. Samples were taken using micro-forceps and a Leica S4E L2 stereo-
microscope (Leica; Buckinghamshire, UK), and are outlined in Table 2-6. 
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Table 2-6: Brain regions and circumventricular organs (CVOs) sampled for the in situ 
brain perfusion technique. 
Brain regions Circumventricular organs (CVOs) 
Frontal cortex (FC) Pineal gland (Pin) 
Caudate nucleus (CN) Choroid plexus (CP) 
Occipital cortex (OC) Pituitary gland (Pit) 
Hippocampus (H)  
Hypothalamus (Hy)  
Thalamus (Th)  
Pons (P)  
Cerebellum (C)  
 
 
Cut-off values for vascular space were used for all brain perfusion experiments based on 
[14C]-sucrose distribution (Table 2-7). These were in accordance with previously 
published values using the same method and in the same strain of mouse (Sanderson et 
al., 2007). In the infrequent event that [14C]-sucrose distribution in a CNS sample 
exceeded this maximum value, the sample was not utilised in any further analyses, as 
excess [14C]-sucrose in a CNS sample indicates loss of brain barrier integrity, due to the 
poor penetrance of sucrose through the brain barriers under normal healthy conditions. 
 
Table 2-7: Cut-off values for [14C]-sucrose distribution in the mouse CNS at 2.5, 10, 
20 and 30 minutes. The success rate for [14C]-sucrose distribution being lower than 
values shown here was above 97%. 
 Maximum [14C]-sucrose distribution (mL⋅100 g-1) 
CNS region 2.5 min 10 min 20 min 30 min 
Choroid plexus 15.0 25.0 35.0 45.0 
Majority of brain regions 2.5 4.0 6.0 8.0 
Cerebellum 3.0 5.0 8.0 10.0 
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2.3.1.2G Capillary depletion analysis 
The microvasculature within a sample of brain tissue can be separated from the brain 
parenchyma using capillary depletion analysis (Triguero et al., 1990). This method was 
previously validated by assaying the separated fractions for γ-glutamyl transpeptidase 
and alkaline phosphatase activity (two vascular enzyme markers). Separation was 
found to be approximately 95% efficient, and thus merely enriches the pellet resulting 
from centrifugation with brain capillary endothelial cells. This facilitates the broad 
examination of respective uptake into both the brain parenchyma fraction and the 
cerebral capillaries.  
Following perfusion, the remaining brain tissue after microdissection of the regions 
described above (typically 200-300 mg) underwent capillary depletion following a 
method slightly modified for mouse (Sanderson et al., 2007). A whole-brain homogenate 
was prepared using physiological capillary depletion buffer (defined in Appendix 1) 
and a manual homogeniser, before adding 26% m/v dextran (final concentration 13% 
m/v, 60-90kDa, MP Biomedicals Europe, France) and homogenising again. Both the 
physiological capillary depletion buffer and dextran solution were maintained at 4 °C 
both to halt any cell metabolism and transport processes, and to reducing any cellular 
or protein damage due to heat generated from the homogenisation process. The 
homogenate (Hom) was centrifuged at 5400 r.c.f and 4 °C to produce an endothelial 
cell-enriched pellet (Pel) and supernatant containing brain parenchyma (Sup). A 
schematic depiction of this process is shown in Figure 2-8. 
An important limitation of the capillary depletion technique is that the capillary-
enriched pellet fraction is also likely to be contaminated with a number of other cells, 
such as smooth muscle cells and pericytes. Furthermore, while steps are taken to reduce 
cell damage it is likely some cells rupture during the process due to the shear forces 
generated by the homogenisation, and their contents may leak out to contaminate the 
supernatant fraction. As such, capillary depletion data should not be used to make firm 
conclusions but merely to better inform further studies.  
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Figure 2-8: Capillary depletion assay. The remainder of the dissected brain is weighed 
and then homogenised in physiological capillary depletion buffer (3-fold volume of brain 
mass) and dextran added (4-fold volume of brain mass). Centrifugation of the 
homogenate at 5400 x r.c.f. for 15 minutes at 4 °C results in an endothelial cell enriched 




Capillary depletion buﬀer 
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2.3.1.2H Liquid scintillation analysis 
All samples (brain regions, capillary depletion brain homogenate, pellet and 
supernatant, CVOs, CSF and plasma samples) were solubilised in 0.5 mL tissue 
solubiliser (Solvable; Perkin-Elmer; Boston, MA, USA). After incubating the samples at 
room temperature for 48 h, 4 mL scintillation fluid (Lumasafe®; Perkin-Elmer; Boston, 
MA, USA) was added to each before vigorous vortexing. The amounts of [3H] and [14C] 
radioactivity in each sample were then quantified using a Packard Tri-Carb 2900TR 
counter (Perkin-Elmer; Boston, MA, USA). Counts per minute were then converted to 
disintegrations per minute (dpm) by the counter using internally stored quench curves 
from standards. 
2.3.1.2I Expression of results 
The distribution of radioactivity in the brain regions, CVOs and CSF is expressed as a 





amount of radioactivity in tissue (dpm/g)
amount of radioactivity in plasma (dpm/mL)





∴RBRAIN = mL ⋅100g
−1
  [2.1] 
Correcting for vascular space involved subtracting the RBRAIN value obtained for [14C]-
sucrose in each sample from the RBRAIN value concurrently obtained for the [3H]-labelled 
solute of interest. 
2.3.1.2J Perfusion time 
As described in section 2.3.1.2 - In situ brain/choroid plexus perfusion, one of 
the advantages of the in situ brain/choroid plexus perfusion technique utilised in these 
studies is the ability to easily vary perfusion time and determine uptake into the CNS 
at these different time points. Multiple-time (2.5, 10, 20 and 30 minute) uptake studies 
were performed in order to measure the respective uptake of [3H]-arginine and [3H]-
ADMA into the mouse CNS over time. For these experiments both the radiolabelled 
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solute of interest and [14C]-sucrose were included in the artificial plasma, and the 
perfusion stopped at the relevant time-points. 
After perfusion the CNS samples were taken and prepared for liquid scintillation 
sampling as described in section 2.3.1.2F - CNS sampling. 
Using these data, the influx of the radiolabelled solutes of interest into the CNS can be 
calculated as the unidirectional transfer constant (Kin). There are two methods to 
determine the Kin value of solutes into the CNS: 
i. Single-time point analysis method, described by equation [2.3] 
ii. Multiple-time point analysis method, described by equation [2.5] 









  [2.2] 
Where Ctissue(T) is radioactivity (dpm) per g of tissue at time-point T (perfusion time 
in minutes), and Cplasma is radioactivity (dpm) per mL of artificial plasma. 
 
This equation assumes that the entry of the radiolabelled solute of interest into the 
CNS is proportional to, but less than, its concentration in the artificial plasma. Efflux 
of the solute from the CNS is therefore ignored (Collins & Dedrick, 1983; Smith & 
Rapoport, 1986; Zlokovic et al., 1986; Williams et al., 1996). Since the concentration of 
the radiolabelled solute of interest was kept constant during these experiments, 
 Cplasma dt0
T






  [2.3] 
It should however be noted that calculating the unidirectional rate constant from blood 
to CNS using this method requires that Rtissue at time T is first corrected for vascular 
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space by subtracting the concurrent Rtissue accumulation value for [14C[-sucrose at that 
time-point. 
The second method (ii) for calculating the unidirectional rate constant from blood to 










+Vi   [2.4] 
Where Ctissue(T) and Cplasma(T) are amounts of radioactivity (dpm) per g of tissue and 
per mL of plasma, respectively; and Vi is the initial volume of distribution (Gjedde, 
1981; Gjedde, 1982; Patlak et al., 1983; Zlokovic et al., 1986). 
 
The following assumptions are made under this model (Williams et al., 1996): 
a. Within the system, artificial plasma is the only source of the solute of interest. 
b. Concentration of the solute of interest may vary over time 
c. The solute of interest does not alter the system 
 
However, since the concentration of the radiolabelled solute of interest remains 






=T  and so equation [2.4] 





= KinT +Vi   [2.5] 
 
Thus, plotting the data points resulting from equation [2.5] at each time point defines a 
straight line (y=mx+c), where Kin is the slope, and Vi is the ordinate intercept. The 
goodness of fit (R2) and p-value for deviation of slope from zero (p) were used to 
determine the suitability of this method for calculating the Kin and Vi values for each 
brain region and sample. Any transport of the radiolabelled solute of interest back from 
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the brain to the blood can be detected by a loss of linearity of the experimental points 
and could more easily be detected in the later time points (Zlokovic et al., 1986). 
2.3.1.2K Self-inhibition experiments 
In situ brain perfusion self-inhibition experiments were performed with a ten-minute 
perfusion time, and each treatment group had N=5, unless otherwise stated. As a point 
of comparison to all other treatments, each set of experiments contained a ‘control’ 
group containing only the radiolabelled solute of interest and [14C]-sucrose as a baseline 
measure.  
The inclusion of solute of interest in its non-radiolabelled form in the artificial plasma 
provides an opportunity to quantify the competition for transport between the 
radiolabelled solute (detectable by liquid scintillation counting) and non-radiolabelled 
solute (undetectable), if any. Since uptake of only radiolabelled solute can be detected 
in the brain, a decrease in the uptake of radiolabelled solute in the presence of an 
excess of non-radiolabelled solute is indicative of a saturable influx transport system. 
Conversely, an increase in the uptake of radiolabelled solute in the presence of an 
excess of non-radiolabelled solute is indicative of a saturable efflux transport system. 
Based on these principles, the uptake of [3H]-arginine was measured in the presence of 
un-labelled L-arginine (Sigma Aldrich; Dorset, UK), and the uptake of [3H]-ADMA 
measured in the presence of un-labelled NG,NG-dimethylarginine dihydrochloride 
(ADMA, Sigma Aldrich; Dorset, UK). A breakdown of the experimental conditions 
used for self-inhibition experiments are shown in Table 2-8 and Table 2-9. 
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Table 2-8: Summary of self-inhibition experiments for [3H]-arginine uptake into the CNS 
as measured by in situ brain perfusion. Experiments were performed in the either the 
presence or absence of un-labelled arginine. 
Radiolabelled compound Added compound 
[3H]-Arginine (11.6 nM) - 




Table 2-9: Summary of self-inhibition experiments for [3H]-ADMA uptake into the CNS 
as measured by in situ brain perfusion. 
Radiolabelled compound Added compound  
[3H]-ADMA (62.5 nM) - 
[3H]-ADMA (62.5 nM) Un-labelled ADMA (0.5 µM) 
[3H]-ADMA (62.5 nM) Un-labelled ADMA (3.0 µM) 
[3H]-ADMA (62.5 nM) Un-labelled ADMA (10.0 µM) 
[3H]-ADMA (62.5 nM) Un-labelled ADMA (100.0 µM) 
[3H]-ADMA (62.5 nM) Un-labelled ADMA (500.0 µM) 
 
 
These concentrations were selected as the plasma concentration for ADMA under 
normal physiological conditions is typically found to be approximately 0.5 µM in 
humans and a number of mammalian species, including mouse (Martens-Lobenhoffer et 
al., 2004; Lajer et al., 2008; Wang et al., 2008; Wang et al., 2009). Plasma 
concentrations for ADMA under pathological conditions are typically in the range of 
3.0 µM (Cakir et al., 2005; Bode-Boger et al., 2007). Concentrations above 10 µM can 
be considered as supraphysiological as ADMA would not ordinarily be found at 
concentrations that high in the body in health or disease. 
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After co-perfusion with the relevant radiolabelled solute of interest, the CNS was 
sampled and prepared for liquid scintillation counting as described earlier (section 
2.3.1.2F - CNS sampling). 
The perfusion of [3H]-ADMA with a range of un-lablled ADMA concentrations 
presented an opportunity for the calculation of Km (half-saturation constant) and Vmax 
(maximal velocity of transport). These were calculated for every sample obtained from 
ADMA self-inhibition studies, as follows: 
1. Divide RBRAIN values for [3H]-ADMA (sucrose-corrected where applicable, 
mL.100g1) by the length of perfusion time (in this case 10 minutes) to obtain 
Kin (mL.min-1 g-1) 
2. Multiply Kin values by the total concentration of ADMA (radiolabelled + un-
labelled, in mM) in the perfusate for each experimental group to obtain total 
flux values (µmol.min-1 g-1) 
3. Plot total flux values (y-axis) against concentration (x-axis) and perform 
Michaelis-Menten kinetics analysis 
4. Determine Kd (diffusion constant, mL.min-1 g-1) by calculating the slope of flux 
vs. concentration for values after saturation using linear regression analysis. 
Saturation can be determined by performing multiple un-paired two-tailed t-
tests comparing the values. The saturation point is the point at which the 
values do not significantly differ from each other. 
5. Multiply Kd values by the range of total ADMA concentrations used for each 
experimental group (in mM). 
6. Subtract these values from the total flux values for each treatment group to 
obtain the saturable component of total flux 
7. Plot values for saturable component of total (y-axis) against concentration (x-
axis) and perform Michaelis-Menten kinetics analysis to obtain Km and V  
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2.3.1.2L Cross-competition experiments 
Based on a similar principle to that explained above (see section 2.3.1.2K - Self-
inhibition experiments), cross-competition experiments involve the inclusion of un-
labelled potential competitors or inhibitors of transport. ADMA and arginine cross-
competition experiments followed the following experimental designs: 
i. Transporter inhibitor experiments 
ii. Direct competition between ADMA & L-arginine 
iii. Pre-loading / trans-stimulation experiments 
After confirming the existence of a saturable transport system via self-inhibition studies 
one can measure the uptake of radiolabelled solutes of interest in the presence of these 
potential competitors or inhibitors. In the event that uptake of the solute of interest in 
the presence of a potential competitor decreases relative to control one can conclude 
that the potential competitor does indeed compete for transport into the brain. 
Conversely, if the uptake of the radiolabelled solute of interest increases this would be 
indicative of competition for efflux from the CNS to the blood. 
Transporter inhibitor experiments 
To examine the involvement of transporters in the uptake of both L-arginine and 
ADMA into the CNS, specific inhibitors of transport were added to the artificial 
plasma. The inclusion of transport inhibitors can correlate with either an increase or 
decrease in the uptake of the solute of interest; which is respectively indicative of an 
efflux from, or influx into the CNS. All experimental groups involved a perfusion time 
of 10 minutes. All transport inhibitors used were purchased from Sigma Aldrich; 
Dorset, UK and were readily soluble in the artificial plasma – requiring no extra steps 
for dissolution beyond standard mechanical stirring and heating to physiological 
temperature (37 °C). A breakdown of the experimental conditions used for transport 
inhibitor experiments are shown in Table 2-10. After co-perfusion with the relevant 
radiolabelled solute of interest, the CNS was sampled and prepared for liquid 
scintillation counting as described earlier. 
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Direct competition between ADMA & L-arginine 
Uptake of [3H]-arginine was also measured in the presence of un-labelled ADMA, and 
the uptake of [3H]-ADMA measured in the presence of un-labelled L-arginine. A 
breakdown of the experimental conditions used for cross-competition experiments are 
shown in Table 2-11 and Table 2-12. 
 
 
Table 2-11: Summary of cross-competition experiments for [3H]-arginine uptake into the 
CNS as measured by in situ brain perfusion. 
Radiolabelled compound Added compound 
[3H]-Arginine (11.6 nM) - 
[3H]-Arginine (11.6 nM) Un-labelled ADMA (0.5 µM) 
[3H]-Arginine (11.6 nM) Un-labelled ADMA (3.0 µM) 
[3H]-Arginine (11.6 nM) Un-labelled ADMA (10.0 µM) 
[3H]-Arginine (11.6 nM) Un-labelled ADMA (100.0 µM) 
[3H]-Arginine (11.6 nM) Un-labelled ADMA (500.0 µM) 
 
 
Table 2-12: Summary of cross-competition experiments for [3H]-ADMA uptake into the 
CNS as measured by in situ brain perfusion. 
Radiolabelled compound Added compound 
[3H]-ADMA (62.5 nM) - 
[3H]-ADMA (62.5 nM) Un-labelled L-arginine (100.0 µM) 
 
 
As described previously, ADMA concentrations were selected at 0.5 and 3.0 µM to 
represent plasma concentrations seen in health and disease, respectively, whereas the 
higher concentrations of ADMA were deliberately selected to recreate conditions of 
excess ADMA. After co-perfusion with the relevant radiolabelled solute of interest, the 
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CNS was sampled and prepared for liquid scintillation counting as described earlier 
(section 2.3.1.2F - CNS sampling). 
 
Pre-loading / trans-stimulation experiments 
As described in section 2.1.1.4B - Trans-stimulation hypothesis, trans-
stimulation is the stimulation of transport of a substrate, by the presence of substrate 
on the opposite side of the membrane. 
To investigate trans-stimulation of ADMA and L-arginine transport at the mouse 
blood-brain barrier, a series of trans-stimulation experiments were designed to 
investigate the influence of supplemental amounts of L-arginine (200 μM L-arginine) on 
the efflux of preloaded ADMA (either radiolabelled or un-labelled), or the effect of 
increasing concentrations of intracellular ADMA on the influx of extracellular [3H]-
arginine into the CNS. The basic premise for these experiments was to pre-load the 
CNS and CNS microvasculature with ADMA to re-create conditions of high ADMA 
concentrations seen in disease, to measure what effect this had on consequent [3H]-
arginine influx into the CNS and [3H]-ADMA efflux from the CNS. 
Based on the previously observed uptake of [3H]-ADMA into the CNS in experiments 
described in section 2.3.1.2J - Perfusion time, the concentration of ADMA pre-
loaded with or without [3H]-ADMA (and [14C]-sucrose) was 500 µM – an excess 
concentration to ensure ADMA accumulated within the brain capillary endothelium 
and CNS. Transport of only one radiolabelled solute of interest was investigated at a 
time per experimental group (i.e. efflux of [3H]-ADMA first in one set of animals, and 
then influx of [3H]-arginine into the CNS in a separate set of animals). [14C]-sucrose was 
included in all experiments as an internal control of blood-CNS barrier integrity, 
measure of vascular space in brain regions and choroid plexus, and extracellular space 
in pineal and pituitary glands, as described in section 2.3.1.2E - Radiolabelled 
solutes of interest. The use of 200 µM un-labelled L-arginine was following the 
observation that the plasma concentration of L-arginine attained after dietary 
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supplementation of L-arginine in patients is 200 µM (Clarkson et al., 1996; Adams et 
al., 1997). 
Pre-loading was achieved by perfusion for 20 minutes with one solution, and then 
switching to a second solution for the remaining 10-minute perfusion. The total 
perfusion time was 30 minutes. Since artificial plasma exits circulation via an incision 
made in the right atrium of the heart, one can be reasonably sure that solutes in the 
perfusate are only exposed to transporters in the circulation once – with a 'single-pass'. 
As an extension of this concept, changing to a new solution of artificial plasma during 
the perfusion should expose the circulation only to the solutes in the new artificial 
plasma, rather than any left behind from the pre-load perfusion. 
A breakdown of the experimental conditions used for trans-stimulation experiments are 
shown in Table 2-13. After the full 30-minute perfusion with the relevant 
radiolabelled solute of interest had elapsed, the CNS was sampled and prepared for 
liquid scintillation counting as described earlier. 
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2.3.1.3 Octanol-saline partition coefficient 
0.75 mL phosphate buffered saline (pH 7.4) containing 1 µCi (0.037 MBq) of either 
[14C]-sucrose (2.5 µM), [3H]-ADMA (542.8 nM) [3H]-arginine (101.0 nM) was added to 
an Eppendorf centrifuge tube containing 0.75 mL octanol (Sigma Aldrich; Dorset, UK) 
before vortexing for 5 seconds. This was then centrifuged (2634 r.c.f for 5 mins) and 
100 µL samples taken from both the hydrophobic (octanol) phase and hydrophilic 
(saline) phase in triplicate for radioactive scintillation counting. The following equation 
was used to calculate the octanol-saline partition coeffecient of the respective drugs and 
expressed as mean±SEM: 
 
 
mean radioactivity in octanol (dpm/mL)
mean radioactivity in saline (dpm/mL)   [2.6] 
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2.3.2 Statistics 
Data from all experiments are presented as mean ± standard error of the mean (SEM). 
Due to the broad range of experimental design and methods, specific details of 
statistical analyses performed on individual data sets will be presented in the context of 
the data in results chapters. Statistical significance was taken as follows: not significant 
(ns) p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. All statistical analyses were 
performed using GraphPad Prism v5.0c graphing and statistics package for Mac. 
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2.4 Results 
2.4.1 Solute uptake using the in situ brain/choroid plexus perfusion 
method 
2.4.1.1 Sucrose baseline 
Since [14C]-Sucrose can only enter the brain and CSF by simple diffusion it is a useful 
molecule to use as an internal control for BBB and BCSFB integrity in each 
experiment. It can also provide an approximation of cerebrovascular space in brain 
regions, and extracellular space formed between choroid plexus capillary endothelium 
and epithelium, and thus is a measure of variation between animals (Sanderson et al., 
2009). [14C]-Sucrose values for all control experiments in all regions were concurrently 
compared to [14C]-sucrose values for treatment experiments (one-way ANOVA with 
Dunnett's post-hoc test comparing means for each region), and found to be not 
significant in any cases (p > 0.05, example of comparison shown in Figure 2-9). Thus, 
none of the experimental conditions affected vascular space or barrier integrity. 
 
Figure 2-9: Example of the distribution of [14C]-Sucrose in the frontal cortex 
following co-perfusion with either [3H]-arginine alone or [3H]-ADMA alone for 10 
minutes. Each bar represents the mean ± SEM of 4-7 animals. Distribution is expressed 
as the percentage ratio of tissue to plasma (mL.100 g-1). Means ± SEM values were 


















for Arg. expts. for ADMA expts.
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Figure 2-10 shows multiple-time uptake plots for [14C]-sucrose distribution in the eight 
brain regions (frontal cortex, caudate nucleus, occipital cortex, hippocampus, 
hypothalamus, thalamus, pons and cerebellum). As demonstrated in all plots, the 
distribution of [14C]-sucrose in all regions of the brain after perfusion is very low. A 
time-dependent increase in the distribution (% RBrain) of [14C]-sucrose was observed in 
all regions (e.g. 2.34±0.23% after 2.5 minutes to 5.86±0.92% after 30 minutes in the 
frontal cortex), however no regional differences were observed (p > 0.05, two-way 
ANOVA with Tukey's multiple comparison test for each brain region compared to all 
others within each time point). The unidirectional transfer constants (Kin) and initial 
volumes of distribution (Vi) for [14C]-sucrose in these regions were respectively 
determined as the slope and ordinate intercept from the plots in Figure 2-10, and are 
shown in Table 2-14. 
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Figure 2-10: The brain distribution of [14C]-Sucrose as a function of time. 
Distribution is expressed as the percentage ratio of tissue to plasma (mL.100 g-1). Each 
point represents the mean ± SEM of 4-7 animals. Kin and Vi values were determined as 
the slope and ordinate intercept of the computed regression lines where appropriate 
(GraphPad Prism 6.0 for Mac).  
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Figure 2-11 shows multiple-time uptake plots for [14C]-sucrose distribution in capillary 
depletion samples. While a time-dependent increase in sucrose distribution was 
observed in whole-brain homogenate, and its components after separation (brain 
parenchyma-containing supernatant and endothelial cell-enriched pellet), only the 
endothelial cell-enriched pellet was found to significantly differ from the other capillary 
depletion samples, and brain regions sampled (p < 0.01, two-way ANOVA with 
Tukey's multiple comparison test for each brain region compared to all others within 
each time point). The unidirectional transfer constants (Kin) and initial volumes of 
distribution (Vi) for [14C]-sucrose in these regions were respectively determined as the 




Figure 2-11: Distribution of [14C]-Sucrose in capillary depletion samples following in 
situ brain perfusion as a function of time. Uptake is expressed as the percentage ratio 
of tissue to plasma (mL.100 g-1). Each point represents the mean ± SEM of 4-7 animals. 
Kin and Vi values were determined as the slope and ordinate intercept of the computed 
regression lines (GraphPad Prism 6.0 for Mac). 
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Multiple-time uptake plots for [14C]-sucrose distribution in the CSF, pineal gland, 
choroid plexus and pituitary gland are shown in Figure 2-12. Maximum values for 
[14C]-sucrose accumulation in the CSF (10.14±0.11% at 30 minutes) are lower than in 
the pineal gland (38.47±3.12% at 10 minutes), choroid plexus (22.30±3.57% at 30 
minutes) or pituitary gland (21.49±2.31% at 20 minutes). This is expected, as CSF 
accumulation values only represent diffusion through the paracellular pathways of the 
choroid plexus. Since the slope of the linear regression line fitted to the multiple-time 
uptake values for [14C]-sucrose in the pineal gland, choroid plexus and pituitary gland 
did not significantly deviate from zero (p > 0.05), calculation of Kin and Vi by the 
multiple-time uptake method was deemed inappropriate. Kin was therefore calculated 
using the single time point method, and shown in Table 2-15. 
 
Figure 2-12: Distribution of [14C]-Sucrose in the CSF, pineal gland, choroid plexus 
and pituitary gland following in situ brain perfusion as a function of time. 
Distribution is expressed as the %age ratio of tissue or CSF to plasma (mL.100 g-1). Each 
point represents the mean±SEM of 4-7 animals. Kin and Vi values were determined where 
appropriate as the slope and ordinate intercept of computed regression lines (GraphPad 
Prism 6.0 for Mac). 
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Kin values shown in Table 2-14 and Table 2-15 were analysed by one-way ANOVA 
with Tukey’s multiple comparisons test. Samples within the group of eight brain 
regions analysed were not found to be significantly different from each other (p > 0.05). 
Within the group of samples obtained from capillary depletion analysis, only the Kin 
value for whole-brain homogenate was found to be significantly greater than that for 
the capillary-enriched pellet. Within the group of CVO samples, only the Kin value for 
the pineal gland was found to be significantly higher than that for the pituitary gland. 
Vi values shown in Table 2-14 and Table 2-15 were also analysed by one-way 
ANOVA with Tukey’s multiple comparisons test. Samples within the group of eight 
brain regions analysed were not found to be significantly different from each other (p > 
0.05). Within the group of samples obtained from capillary depletion analysis, only the 
Vi value for whole-brain homogenate was found to be significantly greater than that for 
the capillary-enriched pellet. 
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2.4.1.2 Arginine: The NO precursor 
As previously mentioned in section 2.3.1.2E - Radiolabelled solutes of interest, 
the molecular weights of [14C]-sucrose and [3H]-arginine are comparable. Furthermore, 
the two compounds are similarly polar; as octanol saline analysis of [14C]-sucrose and 
[3H]-arginine revealed octanol partition coefficients of 0.00105±0.00022 and 
0.00149±0.00016 respectively. 
Figure 2-13 shows the progressive increase in the distribution (% RBrain) of [3H]-
arginine over time (relative to [14C]-sucrose) in the frontal cortex, caudate nucleus, 
occipital cortex, hippocampus, pons and cerebellum. Uptake of [3H]-arginine is 
significantly greater than [14C]-sucrose in all brain regions, at all time points (multiple 
Student's paired t-tests, p < 0.05 in all cases). 
A time-dependent increase in the distribution of [3H]-arginine (corrected for [14C]-
sucrose) was observed in all regions (e.g. 28.96±4.03% after 2.5 minutes to 
176.78±31.60% after 30 minutes in the frontal cortex, Figure 2-13), however no 
regional differences were observed (p > 0.05, two-way ANOVA with Tukey's multiple 
comparison test for each brain region compared to all others within each time point). 
Figure 2-15 shows a time-dependent increase in the distribution of [3H]-arginine in all 
three capillary depletion samples. No differences in the distribution of [3H]-arginine 
between the homogenate and supernatant (containing brain parenchyma) were 
observed, however both of these samples contained a higher distribution than that 
observed in the endothelial cell-enriched pellet (p < 0.01, two-way ANOVA with 
Tukey's multiple comparison test for each sample compared to all others). 
A similar time-dependent increase in the distribution of [3H]-arginine (un-corrected 
data) was observed in the CSF (4.41±1.41% after 2.5 minutes to 120.44±25.08% after 
30 minutes, Figure 2-16). A comparison of the mean [3H]-arginine distributions 
between the pineal gland, choroid plexus and pituitary gland revealed that a significant 
difference is observed between the pineal gland and pituitary gland, but only after a 30 
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minute perfusion (p < 0.001, two-way ANOVA with Tukey's multiple comparison test 
for each sample compared to all others within each time point). 
 
 
Figure 2-13: The brain distribution of [3H]-arginine and [14C]-sucrose as a function 
of time. Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-1). 
Each point represents the mean ± SEM of 4-7 animals. Kin and Vi values were determined 
as the slope and ordinate intercept of the computed regression lines where appropriate. 
Asterisks represent one-tailed, paired student's t-tests comparing mean±SEM at each 
time point, *p < 0.05, **p < 0.01, ***p < 0.001 (GraphPad Prism 6.0 for Mac). 
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Figure 2-14: The distribution of [3H]-arginine and [14C]-sucrose into the mouse 
hypothalamus and thalamus as a function of time. Uptake is expressed as the 
percentage ratio of tissue to plasma (mL.100 g-1). Each point represents the mean ± 
SEM of 4-7 animals. Kin and Vi values could not be determined as the slope and ordinate 
intercept of the computed regression lines for [3H]-arginine, since the ordinate intercept in 
both analyses were negative, and thus these data points are shown with connecting lines 
(GraphPad Prism 6.0 for Mac). Kin values for [3H]-arginine were therefore calculated 
using the single-time uptake method. Asterisks represent one-tailed, paired student's t-
tests comparing mean±SEM at each time point, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 
A time-dependent increase in the distribution of [3H]-arginine (corrected for [14C]-
sucrose) was observed in both the hypothalamus and thalamus (shown in Figure 
2-14). These brain regions are shown separately from the others, as the RBRAIN values 
for 30-minute perfusions were both so high that linear regression analysis produced 
negative Vi values. Since this is impossible it was not deemed appropriate to analyse 
these samples in the same way. Kin values were therefore calculated using the single-
time uptake method, and shown in Table 2-17.  
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Figure 2-15: Distribution of [3H]-arginine and [14C]-sucrose in capillary depletion 
samples following in situ brain perfusion as a function of time. Uptake is expressed as 
the percentage ratio of tissue to plasma (mL.100 g-1). Each point represents the mean ± 
SEM of 4-7 animals. Kin and Vi values were determined as the slope and ordinate 
intercept of the computed regression lines (GraphPad Prism 6.0 for Mac). Kin and Vi 
values could not be determined as the slope and ordinate intercept of the computed 
regression lines for [3H]-arginine distribution in the supernatant and pellet samples, since 
the ordinate intercept in both analyses were negative, and thus these data points are 
shown with connecting lines (GraphPad Prism 6.0 for Mac). Kin values for [3H]-arginine 
were therefore calculated using the single-time uptake method. Asterisks represent one-
tailed, paired student's t-tests comparing mean±SEM at each time point, *p < 0.05, **p 
< 0.01, ***p < 0.001. 
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Figure 2-16: Distribution of [3H]-arginine and [14C]-sucrose in the CSF, pineal gland, 
choroid plexus and pituitary gland following in situ brain perfusion as a function of 
time. Uptake is expressed as the percentage ratio of tissue or CSF to plasma (mL.100 g-
1). Each point represents the mean ± SEM of 4-7 animals. Kin and Vi values were 
determined as the slope and ordinate intercept of the computed regression lines. Asterisks 
represent one-tailed, paired student's t-tests comparing mean±SEM at each time point, 
*p < 0.05, **p < 0.01, ***p < 0.001 (GraphPad Prism 6.0 for Mac). 
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Kin and Vi values for [3H]-arginine in brain regions were respectively determined as the 
slope and ordinate intercept from the plots shown in Figure 2-13, Figure 2-14, 
Figure 2-15 and Figure 2-16, and are shown in Table 2-16. Linear regression 
analysis on these plots produced R-square (R2) for goodness of fit, and p-values relating 
to the deviation of the line slope from 0. P-values were found to be significant for all 
samples (p < 0.05) except for the pituitary gland, and thus it was deemed 
inappropriate to calculate Kin or Vi using the multiple-time uptake method. 
For all remaining samples, the goodness of fit for the linear regression analysis was 
found within acceptable limits (R2 < 0.4). However, Vi values for [3H]-arginine in the 
all samples except for the occipital cortex and choroid plexus were calculated to be 
negative either outright (e.g. -9.82 ± 37.40 mL.100 g-1 for the pineal gland), or when 
considering SEM (e.g. 10.28 ± 17.37 mL.100 g-1 for the frontal cortex). Negative Vi 
values are of course a technical impossibility, and the values shown in Table 2-16 
more likely represent a limitation of this analysis. However, this fact in itself pulls into 
question the credibility of the Kin values calculated by the same multiple-time uptake 
method. Thus the multiple-time uptake method for calculating Kin for these data was 
deemed inappropriate, and values shown in Table 2-16 are therefore more as a point 
of reference to demonstrate how this conclusion was reached. It was therefore deemed 
more appropriate to calculate the Kin value for these regions using the single-uptake 
method – shown in Table 2-17. 
No significant difference was observed for Kin values for [3H]-arginine between any of 
the brain regions, the CSF, or capillary depletion samples (p > 0.05, one-way ANOVA 
with Dunnett's multiple comparisons test). The Kin values for [3H]-arginine in the 
pineal gland, choroid plexus and pituitary gland were however significantly greater 
than those observed for the brain regions, CSF and capillary depletion samples (p < 
0.01, one-way ANOVA with Dunnett's multiple comparisons test), and were also found 
to be significantly different from each other (p < 0.05, one-way ANOVA with 
Dunnett's multiple comparisons test). 
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Table 2-17: [3H]-Arginine Kin values in all samples, calculated from 10-minute co-
perfusions with [14C]-sucrose (single time point equation). 
 Time point Kin 
(µL.min-1 g-1) 
n 
Frontal cortex 10 minutes 5.8375 ± 0.8632 7 














10 minutes 4.9813 ± 0.7216 7 
Hippocampus 10 minutes 4.7148 ± 0.5615 7 
Hypothalamus 10 minutes 7.2549 ± 1.7620 7 
Thalamus 10 minutes 5.8701 ± 1.0730 7 
Pons 10 minutes 5.5758 ± 0.9683 7 
Cerebellum 10 minutes 5.1004 ± 0.5000 7 
    
Homogenate 10 minutes 3.9714 ± 0.6697 7 
Supernat t 10 minutes 2.3470 ± 0.4174 7 
Pellet 10 minutes 0.6959 ± 0.0990 7 
    
CSF 10 minutes 1.0813 ± 0.2413 5 
Pineal gland 10 minutes 9.5071 ± 2.0215 7 
Choroid plexus 10 minutes 28.8541 ± 4.1542 7 
Pituitary gland 10 minutes 19.9429 ± 3.7577 7 
 
 
The above three groups of samples were analysed using three separate one-way 
ANOVA with Tukey’s post-hoc multiple comparisons tests comparing the Kin values ± 
SEM. No statistically significant differences were found between the eight brain regions 
sampled (p > 0.05). The Kin value for the homogenate sample was found to be 
significantly higher than that for the capillary-enriched pellet sample (p < 0.001). The 
Kin value for the CSF sample was found to be significantly less than those for the 
choroid plexus and pituitary gland (p < 0.001 and 0.01 respectively). The Kin value for 
the choroid plexus was also found to be significantly higher than that for the pineal 
gland (p < 0.01). Kin values were only compared using 10-minute perfusions as these 
were found to be the most reproducible and reliable.  
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2.4.1.3 ADMA: The NOS inhibitor 
The molecular weights of [14C]-sucrose and [3H]-ADMA are also comparable and the 
two compounds are similarly polar; as octanol saline analysis of [14C]-sucrose and [3H]-
ADMA revealed octanol partition coefficients of 0.00105±0.00022 and 0.00226±0.00006 
respectively. 
Figure 2-17 shows the progressive increase in the distribution (% RBrain) of [3H]-
ADMA over time (relative to [14C]-sucrose) in the frontal cortex, caudate nucleus, 
occipital cortex, hippocampus, hypothalamus, thalamus, pons and cerebellum. Uptake 
of [3H]-ADMA is significantly greater than [14C]-sucrose in all brain regions, at all time 
points (multiple Student's paired t-tests, p < 0.05 in all cases). 
A time-dependent increase in the distribution of [3H]-ADMA (corrected for [14C]-
sucrose) was observed in all regions up to 20 minutes (e.g. 9.86±1.43% after 2.5 
minutes to 27.64±4.30% after 20 minutes in the frontal cortex), however this was 
followed by a decrease in the distribution of [3H]-ADMA at 30 minutes in all regions 
(e.g. 10.41±2.77%). No regional differences were observed (p > 0.05, two-way ANOVA 
with Tukey's multiple comparison test for each brain region compared to all others 
within each time point). 
A very similar pattern of a time-dependent peak in the distribution of [3H]-ADMA after 
perfusing for 20 minutes was observed in whole brain homogenate and brain 
parenchyma (supernatant) following capillary depletion (Figure 2-18). By contrast, 
the peak in [3H]-ADMA distribution in the endothelial cell-enriched pellet following 
capillary depletion was observed earlier, after only 10 minutes of perfusion. 
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Figure 2-17: Brain distribution of [3H]-ADMA and [14C]-sucrose as a function of 
time. Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-1). Each 
point represents the mean ± SEM of 5 animals. One-tailed, paired student's t-tests 
comparing mean±SEM at each time point, *p < 0.05, **p < 0.01 (GraphPad Prism 6.0 
for Mac). 
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Figure 2-18: Distribution of [3H]-ADMA and [14C]-sucrose in capillary depletion 
samples as a function of time. Uptake is expressed as the percentage ratio of tissue to 
plasma (mL.100 g-1). Each point represents the mean ± SEM of 5 animals. One-tailed, 
paired student's t-tests comparing mean±SEM at each time point, *p < 0.05, **p < 0.01 
(GraphPad Prism 6.0 for Mac). 
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A similar time-dependent increase and then decrease in the distribution of [3H]-ADMA 
was observed in the pineal gland, choroid plexus and pituitary gland, however 
distribution peaked at 10 minutes (Figure 2-19). The mean [3H]-ADMA distribution 
in the choroid plexus, pineal gland and pituitary gland was not significantly different at 
any time point (uncorrected values, two-way ANOVA with Tukey's multiple 
comparison test for each sample compared to all others within each time point). The 
mean [3H]-ADMA distribution in the CSF was significantly lower than all brain regions 
at all time points (uncorrected values, two-way ANOVA with Tukey's multiple 
comparison test for each sample compared to all others within each time point). 
 
 
Figure 2-19: Distribution of [3H]-ADMA and [14C]-sucrose in the CSF, pineal gland, 
choroid plexus and pituitary gland following in situ brain perfusion as a function of 
time. Uptake is expressed as the percentage ratio of tissue or CSF to plasma (mL.100 g-
1). Each point represents the mean±SEM of 5 animals. One-tailed, paired student's t-
tests comparing mean±SEM at each time point, *p < 0.05, **p < 0.01, ***p < 0.001 
(GraphPad Prism 6.0 for Mac). 
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Kin and Vi values for [3H]-ADMA in brain regions were respectively calculated as the 
slope and ordinate intercept from the plots in Figure 2-17, Figure 2-18 and Figure 
2-19. Linear regression analysis on these plots produced R-square (R2, for goodness of 
fit) and p-values (relating to the deviation of the line slope from 0). No p-values were 
found to be significant for any of the brain regions sampled (p > 0.05) and goodness of 
fit was outside acceptable limits (R2 < 0.4), as shown in Table 2-18. It was therefore 
deemed more appropriate to calculate the Kin value for [3H]-ADMA in all regions using 
the single-uptake method – shown in Table 2-19. 
Kin values calculated using the single-uptake method after 10 minutes of perfusion 
revealed no significant difference between the eight brain regions sampled (one-way 
ANOVA with Dunnett's multiple comparisons of means, p > 0.05). The same analysis 
also revealed that the Kin value for [3H]-ADMA in the CSF was not significantly 
different from any of the eight brain regions sampled. By comparison, Kin values for 
the pineal gland, choroid plexus and pituitary gland were significantly higher than all 
other samples (i.e. brain regions and CSF, one-way ANOVA with Dunnett's multiple 
comparisons of means, p < 0.05), but not significantly different from each other. 
All regional differences observed in Kin for [3H]-ADMA after 10-minute perfusions were 
not observed after a 30-minute perfusion (one-way ANOVA with Tukey's multiple 
comparisons of means, p > 0.05, data not shown). A paired, two-tailed Student's t-test 
comparing Kin values in each region at 10 and 30 minutes revealed that values were 
significantly lower at all time points in animals at the later time points (p < 0.05). 
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Table 2-19: [3H]-ADMA Kin values in all samples, calculated from 10-minute co-
perfusions with [14C]-sucrose (single time point equation). 
 Kin (µL.min-1 g-1) n 
Frontal cortex 2.4944 ± 0.3502 5 














2.2517 ± 0.1652 5 
Hippocampus 2.1742 ± 0.1750 5 
Hypothalamus 3.0424 ± 0.2981 5 
Thalamus 2.1000 ± 0.1742 5 
Pons 2.4639 ± 0.3435 5 
Cerebellum 1.6150 ± 0.1907 5 
   
Homogenate 1.2702 ± 0.5550 5 
Supernat t 0.8620 ± 0.1629 5 
Pellet 0.0783 ± 0.1960 5 
   
CSF 2.6954 ± 0.9020 5 
Pineal gland 19.4057 ± 4.8466 5 
Choroid plexus 26.0860 ± 4.2447 5 
Pituitary gland 18.2856 ± 3.2278 5 
 
 
The above three groups of samples were analysed using three separate one-way 
ANOVA with Tukey’s post-hoc multiple comparisons tests comparing the Kin values ± 
SEM. Among the eight brain regions sampled, the only statistically significant 
difference in the Kin values was between the hypothalamus and cerebellum (p > 0.05). 
The Kin value for the homogenate sample was found to be significantly higher than 
that for the capillary-enriched pellet sample (p < 0.001). The Kin value for the CSF 
sample was found to be significantly less than those for the pineal gland, choroid plexus 
and pituitary gland (p < 0.05, 0.01 and 0.05 respectively).   
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2.4.1.4 Comparative amino acid uptake: Arginine vs. ADMA 
Figure 2-20 shows a comparison between the progressive distributions of [3H]-ADMA 
and [3H]-arginine (and [14C]-sucrose from each experiment) in the eight brain regions 
sampled; plotting results from previous figures (Figure 2-10 and Figure 2-17) on the 
same graph. 
In this section, multiple Student's unpaired, two-tailed t-tests were used for the 
comparison of two means. At the time points of 2.5, 10, 20 and 30 minutes, the uptake 
of [3H]-arginine into all eight brain regions was significantly higher than that of [3H]-
ADMA into the same tissue (p < 0.05). In the case of the CSF, pineal gland, choroid 
plexus and pituitary gland, [3H]-arginine distribution was significantly higher than [3H]-
ADMA at 20 and 30 minute time points (p < 0.05). 
In the whole brain homogenate, and resulting supernatant following capillary depletion, 
[3H]-arginine distribution was significantly higher than [3H]-ADMA at 10-, 20- and 30-
minute time points (p < 0.05). In the endothelial cell-enriched pellet resulting from 
capillary depletion, [3H]-arginine distribution was only significantly higher than [3H]-
ADMA for 20- and 30-minute time points (p < 0.01). 
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Figure 2-20: Comparative uptake of [3H]-arginine, [3H]-ADMA and [14C]-sucrose as 
a function of time. Uptake is expressed as the percentage ratio of tissue to plasma 
(mL.100 g-1). Each point represents the mean ± SEM of 4-7 animals (GraphPad Prism 
6.0 for Mac). 
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Figure 2-21: Distribution of [3H]-arginine, [3H]-ADMA and [14C]-sucrose in capillary 
depletion samples as a function of time. Uptake is expressed as the percentage ratio of 
tissue to plasma (mL.100 g-1). Each point represents the mean ± SEM of 5 animals. Kin 
and Vi values were determined as the slope and ordinate intercept of the computed 
regression lines (GraphPad Prism 6.0 for Mac). 
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Figure 2-22: Comparative distribution of [3H]-arginine, [3H]-ADMA and [14C]-
Sucrose in the CSF, pineal gland, choroid plexus and pituitary gland following in 
situ brain perfusion as a function of time. Uptake is expressed as the percentage ratio 
of tissue or CSF to plasma (mL.100 g-1). Each point represents the mean ± SEM of 4-7 
animals (GraphPad Prism 6.0 for Mac). 
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2.4.2 Self-inhibition 
2.4.2.1 Self-inhibition of Arginine transport 
Figure 2-23 shows the effect of an excess of un-labelled arginine on the uptake of [3H]-
arginine into all brain regions. These data indicate that [3H]-arginine uptake into all 
eight brain regions is markedly self-inhibited by an average of approximately 67% (p < 
0.05, unpaired, one-tailed Student's t-test comparing means, Table 2-20). 
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Figure 2-23: The effect of 100µM un-labelled L-arginine on the uptake of [3H]-
arginine in the brain. Uptake is expressed as the percentage ratio of tissue to plasma 
(mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Perfusion time is 10 
minutes. Each bar represents the mean ± SEM of 6-7 animals (GraphPad Prism 6.0 for 
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Table 2-20: Results obtained from self-inhibition studies for [3H]-arginine. Unpaired, 
one-tailed Student's t-test was used to compare two means, with statistical significance 
taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Frontal cortex      
[3H]-arginine alone 6 54.65 ± 9.21 - -  
+ 100 µM un-labelled arginine 7 - 19.30 ± 2.53 64.7 p < 0.01 
      
Caudate nucleus      
[3H]-arginine alone 6 50.38 ± 6.71 - -  
+ 100 µM un-labelled arginine 7 - 16.52 ± 2.89 67.2 p < 0.001 
      
Occipital cortex      
[3H]-arginine alone 6 45.93 ± 7.19 - -  
+ 100 µM un-labelled arginine 7 - 16.29 ± 2.45 64.5 p < 0.001 
      
Hippocampus      
[3H]-arginine alone 6 44.32 ± 5.74 - -  
+ 100 µM un-labelled arginine 7 - 16.10 ± 2.73 63.7 p < 0.001 
      
Hypothalamus      
[3H]-arginine alone 5 74.29 ± 21.67 - -  
+ 100 µM un-labelled arginine 7 - 27.31 ± 3.94 63.2 p < 0.05 
      
Thalamus      
[3H]-arginine alone 6 58.74 ± 12.70 - -  
+ 100 µM un-labelled arginine 7 - 15.84 ± 4.13 73.0 p < 0.01 
      
Pons      
[3H]-arginine alone 6 50.38 ± 9.53 - -  
+ 100 µM un-labelled arginine 7 - 14.98 ± 3.00 70.3 p < 0.001 
      
Cerebellum      
[3H]-arginine alone 6 47.77 ± 4.52 - -  
+ 100 µM un-labelled arginine 7 - 16.09 ± 2.99 66.3 p < 0.001 
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Figure 2-24 shows the effect of an excess of un-labelled arginine on the distribution of 
[3H]-arginine into capillary depletion samples. These data indicate that [3H]-arginine 
uptake is markedly inhibited by an average of approximately 56% (p < 0.05, unpaired, 
one-tailed Student's t-test comparing means, Table 2-21). 
 
 
Figure 2-24: The effect of 100µM un-labelled L-arginine on the distribution of [3H]-
arginine in capillary depletion samples. Uptake is expressed as the percentage ratio of 
tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). 
Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 6-7 animals 
























































+ 100 µM unlabelled L-arginine
[3H]-Arginine
2. ADMA & L-ARGININE 
- 154 - 
Table 2-21: Results obtained from self-inhibition studies for [3H]-arginine in capillary 
depletion samples. Unpaired, one-tailed Student's t-test was used to compare two 
means, with statistical significance taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Homogenate      
[3H]-arginine alone 6 39.71 ± 7.19 - -  
+ 100 µM un-labelled arginine 7 - 14.83 ± 1.78 62.7 p < 0.01 
      
Supernatant      
[3H]-arginine alone 6 24.70 ± 4.91 - -  
+ 100 µM un-labelled arginine 7 - 10.41 ± 1.54 57.9 p < 0.01 
      
Pellet      
[3H]-arginine alone 6 6.87 ± 1.02 - -  
+ 100 µM un-labelled arginine 6 - 3.64 ± 1.25 47.0 p < 0.05 
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Figure 2-25 shows the effect of an excess of un-labelled arginine on the distribution of 
[3H]-arginine into the CSF, pineal gland, choroid plexus and pituitary gland. These data 
indicate that [3H]-arginine uptake is markedly inhibited by an average of approximately 
52% (p < 0.05, unpaired, one-tailed Student's t-test comparing means, Table 2-22). 
 
 
Figure 2-25: The effect of 100µM un-labelled L-arginine on the distribution of [3H]-
arginine in the CSF, choroid plexus and circumventricular organs. Uptake is expressed 
as the percentage ratio of tissue or CSF to plasma (mL.100 g-1). Perfusion time is 10 
minutes. Each bar represents the mean ± SEM of 6-7 animals (GraphPad Prism 6.0 for 
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Table 2-22: Results obtained from self-inhibition studies for [3H]-arginine in CSF, 
choroid plexus & CVOs. Unpaired, one-tailed Student's t-test was used to compare two 
means, with statistical significance taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
CSF      
[3H]-arginine alone 7 24.51 ± 5.10 - -  
+ 100 µM un-labelled arginine 7 - 9.25 ± 1.78 62.2 p < 0.01 
      
Pineal gland      
[3H]-arginine alone 6 128.0 ± 18.11 - -  
+ 100 µM un-labelled arginine 7 - 77.63 ± 16.85 39.4 p < 0.05 
      
Choroid plexus      
[3H]-arginine alone 6 286.1 ± 33.92 - -  
+ 100 µM un-labelled arginine 7 - 122.1 ± 9.96 57.3 p < 0.001 
      
Pituitary gland      
[3H]-arginine alone 6 194.9 ± 36.90 - -  
+ 100 µM un-labelled arginine 6 - 101.2 ± 20.85 48.1 p < 0.05 
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2.4.2.2 Self-inhibition of ADMA transport 
The uptake of [3H]-ADMA is also significantly self-inhibited by 0.5, 3.0, 10, 100 and 500 
µM un-labelled ADMA in all brain regions (Figure 2-26). Table 2-23 shows the 
percentage inhibition and p values for each concentration of ADMA in each brain 
region. The same phenomenon was observed in capillary depletion samples (Figure 
2-27 and Table 2-24). Distribution of [3H]-ADMA into the CSF was inhibited at all 
concentrations of un-labelled ADMA except for 0.5 µM (Figure 2-28 and Table 
2-25). Distribution of [3H]-ADMA into the pineal gland, choroid plexus and pituitary 
gland was significantly self-inhibited by all concentrations of un-labelled ADMA. 
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Figure 2-26: The effect of 0.5, 3, 10, 100 and 500 µM un-labelled ADMA on the 
uptake of [3H]-ADMA in the brain. Uptake is expressed as the percentage ratio of 
tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). 
Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 5 animals. 
Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests comparing 



















































































































































*** *** * *** ***
[3H]-ADMA + 0.5 µM unlabelled ADMA + 3 µM unlabelled ADMA
+ 10 µM unlabelled ADMA + 100 µM unlabelled ADMA + 500 µM unlabelled ADMA
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Table 2-23: Results obtained from self-inhibition studies for [3H]-ADMA in the 
brain. One-way ANOVA with Dunnett's post-hoc test was used to compare means to 
control ([3H]-ADMA alone), with statistical significance taken as p < 0.05. n = number of 
experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Frontal cortex      
[3H]-ADMA alone 5 24.94 ± 3.50 - -  
+ 0.5 µM un-labelled ADMA 5 - 12.14 ± 1.76 51.3 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 8.32 ± 1.30 66.7 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 11.56 ± 1.65 53.6 p < 0.001 
+ 100 µM un-labelled ADMA 5 - 6.96 ± 1.39 72.1 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 4.91 ± 0.43 80.3 p < 0.001 
      
Caudate nucleus      
[3H]-ADMA alone 5 24.07 ± 2.92 - -  
+ 0.5 µM un-labelled ADMA 5 - 11.05 ± 1.60 54.1 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 7.78 ± 1.22 67.7 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 10.76 ± 0.63 55.3 p < 0.001 
+ 100 µM un-labelled ADMA 4 - 7.071 ± 1.22 70.6 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 3.67 ± 0.39 84.7 p < 0.001 
      
Occipital cortex      
[3H]-ADMA alone 5 22.52 ± 1.65 - -  
+ 0.5 µM un-labelled ADMA 5 - 10.34 ± 1.92 54.1 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 8.16 ± 0.87 63.8 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 11.56 ± 1.77 48.7 p < 0.001 
+ 100 µM un-labelled ADMA 4 - 7.67 ± 0.97 65.9 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 5.26 ± 0.38 76.7 p < 0.001 
      
Hippocampus      
[3H]-ADMA alone 5 21.74 ± 1.75 - -  
+ 0.5 µM un-labelled ADMA 5 - 10.66 ± 1.88 51.0 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 7.32 ± 1.32 66.4 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 12.57 ± 1.37 42.2 p < 0.001 
+ 100 µM un-labelled ADMA 4 - 5.60 ± 1.08 74.3 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 3.70 ± 0.24 83.0 p < 0.001 
      
Hypothalamus      
[3H]-ADMA alone 5 30.42 ± 2.98 - -  
+ 0.5 µM un-labelled ADMA 5 - 16.63 ± 3.69 45.3 p < 0.01 
+ 3.0 µM un-labelled ADMA 5 - 9.23 ± 1.40 69.7 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 17.88 ± 1.24 41.2 p < 0.01 
+ 100 µM un-labelled ADMA 4 - 9.72 ± 2.61 68.0 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 6.09 ± 0.55 80.0 p < 0.001 
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(mL.100g-1) % inhibition p 
Thalamus      
[3H]-ADMA alone 5 21.00 ± 1.74 - -  
+ 0.5 µM un-labelled ADMA 5 - 12.78 ± 2.01 39.1 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 7.55 ± 1.13 64.1 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 13.41 ± 0.67 36.1 p < 0.01 
+ 100 µM un-labelled ADMA 4 - 7.27 ± 1.10 65.4 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 4.92 ± 0.28 76.6 p < 0.001 
      
Pons      
[3H]-ADMA alone 5 24.64 ± 3.44 - -  
+ 0.5 µM un-labelled ADMA 5 - 14.41 ± 1.42 41.5 p < 0.01 
+ 3.0 µM un-labelled ADMA 5 - 10.06 ± 1.94 59.2 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 13.53 ± 1.77 45.1 p < 0.01 
+ 100 µM un-labelled ADMA 4 - 7.24 ± 1.61 70.6 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 4.35 ± 0.33 82.4 p < 0.001 
      
Cerebellum      
[3H]-ADMA alone 5 17.65 ± 1.52 - -  
+ 0.5 µM un-labelled ADMA 5 - 10.79 ± 1.01 38.9 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 8.28 ± 1.04 53.1 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 13.15 ± 1.31 25.5 p < 0.05 
+ 100 µM un-labelled ADMA 4 - 7.01 ± 0.79 60.3 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 5.56 ± 0.41 68.5 p < 0.001 
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Figure 2-27: The effect of 0.5, 3, 10, 100 and 500 µM un-labelled ADMA on the 
distribution of [3H]-ADMA in capillary depletion samples. Uptake is expressed as the 
percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose 
(vascular space). Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 
6-7 animals. Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests 























































*** *** ** *** ***
[3H]-ADMA + 0.5 µM unlabelled ADMA + 3 µM unlabelled ADMA
+ 10 µM unlabelled ADMA + 100 µM unlabelled ADMA + 500 µM unlabelled ADMA
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Table 2-24: Results obtained from self-inhibition studies for [3H]-ADMA in capillary 
depletion samples. One-way ANOVA with Dunnett's post-hoc test was used to compare 
means to control ([3H]-ADMA alone), with statistical significance taken as p < 0.05. n = 
number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Homogenate      
[3H]-ADMA alone 5 22.41 ± 3.81 - -  
+ 0.5 µM un-labelled ADMA 5 - 10.52 ± 1.28 53.1 p < 0.01 
+ 3.0 µM un-labelled ADMA 5 - 8.41 ± 1.80 62.5 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 11.37 ± 1.27 49.3 p < 0.01 
+ 100 µM un-labelled ADMA 4 - 3.96 ± 1.07 82.3 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 3.47 ± 0.32 84.5 p < 0.001 
      
Supernatant      
[3H]-ADMA alone 5 13.81 ± 1.24 - -  
+ 0.5 µM un-labelled ADMA 5 - 7.73 ± 0.877 44.0 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 5.08 ± 1.04 63.2 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 8.79 ± 1.07 36.3 p < 0.01 
+ 100 µM un-labelled ADMA 4 - 3.16 ± 0.679 77.1 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 2.51 ± 0.305 81.8 p < 0.001 
      
Pellet      
[3H]-ADMA alone 5 5.27 ± 1.26 - -  
+ 0.5 µM un-labelled ADMA 5 - 1.23 ± 0.158 76.6 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 0.576 ± 0.108 89.1 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 1.41 ± 0.245 73.3 p < 0.001 
+ 100 µM un-labelled ADMA 4 - 0.251 ± 0.251 95.2 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 0.505 ± 0.077 90.4 p < 0.001 
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Figure 2-28: The effect of 0.5, 3, 10, 100 and 500 µM un-labelled ADMA on the 
distribution of [3H]-ADMA in the CSF and circumventricular organs. Uptake is 
expressed as the percentage ratio of tissue or CSF to plasma (mL.100 g-1). Perfusion time 
is 10 minutes. Each bar represents the mean ± SEM of 5 animals. Asterisks represent 
one-way ANOVA with Dunnett’s post-hoc tests comparing mean±SEM to control, *p < 






































































*** *** *** *** ***
[3H]-ADMA + 0.5 µM unlabelled ADMA + 3 µM unlabelled ADMA
+ 10 µM unlabelled ADMA + 100 µM unlabelled ADMA + 500 µM unlabelled ADMA
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Table 2-25: Results obtained from self-inhibition studies for [3H]-ADMA in CSF, 
choroid plexus and CVOs. One-way ANOVA with Dunnett's post-hoc test was used to 
compare means to control ([3H]-ADMA alone), with statistical significance taken as p < 
0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
CSF      
[3H]-ADMA alone 5 26.95 ± 9.02 - -  
+ 0.5 µM un-labelled ADMA 5 - 10.7 ± 4.05 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 4.77 ± 1.00 82.3 p < 0.05 
+ 10 µM un-labelled ADMA 4 - 7.73 ± 2.13 71.3 p < 0.05 
+ 100 µM un-labelled ADMA 2 - 2.99 ± 0.03 89.1 p < 0.05 
+ 500 µM un-labelled ADMA 4 - 3.06 ± 1.21 88.7 p < 0.05 
      
Pineal gland      
[3H]-ADMA alone 5 194.1 ± 48.47 - -  
+ 0.5 µM un-labelled ADMA 5 - 49.78 ± 11.08 74.4 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 25.01 ± 4.47 87.1 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 39.65 ± 6.00 79.6 p < 0.001 
+ 100 µM un-labelled ADMA 5 - 44.67 ± 19.81 77.0 p < 0.01 
+ 500 µM un-labelled ADMA 5 - 10.92 ± 2.31 94.4 p < 0.001 
      
Choroid plexus      
[3H]-ADMA alone 5 260.9 ± 42.45 - -  
+ 0.5 µM un-labelled ADMA 5 - 83.97 ± 19.11 67.8 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 37.17 ± 11.04 85.8 p < 0.001 
+ 10 µM un-labelled ADMA 4 - 84.74 ± 20.27 67.5 p < 0.001 
+ 100 µM un-labelled ADMA 4 - 45.79 ± 5.56 82.4 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 9.43 ± 2.50 96.4 p < 0.001 
      
Pituitary gland      
[3H]-ADMA alone 5 182.9 ± 32.28 - -  
+ 0.5 µM un-labelled ADMA 5 - 55.42 ± 19.82 69.7 p < 0.001 
+ 3.0 µM un-labelled ADMA 5 - 32.45 ± 7.89 82.3 p < 0.001 
+ 10 µM un-labelled ADMA 5 - 52.02 ± 6.24 71.6 p < 0.001 
+ 100 µM un-labelled ADMA 4 - 58.58 ± 13.38 68.0 p < 0.001 
+ 500 µM un-labelled ADMA 5 - 10.81 ± 0.92 94.1 p < 0.001 
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Figure 2-29: Total brain [3H]-ADMA flux is plotted against unlabelled ADMA 
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Figure 2-30: Total [3H]-ADMA flux in capillary depletion samples is plotted against 
unlabelled ADMA concentration. Measured values are mean±SEM for 4-5 animals at 5 
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Figure 2-31: Total [3H]-ADMA flux in pineal gland, choroid plexus and pituitary 
gland is plotted against unlabelled ADMA concentration. Measured values are 
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Table 2-26 shows the values for Km (half saturation constant) and Vmax (maximal 
transport rate), which were derived using non-linear regression analysis (Enzyme 
kinetics – Michaelis-Menten, GraphPad Prism 6.0 for Mac) of the data shown in 
Figure 2-29, Figure 2-30 and Figure 2-31. 
 





   
Frontal cortex 831.4 ± 479.3 6.534 ± 2.428 
Caudate nucleus 327.9 ± 121.9 3.040 ± 0.511 
Occipital cortex 752.8 ± 321.1 6.583 ± 1.750 
Hippocampus 632.7 ± 241.4 4.192 ± 0.0938 
Hypothalamus 552.2 ± 268.4 6.410 ± 1.735 
Thalamus 706.6 ± 242.9 5.932 ± 1.244 
Pons 478.5 ± 176.1 4.250 ± 0.0824 
Cerebellum 1352 ± 946.0 10.30 ± 5.343 
   
Homogenate 2225 ± 319.9 9.442 ± 1.117 
Supernatant 1249 ± 129.6 4.392 ± 3.312 
Pellet 301.4 ± 25.72 4.045 ± 1.367 
   
Pineal gland 281.0 ± 166.7 9.711 ± 2.336 
Choroid plexus 49.96 ± 17.41 6.455 ± 0.555 
Pituitary gland 51.41 ± 16.42 6.160 ± 0.439 
   
 
 
Km and Vmax values for the three groups of samples shown in Table 2-26 were 
analysed by one-way ANOVA with Tukey’s post-hoc multiple comparisons tests. There 
were no statistically significant differences between the Km values for the eight brain 
regions sampled. The Km values for capillary depletion samples were all significantly 
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different from each other (p < 0.05). Among the CVOs, the Km for the pineal gland 
was found to differ from the Km values for the choroid plexus and pituitary gland (p < 
0.05). 
With regards to Vmax values for ADMA in the eight brain regions sampled, no 
statistically significant differences were found. Similarly among the capillary depletion 
samples and the CVO samples respectively there were no statistically significant 
differences (p > 0.05 in both cases).  
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2.4.3 Cross-competition studies 
Cross-competition studies were broken down into the following (see section 2.3.1.2L 
- Cross-competition experiments): 
i. Specific transport inhibition studies based on known inhibitors of transport 
systems 
ii. Direct competition of ADMA on arginine transport 
iii. Direct competition of arginine on ADMA transport 
iv. Pre-loading/trans-stimulation experiments 
2.4.3.1 Identification of specific transport system 
2.4.3.1A Arginine 
The transport of [3H]-arginine across the blood-brain and blood-CSF barriers was 
examined in the presence of specific transport inhibitors (previously described with the 
transporters they inhibit in Table 2-10). All inhibitors were used at previously 
published concentrations known to maximally inhibit the relevant transport systems. In 
this section, one-way ANOVA with Dunnett's multiple comparisons tests were used to 
compare means to each other within each sample/region. 
The uptake of [3H]-arginine is almost totally inhibited (up to 99.7%, Table 2-27) by 
20 mM L-homoarginine in all brain regions (Figure 2-32, p < 0.001 in all regions 
except thalamus (p < 0.01), and pons and hypothalamus (p < 0.05)). While the 
inclusion of 4 mM BCH in artificial plasma caused slight increases in [3H]-arginine 
uptake, these differences did not attain statistical significance in any of the brain 
regions sampled. Inclusion of 500 µM α-methyl-D,L-tryptophan in artificial plasma 
conversely had a tendency to decrease [3H]-arginine uptake, but only attained statistical 
significance in the hippocampus (47.5% inhibition, Table 2-27). These trends were 
also mirrored in whole brain homogenate, supernatant containing brain parenchyma, 
and endothelial cell-enriched pellets following capillary depletion (Figure 2-33). 
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Figure 2-32: The effect of L-homoarginine, BCH and α-methyl-D,L-tryptophan on 
the regional brain uptake of [3H]-arginine (10 minute perfusion). Uptake is expressed 
as the percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose 
(vascular space). Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 
4-6 animals. Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests 
comparing mean±SEM to control, *p < 0.05, **p < 0.01, ***p < 0.001 (GraphPad 










































































































































[3H]-Arginine + 20 mM L-Homoarginine
+ 4 mM BCH + 500 µM α-methyl-D,L-tryptophan
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Table 2-27: Results obtained from specific transport-inhibition studies for [3H]-
arginine in the brain. One-way ANOVA with Dunnett's post-hoc test was used to 
compare means to control ([3H]-arginine alone), with statistical significance taken as p < 
0.05. n = number of experiments. All values corrected for [14C]-sucrose vascular space. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
Frontal cortex      
[3H]-arginine alone 6 54.65 ± 9.12 - -  
+ 20 mM L-homoarginine 5 - 0.46 ± 0.25 99.2 p < 0.001 
+ 4 mM BCH 5 - 82.36 ± 8.99 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 31.16 ± 11.2 - n.s. 
      
Caudate nucleus      
[3H]-arginine alone 6 50.38 ± 6.71 - -  
+ 20 mM L-homoarginine 5 - 0.13 ± 0.07 99.7 p < 0.001 
+ 4 mM BCH 5 - 68.57 ± 9.24 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 24.47 ± 8.11 - n.s. 
      
Occipital cortex      
[3H]-arginine alone 6 45.93 ± 7.19 - -  
+ 20 mM L-homoarginine 5 - 0.30 ± 0.11 99.4 p < 0.001 
+ 4 mM BCH 5 - 63.57 ± 5.83 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 37.83 ± 11.8 - n.s. 
      
Hippocampus      
[3H]-arginine alone 6 44.32 ± 5.74 - -  
+ 20 mM L-homoarginine 5 - 0.18 ± 0.11 99.6 p < 0.001 
+ 4 mM BCH 5 - 57.92 ± 5.88 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 23.32 ± 5.71 47.5 p < 0.05 
      
Hypothalamus      
[3H]-arginine alone 6 66.20 ± 19.5 - -  
+ 20 mM L-homoarginine 4 - 1.31 ± 0.56  98.0 p < 0.05 
+ 4 mM BCH 5 - 87.83 ± 14.3 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 50.19 ± 16.0 - n.s. 
      
Thalamus      
[3H]-arginine alone 6 58.74 ± 12.7 - -  
+ 20 mM L-homoarginine 5 - 0.53 ± 0.35 99.1 p < 0.01 
+ 4 mM BCH 5 - 87.90 ± 16.0 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 36.34 ± 8.20 - n.s. 
      
Pons      
[3H]-arginine alone 6 50.38 ± 9.53 - -  
+ 20 mM L-homoarginine 5 - 1.91 ± 1.11 96.2 p < 0.05 
+ 4 mM BCH 5 - 70.09 ± 20.2 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 65.60 ± 24.3 - n.s. 
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Table 2-27 continued… 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
Cerebellum      
[3H]-arginine alone 6 47.77 ± 4.52 -   
+ 20 mM L-homoarginine 5 - 0.4411 ± 0.14 99.1 p < 0.001 
+ 4 mM BCH 5 - 65.84 ± 4.77 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 31.45 ± 11.4 - n.s. 
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Figure 2-33: The effect of L-homoarginine, BCH and α-methyl-D,L-tryptophan on 
the distribution of [3H]-arginine in capillary depletion samples (10 minute perfusion). 
Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-1) and is 
corrected for [14C]-sucrose (vascular space). Perfusion time is 10 minutes. Each bar 
represents the mean ± SEM of 4-6 animals. Asterisks represent one-way ANOVA with 
Dunnett’s post-hoc tests comparing mean±SEM to control, **p < 0.01 (GraphPad Prism 






















































[3H]-Arginine + 20 mM L-Homoarginine
+ 4 mM BCH + 500 µM α-methyl-D,L-tryptophan
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Table 2-28: Results obtained from specific transport-inhibition studies for [3H]-
arginine in capillary depletion samples. One-way ANOVA with Dunnett's post-hoc test 
was used to compare means to control ([3H]-arginine alone), with statistical significance 
taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
Homogenate      
[3H]-arginine alone 6 39.71 ± 7.19 - -  
+ 20 mM L-homoarginine 5 - 2.80 ± 0.47 93.0 p < 0.01 
+ 4 mM BCH 5 - 44.13 ± 5.30 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 40.66 ± 10.57 - n.s. 
      
Supernatant      
[3H]-arginine alone 6 24.7 ± 4.91 - -  
+ 20 mM L-homoarginine 5 - 1.75 ± 0.14 92.9 p < 0.01 
+ 4 mM BCH 5 - 25.71 ± 4.14 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 19.3 ± 6.16 - n.s. 
      
Pellet      
[3H]-arginine alone 6 6.871 ± 1.02 - -  
+ 20 mM L-homoarginine 5 - 0.58 ± 0.20 91.5 p < 0.01 
+ 4 mM BCH 5 - 9.16 ± 1.68 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 3.18 ± 3.10 - n.s. 
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Figure 2-34: The effect of L-homoarginine, BCH and α-methyl-D,L-tryptophan on 
the distribution of [3H]-arginine in CSF, choroid plexus and CVOs (10 minute 
perfusion). Uptake is expressed as the percentage ratio of tissue or CSF to plasma 
(mL.100 g-1). Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 4-6 
animals. Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests comparing 




The distribution of [3H]-arginine in the pineal gland, choroid plexus and pituitary gland 
was significantly inhibited by 20 mM L-homoarginine, (Figure 2-34 and Table 2-29, 
p < 0.05), however no effect was observed in the CSF (p > 0.05). In line with 
observations in all other samples, the inclusion of either 4 mM BCH or 500 µM α-
methyl-D,L-tryptophan in artificial plasma had no statistically significant effect on the 






































































[3H]-Arginine + 20 mM L-Homoarginine
+ 4 mM BCH + 500 µM α-methyl-D,L-tryptophan
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Table 2-29: Results obtained from specific transport-inhibition studies for [3H]-
arginine in the CSF, choroid plexus and CVOs. One-way ANOVA with Dunnett's post-
hoc test was used to compare means to control ([3H]-arginine alone), with statistical 
significance taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
CSF      
[3H]-arginine alone 6 24.51 ± 5.01 - -  
+ 20 mM L-homoarginine 5 - 15.09 ± 2.95 - n.s. 
+ 4 mM BCH 5 - 35.16 ± 8.34 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 21.93 ± 0.05 - n.s. 
      
Pineal gland      
[3H]-arginine alone 6 128.0 ± 18.11 - -  
+ 20 mM L-homoarginine 5 - 56.07 ± 7.45 56.2 p < 0.05 
+ 4 mM BCH 5 - 141.3 ± 20.9 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 94.54 ± 0.31 - n.s. 
      
Choroid plexus      
[3H]-arginine alone 6 286.1 ± 33.92 - -  
+ 20 mM L-homoarginine 5 - 17.00 ± 3.34 94.1 p < 0.001 
+ 4 mM BCH 5 - 278.8 ± 28.8 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 217.8 ± 29.6 - n.s. 
      
Pituitary gland      
[3H]-arginine alone 6 194.9 ± 36.9 - -  
+ 20 mM L-homoarginine 5 - 16.21 ± 5.45 91.7 p < 0.001 
+ 4 mM BCH 5 - 256.7 ± 39.6 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 110.5 ± 18.3 - n.s. 
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2.4.3.1B ADMA 
The transport of [3H]-ADMA across the blood-brain and blood-CSF barriers was also 
examined in the presence of specific transport inhibitors (previously described with the 
transporters they inhibit in Table 2-10). All inhibitors were used at previously 
published concentrations known to maximally inhibit the relevant transport systems. In 
this section, one-way ANOVA with Dunnett's multiple comparisons tests were used to 
compare means to each other within each sample/region. 
The uptake of [3H]-ADMA is almost totally inhibited by 20 mM L-homoarginine in all 
brain regions (Figure 2-35 and Table 2-30, p < 0.001). Meanwhile, the inclusion of 
either 4 mM BCH, 500 µM α-methyl-D,L-tryptophan, 200 µM L-phenylalanine, 5 mM 
L-leucine, or 2 mM harmaline in artificial plasma also appeared to inhibit [3H]-ADMA 
uptake in brain regions, but to a much lesser degree, and only attaining statistical 
significance in some regions (Figure 2-35 and Table 2-30).  
L-homoarginine also inhibited uptake of [3H]-ADMA in whole brain homogenate and 
brain parenchyma (supernatant) following capillary depletion (Figure 2-36 and Table 
2-31, p < 0.05). L-phenylalanine and L-leucine inhibited [3H]-ADMA in whole brain 
homogenate, but not brain parenchyma (supernatant) following capillary depletion 
(Table 2-31, p < 0.05). None of the inhibitors inhibited uptake in the endothelial cell-
enriched pellet (Figure 2-36 and Table 2-31). 
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Figure 2-35: The effect of L-homoarginine, BCH, α-methyl-D,L-tryptophan, L-
phenylalanine, L-leucine and harmaline on the regional brain uptake of [3H]-ADMA 
(10 minute perfusion). Uptake is expressed as the percentage ratio of tissue to plasma 
(mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Perfusion time is 10 
minutes. Each bar represents the mean ± SEM of 4-5 animals. Asterisks represent one-
way ANOVA with Dunnett’s post-hoc tests comparing mean±SEM to control, *p < 0.05, 



























































































































































[3H]-ADMA + 20 mM L-Homoarginine + 4 mM BCH
+ 500 µM α-methyl-D,L-tryptophan + 200 µM L-phenylalanine + 5 mM L-leucine
+ 2 mM Harmaline
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Table 2-30: Results obtained from specific transport-inhibition studies for [3H]-
ADMA in the brain. One-way ANOVA with Dunnett's post-hoc test was used to 
compare means to control ([3H]-ADMA alone), with statistical significance taken as p < 
0.05. n = number of experiments. 
 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
Frontal cortex      
[3H]-ADMA alone 5 24.94 ± 3.50 -   
+ 20 mM L-homoarginine 5 - 1.06 ± 1.02 95.7 p < 0.001 
+ 4 mM BCH 5 - 15.45 ± 1.98 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 5 - 12.97 ± 3.94 48.0 p < 0.05 
+ 200 µM L-phenylalanine 5 - 10.8 ± 1.35 56.7 p < 0.01 
+ 5 mM L-leucine 5 - 8.785 ± 1.56 64.8 p < 0.001 
+ 2 mM Harmaline 5 - 13.68 ± 2.95 45.1 p < 0.05 
      
Caudate nucleus      
[3H]-ADMA alone 5 24.07 ± 2.92 -   
+ 20 mM L-homoarginine 5 - 0.18 ± 0.13 99.2 p < 0.001 
+ 4 mM BCH 5 - 15.04 ± 2.31 37.5 p < 0.05 
+ 500 µM α-methyl-D,L-tryptophan 5 - 12.24 ± 3.14 49.1 p < 0.01 
+ 200 µM L-phenylalanine 5 - 9.39 ± 0.96 61.0 p < 0.001 
+ 5 mM L-leucine 5 - 7.38 ± 0.99 69.3 p < 0.001 
+ 2 mM Harmaline 5 - 11.94 ± 2.51 50.4 p < 0.01 
      
Occipital cortex      
[3H]-ADMA alone 5 22.52 ± 1.65 -   
+ 20 mM L-homoarginine 5 - 0.49 ± 0.40 97.8 p < 0.001 
+ 4 mM BCH 5 - 14.82 ± 2.41 34.2 p < 0.05 
+ 500 µM α-methyl-D,L-tryptophan 5 - 12.28 ± 2.41 45.5 p < 0.001 
+ 200 µM L-phenylalanine 5 - 8.86 ± 0.59 60.7 p < 0.001 
+ 5 mM L-leucine 5 - 6.69 ± 1.50 70.3 p < 0.001 
+ 2 mM Harmaline 5 - 10.65 ± 1.49 52.7 p < 0.001 
      
Hippocampus      
[3H]-ADMA alone 5 21.74 ± 1.75 -   
+ 20 mM L-homoarginine 5 - 0.20 ± 0.13 99.1 p < 0.001 
+ 4 mM BCH 5 - 13.79 ± 2.21 36.6 p < 0.05 
+ 500 µM α-methyl-D,L-tryptophan 5 - 14.17 ± 3.69 - n.s. 
+ 200 µM L-phenylalanine 5 - 10.05 ± 1.32 53.8 p < 0.01 
+ 5 mM L-leucine 5 - 7.45 ± 1.24 65.7 p < 0.001 
+ 2 mM Harmaline 5 - 11.45 ± 1.97 47.3 p < 0.01 
      
Hypothalamus      
[3H]-ADMA alone 5 30.42 ± 2.98 -   
+ 20 mM L-homoarginine 5 - 1.54 ± 1.12 94.9 p < 0.001 
+ 4 mM BCH 4 - 19.23 ± 2.51 36.8 p < 0.05 
+ 500 µM α-methyl-D,L-tryptophan 3 - 19.34 ± 6.28 - n.s. 
+ 200 µM L-phenylalanine 5 - 12.38 ± 0.89 59.3 p < 0.001 
+ 5 mM L-leucine 5 - 15.81 ± 1.84 48.0 p < 0.01 
+ 2 mM Harmaline 5 - 18.56 ± 2.79 39.0 p < 0.05 
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Thalamus      
[3H]-ADMA alone 5 21.09 ± 1.74 -   
+ 20 mM L-homoarginine 5 - 1.81 ± 0.71 91.4 p < 0.001 
+ 4 mM BCH 5 - 15.82 ± 2.69 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 17.12 ± 6.91 - n.s. 
+ 200 µM L-phenylalanine 5 - 10.54 ± 0.65 49.8 p < 0.05 
+ 5 mM L-leucine 5 - 10.31 ± 1.06 50.9 p < 0.05 
+ 2 mM Harmaline 5 - 13.29 ± 2.03 36.7 n.s. 
      
Pons      
[3H]-ADMA alone 5 24.64 ± 3.44 -   
+ 20 mM L-homoarginine 5 - 2.36 ± 1.06 90.4 p < 0.001 
+ 4 mM BCH 5 - 19.44 ± 2.80 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 20.83 ± 9.92 - n.s. 
+ 200 µM L-phenylalanine 5 - 11.71 ± 1.35 - n.s. 
+ 5 mM L-leucine 5 - 11.38 ± 1.67 - n.s. 
+ 2 mM Harmaline 5 - 11.57 ± 1.29 - n.s. 
      
Cerebellum      
[3H]-ADMA alone 4 17.65 ± 1.52 -   
+ 20 mM L-homoarginine 5 - 0.37 ± 0.19 97.9 p < 0.001 
+ 4 mM BCH 5 - 14.29 ± 1.56 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 5 - 13.55 ± 3.09 - n.s. 
+ 200 µM L-phenylalanine 5 - 9.84 ± 1.27 44.3 p < 0.05 
+ 5 mM L-leucine 5 - 8.66 ± 1.07 51.0 p < 0.05 
+ 2 mM Harmaline 5 - 12.02 ± 2.52 - n.s. 
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Figure 2-36: The effect of L-homoarginine, BCH, α-methyl-D,L-tryptophan, L-
phenylalanine, L-leucine and harmaline on the distribution of [3H]-ADMA in 
capillary depletion samples (10 minute perfusion). Uptake is expressed as the 
percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose 
(vascular space). Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 
4-5 animals. Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests 
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Table 2-31: Results obtained from specific transport-inhibition studies for [3H]-
ADMA in capillary depletion samples. One-way ANOVA with Dunnett's post-hoc test 
was used to compare means to control ([3H]-ADMA alone), with statistical significance 
taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
Homogenate      
[3H]-ADMA alone 5 22.41 ± 3.81 -   
+ 20 mM L-homoarginine 5 - 8.00 ± 3.74 64.3 p < 0.001 
+ 4 mM BCH 5 - 14.71 ± 1.46 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 14.57 ± 4.58 - n.s. 
+ 200 µM L-phenylalanine 5 - 9.48 ± 0.90 57.7 p < 0.05 
+ 5 mM L-leucine 5 - 10.15 ± 1.25 54.7 p < 0.05 
+ 2 mM Harmaline 5 - 14.49 ± 2.33 - n.s. 
      
Supernatant      
[3H]-ADMA alone 5 13.81 ± 1.24 -   
+ 20 mM L-homoarginine 5 - 5.96 ± 2.11 56.9 p < 0.05 
+ 4 mM BCH 5 - 10.31 ± 1.39 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 5 - 10.88 ± 2.59 - n.s. 
+ 200 µM L-phenylalanine 5 - 7.41 ± 0.86 - n.s. 
+ 5 mM L-leucine 4 - 9.60 ± 0.86 - n.s. 
+ 2 mM Harmaline 5 - 11.28 ± 1.96 - n.s. 
      
Pellet      
[3H]-ADMA alone 5 5.27 ± 1.26 -   
+ 20 mM L-homoarginine 5 - 4.03 ± 1.53 - n.s. 
+ 4 mM BCH 5 - 2.38 ± 0.48 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 5 - 2.39 ± 0.99 - n.s. 
+ 200 µM L-phenylalanine 5 - 1.98 ± 0.40 - n.s. 
+ 5 mM L-leucine 4 - 2.53 ± 0.19 - n.s. 
+ 2 mM Harmaline 5 - 2.07 ± 0.32 - n.s. 
      
 
  
2. ADMA & L-ARGININE 
- 184 - 
 
Figure 2-37: The effect of L-homoarginine, BCH, α-methyl-D,L-tryptophan, L-
phenylalanine, L-leucine and harmaline on the distribution of [3H]-ADMA in CSF, 
choroid plexus and CVOs (10 minute perfusion). Uptake is expressed as the 
percentage ratio of tissue or CSF to plasma (mL.100 g-1). Perfusion time is 10 minutes. 
Each bar represents the mean ± SEM of 4-5 animals. Asterisks represent one-way 
ANOVA with Dunnett’s post-hoc tests comparing mean±SEM to control, *p < 0.05, **p 
< 0.01, ***p < 0.001 (GraphPad Prism 6.0 for Mac). 
 
 
None of the inhibitors affected the distribution of [3H]-ADMA in CSF (Figure 2-37). 
All inhibitors inhibited the distribution of [3H]-ADMA in the pineal gland and choroid 
plexus (Figure 2-37 and Table 2-32, p < 0.05). The distribution of [3H]-ADMA in 
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Table 2-32: Results obtained from specific transport-inhibition studies for [3H]-
ADMA in the CSF, choroid plexus and CVOs. One-way ANOVA with Dunnett's post-
hoc test was used to compare means to control ([3H]-ADMA alone), with statistical 
significance taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
CSF      
[3H]-ADMA alone 5 27.26 ± 8.69 -   
+ 20 mM L-homoarginine 5 - 15.44 ± 6.47 - n.s. 
+ 4 mM BCH 5 - 8.45 ± 2.36 - n.s. 
+ 500 µM α-methyl-D,L-tryptophan 4 - 14.60 ± 14.53 - n.s. 
+ 200 µM L-phenylalanine 4 - 16.51 ± 6.79 - n.s. 
+ 5 mM L-leucine 5 - 24.54 ± 2.48 - n.s. 
+ 2 mM Harmaline 5 - 15.18 ± 1.341 - n.s. 
      
Pineal gland      
[3H]-ADMA alone 4 288.7 ± 67.54 -   
+ 20 mM L-homoarginine 5 - 57.42 ± 12.34 80.1 p < 0.001 
+ 4 mM BCH 5 - 92.29 ± 23.82 68.0 p < 0.01 
+ 500 µM α-methyl-D,L-tryptophan 4 - 54.40 ± 23.25 81.2 p < 0.01 
+ 200 µM L-phenylalanine 5 - 83.42 ± 36.06 71.1 p < 0.001 
+ 5 mM L-leucine 5 - 66.28 ± 6.28 77.0 p < 0.001 
+ 2 mM Harmaline 4 - 72.20 ± 18.18 75.0 p < 0.001 
      
Choroid plexus      
[3H]-ADMA alone 5 288.1 ± 47.73 -   
+ 20 mM L-homoarginine 5 - 56.01 ± 22.01 80.6 p < 0.001 
+ 4 mM BCH 5 - 146.8 ± 25.52 49.0 p < 0.01 
+ 500 µM α-methyl-D,L-tryptophan 4 - 138.2 ± 56.18 52.0 p < 0.05 
+ 200 µM L-phenylalanine 5 - 98.36 ± 19.53 65.9 p < 0.001 
+ 5 mM L-leucine 5 - 90.75 ± 5.89 68.5 p < 0.001 
+ 2 mM Harmaline 4 - 109.8 ± 25.53 61.9 p < 0.01 
      
Pituitary gland      
[3H]-ADMA alone 5 198.2 ± 31.93 -   
+ 20 mM L-homoarginine 5 - 22.61 ± 2.81 88.6 p < 0.001 
+ 4 mM BCH 5 - 83.80 ± 12.44 57.7 p < 0.001 
+ 500 µM α-methyl-D,L-tryptophan 4 - 118.4 ± 40.81 - n.s. 
+ 200 µM L-phenylalanine 5 - 45.22 ± 8.45 77.2 p < 0.001 
+ 5 mM L-leucine 5 - 73.04 ± 18.77 63.1 p < 0.001 
+ 2 mM Harmaline 5 - 64.27 ± 1.78 67.6 p < 0.001 
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2.4.3.2 Effect of ADMA on L-arginine transport 
In order to determine the effect of ADMA on the transport of L-arginine across the 
blood-brain and blood-CSF barriers, [3H]-arginine was co-perfused with escalating 
concentrations of un-labelled ADMA. Concentrations of ADMA were specifically 
selected to mimic plasma concentrations under normal conditions (0.5 µM), 
pathophysiological conditions (3.0 µM), and then supraphysiological concentrations (10, 
100 and 500 µM); see section 2.3.1.2L - Cross-competition experiments 
(Direct competition between ADMA & L-arginine). 
Figure 2-38 shows the effect of an excess of unlabelled ADMA on the uptake of [3H]-
arginine into all brain regions. These data indicate that [3H]-arginine uptake is only 
inhibited by 500 µM unlabelled ADMA by an average of approximately 70% (Table 
2-33, one-way ANOVA with Dunnett's post-hoc test comparing means to control, p < 
0.05). Capillary depletion analysis of remaining whole brain tissue revealed that 
distribution of [3H]-arginine in only the whole brain homogenate and resulting 
supernatant (brain parenchyma) was inhibited by 500 µM unlabelled ADMA by 65.1% 
and 72.0%, respectively (Figure 2-39 and Table 2-34, p < 0.05). 
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Figure 2-38: The effect of unlabelled ADMA on the regional brain uptake of [3H]-
arginine (10 minute perfusion). Uptake is expressed as the percentage ratio of tissue to 
plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Perfusion time is 
10 minutes. Each bar represents the mean ± SEM of 4-7 animals. Asterisks represent 
one-way ANOVA with Dunnett’s post-hoc tests comparing mean±SEM to control, *p < 
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Table 2-33: Results obtained from cross-competition studies for [3H]-arginine and 
un-labelled ADMA in the brain. One-way ANOVA with Dunnett's post-hoc test was 
used to compare means to control ([3H]-ADMA alone), with statistical significance taken 
as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Frontal cortex      
[3H]-arginine alone 7 53.21 ± 7.92 -   
+ 0.5 µM un-labelled ADMA 5 - 58.20 ± 11.79 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 43.57 ± 7.75 - n.s. 
+ 10 µM un-labelled ADMA 4 - 54.48 ± 13.07 - n.s. 
+ 100 µM un-labelled ADMA 5 - 52.10 ± 3.45 - n.s. 
+ 500 µM un-labelled ADMA 4 - 16.61 ± 1.33 68.8 p < 0.05 
      
Caudate nucleus      
[3H]-arginine alone 7 48.85 ± 5.87 -   
+ 0.5 µM un-labelled ADMA 5 - 56.13 ± 13.66 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 33.18 ± 5.81 - n.s. 
+ 10 µM un-labelled ADMA 4 - 47.53 ± 11.24 - n.s. 
+ 100 µM un-labelled ADMA 5 - 45.84 ± 3.67 - n.s. 
+ 500 µM un-labelled ADMA 4 - 13.98 ± 1.36 71.4 p < 0.05 
      
Occipital cortex      
[3H]-arginine alone 7 46.20 ± 6.09 -   
+ 0.5 µM un-labelled ADMA 5 - 49.74 ± 9.69 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 39.06 ± 6.48 - n.s. 
+ 10 µM un-labelled ADMA 4 - 42.77 ± 5.88 - n.s. 
+ 100 µM un-labelled ADMA 5 - 43.43 ± 2.22 - n.s. 
+ 500 µM un-labelled ADMA 4 - 15.79 ± 1.39 65.8 p < 0.01 
      
Hippocampus      
[3H]-arginine alone 7 44.13 ± 4.85 -   
+ 0.5 µM un-labelled ADMA 5 - 53.32 ± 10.27 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 39.66 ± 9.53 - n.s. 
+ 10 µM un-labelled ADMA 4 - 44.99 ± 7.51 - n.s. 
+ 100 µM un-labelled ADMA 5 - 44.46 ± 2.53 - n.s. 
+ 500 µM un-labelled ADMA 4 - 14.04 ± 0.95 68.2 p < 0.05 
      
Hypothalamus      
[3H]-arginine alone 7 84.99 ± 24.32 -   
+ 0.5 µM un-labelled ADMA 5 - 94.63 ± 21.58 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 55.98 ± 5.30 - n.s. 
+ 10 µM un-labelled ADMA 4 - 79.37 ± 20.00 - n.s. 
+ 100 µM un-labelled ADMA 5 - 55.70 ± 5.46 - n.s. 
+ 500 µM un-labelled ADMA 4 - 22.26 ± 3.43 73.8 p < 0.05 
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(mL.100g-1) % inhibition p 
Thalamus      
[3H]-arginine alone 7 57.62 ± 10.79 -   
+ 0.5 µM un-labelled ADMA 5 - 52.52 ± 9.79 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 39.20 ± 7.60 - n.s. 
+ 10 µM un-labelled ADMA 4 - 53.25 ± 10.14 - n.s. 
+ 100 µM un-labelled ADMA 5 - 52.89 ± 4.77 - n.s. 
+ 500 µM un-labelled ADMA 4 - 19.79 ± 3.66 65.7 p < 0.05 
      
Pons      
[3H]-arginine alone 7 55.14 ± 9.35 -   
+ 0.5 µM un-labelled ADMA 5 - 64.64 ± 12.04 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 52.20 ± 14.12 - n.s. 
+ 10 µM un-labelled ADMA 4 - 62.40 ± 20.13 - n.s. 
+ 100 µM un-labelled ADMA 5 - 54.23 ± 8.06 - n.s. 
+ 500 µM un-labelled ADMA 4 - 14.03 ± 1.39 74.6 p < 0.05 
      
Cerebellum      
[3H]-arginine alone 7 49.58 ± 4.22 -   
+ 0.5 µM un-labelled ADMA 5 - 54.26 ± 10.09 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 38.99 ± 7.67 - n.s. 
+ 10 µM un-labelled ADMA 4 - 51.31 ± 12.62 - n.s. 
+ 100 µM un-labelled ADMA 5 - 41.96 ± 4.64 - n.s. 
+ 500 µM un-labelled ADMA 4 - 15.41 ± 1.022 68.9 p < 0.05 
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Figure 2-39: The effect of unlabelled ADMA on the distribution of [3H]-arginine in 
capillary depletion samples (10 minute perfusion). Uptake is expressed as the 
percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose 
(vascular space). Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 
4-7 animals. Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests 
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Table 2-34: Results obtained from cross-competition studies for [3H]-arginine and 
unlabelled ADMA in capillary depletion samples. One-way ANOVA with Dunnett's 
post-hoc test was used to compare means to control ([3H]-arginine alone), with statistical 
significance taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
Homogenate      
[3H]-arginine alone 6 39.71 ± 7.19 -   
+ 0.5 µM un-labelled ADMA 5 - 40.11 ± 10.81 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 27.95 ± 5.24 - n.s. 
+ 10 µM un-labelled ADMA 4 - 42.20 ± 9.68 - n.s. 
+ 100 µM un-labelled ADMA 5 - 35.96 ± 1.79 - n.s. 
+ 500 µM un-labelled ADMA 4 - 13.85 ± 0.64 65.1 p < 0.05 
      
Supernatant      
[3H]-arginine alone 6 24.70 ± 4.91 -   
+ 0.5 µM un-labelled ADMA 5 - 24.80 ± 5.66 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 16.83 ± 2.92 - n.s. 
+ 10 µM un-labelled ADMA 4 - 22.99 ± 4.68 - n.s. 
+ 100 µM un-labelled ADMA 5 - 22.29 ± 0.94 - n.s. 
+ 500 µM un-labelled ADMA 4 - 6.92 ± 0.32 72.0 p < 0.05 
      
Pellet      
[3H]-arginine alone 6 6.87 ± 1.02 -   
+ 0.5 µM un-labelled ADMA 5 - 6.17 ± 1.81 - n.s. 
+ 3.0 µM un-labelled ADMA 5 - 4.40 ± 0.81 - n.s. 
+ 10 µM un-labelled ADMA 4 - 7.24 ± 1.95 - n.s. 
+ 100 µM un-labelled ADMA 5 - 6.39 ± 1.14 - n.s. 
+ 500 µM un-labelled ADMA 4 - 2.47 ± 0.87 - n.s. 
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Figure 2-40: The effect of unlabelled ADMA on the distribution of [3H]-arginine in 
CSF, choroid plexus and CVOs (10 minute perfusion). Uptake is expressed as the 
percentage ratio of tissue or CSF to plasma (mL.100 g-1). Perfusion time is 10 minutes. 
Each bar represents the mean ± SEM of 4-7 animals. Asterisks represent one-way 
ANOVA with Dunnett’s post-hoc tests comparing mean±SEM to control, **p < 0.01 
(GraphPad Prism 6.0 for Mac). 
 
Distribution of [3H]-arginine in the CSF, pineal gland and pituitary gland was not 
affected by any of the concentrations of unlabelled ADMA included in artificial plasma 
(Figure 2-40). However, 500 µM unlabelled ADMA inhibited the distribution of [3H]-
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Table 2-35: Results obtained from cross-competition studies for [3H]-arginine and 
unlabelled ADMA in the CSF, choroid plexus and CVOs. One-way ANOVA with 
Dunnett's post-hoc test was used to compare means to control ([3H]-arginine alone), with 
statistical significance taken as p < 0.05. n = number of experiments. 
Tissue n RBRAIN (mL.100g-1) 
% 
inhibition p 
CSF      
[3H]-arginine alone 7 24.51 ± 5.10    
+ 0.5 µM un-labelled ADMA 5  31.47 ± 9.16 - n.s. 
+ 3.0 µM un-labelled ADMA 4  14.68 ± 1.74 - n.s. 
+ 10 µM un-labelled ADMA 5  35.63 ± 8.98 - n.s. 
+ 100 µM un-labelled ADMA 5  22.8 ± 3.44 - n.s. 
+ 500 µM un-labelled ADMA 4  19.75 ± 6.47 - n.s. 
      
Pineal gland      
[3H]-arginine alone 6 128.0 ± 18.11    
+ 0.5 µM un-labelled ADMA 4  127.3 ± 22.82 - n.s. 
+ 3.0 µM un-labelled ADMA 5  108.6 ± 19.69 - n.s. 
+ 10 µM un-labelled ADMA 4  137.4 ± 25.97 - n.s. 
+ 100 µM un-labelled ADMA 4  168.6 ± 4.32 - n.s. 
+ 500 µM un-labelled ADMA 4  109.8 ± 20.36 - n.s. 
      
Choroid plexus      
[3H]-arginine alone 6 286.1 ± 33.92    
+ 0.5 µM un-labelled ADMA 5  180.6 ± 26.14 - n.s. 
+ 3.0 µM un-labelled ADMA 4  155.1 ± 38.01 - n.s. 
+ 10 µM un-labelled ADMA 5  205.5 ± 33.67 - n.s. 
+ 100 µM un-labelled ADMA 5  227.7 ± 36.44 - n.s. 
+ 500 µM un-labelled ADMA 4  78.39 ± 8.84 72.6 p < 0.01 
      
Pituitary gland      
[3H]-arginine alone 7 194.9 ± 36.90    
+ 0.5 µM un-labelled ADMA 5  215.5 ± 49.53 - n.s. 
+ 3.0 µM un-labelled ADMA 4  155.8 ± 61.71 - n.s. 
+ 10 µM un-labelled ADMA 5  180.3 ± 66.64 - n.s. 
+ 100 µM un-labelled ADMA 5  204.2 ± 17.10 - n.s. 
+ 500 µM un-labelled ADMA 4  84.24 ± 28.48 - n.s. 
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While 100 µM unlabelled ADMA did not inhibit the distribution of [3H]-arginine in any 
of the samples analysed, 100 µM L-arginine was sufficient to significantly inhibit 
distribution of [3H]-arginine. This is demonstrated in Figure 2-41 by combining data 
from self-inhibition experiments for [3H]-arginine (see section 2.4.2.1 - Self-
inhibition of Arginine transport) with data in this section in the frontal cortex 
and choroid plexus. In both samples, 100 µM unlabelled L-arginine was sufficient to 
inhibit [3H]-arginine uptake into the frontal cortex and distribution in the choroid 
plexus, while 100 µM unlabelled ADMA had no effect. 
 
 
Figure 2-41: Effect of either 100 µM unlabelled L-arginine or 100 µM unlabelled 
ADMA on the respective uptake and distribution of [3H]-arginine in frontal cortex 
and choroid plexus. Uptake is expressed as the percentage ratio of tissue or CSF to 
plasma (mL.100 g-1). Perfusion time is 10 minutes. Each bar represents the mean ± SEM 
of 4-7 animals (GraphPad Prism 6.0 for Mac). One-way ANOVA with Dunnett's post-hoc 
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2.4.3.3 Effect of L-arginine of ADMA transport 
In order to determine the effect of L-arginine on the transport of ADMA across the 
blood-brain and blood-CSF barriers, [3H]-ADMA was co-perfused with 100 µM L-
arginine.  
Figure 2-42 shows the effect of an excess of unlabelled L-arginine on the uptake of 
[3H]-ADMA into all brain regions. These data indicate that [3H]-ADMA uptake is 
inhibited by 100 µM unlabelled L-arginine by up to 80.4% (Table 2-36, one-tailed 
unpaired Student's t-test comparing means, p < 0.001). This trend was also mirrored in 
samples from capillary depletion analysis where 100 µM L-arginine inhibited [3H]-
ADMA distribution in all samples by up to 80.0% (Figure 2-43 and Table 2-37, p < 
0.01). 
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Figure 2-42: The effect of unlabelled L-arginine on the regional brain uptake of 
[3H]-ADMA (10 minute perfusion). Uptake is expressed as the percentage ratio of 
tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). 
Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 5 animals. 
Asterisks represent unpaired, one-tailed Student’s t-tests comparing mean±SEM, *p < 

















































































































































[3H]-ADMA + 100 µM unlabelled L-arginine
2. ADMA & L-ARGININE 
- 197 - 
Table 2-36: Results obtained from cross-competition studies for [3H]-ADMA and 
unlabelled L-arginine in the brain. Unpaired, one-tailed Student's t-test was used to 
compare two means, with statistical significance taken as p < 0.05. n = number of 
experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Frontal cortex      
[3H]-ADMA alone 5 24.94 ± 3.50 - -  
+ 100 µM un-labelled arginine 4 - 5.98 ± 10.6 76.0 p < 0.001 
      
Caudate nucleus      
[3H]-ADMA alone 5 24.07 ± 2.92 - -  
+ 100 µM un-labelled arginine 4 - 4.81 ± 0.67 80.0 p < 0.001 
      
Occipital cortex      
[3H]-ADMA alone 5 22.52 ± 1.65 - -  
+ 100 µM un-labelled arginine 4 - 4.80 ± 0.95 78.7 p < 0.001 
      
Hippocampus      
[3H]-ADMA alone 5 21.74 ± 1.75 - -  
+ 100 µM un-labelled arginine 4 - 4.75 ± 1.04 78.2 p < 0.001 
      
Hypothalamus      
[3H]-ADMA alone 5 30.42 ± 2.98 - -  
+ 100 µM un-labelled arginine 4 - 7.77 ± 0.61 74.5 p < 0.001 
      
Thalamus      
[3H]-ADMA alone 5 21.09 ± 1.74 - -  
+ 100 µM un-labelled arginine 4 - 5.66 ± 1.47 73.2 p < 0.001 
      
Pons      
[3H]-ADMA alone 5 24.64 ± 3.44 - -  
+ 100 µM un-labelled arginine 4  4.83 ± 0.77 80.4 p < 0.001 
      
Cerebellum      
[3H]-ADMA alone 5 17.65 ± 1.52 - -  
+ 100 µM un-labelled arginine 4 - 4.45 ± 1.16 74.8 p < 0.001 
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Figure 2-43: The effect of unlabelled L-arginine on the distribution of [3H]-ADMA in 
capillary depletion samples (10 minute perfusion). Uptake is expressed as the 
percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose 
(vascular space). Perfusion time is 10 minutes. Each bar represents the mean ± SEM of 5 
animals. Asterisks represent unpaired, one-tailed Student’s t-tests comparing mean±SEM, 
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Table 2-37: Results obtained from cross-competition studies for [3H]-ADMA and 
unlabelled L-arginine in capillary depletion samples. Unpaired, one-tailed Student's t-
test was used to compare two means, with statistical significance taken as p < 0.05. n = 
number of experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
Homogenate      
[3H]-ADMA alone 5 22.41 ± 3.81 - -  
+ 100 µM un-labelled arginine 4 - 6.30 ± 0.84 71.9 p < 0.001 
      
Supernatant      
[3H]-ADMA alone 5 13.81 ± 1.24 - -  
+ 100 µM un-labelled arginine 4 - 4.76 ± 0.67 65.5 p < 0.001 
      
Pellet      
[3H]-ADMA alone 5 5.27 ± 1.26 - -  
+ 100 µM un-labelled arginine 4 - 1.01 ± 0.21 80.8 p < 0.01 
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Figure 2-44: The effect of unlabelled L-arginine on the distribution of [3H]-ADMA in 
CSF, choroid plexus and CVOs (10 minute perfusion). Uptake is expressed as the 
percentage ratio of tissue or CSF to plasma (mL.100 g-1). Perfusion time is 10 minutes. 
Each bar represents the mean ± SEM of 5 animals. Asterisks represent unpaired, one-
tailed Student’s t-tests comparing mean±SEM, *p < 0.05, **p < 0.01, ***p < 0.001 
(GraphPad Prism 6.0 for Mac). 
 
Figure 2-44 shows the effect of an excess of un-labelled L-arginine on the distribution 
of [3H]-ADMA into the CSF, pineal gland, choroid plexus and pituitary gland. These 
data indicate that [3H]-ADMA uptake is markedly inhibited by up to 78.6% and (p < 
0.05, unpaired, one-tailed Student's t-test comparing means, Table 2-38). The 
inclusion of unlabelled L-arginine however had no effect on the distribution of [3H]-
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Table 2-38: Results obtained from cross-competition studies for [3H]-ADMA and 
unlabelled L-arginine in the brain. Unpaired, one-tailed Student's t-test was used to 
compare two means, with statistical significance taken as p < 0.05. n = number of 
experiments. 
Tissue n RBRAIN (mL.100g-1) % inhibition p 
CSF      
[3H]-ADMA alone 5 27.26 ± 8.69 - -  
+ 100 µM un-labelled arginine 4 - 16.24 ± 6.77 - n.s. 
      
Pineal gland      
[3H]-ADMA alone 5 256.2 ± 61.56 - -  
+ 100 µM un-labelled arginine 4 - 91.51 ± 24.05 64.3 p < 0.05 
      
Choroid plexus      
[3H]-ADMA alone 5 288.1 ± 47.73 - -  
+ 100 µM un-labelled arginine 4 - 61.57 ± 5.26 78.6 p < 0.001 
      
Pituitary gland      
[3H]-ADMA alone 5 198.2 ± 31.93 - -  
+ 100 µM un-labelled arginine 4 - 60.03 ± 18.48 69.7 p < 0.01 
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The degree of inhibition of [3H]-ADMA distribution respectively exerted by the 
inclusion of either 100 µM unlabelled L-arginine (cross-competition) and 100 µM 
unlabelled ADMA (self-inhibition) appears to be identical. This is demonstrated in 
Figure 2-45 by combining data from self-inhibition experiments for [3H]-ADMA (see 
section 2.4.2.2 - Self-inhibition of ADMA transport) with data in this section 
in the frontal cortex and choroid plexus. Both 100 µM unlabelled L-arginine and 100 
µM unlabelled ADMA significantly inhibited [3H]-ADMA uptake into the frontal cortex 
and distribution in the choroid plexus (p < 0.001, one-way ANOVA with Dunnett's 
post-hoc test comparing means to control). [3H]-ADMA distribution in the presence of 
either 100 µM unlabelled ADMA or L-arginine were found to not be significantly 




Figure 2-45: Effect of either 100 µM unlabelled ADMA or 100 µM unlabelled L-
arginine on the respective uptake and distribution of [3H]-ADMA in frontal cortex 
and choroid plexus. Uptake is expressed as the percentage ratio of tissue or CSF to 
plasma (mL.100 g-1). Perfusion time is 10 minutes. Each bar represents the mean ± SEM 
of 4-5 animals (GraphPad Prism 6.0 for Mac). One-way ANOVA with Dunnett's post-hoc 
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2.4.3.4 Trans-stimulation of L-arginine influx by ADMA 
In order to determine if L-arginine transport across the blood-brain and blood-CSF 
barriers is subject to trans-stimulation by ADMA, experiments were designed to mimic 
pre-loading with ADMA. Following pre-perfusion with 500 µM unlabelled ADMA for 
20 minutes, mice were perfused with [3H]-arginine (with or without 200 µM unlabelled 
L-arginine). As mentioned in section 2.3.1.2L - Cross-competition experiments 
(Pre-loading / trans-stimulation experiments) a concentration of 200 µM 
unlabelled L-arginine was selected to mimic the concentration of L-arginine achieved in 
plasma following oral supplementation in human patients (Clarkson et al., 1996; Adams 
et al., 1997).  
The 'control' comparison for this set of experiments involved a 20-minute pre-perfusion 
with artificial plasma containing no additives followed by a 10-minute perfusion with 
artificial plasma containing [3H]-arginine alone. All comparisons made in this section 
are relative to the [3H]-arginine distribution in samples under these 'control' conditions. 
A reminder of the overall experimental design for this group of experiments is shown 
schematically in Figure 2-46. 
 
 
Figure 2-46: Schematic representation of experiments designed to investigate the possible 
trans-stimulation effect of ADMA on [3H]-arginine flux into the brain. 
 
Figure 2-47 shows that [3H]-arginine distribution is increased in all regions except for 
hypothalamus and thalamus when pre-loading with 500 µM unlabelled ADMA and 
then perfusing with [3H]-arginine and 200 µM unlabelled L-arginine (one-way ANOVA 
with Dunnett's post-hoc test comparing means to control, p < 0.05). Interestingly, this 
‘Empty’ plasma 500µM ADMA 500µM ADMA Pre-load (20 min) 
Post-perfusion 
(10 min) 
[3H]-Arginine [3H]-Arginine [3H]-Arginine + 200µM L-Arginine 
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was not observed if the artificial plasma for 'post-perfusion' did not contain 200 µM 
unlabelled L-arginine in addition to [3H]-arginine. The comparative increase in [3H]-
arginine uptake when combined with 200 µM unlabelled L-arginine (relative to the 
control, where neither 500 µM unlabelled ADMA is pre-perfused, nor 200 µM 
unlabelled L-arginine included in the post-perfusion) can be compared to the self-
inhibition experiments for [3H]-arginine described in section 2.4.2.1 - Self-
inhibition of Arginine transport. Following from these experiments one would 
expect the 200 µM unlabelled L-arginine would compete for transport with 
radiolabelled [3H]-arginine, resulting in a decrease in [3H]-arginine uptake. 
Interestingly, this trend was mirrored in whole-brain homogenate and particularly 
endothelial cell-enriched pellet samples from capillary depletion analysis (p < 0.01), but 
not brain parenchyma-containing supernatant (p > 0.05, one-way ANOVA with 
Dunnett's post-hoc test comparing means to control). These data are shown in Figure 
2-48. 
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Figure 2-47: Effect of pre-perfusion with 500 µM ADMA on [3H]-arginine uptake in 
brain regions. Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-
1) and is corrected for [14C]-sucrose (vascular space). Each bar represents the mean ± 
SEM of 5 animals. Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests 










































































































































500 µM unlabelled ADMA 500 µM unlabelled ADMA
[3H]-arginine [3H]-arginine + 200 µM L-arginine
2. ADMA & L-ARGININE 
- 206 - 
 
Figure 2-48: Effect of pre-perfusion with 500 µM ADMA on [3H]-arginine 
distribution in capillary depletion samples. Uptake is expressed as the percentage ratio 
of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Each 
bar represents the mean ± SEM of 5 animals. Asterisks represent one-way ANOVA with 
Dunnett’s post-hoc tests comparing mean±SEM to control, **p < 0.01, ***p < 0.001 
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Figure 2-49: Effect of pre-perfusion with 500 µM ADMA on [3H]-arginine 
distribution in choroid plexus and CVOs. Uptake is expressed as the percentage ratio of 
tissue to plasma (mL.100 g-1). Each bar represents the mean ± SEM of 5 animals. 
Asterisks represent one-way ANOVA with Dunnett’s post-hoc tests comparing 
mean±SEM to control, *p < 0.05, ***p < 0.001 (GraphPad Prism 6.0 for Mac). 
 
Pre-perfusing with 500 µM unlabelled ADMA followed by [3H]-arginine and 200 µM 
unlabelled L-arginine significantly increased the distribution of [3H]-arginine in the 
pineal gland, choroid plexus and pituitary gland (Figure 2-49, p < 0.05, one-way 
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2.4.3.5 Effect of L-arginine on ADMA efflux 
In order to determine if ADMA transport across the blood-brain and blood-CSF 
barriers is subject to trans-stimulation by L-arginine, experiments were designed to 
mimic pre-loading with [3H]-ADMA and then measuring its efflux from the brain after 
perfusing with artificial plasma containing 200 µM unlabelled L-arginine. Following pre-
perfusion with [3H]-ADMA for 20 minutes, mice were perfused for 10 minutes with 
either artificial plasma alone, or artificial plasma containing 200 µM unlabelled L-
arginine (section 2.3.1.2L - Cross-competition experiments (Pre-loading / 
trans-stimulation experiments)). 
The 'control' comparison for this set of experiments involved a 20-minute perfusion 
with artificial plasma containing [3H]-ADMA alone (taken from multiple-time uptake 
experiments for [3H]-ADMA, see section 2.4.1.3 - ADMA: The NOS inhibitor). 
All comparisons made in this section are relative to the [3H]-ADMA distribution in 
samples under these 'control' conditions. A reminder of the overall experimental design 
for this group of experiments is shown schematically in Figure 2-50. Multiple 
individual student's t-tests comparing means±SEM under each experimental condition 
were performed per sample for all comparisons made in this section. 
 
 
Figure 2-50: Schematic representation of experiments designed to investigate the possible 
trans-stimulation effect of L-arginine on [3H]-ADMA flux from the brain. 
 
Figure 2-51 shows that [3H]-ADMA distribution in all brain regions is significantly 
decreased following 20 minutes of pre-perfusion with [3H]-ADMA followed by post-
perfusion with artificial plasma with no additives relative to control (no post-perfusion, 
p < 0.01). In contrast, including 200 µM unlabelled L-arginine in the post-perfusion 
[3H]-ADMA [3H]-ADMA [3H]-ADMA Pre-load (20 min) 
Post-perfusion 
(10 min) 
N/A ‘Empty’ plasma + 200µM L-Arginine 
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artificial plasma only significantly reduces the distribution of [3H]-ADMA relative to 
control in the thalamus (p < 0.05, significance not shown on graph). When comparing 
the effect of including 200 µM unlabelled L-arginine in the post-perfusion artificial 
plasma to post-perfusion with artificial plasma alone, it is clear that [3H]-ADMA 
distribution is significantly increased (p < 0.05). 
In the case of capillary depletion samples, shown in Figure 2-52, the 'wash-out' effect 
of reducing [3H]-ADMA distribution following post-perfusion with artificial plasma that 
contained no additives was only observed in whole-brain homogenate (p < 0.05). No 
statistically significant differences in [3H]-ADMA distribution were found in the 
parenchyma-containing supernatant or capillary endothelial cell-enriched pellet 
samples. 
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Figure 2-51: Effect of post-perfusion with 200 µM L-arginine on [3H]-ADMA uptake 
in brain regions. Uptake is expressed as the percentage ratio of tissue to plasma 
(mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Each bar represents the 
mean ± SEM of 5 animals, multiple individual student's T-tests for each region, ***p < 
0.001, **p < 0.01, *p < 0.05 (GraphPad Prism 6.0 for Mac). Experiments performed to 
detect efflux of pre-loaded [3H]-ADMA under conditions designed to re-create 
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Figure 2-52: Effect of post-perfusion with 200 µM L-arginine on [3H]-ADMA 
distribution in capillary depletion samples. Uptake is expressed as the percentage ratio 
of tissue to plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Each 
bar represents the mean ± SEM of 5 animals, multiple individual student's T-tests for 
each region, *p < 0.05  (GraphPad Prism 6.0 for Mac). Experiments performed to detect 
efflux of pre-loaded [3H]-ADMA under conditions designed to re-create supplementation of 






















































2. ADMA & L-ARGININE 
- 212 - 
 
Figure 2-53: Effect of post-perfusion with 200 µM L-arginine on [3H]-ADMA 
distribution in choroid plexus and CVOs. Uptake is expressed as the percentage ratio of 
tissue to plasma (mL.100 g-1). Each bar represents the mean ± SEM of 5 animals, 
multiple individual student's T-tests for each region, ***p < 0.001, *p < 0.05  (GraphPad 
Prism 6.0 for Mac). Experiments performed to detect efflux of pre-loaded [3H]-ADMA 
under conditions designed to re-create supplementation of L-arginine in pathologies 
relating to the L-arginine paradox. 
 
As was observed in the brain regions sampled, [3H]-ADMA distribution in the pineal 
gland, choroid plexus and pituitary gland was decreased by post-perfusing for 10 
minutes with artificial plasma containing no additives (p < 0.05, shown in Figure 
2-53). The distribution of [3H]-ADMA was then increased by the inclusion of 200 µM 
unlabelled L-arginine in the post-perfusion artificial plasma in the case of the pineal 
and pituitary glands relative to post-perfusing with artificial plasma with no additives 
(p < 0.05). In the choroid plexus, the inclusion of 200 µM unlabelled L-arginine results 
in a significant decrease (p < 0.05) in the distribution of [3H]-ADMA relative to post-
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2.5 Discussion 
This chapter has examined the transport of two, structurally related cationic amino 
acids across the blood-CNS barriers using an in vivo mouse model of in situ brain and 
choroid plexus perfusion. Results indicate that [3H]-arginine and [3H]-ADMA have 
differing abilities to accumulate in the brain and CSF, and that transporters play a 
significant role in their transfer between the blood and CNS. Further interpretation of 
the data suggest that [3H]-arginine uses only one transport system for transport across 
the blood-CNS barriers, while [3H]-ADMA may interact with multiple transport 
systems with varying directions of transport, leading to more complex kinetics. The 
transport systems used by ADMA and L-arginine at the blood-CNS barriers also 
appear to be shared to some degree, as they each affect the others' transport, but to a 
different extent. Attempts to dissect these subtleties have been made with the 
experiments contained in this chapter, also extending to probing the possibility of the 
transport of ADMA and L-arginine in explaining the L-arginine paradox. 
These findings will be discussed in greater detail in the sections that follow. 
2.5.1 Sucrose as a marker molecule 
[14C]-sucrose was used to assess the integrity of the brain barriers and as a measure of 
vascular space in brain regions and extracellular space in the choroid plexus/CVOs. As 
described previously, the poor penetration of sucrose into the CNS (Levin et al., 1976), 
as well as its similarities to both ADMA and L-arginine in both size and charge, make 
[14C]-sucrose a particularly suitable marker molecule for these studies.  
Furthermore, the use of [14C]-sucrose in the protocol for in situ brain/choroid plexus 
perfusion via the heart used in the assimilation of these data provides a useful 
comparison to other validated methods for measuring brain accumulation of solutes in 
vivo. For the majority of brain regions sampled in this study, and under all treatment 
conditions, the [14C]-sucrose (vascular) space was found to be approximately 2 mL.100g-
1, which is very similar to the value of 1.5 ± 0.2 mL.100g-1 published previously using 
this technique (Sanderson et al., 2007), and indeed the value of 1.3 ± 0.2 mL.100g-1 
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typically observed after perfusing the CNS via the carotid artery in mice (Dagenais et 
al., 2000). 
With respect to the blood-CSF barrier, the physiology of choroid plexus capillaries (as 
described in chapter 1) allows sucrose to penetrate into the stromal space, but sucrose 
does not gain access to the cellular compartment of the choroid plexus (Quinton et al., 
1973). Thus the use of [14C]-sucrose in this work represents the vascular and interstitial 
fluid spaces within the choroid plexus and CVOs. The movement of sucrose through 
the apical membrane of the choroid plexus into the CSF is limited by TJs situated 
towards the apical surface of the choroid plexus epithelium (Quinton et al., 1973), and 
thus CSF accumulation of [14C]-sucrose represents slow paracellular diffusion through 
these TJs. 
An interesting high-level observation of [14C]-sucrose permeability across the blood-
brain and blood-CSF barriers measured in this study is the difference in accumulation 
over time between so-called ‘tight’ and ‘leaky’ tissues. A steady, linear time-dependent 
increase in [14C]-sucrose accumulation was observed in all brain regions sampled and 
CSF, but not in the pineal gland, choroid plexus and pituitary glands. One possible 
explanation for this observation could be that a higher degree of non-specific, non-
saturable transport of [14C]-sucrose into the CVOs (relative to other regions) allows for 
more rapid equilibration across the membranes involved (e.g. basolateral membrane of 
the choroid plexus epithelial cells), which does not occur within 30 minutes in brain 
regions where the BBB is present. Another possibility is that low-level pinocytosis in 
BCECs provides a route for time-dependent increases in [14C]-sucrose accumulation into 
those regions where TJs do not allow paracellular flux. 
The poor permeability of [14C]-sucrose through the BBB and BCSFB is shown in 
Figure 2-10, Figure 2-11 and Figure 2-12, but also demonstrated by the very low 
Kin values shown in Table 2-14 and Table 2-15. 
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2.5.2 [3H]-Arginine transport across the BBB and BCSFB is 
predominantly mediated by system y+ 
This study investigated the ability of [3H]-arginine to cross the mouse blood-CNS 
barriers and accumulate within the CNS. Section 2.5.2.1 provides a brief summary of 
the results from this part of the study, while their biological relevance will be 
interpreted in depth in the ensuing sections. 
2.5.2.1 Summary of results 
Multiple-time uptake studies (Figure 2-13, Figure 2-14 and Figure 2-16) measured 
substantial [3H]-arginine uptake into all brain regions, CSF, choroid plexus and CVOs 
(significantly higher than [14C]-sucrose at all time points). Capillary depletion analysis 
(Figure 2-15) suggests that [3H]-arginine could cross the endothelial cell luminal 
membrane (as measured by the pellet sample) and could accumulate in the brain 
parenchyma (as measured by the supernatant sample) following perfusion. A departure 
from a linear rate of [3H]-arginine uptake was observed between 20 and 30 minutes in 
the hypothalamus and thalamus, also observed in the brain parenchyma and capillary 
endothelial cells following capillary depletion analysis, but not in whole-brain 
homogenate. 
2.5.2.2 [3H]-Arginine uptake into the CNS 
2.5.2.2A Brain regions 
Of the two radiolabelled cationic amino acids of interest studied, [3H]-arginine 
demonstrated the greatest ability (more than two-fold in most cases) to cross the BBB 
and accumulate within all eight brain regions sampled (Figure 2-13). While in situ 
brain/choroid plexus perfusion has previously been used to study [3H]-arginine uptake 
into the rat brain (Stoll et al., 1993), no absolute values were published, and thus there 
is no previously published comparison to make to the results described here.  
After 30 minutes, brain uptake of [3H]-arginine as a percentage of perfused plasma 
levels reached a maximum of 185.1 ± 30.7% in the pons, but was similarly high in the 
majority of other brain regions, including the frontal cortex, caudate nucleus, occipital 
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cortex, hippocampus, and cerebellum (Figure 2-13). An interesting observation for 
these data is the very high [3H]-arginine uptake in the hypothalamus and thalamus at 
30 minutes relative to the earlier time-points (Figure 2-14). The biological relevance 
of this is not immediately clear, although the prototypical cationic amino acid 
transporter CAT-1 was very recently shown to be expressed at particularly high levels 
in the hypothalamus and thalamus (Jager et al., 2013). Furthermore, the increased 
uptake of [3H]-arginine observed in these two regions could be due to a difference in 
transporter expression at the abluminal membrane, as afforded by the presence of TJs 
(described in section 1.1.1.1A - Presence of complex tight junctions). 
Transport systems such as system y+ have previously been detected at both luminal 
and abluminal membranes, however not necessarily in a symmetric expression pattern 
(O'Kane et al., 2006). Capillary depletion analysis confirmed that [3H]-arginine could 
cross the BBB to accumulate in the brain parenchyma, whilst negligible levels of drug 
remained trapped in BCECs until 30 minutes (Figure 2-15). After 30 minutes it 
appears that [3H]-arginine accumulates within the brain parenchyma and BCECs at 
levels greater than plasma levels (RBrain > 100%). One may predict that this would 
create a concentration gradient favouring flux of [3H]-arginine from the brain and 
endothelial cells back into the plasma, at least under the experimental conditions 
presented here ([3H]-arginine plasma concentration of 11.6 nM). However, this is 
unlikely to occur in vivo under normal conditions as the concentration of L-arginine in 
plasma is typically 100 µM in humans (Boger & Bode-Boger, 2001) and 140 µM in mice 
(Hallemeesch et al., 2004), while brain concentrations in both mice and humans are 
typically much lower at approximately 0.2-0.3 µM (Leypoldt et al., 2009; Jung et al., 
2012). This creates a concentration gradient that overwhelmingly favours facilitated 
transport of L-arginine from plasma into the brain. 
2.5.2.2B CSF 
[3H]-arginine was also able to cross the blood-CSF barrier, and levels in the CSF 
reached approximately 120% of plasma levels after 30 minutes (Figure 2-16). While 
the transport of L-arginine from plasma to CSF in any species has not previously been 
published to provide a direct comparison, saturable L-arginine transport that was 
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sensitive to inhibition by L-NMMA has been reported at the rat choroid plexus 
(Stuhlmiller & Boje, 1995). The accumulation of [3H]-arginine in the CSF over time is 
not an unexpected observation, since the presence of L-arginine in the extracellular 
CSF is known to be a requirement for the production of inducible NO by brain 
astrocytes following transport of L-arginine into the cell by CAT-2 (Stevens et al., 
1996). 
2.5.2.2C Pineal gland, choroid plexus and pituitary gland 
[3H]-arginine uptake into the pineal gland and choroid plexus was substantial (Figure 
2-16); respectively reaching 634.2 ± 153.2% and 379.1 ± 63.1% of plasma levels after 
30 minutes. [3H]-Arginine uptake into the pituitary gland was also significant, however 
a peak in the accumulation of [3H]-arginine was observed at 20 minutes (327.7 ± 32.5% 
of plasma levels), which then fell to 141.7 ± 10.2% of plasma levels after 30 minutes. 
This would imply the existence of [3H]-arginine efflux (passive or otherwise) from the 
pituitary gland and that the rate of [3H]-arginine efflux begins to override the rate of 
influx at 30 minutes, after initial accumulation. The biological relevance of this could 
possibly be revealed when considering the role of L-arginine in the physiological 
functions and processes of the pituitary gland, relative to the pineal gland and choroid 
plexus. Beyond the dependence on L-arginine for the normal physiological processes of 
the cell (such as protein synthesis), L-arginine has an active role in promoting the 
release of growth hormone by the pituitary gland, likely by blocking somatostatin 
activity via NO signalling (Valverde et al., 2001; Adriao et al., 2004). It is therefore 
possible, that an efflux transport system for L-arginine exists at the pituitary gland to 
regulate the release of growth hormone – an excess of which leads to acromegaly 
(chronic body tissue growth) and tumours. 
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2.5.2.3 [3H]-Arginine transporter identification 
Saturable transport of L-arginine, L-lysine and L-ornithine across rat BBB has 
previously been observed using in situ brain/choroid plexus perfusion (Kavanaugh, 
1993; Stoll et al., 1993). These studies found that the Km (half-saturation constant) for 
these amino acids was 56-110 µM, with a Vmax (maximal influx rate) of 24 nmol.min-1.g-
1 and attributed the transport to system y+. Subsequent to these initial observations, 
system y+ was proposed to be the only transport system responsible for cationic amino 
acid transport across the BBB (O'Kane et al., 2006). Saturable transport of L-arginine 
was also identified at the ovine blood-CSF barrier and attributed to system y+ (Segal et 
al., 1990; Preston & Segal, 1992). Experiments designed to identify the transport 
systems involved in L-arginine transport at the murine BBB and BCSFB are described 
below. 
2.5.2.3A Summary of results 
Self-inhibition studies with 100 µM unlabelled L-arginine (Figure 2-23 and Figure 
2-25) were utilised to assess the involvement of transporters in [3H]-arginine movement 
across the blood-CNS barriers. It was found that [3H]-arginine uptake into all brain 
regions, CSF, choroid plexus and CVOs (including the pituitary gland) was reduced in 
the presence of unlabelled L-arginine, implying that [3H]-arginine influx into the brain, 
choroid plexus and CVOs involves at least one saturable transport system. Capillary 
depletion analysis (Figure 2-24) revealed that the inhibition of [3H]-arginine uptake 
into BCECs by unlabelled L-arginine results in reduced influx of [3H]-arginine into the 
brain parenchyma. 
Specific transport inhibitor studies (Figure 2-32) revealed the transporter(s) for [3H]-
arginine influx into the brain regions sampled is sensitive to inhibition by L-
homoarginine, which almost completely prevented the entry of [3H]-arginine into the 
brain regions sampled. Capillary depletion analysis (Figure 2-33) revealed that the 
inhibition of [3H]-arginine uptake into BCECs by L-homoarginine results in reduced 
influx of [3H]-arginine into the brain parenchyma – a phenomenon observable on the 
scale of whole-brain homogenate. The transport inhibitors BCH and α-methyl-D,L-
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tryptophan did not significantly alter the uptake of [3H]-arginine in any of the brain 
regions sampled, except for in the hippocampus; where α-methyl-D,L-tryptophan 
significantly inhibited [3H]-arginine uptake, albeit to a much lesser degree than the 
inhibitory effect of L-homoarginine (47.5% vs. 99.6% inhibition, respectively). None of 
the transport inhibitors utilised in this group of experiments affected the accumulation 
of [3H]-arginine in the CSF. However, of the three transport inhibitors utilised, only L-
homoarginine significantly inhibited the accumulation of [3H]-arginine in the pineal 
gland, choroid plexus and pituitary gland (Figure 2-34). 
2.5.2.3B BBB 
It has been known for some time that L-arginine transport across the rat BBB is 
saturable at concentrations as low as 100 µM (Pardridge & Oldendorf, 1975a). Results 
from self-inhibition experiments carried out in this present study (Figure 2-23) 
demonstrated that unlabelled 100 µM L-arginine had a significant inhibitory effect on 
[3H]-arginine uptake into all brain regions sampled at 10 minutes. The degree of 
inhibition exerted by unlabelled 100 µM L-arginine was very similar in all brain 
regions, but highest (73.0% inhibition) in the thalamus (Table 2-20). This effect was 
also observed in BCECs following capillary depletion analysis, and translated to 
significant inhibition of [3H]-arginine accumulation in the brain parenchyma (Table 
2-21). 
Further investigation was undertaken to establish the identity of the saturable 
transport system for [3H]-arginine at the BBB. Since the primary transport system 
identified for L-arginine identified at the BBB of other species is system y+ (described 
above), [3H]-arginine uptake into brain regions was measured in the presence of the 
system y+ specific inhibitor, L-homoarginine (Figure 2-32). [3H]-arginine uptake in all 
brain regions and capillary depletion samples was highly sensitive to inhibition by 20 
mM L-homoarginine, with almost 100% inhibition in some samples (Table 2-27). This 
suggests that [3H]-arginine transport into the brain via the BBB is almost entirely 
mediated by system y+. While there was a tendency for [3H]-arginine uptake to increase 
in the presence of the system L and system B0,+ inhibitor BCH, and decrease in the 
presence of the system B0,+ specific inhibitor α-methyl-D,L-tryptophan, a lack of 
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statistical significance makes it difficult to rule out inherent experimental variability. It 
should be noted, however, that [14C]-sucrose space for all samples in these did not differ 
(one-way ANOVA with Dunnett's multiple comparisons test, p > 0.05, graphs not 
shown).  
While the specificity of specific transport inhibitors can always be questioned, as can 
the possibility of compensation by other transporters, in this specific case, L-lysine 
transport at BBB is known not to be affected by BCH at concentrations up to 10 mM 
(O'Kane & Hawkins, 2003). The observed slight effects on [3H]-arginine uptake by 4 
mM BCH can therefore be attributed to experimental variability, rather than a real 
effect. 
2.5.2.3C BCSFB and CVOs 
Accumulation of [3H]-arginine in the CSF, pineal gland, choroid plexus and pituitary 
gland was sensitive to inhibition by unlabelled 100 µM L-arginine – indicative of a 
saturable transport system at the blood-CSF barrier (Figure 2-25). However, 
transport inhibitor studies revealed that accumulation of [3H]-arginine in the CSF was 
not affected by any of the three specific transport inhibitors used in these studies 
(Figure 2-34, L-homoarginine, BCH and α-methyl-D,L-tryptophan). The reason for 
this is not entirely clear, as the accumulation of [3H]-arginine in the CSF appears to be 
susceptible to self-inhibition by 100 µM L-arginine (Figure 2-25). One possible 
explanation for this observation may be that L-arginine is able to access transporters in 
a location (such as the apical membrane of the choroid plexus epithelium), that the 
transport inhibitors used in this study are unable to. It would not be possible to 
confirm this hypothesis without knowing whether the transport inhibitors in question 
can themselves be transported. In the cases of the pineal gland, choroid plexus and 
pituitary gland, the only specific inhibitor to significantly inhibit the uptake of [3H]-
arginine was L-homoarginine – suggesting that [3H]-arginine uptake into these organs is 
mediated only by system y+. 
While the available data on amino acid concentrations in the CSF is inconsistent, it is 
clear that CSF to plasma ratios are typically much less than 1, creating a concentration 
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gradient that favours influx of amino acids from the blood to the CSF (Abbott et al., 
2010). While a saturable transport system for [3H]-arginine has been identified in the 
studies discussed in this section, the fact that L-homoarginine does not inhibit [3H]-
arginine accumulation in the CSF presents something of a puzzle. Despite the fact that 
[3H]-arginine is similar in size and charge to [14C]-sucrose (octanol-saline partition 
coefficients of 0.00149±0.00016 and 0.00105±0.00022 respectively), it is clear from the 
multiple-time uptake studies shown in Figure 2-16 that the difference between [3H]-
arginine and [14C]-sucrose accumulation in the CSF after a 10 minute perfusion (p < 
0.05) is greater at 30 minutes (p < 0.001). The existence of tight-junctions at the apical 
membrane between epithelial cells of the choroid plexus means that the passage of a 
polar molecule such as [3H]-arginine from the plasma into the CSF via the BCSFB is 
likely to require transport systems at both the basolateral and apical membranes of the 
choroid plexus epithelium working in concert. System y+ has thus far been identified at 
the basolateral (blood-facing) side of the ovine choroid plexus (Segal et al., 1990; 
Preston & Segal, 1992), and the system y+ activity demonstrated by these experiments 
is also likely to be due to transporters at the basolateral membrane, since this is the 
first choroid plexus membrane encountered by [3H]-arginine during in situ 
brain/choroid plexus perfusion. A better technique to detect apical transport at the 
choroid plexus is the isolated incubated choroid plexus technique, as it would involve 
the introduction of [3H]-arginine on the apical side of the choroid plexus before 
measuring transport through this membrane. 
Since the observed efflux of [3H]-arginine from the pituitary gland in multiple-time 
uptake experiments (Figure 2-16) did not manifest until 30 minutes, one would expect 
that identification of the transport system responsible for this would be improved by 
extending the perfusion time for the transport inhibitor experiments from 10 to 30 
minutes. 
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2.5.3 [3H]-ADMA transport across the BBB and BCSFB mainly 
involves system y+ but also a number of additional transport 
systems 
This study investigated the ability of [3H]-ADMA to cross the mouse blood-CNS 
barriers and accumulate within the CNS. Section 2.5.3.1 provides a brief summary of 
the results from this part of the study, while their biological relevance will be 
interpreted in depth in the ensuing sections. 
2.5.3.1 Summary of results 
Multiple-time uptake studies (Figure 2-17 and Figure 2-19) measured substantial 
[3H]-ADMA uptake into all brain regions, choroid plexus and CVOs (significantly 
higher than [14C]-sucrose at all time points, one-tailed, paired student's t-test, p < 
0.05). However, transport of [3H]-ADMA appears to be bi-phasic in nature, with a peak 
in accumulation being reached at 20 minutes before decreasing at 30 minutes brain 
regions. Capillary depletion analysis (Figure 2-18) confirmed that [3H]-ADMA 
accumulates in the brain parenchyma following perfusion in the same manner. 
However, rather than accumulation peaking at 20 minutes in BCECs, the peak 
accumulation of [3H]-ADMA in the capillary endothelial cell-enriched pellet was 
observed after 10 minutes. This pattern of peak accumulation of [3H]-ADMA after 10 
minutes was also observed in the pineal gland, choroid plexus and pituitary gland 
(Figure 2-19). 
2.5.3.2 [3H]-ADMA uptake into the CNS 
2.5.3.2A Brain regions 
While the accumulation of [3H]-ADMA within the brain regions sampled was found 
typically to be 50% or less of the accumulation of [3H]-arginine (Figure 2-20), [3H]-
ADMA accumulation in the brain regions sampled did reach significantly higher levels 
than values observed for [14C]-sucrose (p < 0.05, Figure 2-17). The data presented 
here represent the first study to ever investigate the transport of ADMA across any 
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biological membrane in vivo, and certainly the first to investigate the movement of 
ADMA from plasma into the brain. 
The observed decrease in [3H]-ADMA accumulation in brain regions after 30 minutes 
(Figure 2-17) implies the existence of an efflux mechanism that removes accumulating 
ADMA. The fact that his effect is mirrored exactly in the brain parenchyma following 
capillary depletion analysis (Figure 2-18), but occurs 10 minutes earlier (after 20 
minutes) in BCECs suggests this is a real effect whereby efflux is occurring at the level 
of capillaries supplying the brain regions, and contributing to removal from the brain 
back into plasma. These data alone are insufficient to predict whether the candidate 
efflux transport system utilises active processes, or if it merely reflects transport 
mediated by one or more facilitative transport systems after [3H]-ADMA has 
accumulated in the brain parenchyma and BCECs above the concentration of [3H]-
ADMA in artificial plasma (62.5 nM). The identity of the system(s) mediating ADMA 
transport across the BBB will be discussed in section 2.5.3.3 - Transporter 
identification. It is also possible that ADMA may be broken down by DDAH, the 
enzyme responsible for ADMA metabolism described in section 2.1.1.3B - ADMA 
clearance. The expression of DDAH in the brain approximately mirrors the expression 
profile for NOS, with DDAH-1 often being expressed in neuronal tissue with nNOS, 
and DDAH-2 being expressed in the capillary endothelium, along with eNOS (Leiper et 
al., 1999; Palm et al., 2007). Metabolism of [3H]-ADMA at the BBB cannot entirely be 
ruled out in this instance without performing HPLC with radiodetector analysis of 
capillary depletion samples (brain parenchyma and BCECs). While several attempts 
were made to carry out these aforementioned HPLC analyses (data not shown), the 
structural similarity of L-arginine, ADMA and its metabolite L-citrulline meant that 
co-elution was a significant problem, and distinguishing between the three in our 
samples impossible. 
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2.5.3.2B CSF 
[3H]-ADMA was also able to cross the blood-CSF barrier, and levels in the CSF reached 
approximately 30% of plasma levels after 10 minutes (Figure 2-16). This study 
represents the first investigation into the movement of ADMA from plasma to CSF and 
thus no data has previously been published to provide a direct comparison. It should be 
noted that [3H]-ADMA accumulation in the CSF was only significantly higher (p < 
0.05) from [14C]-sucrose at 10- and 20- minute time-points (Figure 2-16). This re-
affirms the efflux of [3H]-ADMA observed at the BBB, described above. 
2.5.3.2C Pineal gland, choroid plexus and pituitary gland 
[3H]-ADMA accumulation in the pineal gland, choroid plexus and pituitary gland was 
highest after 10 minutes (Figure 2-19); respectively reaching 194.1 ± 48.5%, 260.9 ± 
42.5% and 182.9 ± 32.3% of plasma levels. In all three organs the accumulation of [3H]-
ADMA declines after 20 and then 30 minutes, returning to levels observed after just 2.5 
minutes of perfusion. This would imply the existence of an efflux transport system for 
ADMA at the pineal gland, choroid plexus and pituitary gland, and that the rate of 
[3H]-ADMA efflux begins to override the rate of influx at some point between 10 and 20 
minutes, following initial accumulation.  
Taking into consideration that [3H]-ADMA efflux exists in all of the samples 
investigated in this study, it is clear that efflux mechanisms for ADMA at the BBB 
and BCSFB may be an evolutionary adaptation to prevent the CNS-accumulation of 
ADMA circulating in the plasma. 
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2.5.3.3 Transporter identification 
Following the observations that [3H]-ADMA in artificial plasma can accumulate and 
then be removed from the murine brain, experiments were designed to identify the 
transport system(s) responsible. 
2.5.3.3A Summary of results 
Self-inhibition studies with a range of concentrations of unlabelled ADMA from 0.5 – 
500 µM (Figure 2-26 and Figure 2-28) were utilised to assess the involvement of 
transporters in [3H]-ADMA movement across the blood-CNS barriers at 10 minutes. It 
was found that [3H]-ADMA uptake into all brain regions, choroid plexus and CVOs was 
reduced in the presence of unlabelled ADMA at all concentrations, implying that [3H]-
ADMA influx into the brain, choroid plexus and CVOs involves at least one saturable 
transport system. Capillary depletion analysis (Figure 2-27) suggests that the 
inhibition of [3H]-ADMA uptake into BCECs by unlabelled ADMA results in reduced 
influx of [3H]-ADMA into the brain parenchyma, however the previously discussed 
susceptibility of the capillary depletion technique to contamination means that further 
analysis would be required to be sure of this. 
The utilisation of a range of unlabelled ADMA concentrations enabled the calculation 
of the half saturation constant, Km, for ADMA flux into the brain regions sampled, 
which varied from 327.9 ± 121.9 µM in the caudate nucleus to 1352 ± 946.0 µM in the 
cerebellum. The Km values for ADMA accumulation into the pineal gland, choroid 
plexus and pituitary gland was comparatively lower, at 281.0 ± 166.7 µM, 49.96 ± 
17.41 µM and 51.41 ± 16.42 µM respectively. 
[3H]-ADMA uptake into brain regions during 10-minute perfusions was sensitive to 
inhibition by all specific inhibitors utilised in this study to varying degrees, but with no 
obvious consistency or pattern between the different brain regions sampled (Figure 
2-35). The complexity of interactions between [3H]-ADMA and different transport 
systems at the BBB was reaffirmed by capillary depletion analysis, where [3H]-ADMA 
was found to be sensitive to 20 mM L-homoarginine, 200 µM L-phenylalanine and 5 
mM L-leucine in the whole-brain homogenate, but only to 20 mM L-homoarginine in 
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the parenchyma, and completely insensitive in BCECs (Figure 2-36). [3H]-ADMA 
accumulation in the CSF was also completely insensitive to inhibition by any of the 
inhibitors utilised, while seemingly sensitive to all inhibitors in the pineal gland and 
choroid plexus, and all bar 500 µM α-methyl-D,L-tryptophan in the pituitary gland. 
2.5.3.3B BBB 
Self-inhibition studies revealed that [3H]-ADMA influx into brain regions after 10 
minutes is sensitive to inhibition by unlabelled ADMA at concentrations as low as 0.5 
µM (Figure 2-26). Capillary depletion analysis revealed that this phenomenon appears 
to also be robustly observed in whole-brain homogenate, BCECs, and brain 
parenchyma, assuming there is no fraction-to-fraction contamination (Figure 2-27). 
Half-saturation constant (Km) values for [3H]-ADMA at the BBB calculated from these 
experiments and described above are higher than previously published Km values of 50-
100 µM for influx of the other cationic amino acids, L-lysine, L-arginine and L-
ornithine at the rat BBB (Stoll et al., 1993). While not a direct species comparison, the 
larger Km observed for BBB uptake of [3H]-ADMA in the present study would suggest 
that the transport system(s) responsible (if shared) have a higher affinity for these 
cationic amino acids over ADMA. 
Taken alone, the almost complete inhibition of [3H]-ADMA uptake in all brain regions 
sampled in the presence of 20 mM L-homoarginine would suggest that ADMA 
transport at the BBB, as with [3H]-arginine, is almost exclusively mediated by system 
y+ (Figure 2-35). However, the inhibition of [3H]-ADMA uptake in brain regions 
(albeit to a lesser degree) in the presence of the additional five transport inhibitors 
utilised makes it very difficult to pinpoint ADMA transport at the BBB to just one 
transport system. In light of the approximately equal sensitivity of [3H]-ADMA to 
inhibition by 2 mM BCH and 500 µM α-methyl-D,L-tryptophan, ADMA may be 
interacting with system B0,+ for transport from plasma to the brain. Furthermore, the 
sensitivity of [3H]-ADMA to inhibition by 200 µM L-phenylalanine may indicate system 
L transport, while sensitivity to 5 mM L-leucine and 2 mM harmaline respectively 
indicate system y+L and b0,+ transport. 
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[3H]-ADMA thus appears to be a highly promiscuous molecule with respect to 
interactions with transport systems at the BBB, and has a highly complex transport 
profile that can unfortunately not be dissected on the evidence from these experiments 
alone. However, it is clear that system y+, as hypothesised, is a major contributor to 
[3H]-ADMA transport across the BBB. The hypothesis that ADMA may use system y+ 
for transport was based entirely on the observation that supraphysiological 
concentrations of ADMA were able to inhibit L-arginine accumulation in vitro (Closs et 
al., 1997). However, the experiments reported in this thesis are among the first to 
confirm system y+ as the main transporter for ADMA through direct empirical 
observation. The other publication reporting this finding was published after these 
experiments were performed but only relate to in vitro observations (Strobel et al., 
2012), and thus the results presented in this study represent the first identification of 
system y+ mediated transport of ADMA in vivo. 
While the canonical system y+ transporter CAT-1 has been shown to be capable of 
mediating ADMA efflux (Strobel et al., 2012), these experiments are not sufficient to 
determine if the efflux of [3H]-ADMA from the CNS (described in section 2.5.3.2 - 
[3H]-ADMA uptake into the CNS) is mediated by system y+. An interesting 
point of comparison would be repeating these experiments at 30 minutes to identify 
efflux transporters, since this would allow the detection of the transport system(s) 
mediating efflux following the initial accumulation of [3H]-ADMA after 10 minutes. 
This is discussed in greater detail in section 2.5.8 - Future work. 
2.5.3.3C BCSFB 
Accumulation of [3H]-ADMA in the CSF was sensitive to inhibition by unlabelled 
ADMA concentrations of 3, 10 and 500 µM (Figure 2-28), but not 0.5 and 100 µM. 
The reasons for this are not entirely clear, since [3H]-ADMA accumulation in the pineal 
gland, choroid plexus and pituitary gland was sensitive to inhibition by unlabelled 
ADMA at all concentrations from 0.5-500 µM - indicative of a saturable transport 
system at the blood-CSF barrier. One possible explanation could be that the inherent 
technical difficulty of obtaining CSF samples is likely to have contributed to high 
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variability between samples. Km values for [3H]-ADMA influx into the pineal gland, 
choroid plexus and pituitary gland were calculated to be 281.0 ± 166.7, 49.96 ± 17.41 
and 51.41 ± 16.42 µM – all of which are higher than previously published Km value of 
25 µM for L-arginine at the ovine choroid plexus (Segal et al., 1990; Preston & Segal, 
1992). This provides yet more evidence that transporters at the BBB and BCSFB have 
higher affinity for L-arginine over ADMA. 
Transport inhibitor studies revealed a similarly complex interaction for [3H]-ADMA 
with a variety of different transport systems, as indicated by its sensitivity to inhibition 
by a number of different transport inhibitors (Figure 2-37). Despite being susceptible 
to self-inhibition by un-labelled ADMA, [3H]-ADMA accumulation in the CSF does not 
appear to be sensitive to any of the transport inhibitors used in these experiments 
(Figure 2-37). The sensitivity to inhibition by all transport inhibitors used in the 
pineal gland and choroid plexus make identifying specific interactions with transport 
systems in these sub-organs of the brain very difficult. In the pituitary gland, [3H]-
ADMA accumulation was found to be sensitive to all inhibitors used except for 500 µM 
α-methyl-D,L-tryptophan, suggesting perhaps that ADMA may interact with system L 
at the pituitary gland, and not system B0,+. It is however clear in that [3H]-ADMA 
accumulation in the pineal gland, choroid plexus and pituitary gland is highly sensitive 
to inhibition by the system y+ inhibitor L-homoarginine, being inhibited by up to 
88.6% in the pituitary gland. 
Since efflux of [3H]-ADMA was detected at the BCSFB in multiple-time uptake 
experiments (Figure 2-19), extending the perfusion time for these experiments to 30 
minutes may also be beneficial in identifying the transporters responsible. 
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2.5.4 ADMA does not inhibit [3H]-arginine transport across the BBB 
and BCSFB in physiologically- or pathologically-relevant 
conditions 
The first proposed hypothesis to explain the L-arginine paradox was that pathological 
increases in circulating levels of ADMA resulted in ADMA outcompeting L-arginine for 
transport into endothelial cells (including those of the BBB), and subsequently a 
reduction in NO production observed in a number of cardiovascular and 
cerebrovascular diseases. In this situation, oral supplementation of L-arginine could 
putatively restore the L-arginine:ADMA ratio in plasma to switch competition for 
transport back in favour of L-arginine (see section 2.1.1.4A - Competition 
hypothesis). 
Cross competition experiments were designed to test this hypothesis, whereby a range 
of unlabelled ADMA concentrations were co-perfused with [3H]-arginine to measure 
their effect on [3H]-arginine transport across the murine BBB and BCSFB. 
2.5.4.1 Summary of results 
Cross-competition studies (Figure 2-38) utilising escalating concentrations of 
unlabelled ADMA (0.5, 3.0, 10.0, 100 and 500 µM) were designed to determine the 
effect of ADMA on the movement of [3H]-arginine across the blood-CNS barriers. In all 
brain regions sampled, only 500 µM unlabelled ADMA inhibited the uptake of [3H]-
arginine. Capillary depletion analysis suggests the same observation can be seen in both 
the whole-brain homogenate and brain parenchyma, however the observed reduction of 
[3H]-arginine uptake in BCECs following co-perfusion with 500 µM unlabelled ADMA 
did not attain statistical significance (Figure 2-39). Unlabelled ADMA did not appear 
to affect the accumulation of [3H]-arginine in the CSF, pineal gland or pituitary gland 
at any of the concentrations utilised in this study, however a significant inhibition of 
[3H]-arginine accumulation was observed in the choroid plexus following perfusion with 
500 µM unlabelled ADMA (Figure 2-40). 
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2.5.4.2 Effect of ADMA on [3H]-arginine transport across the BBB 
One of the earliest in vivo studies demonstrating cross-competition of transport 
between L-arginine and L-lysine revealed that each could inhibit the transport of the 
other into the rodent brain (Banos et al., 1974). It was then theorised that all three 
cationic amino acids share the same transport system at the BBB. A later study 
revealed a preference for the transport of these three different cationic amino acids by 
system y+, differing following the scheme arginine > lysine > ornithine (highest affinity 
first, (O'Kane et al., 2006)). As the primary transport system mediating [3H]-arginine 
uptake at the BBB has been found by this study and others to be system y+, it would 
not be unreasonable to predict that system y+ may have a differing affinity to ADMA. 
ADMA has previously been shown to inhibit uptake of L-arginine into Xenopus laevis 
oocytes expressing the system y+ transporters, CAT-2B (Closs et al., 1997). In 
accordance with these earlier observations, the cross-competition experiments 
performed for this study show that [3H]-arginine uptake in the brain regions sampled 
was inhibited by unlabelled 500 µM ADMA, but no concentrations below 100 µM 
(Figure 2-38). Capillary depletion analysis showed the same phenomenon in whole-
brain homogenate and brain parenchyma, but not in BCECs (Figure 2-39). Taking 
into consideration that the concentration of [3H]-arginine in the artificial plasma for 
these experiments was only 11.6 nM, it would appear that system y+ at the BBB 
overwhelmingly favours transport of L-arginine over ADMA. These findings are in 
accordance with a very recent publication that observed that L-arginine uptake in 
human embryonic kidney (HEK) cells overexpressing the canonical system y+ 
transporter CAT-1 is only sensitive to inhibition by ADMA at concentrations above 
300 µM (Strobel et al., 2012). The affinity and capacity of CAT-1 to ADMA was found 
to be higher than that for L-arginine in HEK cells, which would appear to contradict 
the findings shown here in vivo at the murine BBB. However, the IC50 for the 
inhibition of L-arginine uptake by ADMA in HEK cells was calculated to be 758 µM, 
which is unlikely to be of any direct relevance in vivo, since ADMA plasma 
concentrations have never been measured as exceeding 3 µM, even in pathological 
conditions (Cakir et al., 2005; Bode-Boger et al., 2007). 
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2.5.4.3 Effect of ADMA on [3H]-arginine transport across the BCSFB 
[3H]-arginine accumulation in the CSF, pineal gland and pituitary gland was not 
inhibited by ADMA at any of the concentrations added to the artificial plasma 
(Figure 2-40). [3H]-arginine accumulation in the choroid plexus was only sensitive to 
inhibition by 500 µM unlabelled ADMA, and not any of the concentrations below this. 
This would suggest that the Ki for ADMA's inhibitory effect on [3H]-arginine transport 
at the BCSFB is even higher than that for the BBB. 
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2.5.5 L-arginine inhibits [3H]-ADMA transport across the BBB and 
BCSFB under physiologically-relevant conditions 
2.5.5.1 Summary of results 
Cross-competition studies utilising unlabelled 100 µM L-arginine were designed to 
determine the effect of L-arginine on the movement of [3H]-ADMA across the blood-
CNS barriers. In all brain regions sampled, 100 µM unlabelled L-arginine inhibited the 
uptake of [3H]-ADMA (Figure 2-42). Capillary depletion analysis revealed the same 
observation at the level of the whole-brain homogenate, but also in both the brain 
parenchyma and BCEC fractions (Figure 2-43). Unlabelled 100 µM L-arginine did not 
appear to affect the accumulation of [3H]-ADMA in the CSF, however a significant 
inhibition of [3H]-ADMA accumulation was observed in the pineal gland, choroid plexus 
and pituitary gland following perfusion with 100 µM unlabelled L-arginine (Figure 
2-44). 
2.5.5.2 Effect of L-arginine on [3H]-ADMA transport across the BBB 
Following on from the observations that only supraphysiological concentrations of 
ADMA never observed in vivo have an effect on [3H]-arginine transport across the BBB 
and BCSFB described in section 2.5.4, the present study found that [3H]-ADMA 
transport across the BBB is highly sensitive to inhibition by physiological (100 µM) L-
arginine. The biological implications for this are that L-arginine transport across the 
BBB from plasma into brain is likely to predominate under both physiological 
conditions, but also pathological conditions where plasma ADMA is elevated.  
This is also very elegantly demonstrated by the almost identical respective inhibition of 
unlabelled 100 µM L-arginine and 100 µM ADMA on the distribution of [3H]-ADMA in 
the frontal cortex, as shown in Figure 2-45. 
2.5.5.3 Effect of L-arginine on [3H]-ADMA transport across the BCSFB 
Just as [3H]-ADMA is highly sensitive to inhibition by physiological concentrations of 
L-arginine at the BBB, the same holds true for the BCSFB. This is also demonstrated 
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by the almost identical respective inhibition of unlabelled 100 µM L-arginine and 100 
µM ADMA on the distribution of [3H]-ADMA in the choroid plexus, as shown in 
Figure 2-45. Perhaps the lack of inhibition of [3H]-ADMA accumulation in the CSF 
by unlabelled 100 µM L-arginine may be an indication that the accumulation that is 
observed is due to passive paracellular diffusion of [3H]-ADMA across the BCSFB, 
although this study alone would be insufficient to make a firm conclusion. 
2.5.5.4 Implications for the ‘competition hypothesis’ to explain the L-arginine 
paradox 
In analysis of the feasibility of the 'competition hypothesis' to explain the L-arginine 
paradox (in the context of the BBB and BCSFB), there are several pieces of evidence 
uncovered by the studies discussed in this chapter that suggest that an alternative 
hypothesis is needed: 
i. While transport systems that can transport ADMA into BCECs from plasma 
exist, it would appear that efflux of ADMA pre-dominates. 
ii. Km values for ADMA influx at the BBB and BCSFB are higher than those 
previously published for influx of other cationic amino acids such as L-arginine. 
iii. The biggest contributor to ADMA and L-arginine transport at the BBB and 
BCSFB is system y+. 
iv. Neither physiological nor pathological concentrations of ADMA in plasma have 
any inhibitory effect on L-arginine transport across the BBB and BCSFB in 
vivo. ADMA concentrations must be increased to supraphysiological 
concentrations of 500 µM to observe any inhibition of L-arginine transport, in 
agreement with observations recently made in vitro (Strobel et al., 2012). 
It is therefore highly unlikely that the L-arginine paradox is due to competition for 
transport by system y+ between L-arginine and ADMA, and this hypothesis should be 
discounted. 
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2.5.6 Trans-stimulation of L-arginine and ADMA transport 
2.5.6.1 Trans-stimulation of [3H]-arginine transport 
Trans-stimulation was first proposed by (Teerlink et al., 2009) to explain the L-
arginine paradox, where it was hypothesised that supplemented L-arginine may trans-
stimulate the removal of ADMA from the cell, and restoring influx of L-arginine for 
conversion into NO (see section 2.1.1.4B - Trans-stimulation hypothesis). 
Of all CAATs, y+ is by far the most sensitive to trans-stimulation, particularly CAT-1 
(Hatzoglou et al., 2004), although systems y+L (Mann et al., 2003) and b0,+ (Nguyen et 
al., 2007) both display trans-stimulation to lesser degrees. No evidence of system B0,+ 
trans-stimulation has been documented.  
In vitro cell culture is more ideally suited to investigating trans-stimulation since cells 
essentially constitute a closed system whereby the movement of solutes between 
extracellular and intracellular compartments can be studied and quantified. The 
investigation of ADMA/L-arginine trans-stimulation at the BBB and BCSFB in vivo is 
complicated by the presence of several intracellular and extracellular compartments, 
each containing different concentrations of endogenous ADMA and L-arginine, and 
expressing different transporters, with different substrate specificities. It is therefore 
much more difficult to predict how the solutes of interest will equilibrate between these 
compartments, and analyse data from these experiments. Despite this limitation, 
experiments were designed to investigate the ability of high levels of intracellular 
ADMA to trans-stimulate [3H]-arginine uptake at the BBB and BCSFB following 
supplementation with L-arginine, and are discussed below. 
2.5.6.1A Summary of results 
Experiments involving a 20-minute 'pre-perfusion' followed by 10-minute 'post-
perfusion' were designed to investigate if [3H]-arginine transport across the blood-CNS 
barriers is subject to trans-stimulation under conditions recreating L-arginine 
supplementation in NO-deficient patients (Figure 2-47 and Figure 2-49). Trans-
stimulation is a phenomenon whereby the presence of substrate on one side of a cellular 
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membrane, stimulates the transport of substrate on the other (trans) side of the 
membrane. [3H]-arginine uptake in all brain regions except for hypothalamus and 
thalamus was found to be trans-stimulated by high levels of intracellular ADMA 
(following perfusion with 500 µM unlabelled ADMA), but only when [3H]-arginine in 
the post-perfusion was co-perfused with 200 µM unlabelled L-arginine (Figure 2-47). 
This trans-stimulation of [3H]-arginine uptake was also seen in the whole-brain 
homogenate, and very strongly in BCECs (p < 0.001), but not in brain parenchyma 
following capillary depletion (Figure 2-48). [3H]-arginine uptake was also trans-
stimulated in a similar manner in the pineal gland, choroid plexus and pituitary gland 
(Figure 2-49). 
2.5.6.1B Trans-stimulation of [3H]-arginine transport across the BBB 
The first comparison for this batch of experiments involved determining the effect of 
pre-perfusing with 500 µM unlabelled ADMA on [3H]-arginine transport across the BBB 
(Figure 2-47). The 'control' comparison for these experiments was a 20-minute pre-
perfusion with artificial plasma containing no additives, followed by a 10-minute 
perfusion with artificial plasma containing [3H]-arginine alone. The act of pre-loading 
the brain capillary endothelium with 500 µM ADMA with a 20-minute pre-perfusion 
caused no changed in the accumulation of [3H]-arginine in any of the brain regions 
sampled, or capillary depletion analysis samples (Figure 2-47). 
This comparison was then extended to more accurately reflect the situation of 
supplemented 200 µM unlabelled L-arginine – the third experimental condition for 
comparison in these experiments. Pre-loading the brain capillary endothelium with 500 
µM ADMA, and then perfusing with [3H]-arginine supplemented with 200 µM 
unlabelled L-arginine produced a significant increase in [3H]-arginine distribution in all 
brain regions sampled, except for the hypothalamus and thalamus (Figure 2-47). 
Capillary depletion analysis appears to demonstrate this effect in the whole-brain 
homogenate, and BCECs, but not in the brain parenchyma itself (assuming there is no 
fraction-to-fraction contamination). 
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While system y+ is expressed on both the luminal and abluminal membrane, with 
expression levels higher on the abluminal membrane (O'Kane et al., 2006), the 
unlabelled ADMA in 'pre-perfusion' artificial plasma, and [3H]-arginine and unlabelled 
L-arginine in 'post-perfusion' artificial plasma would all be exposed to transporters at 
the luminal membrane first. It is therefore possible that the observed effect of trans-
stimulation being amplified in BCECs but not brain parenchyma following capillary 
depletion relates directly to the luminal system y+ transporters. It would not be un-
reasonable to expect that abluminal y+ is just as susceptible to trans-stimulation as 
luminal y+, however the presence of system y+ on both luminal and abluminal 
membranes means they are susceptible to different substrate concentrations on each 
side of the membrane. Luminal system y+ would be subject to concentration gradients 
for L-arginine and ADMA created by differences in respective concentrations in 
intracellular and plasma compartments. In contrast, abluminal system y+ is subject to 
entirely different concentration gradients created by differences in respective 
concentrations of ADMA and L-arginine in intracellular and ISF/CSF compartments. 
An additional consideration to be made relates to the nature of system y+ transporters 
themselves; since they are bi-directional but still uniport transporters that do not 
simultaneously exchange substrates across the membrane. 
These observations of trans-stimulation of L-arginine transport by intracellular ADMA 
are in accordance with currently unpublished data relating to the same experiments 
performed using the human BBB in vitro model hCMEC/D3 cell line (Watson, 2012). 
A possible explanation of the observed effects presented in this section is therefore that 
unlabelled 500 µM ADMA accumulates inside BCECs during the 'pre-perfusion', 
preventing influx of [3H]-arginine from the circulating artificial plasma. The 
introduction of 200 µM L-arginine may then be trans-stimulating system y+ to remove 
the accumulated ADMA from BCECs until the concentration gradient favouring [3H]-
arginine transport into the BCECs via y+ overwhelms the concentration gradient 
favouring efflux of ADMA via y+. The experiments testing this hypothesis are discussed 
below in section 2.5.6.2 - Trans-stimulation of [3H]-ADMA transport. 
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2.5.6.1C Trans-stimulation of [3H]-arginine transport across the BCSFB 
The observed effect of apparent trans-stimulation of [3H]-arginine transport across the 
BBB also holds true for the pineal gland, choroid plexus and pituitary gland (Figure 
2-49). The accumulation of [3H]-arginine in these organs appears to be trans-stimulated 
when they are pre-loaded with unlabelled 500 µM ADMA and then perfused with 
artificial plasma containing both [3H]-arginine and unlabelled 200 µM L-arginine. 
2.5.6.2 Trans-stimulation of [3H]-ADMA transport 
2.5.6.2A Summary of results 
[3H]-ADMA accumulation in all brain regions, pineal gland, choroid plexus and 
pituitary gland was significantly lower when perfusing for 20 minutes with [3H]-ADMA 
and then 10 minutes of artificial plasma containing no additives, relative to control 
conditions of just a 20-minute perfusion with [3H]-ADMA (Figure 2-51 and Figure 
2-53). Capillary depletion analysis revealed that this phenomenon was only observable 
in whole-brain homogenate, but not in brain parenchyma or BCECs (Figure 2-52). 
The second comparison in this study relates to [3H]-ADMA accumulation after 
perfusing for 20 minutes followed immediately by a 10-minute perfusion of either 
artificial plasma containing no additives, or artificial plasma containing unlabelled 200 
µM L-arginine. In all brain regions sampled, pineal gland and pituitary gland, [3H]-
ADMA accumulation was significantly higher when including unlabelled 200 µM L-
arginine in the 10-minute 'post-perfusion'. Comparisons for capillary depletion analysis 
samples between these two experimental groups again revealed no significant 
differences. 
2.5.6.2B Trans-stimulation of [3H]-ADMA transport across the BBB 
For the trans-stimulation hypothesis to explain the L-arginine paradox to be proved 
correct, one would predict that the increased intracellular ADMA would trans-
stimulate the influx of L-arginine in plasma through system y+ at the luminal 
membrane. The experiments described in this study were devised to test this prediction 
by attempting to pre-load BCECs with [3H]-ADMA with an aim of observing increased 
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efflux due to trans-stimulation by unlabelled 200 µM un-labelled in artificial plasma 
(mimicking the concentration of L-arginine achieved in the plasma by dietary 
supplementation in patients (Clarkson et al., 1996; Adams et al., 1997)). 
Trans-stimulation of [3H]-ADMA efflux by high levels of extracellular L-arginine was 
found to be robustly present in the human BBB in vitro model hCMEC/D3 cell line 
(Watson, 2012), data published as PhD thesis only at time of writing. However, the 
lack of this phenomenon at the murine BBB in this present study may be due to a 
number of reasons: 
i. [3H]-ADMA may have already begun to be removed from BCECs after 10 
minutes of the 'pre-perfusion' phase of these experiments, as per the findings of 
the multiple-time uptake studies discussed in section 2.5.3.2. 
ii. Trans-stimulation is a difficult phenomenon to observe in vivo and particularly 
at the BBB due to the number of available compartments for substrates to 
equilibrate between, but also because of the number of different transporters 
that [3H]-ADMA appears to interact with, as discussed in section 2.5.3.3. 
The fact that [3H]-ADMA accumulation actually increases when unlabelled 200 µM L-
arginine is included in the 'post-perfusion' phase is interesting as it suggests that L-
arginine actually blocks the efflux of [3H]-ADMA during the 10-minute 'post-perfusion' 
phase in that experimental group. This implies that [3H]-ADMA efflux from BCECs is 
mediated by a transporter that can also mediate L-arginine influx at the BBB. The 
present study, and others, have identified system y+ as the most likely candidate for 
this system, and as previously described, this is a bi-directional uniport transport 
system (White, 1985; Stoll et al., 1993). Having shown that L-arginine outcompetes 
ADMA on the cis- side of the plasma membrane for transport via system y+ in this 
chapter, it is entirely plausible that L-arginine also outcompetes ADMA on the trans-
side of the plasma membrane. One method to test this would be to co-perfuse [3H]-
ADMA with 20 mM L-homoarginine as discussed in section 2.5.3.3, but extend the 
perfusion time from 10 minutes to 30 minutes with an aim of observing the transport 
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system in the state of [3H]-ADMA efflux. Should this be found to be true, and in light 
of the fact that trans-stimulation of [3H]-ADMA efflux was not observed in the 
experiments discussed here, another future experiment could be to pre-load with [3H]-
ADMA for only 10 minutes, rather than 20 minutes. 
2.5.6.2C Trans-stimulation of [3H]-ADMA transport across the BCSFB 
The observed lack of trans-stimulation of [3H]-ADMA efflux across the BBB also holds 
true for the pineal gland and pituitary gland (Figure 2-53). However, the efflux of 
[3H]-ADMA in the choroid plexus appeared to be trans-stimulated by the presence of 
unlabelled 200 µM L-arginine in the artificial plasma during the 10-minute 'post-
perfusion' phase of the experiment, indicated by a significant decrease relative to the 
experimental group where no additives were present in the artificial plasma for the 10-
minute 'post-perfusion' phase. This is an interesting difference between the choroid 
plexus and the pineal and pituitary glands that appears to be unique to this particular 
set of experiments; since interactions of [3H]-ADMA with the BCSFB in all other 
studies performed for this thesis were relatively uniform between these sub-organs of 
the brain (e.g. Figure 2-19, Figure 2-28 etc.). Determining the biological significance 
of this particular difference is thus difficult on the basis of these data alone, and thus 
further investigation of this effect in the choroid plexus under these conditions is 
warranted. 
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2.5.7 Conclusions 
A number of experimental variations to the murine in situ brain/choroid plexus 
perfusion technique were devised and performed to characterise the transport of L-
arginine and ADMA transport across the murine BBB and BCSFB. [3H]-ADMA and 
[3H]-arginine were used as substrates in addition to their unlabelled counterparts in 
different combinations and concentrations, as well as a number of specific transport 
inhibitors to compare transport and inhibition kinetics. The principal findings for these 
experiments are as follows: 
1. Saturable transport systems for both ADMA and L-arginine exist at both the 
BBB and BCSFB in mouse. 
2. A major contributor to the transport of both ADMA and L-arginine at both the 
BBB and BCSFB is system y+, seemingly transporting L-arginine from plasma 
into the CNS, and ADMA in both directions in a time and concentration 
dependent manner. 
3. ADMA also has complex interactions with a wide range of transport systems 
expressed at the BBB and BCSFB. 
4. The most likely transporter mediating ADMA efflux from the CNS at both the 
BBB and BCSFB is system y+. 
5. ADMA does not compete with L-arginine for transport under physiological or 
pathophysiological conditions. 
6. On the basis of the data shown in this study, the trans-stimulation hypothesis is 
partially correct, since intracellular ADMA appears to be able to trans-
stimulate L-arginine influx in conditions mimicking dietary supplementation. 
This study was unable to detect trans-stimulation of ADMA efflux at the 
murine BBB in vivo, under these conditions. 
While trans-stimulation of ADMA efflux by extracellular L-arginine has been observed 
at the human BBB in vitro (Watson, 2012), it is currently unclear if the phenomenon 
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also exists at the mouse BBB and BCSFB in vivo. As with all in vitro data, the 
limitations of studying this phenomenon in cultured cells include culture-induced 
changes in transporter expression, as well as a lack of transporter polarisation into 
luminal and abluminal membrane microenvironments to the extent that exists in vivo. 
Furthermore, the hCMEC/D3 cells have much lower TEER values when compared to 
BCECs in vivo.  
2.5.7.1 Implications of NO synthesis 
As L-arginine is the precursor for NO synthesis, and ADMA a potent inhibitor of NO 
synthesis (Vallance et al., 1992a; Vallance et al., 1992b) the interplay between the 
respective transport of these two amino acids across plasma membranes has been 
widely predicted to relate directly to NO production. Credence is lent to this 
hypothesis by the fact that the canonical system y+ transporter CAT-1 that is 
responsible for L-arginine transport across most biological membranes co-localizes with 
caveolae and eNOS in endothelial cells (McDonald et al., 1997). Moreover, the over-
expression of murine CAT-1 in bovine aortic endothelial cells has previously been 
shown to lead to increased L-arginine transport and NO production (Zani & Bohlen, 
2005). 
One experiment to definitively test if system y+ transport is a rate-determining step in 
the production of NO (and therefore if it is likely to be involved in the L-arginine 
paradox) may be to measure the effect of inhibition of L-arginine transport by L-lysine 
on NO production. Since L-lysine is a system y+ substrate but not an inhibitor of NOS 
one may predict that should the transport of L-arginine be a critical step in NO 
production, that L-lysine would also inhibit NO production without directly inhibiting 
NOS. Data relating to this has thus far been conflicting/inconclusive; with one group 
finding that NO production is sensitive to L-lysine inhibition (Wu et al., 2000), while 
another has found the opposite is true (Zani & Bohlen, 2005). 
In vitro studies appear to dominate as an approach to investigating the involvement of 
L-arginine and ADMA transport on NO production, and it has been observed that 5 
µM ADMA can inhibit NO production in the presence of 100 µM L-arginine in bovine 
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endothelial cells (Cardounel et al., 2007). Considering the fact that data presented in 
this thesis, and elsewhere (Strobel et al., 2012), overwhelmingly indicates that 
transport of L-arginine by system y+ would not be affected by ADMA at those 
concentrations, an alternative transport system may possibly be playing a role in the L-
arginine paradox. While system y+ is an important system for the transport of L-
arginine and its related methylarginines, it is not the exclusive transport system for 
these substrates. Indeed, data presented here for the identification of transporters 
mediating [3H]-ADMA transport across the murine BBB and BCSFB have identified a 
number of interactions with different transport systems. It has previously been 
proposed that L-arginine transport in endothelial cells has two components – a high 
affinity, low capacity system (y+), and an additional low affinity, high capacity system 
(Preik-Steinhoff et al., 1995). The exact identity of this system y+-independent 
component of L-arginine transport was not found in that study, however one possible 
candidate is the y+L system, which is known to be required for NO synthesis under 
certain experimental conditions (Arancibia-Garavilla et al., 2003). In addition to 
transporting L-arginine (Deves & Boyd, 1998; Omidi et al., 2003), system y+L has also 
been shown to have the capacity to transport ADMA (Slenzka et al., 2011); 
observations corroborated by the data presented here in the context of the murine BBB 
and BCSFB. 
In summary, while the data presented here contribute to the current understanding of 
the interplay between ADMA and L-arginine transport across biological membranes, 
and particularly those of the BBB and BCSFB, further experimentation is required to 
solve the L-arginine paradox. 
A schematic of the involvement of trans-stimulation in explaining the arginine paradox 
from the observations in this study are shown in Figure 2-54. 
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Figure 2-54: Summary of trans-stimulation involving L-arginine and ADMA 
transport across the murine BBB. An increase in the plasma concentration of L-
arginine following oral supplementation combined with high intracellular concentrations of 
ADMA appears to trans-stimulate the influx of L-arginine into the BCEC via luminal 
CAT-1. This study was unable to measure trans-stimulated efflux of ADMA from BCECs 
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2.5.8 Future work 
2.5.8.1 Role of system y+L in transport of L-arginine at the BBB 
As mentioned above, system y+L is a possible candidate for a second transport system 
regulating the transport of L-arginine into endothelial cells. Since system y+L is 
inhibited by L-leucine (Estevez et al., 1998; Rotmann et al., 2007), this could be 
investigated at the BBB through the co-perfusion of L-leucine with [3H]-arginine. 
2.5.8.2 L-arginine transport at the apical membrane of the choroid plexus 
The transport of L-arginine across the apical membrane of the choroid plexus could be 
investigated using the isolated incubated choroid plexus technique, since the greatest 
contributor to transport observed in the choroid plexus using the in situ brain/choroid 
plexus technique is the basolateral membrane. The isolated incubated choroid plexus 
technique could be expected to reveal whether or not there an apical transporter for L-
arginine exists. The implications of these findings would be to determine if the BBB is 
the main transport interface for providing L-arginine to brain (where observed 
basolateral arginine transport serves to merely supply choroid plexus epithelium), or if 
BCSFB also contributes. 
2.5.8.3 Further probing of L-arginine and ADMA efflux 
Following the observations in this study that L-arginine may be effluxed from the 
pituitary gland after 30 minutes, extending the perfusion time of experiments where 
[3H]-arginine was co-perfused with specific transport inhibitors to 30 minutes could be 
expected to identify any transport systems potentially involved in this process. 
Similarly, extending the perfusion time of the same set of experiments with [3H]-ADMA 
could also identify any transport systems involved in the efflux of ADMA (if any). It 
should be noted that any efflux of either ADMA or L-arginine could be passive and 
merely due to a change in concentration gradients during the perfusion. 
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2.5.8.4 Trans-stimulation experiments 
Following the observation that the highest accumulation of [3H]-ADMA in brain regions 
over the course of 30 minutes is after 10 minutes, a possible extension to the 
experiments reported here could be to reduce the ‘pre-perfusion’ phase from 20 minutes 
to 10 minutes. This could potentially reveal why the phenomenon of trans-stimulation 
was observed to be robust at the choroid plexus but not in brain regions. 
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3  
Brain delivery of small molecules 
through specific inhibition of 




The efficient delivery of drugs to the CNS has proved to be a difficult task over the 
years, and the cumulative success rates for CNS drugs progressing through clinical 
development is often much lower than those seen for cardiovascular or cancer drugs 
(Figure 3-1). The underlying cause for this trend is most likely to be multi-factorial, 
and the topic of a number of reviews elsewhere (Alavijeh et al., 2005; Pardridge, 2005). 
However, the presence of the blood-CNS barriers with their unique abilities to tightly 
and specifically regulate the movement of molecules into the CNS no doubt make the 
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Figure 3-1: The cumulative success rates for drugs in clinical development. CNS 
drugs have much lower success rates during phase I, II and III clinical trials relative to 
cardiovascular or cancer drugs. Adapted from (Alavijeh et al., 2005). 
 
The BBB alone excludes more than 98% of small molecule diagnostics and therapeutics, 
and almost 100% of large biologics such as monoclonal antibodies from the CNS 
(Pardridge, 2005). Molecules that are known to reach the CNS in pharmacologically 
relevant amounts typically have a low molecular weight of approximately 0.5 kDa, and 
a high degree of lipid solubility (Pardridge, 2005) – characteristics that also make them 
more likely to be substrates for removal from the CNS by ABC efflux transporters 
outlined in chapter 1. With the success rates shown in Figure 3-1, it is thought that 
a large number of CNS conditions could benefit from improved therapies (Pardridge, 
2005). Understanding and manipulating the processes that dictate CNS entry may 
facilitate the rational design of drugs and drug carriers to facilitate the efficient delivery 
of drugs to treat CNS pathologies. One such CNS pathology that is particularly 
underserved by the pharmaceutical research community (more so in recent years) is 
Human African Trypanosomiasis (HAT), also known as 'sleeping sickness'. 
3.1.1 Human African Trypanosomiasis (HAT) 
HAT is a parasitic disease endemic in sub-Saharan Africa that is caused by infection 
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Cumulative success rates for drugs in development 
% success rate 
Cardiovascular Cancer CNS 
Source: Alavijeh, M.S. et al. (2005) 
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Trypanosoma brucei gambiense. The parasites are transmitted by the bite of insect 
vectors belonging to the genus Glossina (Tsetse flies), and display a life cycle strategy 
that is equally spread between human and insect hosts (Brun et al., 2010). Both 
parasite species cause a similar clinical disease, but with differing degrees of virulence, 
and can be distinguished using molecular methods (Radwanska et al., 2002; Picozzi et 
al., 2008). However, these methods are often unavailable in the field, and the 
differential diagnosis of HAT often relies on the parasites' discrete geographical 
distributions (T.b. gambiense in West and Central Africa, and T.b. rhodesiense in East 
Africa, shown in Figure 3-2), although there are concerns that the distributions may 
be blurring in recent years (Picozzi et al., 2005). There are currently around 10,000 
new cases of HAT reported each year (latest figures, (WHO, 2010)), and likely a 
substantial number of more cases that go unreported, with a total of 48,000 deaths due 
to HAT in 2008 (WHO, 2009). 
The disease progression for HAT can be separated into two distinct phases, with 
differing symptoms. Stage 1 HAT is known as the haemolymphatic or blood phase, and 
is caused by the parasite invading the circulatory and lymphatic systems (Priotto et 
al., 2007). Stage 1 HAT starts asymptomatically, but as parasitaemia increases patients 
often present with chronic and intermittent fever, severe itching of the skin and severe 
swelling of the lymph nodes (Brun et al., 2010). Having entered the circulation, 
trypanosomes have several effective strategies to avoid the host's immune system, 
including a wide repertoire of genes encoding variant surface glycoproteins (VSG) that 
coat their outer layer and can be interchanged and even intragenetically shuffled at will 
to avoid antibody binding (Donelson et al., 1998). Only one VSG protein is expressed 
on the outer layer of the parasite at any given time, and since an antibody response to 
this protein is raised roughly once every ten days, the parasite changes the VSG 
protein it expresses by antigenic variation (Turner, 1997; Cross et al., 1998). This 
process leads to characteristic waves of parasitaemia, and eventually the disease 
progresses to stage 2 – the meningoencephalitic or CNS phase. 
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Figure 3-2: Geographical distribution of HAT in sub-Saharan Africa. Incidence of 
HAT caused by T.b. gambiense has historically been restricted to West and Central 
Africa, while T.b. rhodesiense has been restricted to East Africa. There are concerns that 
there may be some overlap in this distribution in recent years. Adapted from (Simarro et 
al., 2008). 
 
The time taken for HAT to progress to stage 2 appears to vary depending on the 
parasite involved. T.b. rhodesiense is typically the more virulent of the two, 
progressing to stage 2 within months; while T.b. gambiense can take years after the 
initial infection to progress to stage 2 (Odiit et al., 1997; Checchi et al., 2008). Stage 2 
of HAT arises when the parasite leaves the circulation and lymphatic system to invade 
the CNS. The precise mechanism for how the parasite is able to do this is a subject of 
debate. One school of thought hypothesises that the parasite crosses the BBB by 
transcytosis without affecting paracellular permeability and TJ protein expression 
(Mulenga et al., 2001), or by another as yet unidentified mechanism involving 
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that trypanosomes are more opportunistic and require transient increases in BBB 
paracellular permeability to infect the CNS (Philip et al., 1994; Grab & Kennedy, 
2008). Most recently, the choroid plexus has been put forward as the only site of entry 
for trypanosomes into the CNS, excluding the BBB, by virtue of the fact that parasites 
are consistently detected in the choroid plexus epithelium before the brain parenchyma 
(Wolburg et al., 2012). 
Once in the CNS, the parasites cause changes in the sleeping cycle and insomnia – 
characteristic features of the disease that lend themselves to the nickname 'sleeping 
sickness'. These symptoms are often accompanied by other neurological symptoms, 
such as motor weakness, limb paralysis and Parkinsonian tremors due to muscular 
hypertension (Kristensson et al., 2010). Once established, and if left untreated, these 
symptoms worsen in 100% of cases until the patient falls into a coma, soon followed by 
death. The increased virulence in stage 1 HAT displayed by T.b. rhodesiense continues 
through to stage 2, with a much more aggressive disease progression (Balasegaram et 
al., 2009). 
3.1.1.1 Treatment of HAT 
A very small number of drugs are currently available for the treatment of HAT, and 
these have historically been categorised as drugs for the treatment of stage 1 HAT, and 
drugs for the treatment of stage 2 HAT (Table 3-1). For stage 1 HAT, the current 
drug of choice for the treatment of T.b. rhodesiense is suramin – a potent trypanocidal 
drug that has been used since 1922 (Docampo & Moreno, 2003). Suramin therapy 
typically involves a dosing regimen of six, weekly intravenous injections and is often 
associated with a number of adverse reactions, including rash (incidence: 90%, not 
dose-limiting), adrenal cortical damage (incidence: 50%) and peripheral neuropathy 
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The drug used for the treatment of stage 1 T.b. gambiense infection is pentamidine, 
and will be discussed in greater detail in section 3.1.1.1A - Focus on 
Pentamidine. 
Traditionally, the most frequently used drug for the treatment of stage 2 HAT is 
melarsoprol – dosed intravenously at 2.2 mg kg-1 daily for 12 consecutive days (Burri et 
al., 2000). However, this is due to a lack of alternatives and does not reflect the very 
poor safety profile of melarsoprol, which is an organic arsenic derivative that melts 
plastic (Lancet, 2010), and has poor solubility in water, ether or alcohol. This means 
that melarsoprol must be dissolved in the solvent propylene glycol for administration, 
which as an excipient/vehicle itself causes extreme pain upon injection (Docampo & 
Moreno, 2003). Furthermore, melarsoprol is extremely toxic to patients, with 5-10% 
developing severe encephalopathy (resulting in death in 50% of cases) (Kennedy, 2004). 
Such adverse reactions mean that the use of melarsoprol for the treatment of stage 2 
HAT is on the decline, with either eflornithine or nifurtimox/eflornithine combination 
therapy (NECT, 7 days of twice daily intravenous and 10 days of 4 times daily oral 
therapy) preferred where possible (Simarro et al., 2011). The use of eflornithine is 
limited both by its expense, and its inability to treat T.b. rhodesiense due to the 
parasite's high ornithine decarboxylase turnover conferring resistance (Iten et al., 
1997). Eflornithine is however effective in treating stage 2 T.b. gambiense infection, and 
while the absolute number of patients being treated for Stage 2 caused by T.b. 
gambiense is decreasing, it remains steady at approximately 60% of new infections 
annually (Simarro et al., 2011). 
3.1.1.1A Focus on Pentamidine 
Pentamidine (1,5-4’-aidinophenoxypentane isethionate salt) is the current drug of 
choice for the treatment of stage 1 T.b. gambiense infection, and was developed after a 
related compound (synthalin) was discovered to have trypanocidal activity (Sands et 
al., 1985). Pentamidine is administered via intramuscular injection or by slow 
intravenous infusion (Docampo & Moreno, 2003) and there are a number of putative 
mechanisms of action for its trypanocidal activity – namely through selective inhibition 
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of Ca2+-ATPase (Benaim et al., 1993) or non-specific inhibition of tRNA 
aminoacylation in the trypanosomal mitochondria (Sun & Zhang, 2008). While the 
exact mechanism of action for pentamidine trypanocidal activity is not clear 
(Calderano et al., 2011), its success in the treatment of HAT has led to the 
development of other diamidine compounds (Sturk et al., 2004). 
 
 
Figure 3-3: Chemical structure of pentamidine. 
 
Pentamidine is generally considered to be one of the lesser toxic anti-HAT drugs, 
however peripheral side-effects include hypoglycaemia (incidence: 5-40%) and diabetes 
mellitus (incidence: occasional) – often dose-limiting factors that can lead to incomplete 
treatment (Burri, 2010). Despite being historically viewed as a stage 1 HAT drug 
(Raseroka & Ormerod, 1986), pentamidine has been found to be effective in treating 
the very early stages of stage 2 HAT (Doua et al., 1996). After the first observation 
that trypanosomes may be accumulating in CVOs prior to infecting the CNS 
(Lundkvist et al., 2004), later confirmed (Wolburg et al., 2012), it was hypothesised 
that the separation of stage 1 and 2 HAT drugs (and their efficacy therein) was due to 
their ability or inability to cross the blood-CNS barriers (Sanderson et al., 2007; 
Sanderson et al., 2008; Sanderson et al., 2009).  
In the case of pentamidine, it was observed that intact drug could be detected in the 
brain, having crossed both the luminal and abluminal membranes of the BBB, but that 
a considerable amount was being trapped by the capillary endothelium (Sanderson et 
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brain capillary endothelium, but brain concentrations that were attained were deemed 
to not be high enough to be efficacious against trypanosomes (Sanderson et al., 2009). 
Brain concentrations of pentamidine were however significantly increased in mdr1a/1b -
/- (P-gp double knockout) mice, as well as in the choroid plexus in wild-type mice 
dosed with a selective inhibitor of MRP-1 efflux (Sanderson et al., 2009). Taken 
together, these data would suggest that a strategy that is able to attenuate these efflux 
mechanisms at the BBB and BCSFB should be effective in increasing CNS 
concentration of pentamidine. 
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3.1.2 Nanotechnology: Focus on Pluronic® P85 
Pluronic® P85 belongs to a family of triblock copolymers characterised by a central 
hydrophobic block of poly(propylene oxide) (PPO) flanked by two hydrophilic blocks of 
poly(ethylene oxide) (PEO). 
 
 
Figure 3-4: Chemical structure of Pluronic® P85. 
 
Pluronic® P85 is thus an amphiphilic compound, as the individual PPO and PEO 
domains respectively have hydrophobic (water insoluble) and hydrophilic (water 
soluble) properties.  
In very dilute conditions, Pluronics are present in solution as individual polymer 
chains, termed ‘unimers’. As the concentration of the polymer in solution increases, a 
threshold point is reached whereby the unimers begin to aggregate into energetically 
favourable three-dimensional structures: micelles (Figure 3-5, panel 3). This is due to 
the amphiphilic nature of the molecules, which results in the molecules arranging in a 
conformation that reduces interactions between their hydrophobic domains and the 
polar water molecules. Micelles ordinarily have an anisotropic distribution of water 
within their structure – that is to say that the concentration of water decreases from 
the surface towards the hydrophobic core of the micelle; where water is largely 
excluded. In the case of Pluronics, however, a large fraction of water is still associated 
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The concentration at which micelles are formed is termed the critical micelle 
concentration (CMC). Above the CMC, unimers are still present at a concentration 
that is equal to the CMC, and any additional molecules are incorporated into micelles. 
When dissolved in solution, amphiphilic molecules adsorb at the water-interface, 
lowering the surface tension (Figure 3-5, panel 2), and thus acting as surface-active-
agents or ‘surfactants’. This is because it is energetically more favourable for the 
hydrophobic domains of the molecules to avoid the contact with water. As a result, the 
surface tension of a liquid containing surfactants decreases with increasing surfactant 
concentration up to the CMC, where the interface becomes saturated and the formation 
of micelles in the bulk solution does not lead to further decrease of the surface tension. 
 
 
Figure 3-5: Behaviour of triblock copolymers such as Pluronic® P85 in aqueous 
solution. The hydrophilic domains of Pluronic® P85 are shown here in dark blue, with the 
hydrophobic domain in red. At low concentrations (panel 2) surfactants initially form 
layers on the surface of the liquid to minimise the contact of hydrophobic domains with 
polar water molecules. Increasing the concentration of surfactant eventually results in the 
formation of micelles with hydrophobic cores (panel 3). The concentration at which this 
occurs is termed the critical micelle concentration (CMC). 
 
The unique structure of micelles presents a useful pharmaceutical opportunity to 
solubilise drugs that would ordinarily have poor solubility in aqueous solution. The 
spatial localisation of a drug within a micelle depends on its exact chemical structure 
and its polarity. Nonpolar molecules are usually solubilised within the micellar core, 
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palisade/coronal layer and the hydrophobic core (Rangel-Yagui et al., 2005a), or even 
at the water/micelle interface, in the case of more hydrophilic drugs.  
One very important consideration when designing a micellar drug delivery system is the 
CMC of the surfactant molecule, since this is the parameter that ultimately determines 
the stability of the delivery system (Kabanov & Alakhov, 2002; Rangel-Yagui et al., 
2005a). The biological relevance of the CMC in the context of designing an optimised 
drug delivery system is three-fold: 
i. Circulation time 
ii. Inhibitory effect of unimers on efflux transporters 
iii. Decreased drug-related toxicity 
These three important parameters are discussed in greater detail in the sections that 
follow. 
3.1.2.1 Circulation time 
A long systemic circulation time for an intravenous drug is often a desirable property 
to improve the likelihood of the drug reaching its intended target site or tissue before it 
is removed from the blood by the kidneys or metabolised. One possible strategy for 
increasing the circulation half-life of drugs is by encapsulation within specifically 
designed nano- or microscopic drug carriers, which include micelles (Kabanov & 
Alakhov, 2002; Rangel-Yagui et al., 2005a). 
From a pharmacological perspective, knowledge of the CMC value is of critical 
importance, since any micellar formulation is subject to dilution in biological fluids 
(e.g. blood) upon administration, and micelles with a high CMC can dissociate into 
unimers and prematurely release the drug into the blood (Yokoyama, 1992). Micelles 
made from a surfactant with low CMC are more likely to retain their integrity in 
circulation and reach the target site before decaying into unimers (Lavasanifar et al., 
2002; Adams et al., 2003). In this prospect, polymeric surfactants such as Pluronics® 
are advantageous since they usually present a much lower CMC than conventional, low 
molecular weight surfactants. 
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When developing polymeric or colloidal drug delivery systems, an important 
consideration should be to avoid clearance by the reticuloendothelial system (RES) 
following protein adsorption in the blood, which typically results in accumulation of the 
drug carrier in the liver or spleen. It has been observed that the extent of clearance by 
the RES is reduced if the drug delivery system is smaller than 200 nm in diameter, 
facilitating a longer circulation time (Stolnik et al., 1995). Micelles formed by 
Pluronic® P85 are approximately 20 nm in diameter, with a circulation half-life in mice 
of between 60 to 90 hours (Batrakova et al., 2004a). The accumulation of Pluronic® 
P85 in the liver following systemic administration is greatly reduced if the 
concentration of Pluronic® P85 is above the CMC. However, the existence of Pluronic® 
P85 in circulation as micelles rather than unimeric form appears not to affect the 
overall clearance characteristics – indicating that elimination of Pluronic® P85 from the 
bloodstream is largely due to renal clearance rather than the disposition or 
disintegration of circulating micelles (Batrakova et al., 2004a). 
The ability of Pluronic® micelles to avoid detection and clearance by the RES is 
further enhanced by the hydrophilic corona formed by the PEO domain. This 
hydrophilic shell stabilises the micelle while also preventing the adsorption of 
circulating proteins, conferring it ‘stealth’ properties (Alvarez-Lorenzo et al., 2010). 
Thus, the CMC is a vital consideration when designing any micelle-based drug delivery 
system, as is the diameter of the resulting micelles. 
3.1.2.2 Inhibitory effect of unimers on efflux transporters 
The high tolerability of Pluronics® in vivo – as well as their simple chemical structure 
– initially led investigators to believe that they were biologically inert compounds that 
could be used simply as drug solubilisers. However, there is growing evidence that some 
Pluronics® can have a significant effect on specific cellular responses (Kabanov et al., 
2005a; Kabanov et al., 2005b; Kabanov, 2006). Pluronic® P85, in particular, has been 
shown to be remarkably effective in sensitising multi-drug resistant cancer cells and 
potentiating the delivery of drugs across cellular barriers, including the brain capillary 
endothelium (Kabanov et al., 2002b; Kabanov et al., 2002a). This effect appears to 
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mainly be due to the Pluronic® unimers (Miller et al., 1997; Batrakova et al., 1999a) 
and is thought to stem (in part) from the ability of Pluronic® 85 to be incorporated 
into the plasma membrane and decrease microviscosity at a local level, inhibiting active 
efflux transporters (Batrakova et al., 2001b). As described in chapter 1, the lipid 
microenvironment of biological membranes appears to have a critical role in the 
mechanisms underlying efflux mediated by ABC transporters such as P-gp and MRP 
(Romsicki & Sharom, 1998; Romsicki & Sharom, 1999). The inhibition of efflux 
transporters by Pluronics® is thought to result from conformational changes in the 
efflux proteins themselves and/or the steric interference with sites in the protein 
involved in protein-drug interactions (Batrakova et al., 2004b). 
In addition to the direct effect of Pluronic® P85 on efflux transporters and the 
surrounding lipid microenvironment described above, there appears to be an additional, 
indirect effect of Pluronic® P85 on multi-drug resistant cancer cells and barrier cells 
that may contribute to the inhibition of active efflux. Pluronic® P85 unimers are 
known to translocate across the plasma membrane into cells; reaching certain 
intracellular compartments and transiently depleting cells of ATP (Batrakova et al., 
2003). This transient depletion of ATP could inhibit active efflux transporters that 
require ATP to function (Batrakova et al., 2003).  
Internalisation of Pluronic® P85 unimers occurs by caveolae-mediated endocytosis, 
while Pluronic® P85 micelles are internalised by clathrin-mediated endocytosis (Sahay 
et al., 2008). Caveolae trafficking often delivers endosomes to the endoplasmic 
reticulum (Carver & Schnitzer, 2003) but also to mitochondria (McMahon et al., 2006; 
Bozidis et al., 2008), and thus it has been proposed that this is the mechanism by 
which Pluronic® P85 unimers may reach mitochondria (Minko et al., 2005). Pluronic® 
P85 concentrations as low as 0.001% have been shown to inhibit respiratory chain 
complexes I and IV (but not II and III) in mitochondria isolated from multi-drug 
resistant cancer cells (Alakhova et al., 2010), and thus, by transiently disrupting the 
electron transport chain, less ATP is available to supply active efflux transporters. 
Interestingly, this phenomenon appears to be selective between cancer cells that are 
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multi-drug resistant or sensitive both in vitro and in vivo (Batrakova et al., 2001a; 
Alakhova et al., 2010). The proposed explanation for this selectivity relates to 
differences in the respiration rates and fuel sources used by multi-drug resistant and 
sensitive cells (fatty acids vs. glucose, respectively) (Harper et al., 2002) as Pluronic® 
P85 may also be interacting with fatty acid molecules (Harper et al., 2002). 
In the context of the blood-CNS barriers, a precedent has already been set for the 
enhanced delivery of therapeutic agents across BCECs both in vitro (Batrakova et al., 
1998; Batrakova et al., 1999b) and in vivo (Batrakova et al., 2001c) using Pluronics®. 
Digoxin is a P-gp substrate whose CNS-delivery is greatly enhanced in P-gp knockout 
mice (relative to wild-type) (Batrakova et al., 2001c). Furthermore, the co-formulation 
of digoxin with Pluronic® P85 produces a similarly enhanced delivery of digoxin to the 
CNS in wild-type mice (Batrakova et al., 2001c). Notably, it would appear that both 
membrane fluidisation and ATP depletion is required for the effective inhibition of drug 
efflux by P-gp at the BBB (Batrakova et al., 2001b). 
3.1.2.3 Decreased drug-related toxicity 
One of the more frequently observed side effects of pentamidine administration is 
hyperglycaemia (Waskin et al., 1988), which often responds well to treatment upon 
presentation. However, pentamidine treatment can also lead to or worsen diabetes 
mellitus, with an incidence of approximately 10% (Jha & Sharma, 1984; Thakur et al., 
1991). Pentamidine has been shown to activate the hepatic T1 protein, a transport 
protein that is part of the glucose-6-phosphotase system (Scott & Burchell, 1991). It 
has been proposed that the increased activation of T1 increases the transport of 
glucose-6-phosphate into the lumen of the endoplasmic reticulum, where it is broken 
down to glucose by the enzyme glucose-6-phosphatase, and resulting in hyperglycaemia 
(Scott & Burchell, 1991). Furthermore, pentamidine was found to irreversibly damage 
pancreatic β-cells in vitro, leading to hyperinsulinaemia at sub-stimulatory glucose 
concentrations and decreased glucose-induced insulin release (Sai et al., 1983; Zhou & 
Ipp, 1989). 
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Here, we propose that encapsulation of pentamidine within Pluronic® P85 micelles 
could reduce the exposure of pentamidine to the pancreas, as would otherwise result 
from systemic administration of free pentamidine through conventional needs. 
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3.2 Rationale and aims 
As discussed in the previous sections of this chapter, pentamidine is efficacious against 
stage 1 HAT, but is blocked from reaching the brain by efflux mechanisms at the 
blood-CNS barriers. The proposed solution presented in here is to co-formulate 
pentamidine with Pluronic® P85 to inhibit these efflux mechanisms and increase the 
delivery of pentamidine to the CNS with the aim to achieve the following: 
i. Effectively treat stage 2 HAT, by achieving pharmacologically relevant 
concentrations of pentamidine in the CNS. 
ii. Reduce adverse reactions to pentamidine due to pancreatic toxicity by reducing 
the free fraction of pentamidine in circulation after administration. 
iii. Shorten length of pentamidine treatment required to treat stage 1 disease. 
One of the major benefits of this solution is that Pluronics® are FDA approved as 
pharmaceutical excipients. Indeed, a formulation containing Pluronics® L61 and F127 
is in phase 2 clinical trials for the treatment of chemotherapy resistant oesophageal 
cancer (Valle et al., 2011). While either Pluronics® L61 or F127 could have been 
selected as the first co-polymers to test as a candidate drug carrier for enhanced 
delivery of pentamidine to the CNS, Pluronic® P85 was selected due to its known 
ability to inhibit P-gp at the BBB (Batrakova et al., 2003), and is known itself to cross 
the BBB (Price et al., 2010). 
Pluronic® P85 micelles and unimers are known to be internalised by cells through 
endocytotic mechanisms (Sahay et al., 2008), and since HAT results in an increase in 
endocytic vesicle formation at the BBB (Sanderson et al., 2008) it is hypothesised that 
Pluronic® P85 nanocarriers would be internalised by BCECs through similar 
mechanisms. 
It is not anticipated that either pentamidine or Pluronic® P85 will be toxic to the brain 
since 5 µM pentamidine is known not to induce any neurotoxicity (Reynolds & 
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Aizenman, 1992), and Pluronic® P85 is also well tolerated in the brain (despite slightly 
altering the transport of lactate by MCT transporters (Batrakova et al., 2004c)).  
The precise mechanism of Pluronic® P85 micelle transport across the BBB is not 
currently known, however Pluronic® P85 conjugated to leptin is transported across the 
BBB in vivo using a leptin-transporter independent, non-saturable mechanism (Price et 
al., 2010). Furthermore, Pluronic® P85 micelles enhance the delivery of the P-gp 
substrate, digoxin, to the brain, crossing endothelial cell monolayers in vitro and the 
BBB in vivo (Batrakova et al., 2001c). 
A summary of what is currently known about the interactions of pentamidine with the 
blood-CNS barriers is shown schematically in Figure 3-6, and the proposed solution to 
increase pentamidine transport into the CNS in Figure 3-7. 
 
Figure 3-6: Current understanding of the interaction of pentamidine with the blood-
CNS barriers. Pentamidine appears to interact with a broad range of transporters 
(including P-gp) expressed on the luminal side of the BBB and is removed by active efflux 
transporters that utilise energy from ATP hydrolysis to pump pentamidine back out into 
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Figure 3-7: Proposed model for increasing pentamidine uptake at the blood-CNS 
barriers using Pluronic® P85. Pentamidine is either encapsulated within, or associated 
with Pluronic® P85 micelles, and taken up by clathrin-mediated endocytosis. Once in the 
vesicles, Pluronic® P85 unimers are translocated to mitochondria where they inhibit ATP 
synthesis, thus depleting the cell of ATP available for active efflux. Pluronic® P85 
unimers in circulation also microfluidise the lipid membrane microenvironment surrounding 
efflux transporters in the luminal membrane and directly inhibit efflux. The net result is a 
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3.3 Methods 
The complexity of the blood-CNS interface, combined with limitations of the respective 
experimental techniques used to study it, make it difficult to predict and quantify 
barrier transport characteristics using one experimental approach alone. With this in 
mind, the hypotheses tested in this work utilised a combination of in silico, in vitro 
and in vivo procedures. 
In this chapter, the different methodologies employed are presented as three broad 
approaches outlined below: 
2.3.1. Physico-chemical characterisation of drug/polymer formulations 
2.3.2. Blood-CNS model & accessory methodologies 
2.3.3. Peripheral free-fraction (pancreatic toxicity) experiments 
3.3.1 Physico-chemical characterisation of drug/polymer formulations 
Biophysical properties of Pluronic P85® and/or drug/Pluronic P85® formulations were 
predicted using (a) computational (in silico) means and/or (b) then empirically 
quantified using a combination of spectrophotometry-based techniques.  
The following parameters were quantified: 
i. Critical Micelle Concentration (CMC) – The concentration at which 
Pluronic® P85 micelles spontaneously form in solution. 
ii. Aggregation number (Nagg) – The mean number of polymeric chains present 
in a micelle at a given concentration above the CMC. 
iii. Drug partitioning (P) – The partitioning of the drug within the micelles. 
iv. Mean hydrodynamic diameter (D) – Diameter of micelles in solution as 
measured by dynamic light scattering. 
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This information was then used as a basis for a formulation rationale to take the most 
promising formulation(s) forward into in vivo studies, which also meant reducing the 
number of animals used in experimentation. 
3.3.1.1 In silico simulations 
Molecular dynamics modelling is a useful approach to predict structural and electronic 
properties of biological and chemical systems. The simulations conducted as part of this 
thesis were classical molecular dynamics simulation, in which the smallest individual 
units modelled were either atoms (atomistic) or segments of molecules (coarse-grain) 
represented as spheres, which can be connected together to create larger molecules.  
In silico simulations were run in collaboration with Dr Chris D. Lorenz (King’s College 
London, Department of Physics), following previously described methods (Anderson et 
al., 2008), using the LAMMPS molecular dynamics software package (Plimpton, 1995). 
Two types of simulations were used: 
i. Atomistic simulations to probe the detail of interactions between Pluronic® P85 
unimers within a single micelle at the atomistic level. 
ii. Coarse-grain simulations to determine the Critical Micelle Concentration 
(CMC) and aggregation number (Nagg) of Pluronic® P85. 
3.3.1.1A General background 
In essence, the behaviour of the molecules over time can be predicted from an initial set 
of coordinates and randomly assigned initial velocities for each of the atoms (or beads) 
in the simulated systems. Solving Newton’s second law of motion ( , where F is 
force, m is mass, and a is acceleration) for each atom or bead then allows for the 
calculation of trajectories in space and time (Allen, 2004). 
There are a number of mathematical equations and associated constants used to 
describe the potential energy (whether inter- or intramolecular) between the molecules 
during the simulation, known as ‘force fields’. The derivation of these functions is the 
result of both empirical and quantum mechanics calculations, and in the interest of 
 F = ma
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brevity these will not be discussed here. In its simplest terms, a force field (Etotal) can be 
described as a combination of terms that relate to atoms that are either ‘bonded’ 
(linked by covalent bonds, Ebonded), or ‘nonbonded’ (van der Waals & electrostatic 
interactions, Enonbonded). This relationship is represented in equation [3.1]:	  
   [3.1] 
Equation [3.2] shows the constituent terms that make up Ebonded, which are also 
diagrammatically represented in Figure 3-8: 
   [3.2] 
  
 Etotal = Ebonded + Enonbonded
 Ebonded = Ebond + Eangle + Edihedral
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The level of detail with which the systems can be modelled are limited to the 
computational power that one has at their disposal. Similarly, simulating processes that 
occur over long timescales can also be highly resource intensive. As such, detailed 
simulations where atoms are explicitly modelled typically operate over the femtosecond 
timescale. These simulations can be simplified and run over longer periods of time; for 
example by modelling hydrogen-containing groups as one “atom” (i.e. united atom 
model). Further simplification and thus longer timescales can be achieved by using so-
called “coarse-grained” models (where the simplest representations are known as “bead-
spring” models), where beads are used to represent groups of atoms and springs 
represent bonds between them. Coarse-graining is particularly useful for the study of 
reduced representations of polymeric compounds where each bead can represent several 
monomers. 
3.3.1.1B Atomistic simulations 
Atomistic molecular dynamics simulations were carried out in order to obtain a 
detailed description of a single micelle. These simulations utilised the aggregation 
number, Nagg, that was determined empirically for Pluronic® P85 (see section 3.3.1.3 
- Determination of aggregation number (Nagg) for method description) to define 
the number of Pluronic® P85 molecules to place into the simulation box. 
In these simulations, each Pluronic® P85 molecule was given an interactive bead 
representing each individual atom in the molecule, and the interactions between the 
molecules modelled using the CHARMM force fields (Vorobyov et al., 2007; Lee et al., 
2008). These simulations were carried out in a simulation box (to ensure a constant 
volume) such that the overall Pluronic® P85 concentration was 1.0% m/v. Simulations 
were first conducted with solvent implicitly modelled at 400 K (127 °C) to accelerate 
diffusion and allow the Pluronic® P85 molecules to self-assemble into an aggregate, 
before cooling the system down to 310 K (37 °C) to match body temperature. Once the 
structure of the aggregate had reached a constant size in the implicit solvent 
simulation, the simulation box was solvated with explicitly modelled water molecules to 
obtain a more detailed description of the interaction between the Pluronic® P85 and 
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water molecules. The system was then allowed to equilibrate using the Isothermal–
isobaric NPT ensemble at a constant pressure of 1 atmosphere (atm) before taking 
aggregate size measurements. 
3.3.1.1C Coarse-grain simulations 
With the aim to model a solution containing Pluronic® P85 at concentrations 
representative of the experimental conditions, polymers are modelled by coarse-grained 
beads in an implicit solvent. Pluronic® are generally tri-block co-polymers with ABA 
arrangements, where two hydrophilic poly(ethylene oxide), A, blocks flank a 
hydrophobic poly(propylene oxide) block, B.  
In this instance, the polymer studied (Pluronic® P85) has the following chemical 
structure: 
HO(CH2CH2O)26(CH2CH(CH3)O)40(CH2CH2O)26H 
This can also be represented as: 
A26B40A26 
In the coarse-grain strategy used here (Anderson & Travesset, 2006; Anderson et al., 
2008), one coarse-grain bead was modelled to represent ten monomers in the actual 
polymer, to achieve the following final bead representation: 
A3B4A3 
This is shown more clearly in Figure 3-9: 
 
Figure 3-9: Flexible bead model of Pluronic® P85. Poly(ethylene) oxide A domains are 
represented as 3 repeats of 10 monomers (blue, 3 beads each), and poly(propylene) oxide 
B domain as 4 repeats of 10 monomers (red, 4 beads). 
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All non-bonded interactions between the coarse grain beads that make up the 
hydrophobic B block are modelled using the attractive Lennard-Jones potential 
(equation [3.3]), where σ and ε are the characteristic size and energy of a bead, 
respectively:  
   [3.3] 
The potential energy, UBB(r), between any two beads, is a function of these two 
constants (ε and σ) and the distance between the two beads, r. 
Meanwhile, a purely repulsive potential is used to model the nonbonded interactions 
between the hydrophilic coarse grain beads A and between coarse grain beads A and B:  
   [3.4] 
The pair potentials are cut off to zero at r = 3.0σ. In this study, we use the same 
values for the mass of the beads = 1.0, σ = 1.0 and ε = 1.0 for all coarse-grain beads 
in our system. Within a given Pluronic® molecule, the coarse-grain beads are connected 
to their neighbouring atoms via harmonic springs to represent their covalent bonds, 
such that the bond potential energy is given by the equation:  
   [3.5] 
For the purposes of these simulations, kbond = 330.0 and l0 = 0.84.  
The simulation boxes used here were cubic with periodic boundary conditions, and the 
volume of the box was held constant throughout the simulation. A timestep of 
 was used for all simulations. The simulations were conducted 
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Simulations were carried out using seven different concentrations of Pluronic® P85, 
ranging from 0.03% m/v to 1.0% m/v. In doing so, the distribution of aggregate size 
was also measured in order to calculate the predicted CMC and Nagg of the resulting 
micelles. 
3.3.1.2 Empirical measurement of critical micelle concentrations (CMC) 
Two different experimental methods were used to determine the CMC of Pluronic® 
P85, and are outlined below. Both methods were based on a similar principle: the 
hydrophobic dye or fluorescent probe either change their absorption maximum 
wavelength (Eosin Y method), or their fluorescence emission intensity (Pyrene method) 
when incorporated into the hydrophobic microenvironments which are created when 
micelles start aggregating. 
3.3.1.2A Eosin Y method to determine CMC 
Experiments to measure the CMC of Pluronic® P85 using eosin Y dye (ACROS 
Organics; Geel, Belgium) were performed with Miss Ann-Charlott Berglar (MSc 
research project student, King's College London) according to a previously published 
method (Patist et al., 2000).  
Eosin Y is typically used as tissue stain, however in water it shows an absorbance 
maximum at 518 nm, which shifts to 542 nm upon the formation of micelles (Figure 
3-10). As explained above, this is due to a change in the microenvironment of the dye 
from hydrophilic to hydrophobic, provided by the formation of a micellar core in which 
it preferentially partitions (Figure 3-11). This shift in absorbance is observed as a 
colour change in solution and can be measured quantitatively by spectrophotometry 
(Patist et al., 2000).  
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Figure 3-10: Absorbance spectrum of eosin Y in an aqueous solution (dH2O) 
containing varying concentrations of Pluronic® P85. Micelle formation coincides with 
a shift of the wavelength maximum (λmax) from 518 nm to 538 nm, however the greatest 
difference in the range of absorbance for given concentration range of Pluronic® P85 





Figure 3-11: Eosin Y probe fluoresces at 542 nm when in the hydrophobic core 
environment of micelles. 
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Method optimisation 
The method was first optimised in dH2O with respect to the concentration range for 
Pluronic® P85 (kindly donated by BASF; NJ, USA), and temperature of sample 
measurements. These optimised parameters were then taken forward for determination 
of the CMC in Krebs-Henseleit mammalian Ringer solution (the composition of which 
is given in Appendix 1); henceforth referred to as ‘artificial plasma'. Artificial plasma 
is the perfusate later used in the in situ brain perfusion technique (described in section 
3.3.2 - Blood-CNS barrier models & accessory methodologies), and thus it 
was used to better mimic micelle formation under the conditions used in the in vivo 
experiments. 
However, it was observed that certain constituents of the artificial plasma in the assay 
were reacting with eosin Y to produce artefacts, where the same degree of colorimetric 
change was measured in all samples, regardless of Pluronic® P85 concentration. The 
precise cause of this was not determined, however it is known that eosin Y binds to 
albumin in solution, resulting in a change in eosin Y's fluorescence emission (Waheed et 
al., 2000). BSA was therefore omitted from the artificial plasma for these CMC 
experiments, as was dextran (with which Eosin Y could also interact) and Evan's blue 
(a dye that would make measuring changes in fluorescence impossible). This modified 
form of artificial plasma will be henceforth referred to as 'optimised plasma'. 
Validated method 
Following optimisation of the method, the CMC of Pluronic® P85 was determined 
using eosin Y in the following solvents: 
i) Distilled H2O (dH2O)  
ii) Artificial plasma with dextran, BSA and Evan's Blue omitted; henceforth 
referred to as 'optimised plasma'. 
iii) Optimised plasma with added 10 µM pentamidine (1,5-bis-4′-
amidinophenoxypentane) isethionate salt (mol. wt., 592.68; 98% purity, 
Sigma Aldrich; Dorset, UK) to assess the effect of the drug on the CMC. 
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The effect of the following parameters on the CMC was investigated: 
Table 3-2: Outline of factors investigated using eosin Y method for CMC determination 
of Pluronic® P85. 
Solvent Temperatures measured 
dH2O 25 °C; 37 °C 
Optimised plasma 25 °C; 37 °C 
Optimised plasma + 10 µM pentamidine isethionate 37 °C 
 
 
Pluronic® P85 was dissolved in dH2O or optimised plasma by mechanical stirring (or 
sonication, as shown in Table 3-2) at 37 °C until completely dissolved (typically a 
minimum of 20 minutes) to prepare a 10.0% m/v stock solution. From the stock 
solution, dilutions between 0% and 10.0% m/v were prepared in triplicate. The 
following concentrations of Pluronic® P85 solutions were prepared: 0, 0.001, 0.005, 0.01, 
0.05, 0.1, 0.5, 1.0, 5.0, 10.0% m/v.  
Two blank readings for each Pluronic® P85 concentration were taken in 1.5 mL 
disposable methacrylate UV cuvettes purchased from Fisher Scientific; Leicestershire, 
UK (containing 990 μL of Pluronic® P85 in dH2O or optimised artifical plasma) at 542 
nm. 10 μL of 1.9 mM eosin Y aqueous solution were then added to each cuvette to 
achieve a final dye concentration of 19 µM. The cuvettes were mixed first by inverting 
them and then incubated with shaking on a platform shaker at 500rpm and 37 °C for 
60 minutes. Absorbance readings at 542 nm were then taken at 20 °C or 37 °C using a 
Unicam UV1 spectrophotometer. Sample temperature was maintained using a Stuart 
S160D perspex fan incubator immediately prior to removing each cuvette individually 
to measure absorbance. 
Absorbance at 542 nm (A542) was plotted as a function of Pluronic® P85 concentration 
(log scale) and analysed using GraphPad Prism® 6 software. After plotting the data 
points, a trend line curve was fitted using the default curve-fit log(agonist) vs. response 
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– variable slope option in GraphPad Prism® 6. A table of XY coordinates of the fitted 
curve was then generated and a new graph drawn using the values from the linear part 
of the curve. The CMC was then derived by extrapolating from the linear part of the 
curve (the point at which it inflects), and determining the point at which this line 
intersects with the baseline (y = absorbance of the aqueous dye solution at 1.9 µM 




Figure 3-12: Example absorbance plot demonstrating the extrapolation of the linear 
portion of the curve through the inflection point. The x-intercept for the point at 
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3.3.1.2B Pyrene method to determine CMC 
Experiments were designed in collaboration with Dr Cécile Dreiss (Institute of 
Pharmaceutical Science, King’s College London) and Dr Margarita Valero (Department 
of Physical Chemistry, Universidad de Salamanca) following a previously outlined 
method (Wolszczak & Miller, 2002). 
Pyrene (Sigma Aldrich; Dorset, UK) is a fluorophore that is sensitive to polar 
surroundings; its fluorescence intensity increases when it is incorporated into apolar 
environments (Wolszczak & Miller, 2002). This technique takes advantage of this 
phenomenon, using the change in fluorescence intensity as a surrogate measure for the 
formation of micelles once pyrene is incorporated into their hydrophobic cores. 
To determine the CMC, a stock solution containing 500 nM pyrene (pyrene:dH2O) was 
prepared by dissolving an appropriate volume of 10 mM pyrene in absolute ethanol into 
dH2O. This stock solution was then split into two equal parts, and Pluronic® P85 
added to one of the parts to achieve a final concentration of 1.0% m/v in pyrene:dH2O. 
The resulting solutions of pyrene:dH2O (with and without Pluronic® P85) were then 
mixed in varying mass ratios (using an OHAUS Adventurer SL microbalance for 
greater accuracy) to achieve the Pluronic® P85 concentrations shown in Table 3-3. 
Preparing the solutions in this way facilitates the variation in Pluronic® P85 
concentrations while maintaining a constant concentration of pyrene at 500 nM in all 
solutions. This process was also repeated using optimised plasma in place of dH2O to 
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Emission spectra were obtained for each concentration of Pluronic® P85 outlined in 
Table 3-3 by pipetting 1 mL of each into a Fluorescence QS 10 mm cuvette made 
from Suprasil© quartz (Hellma, Type 114F-QS). The cuvette was cleaned twice using 
dH2O, then with absolute ethanol, and then dried between each sample. The cuvette 
was placed in a Varian Cary Eclipse spectrophotometer with single water thermo cell 
holder and temperature controller, using Cary Eclipse software. The emission spectra 
were obtained between 350 nm and 450 nm after excitation at 340 nm. Measurements 
were therefore taken using the settings: λex = 340 nm, λem = 350-450 nm, slit = 5 nm 
and lamp intensity of 700 V (selected to provide optimum intensity over the broad 
concentration of Pluronic® P85 used). Experiments were carried out both at 20 °C and 
at 37 °C for Pluronic® P85 dissolved in both pyrene:dH2O and pyrene:optimised 
plasma. 
The resulting emission spectra typically had two peaks of maximum fluorescence 
intensity at approximately 374 nm and 393 nm, an example of which is shown in 
Figure 3-13A. Spectra were analysed by plotting the maximum fluorescence 
intensities as a function of Pluronic® P85 concentration. Two straight trend lines were 
then fitted through the resulting data points, and the point at which these lines 
intersect calculated. The abscissa (x-intersect) for this point is the CMC, as shown in 
Figure 3-13B. 
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Figure 3-13: Pyrene fluorescence measurement for the determination of the Critical 
Micelle Concentration (CMC). A: Example of pyrene emission spectra between 350-450 
nm for a range of Pluronic® P85 concentrations. Fluorescence intensity increases with 
increasing concentration of Pluronic® P85. B: Example of data analysis for the 
fluorescence intensity measurements taken at the peak of the emission spectra. Two 
straight lines are fitted through the data points on both sides of the break-point, and the 
intersect calculated algebraically. The abscissa (x-coordinate) of this intersect is defined 
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3.3.1.3 Determination of aggregation number (Nagg) 
The fluorometric determination of Nagg was performed following a previously published 
method (Junquera et al., 1997). This technique utilises the fluorescent properties of 
pyrene (also described in the fluorometric determination of CMC using pyrene in 
section 3.3.1.2B - Pyrene method to determine CMC). The steady-state 
fluorescence of pyrene within the micelles can be quenched with cetylpyridinium 
chloride monohydrate (Q, purchased from Sigma Aldrich; Dorset, UK), and utilised to 
calculate the mean number of unimers present per micelle at or above the CMC 
(Junquera et al., 1997). 
Solutions of pyrene:dH2O was prepared as described in section 3.3.1.2B - Pyrene 
method to determine CMC. This solution formed the basis for the calculation of 
Nagg for Pluronic® P85 in either dH2O or optimised plasma and was utilised to create a 
further stock solution including both 1.0% m/v Pluronic® P85 and 270 µM Q. This 
solution was then mixed with pyrene:dH2O or optimised plasma containing 1.0% m/v 
Pluronic® P85 alone to create the working solutions containing varying quantities of Q, 
as outlined in Table 3-3, while keeping the concentration of pyrene and Pluronic® P85 
constant. 
The fluorescence intensity of all pyrene:dH2O and pyrene:optimised plasma was then 
measured using the same equipment and following the same method described in 
section 3.3.1.2B - Pyrene method to determine CMC. The natural logarithm 
value of the fluorescence intensity was then plotted as a function of [Q], as shown in 
Figure 3-14. A linear trend line, , was then fitted to the data, 
corresponding to: 
   [3.6] 
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Thus, from the slope ‘m’ term of the trend line defined, Nagg was derived as follows: 
   [3.7] 
 
Figure 3-14: Example plot showing the natural log of the fluorescence intensity as a 
function of the concentration of the quencher cetylpyridinium chloride monohydrate 










[Q], mol L-1 
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3.3.1.4 Determination of partition coefficient (P) 
Measurement of the partition of pentamidine within Pluronic® P85 micelles requires 
the knowledge of the density and partial molar volume of Pluronic® P85 in solution. A 
description of the experimental steps taken to measure the partition coefficient is given 
below. 
3.3.1.4A Measurement of Pluronic® P85 density and partial molar volume using 
Pycnometry 
Pycnometry is a technique used to determine the density of liquids or gases as a ratio 
of mass to volume. By accurately measuring the mass of a known volume of a liquid, 
one can calculate the density of the liquid, with reference to dH2O. 
In order to measure the density of 1.0% m/v Pluronic® P85(aq), a glass pycnometer with 
an approximate volume of 10 mL was used, and the experiment carried out in its 
entirety at a room temperature of 22.3 °C. The glass pycnometer has a glass stopper 
with a glass capillary tube running through it, to allow air bubbles to escape from the 
flask. The flask (with stopper) was cleaned and then dried thoroughly before accurately 
weighing (mdry). The pycnometer was then filled completely with dH2O, and then very 
slowly sealed with the glass stopper. In doing so, excess dH2O was slowly displaced (due 
to Archimedes Principle) by the glass stopper, and allowed to escape via the capillary 
tube in the stopper, ensuring constant volume in the pycnometer. The pycnometer was 
then weighed again (mwet) and the exact volume of dH2O in the pycnometer (Vpyc) 
calculated using the following equation: 
   [3.8] 
Where is the density of dH2O at 22.3 °C = 0.997704. 
This process was performed three times to obtain a mean volume for the pycnometer at 
room temperature. 
 Vpyc = ρrt mwet −mdry( )
 ρrt
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The pycnometer was then cleaned and dried thoroughly before filling with 1.0% m/v 
Pluronic® P85(aq), and the process described above repeated again in triplicate before 
calculating the density of 1.0% m/v Pluronic® P85(aq) as follows: 
   [3.9] 
Thus, the density of 1.0% m/v Pluronic® P85 alone ( ) was calculated as follows: 
   [3.10] 
Where C is the m/v concentration of P85, in this case 0.01 (1.0%). 
Finally, the partial molar volume of P85 (the volume which 1 mol of P85 occupies in 
dH2O, ) was calculated as follows: 
   [3.11] 
Where Mw is the molecular weight of P85 = 4600 
 
3.3.1.4B Measurement of partition coefficient (P) 
Fluorometric determination of the partition coefficient of pentamidine isethionate 
(Sigma Aldrich; Dorset, UK) in Pluronic® P85 micelles followed a previously published 
method (de La Guardia et al., 1991). This technique makes use of the natural 
fluorescence of pentamidine, which varies in intensity when incorporated into the less 
polar environment of Pluronic® P85 micelles. A stock solution of 10 µM pentamidine 
isethionate was prepared in dH2O. Working dilutions of Pluronic® P85 shown in Table 
3-3 were then prepared, before measuring the fluorescence intensity in samples using 













1 ÷ ρP85:dH2O( )
mass of P85(aq) × Mw  of P85( )
=
Mw  of P85
ρP85
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intensity as outlined in section 3.3.1.2B - Pyrene method to determine CMC. 
Measurements were taken using the settings: λex = 260 nm, λem = 300-450 nm, slit = 5 
nm and lamp intensity of 800 V. Experiments were carried out at 20 °C for Pluronic® 
P85 dissolved in pentamidine:dH2O and then repeated at 20 °C and 37 °C in 
pentamidine:optimised plasma. 
When calculating the interactions of drugs with micelles, two methods are typically 
cited in the literature (Rangel-Yagui et al., 2005b): 
i. Partition coefficient (P) – The partition of drug between aqueous media and 
micellar phases. 
ii. Drug binding (K) – The binding of drug to micelles. 
For the purposes of these experiments, the true partition of drug within the micelles 
was deemed more relevant than the binding of the drug to micelles. Therefore the 
parameter selected for measurements was the partition coefficient (P), defined in 
equation [3.12] below: 
   [3.12] 
Where  is referred to the micellar volume ( ), and  is 
referred to the overall solution volume ( ), provided that the surfactant 
concentration (and thus the micellar volume) is very low relative to the aqueous 
volume ( ). This is because the overall solution volume is comprised of 
the micellar volume and volume of water, and in dilute surfactant solutions the overall 
micellar volume is negligible. In concentrated surfactant solutions where  is high, 
 should be referred to the aqueous volume ( ). The 
equation to define  is as follows (Santos et al., 2003): 
   [3.13] 
 
P = [drug ]micelle[drug ]H2O




 [drug ]H2O  VH2O =Vtotal −Vmicellar
 Vmicellar
 Vmicellar =Cs ×Vsolution × γ
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Where Cs is the total moles of surfactant and γ is the molar volume of Pluronic® P85 
calculated from equation [3.11], also known as . 
Determining the concentrations of the drug in each of the media by fluorescence 
spectroscopy requires the definition of a new parameter, α (Coutinho & Prieto, 1995): 
 
  [3.14] 
Where α is detected changes in fluorescence intensity, I is the fluorescence intensity of 
the drug in the presence of micelles, I0 is the fluorescence intensity of the drug in the 
absence of micelles, and I∞ is the maximum possible fluorescence intensity of the drug 
when it is 100% solubilised. The derivation of this equation can be found in Appendix 
2. 
 
Since complete solubilisation of pentamidine within the micelles cannot be achieved 
experimentally, fluorescence intensity at this point (I0) can also not be measured 
empirically. Therefore, an alternative equation was used to calculate the partition 
coefficient (Coutinho & Prieto, 1995): 
   [3.15] 
Where  is the change in fluorescence intensity in the absence and presence of 
Pluronic® P85, and  the maximum possible measurable difference in fluorescence 
intensity. P is the partition coefficient of pentamidine between aqueous and micelle 
phases, and γ the molar volume of Pluronic® P85 (calculated by pycnometry, as 
described in section 3.3.1.4A - Measurement of Pluronic® P85 density and 








I − I 0
I∞ − I 0
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Substituting in terms from equation [3.14] gives: 
   [3.16] 
Equation [3.16] can then be re-arranged to give: 
   [3.17] 
And rearranged further still: 
   [3.18] 
   [3.19] 
   [3.20] 
   [3.21] 
At this point, we have a linear equation in the format , where 
 and   (with [P85] being the micellised surfactant). Thus, by 
dividing the y-intercept, c, by the slope of the line, m, one obtains Pγ. Since γ is the 
partial molar volume calculated from pycnometry experiments, one can divide Pγ by 
the partial molar volume of Pluronic® P85 to obtain the partition coefficient, P. 
  
 
(I − I 0) =
(I∞ − I 0)[P85]
1 /(Pγ )+ [P85]
 
1
(Pγ ) + [P85] =
(I∞ − I 0)[P85]





[P85] + 1 =
(I∞ − I 0)





[P85] + 1 =
(I∞ − I 0)








[P85] + 1 =


















I − I 0( )
=
I 0











 y = c × (mx + 1)
 
y = I 0
I − I 0( )  
x = 1[P85]
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3.3.1.5 Determination of micelle hydrodynamic diameter 
A Nano ZS Zetasizer (Malvern Instruments Ltd., Malvern, Worcestershire, UK) and 
workspace were kindly provided by Dr Marie-Christine Jones (King’s College London, 
Institute of Pharmaceutical Science, University of London) to measure the mean 
hydrodynamic diameter of Pluronic® P85 micelles. Samples were prepared in disposable 
1 mL UV cuvettes in either dH2O or optimised plasma, and the mean hydrodynamic 
diameter and polydispersity analysed by the zetasizer using dynamic light scattering. 
The zetasizer was calibrated prior to measuring the samples by defining the solvent 
used in the sample (i.e. explicitly defining contents and concentrations of salts in 
optimised plasma). All sample measurements were taken at 37 °C. 
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3.3.2 Blood-CNS barrier models & accessory methodologies 
Since many of the experimental procedures utilised in the generation of data for this 
chapter followed the same format as those described in section 2.3.1 - Blood-CNS 
barrier model & accessory methodologies, the reader is referred to chapter 2 for 
information on the following: 
i. Animals & anaesthesia 
ii. In situ brain/choroid plexus perfusion 
a. Surgical preparation 
b. Experimental procedure 
c. Perfusion circuit 
d. Composition of artificial plasma 
e. CNS sampling 
f. Capillary depletion analysis 
g. Liquid scintillation analysis 
In the interests of brevity, the sections that follow will only include those where there 
were differences in the experimental procedures performed. 
3.3.2.1A Radiolabelled solutes of interest 
Pentamidine 
As described in section 3.1.1 - Human African Trypanosomiasis (HAT), the 
stage 1 drug, pentamidine, is known to treat the blood- and transition-stage of HAT, 
but cannot treat the CNS stage of the disease, as it does not sufficiently penetrate the 
blood-CNS barriers (Sanderson et al., 2009). As the model drug selected to take 
forward in the development of a co-formulation with Pluronic® P85, [3H]-pentamidine 
(mol. wt., 340.4 g/mol; specific activity, 5 Ci/mmol; 99% radiochemical purity) was 
synthesised and tritiated by Moravek Biochemicals, Brea, CA. 
The inclusion of [3H]-pentamidine as a radiolabelled solute of interest in the artificial 
plasma thus facilitated the measurement of its penetration into the CNS after 
perfusion. 
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Sucrose (baseline) 
In addition to [3H]-pentamidine, [14C]-sucrose (mol. wt., 342.3 g/mol; specific activity, 
0.412 Ci/mmol; 99% radiochemical purity; Moravek Biochemicals, Brea, CA), was also 
present in the artificial plasma for these experiments. The molecular weight of [14C]-
sucrose is comparable to that of [3H]-pentamidine (340.4 g/mol), and so the inclusion of 
[14C]-sucrose provides a useful comparison of variation between animals and indicator of 
BBB permeability, as it is a known compound that has poor penetration through the 
blood-CNS barriers. Thus, by correcting brain uptake for vascular space one also 
accounts for transport due to passive paracellular diffusion. 
The use of [14C]-sucrose as a vascular space marker was described in chapter 2, and 
the reader is referred to section 2.3.1 - Blood-CNS barrier model & accessory 
methodologies should further explanation be required. 
3.3.2.1B Perfusion time 
The in situ brain/choroid plexus perfusion technique has been validated for perfusions 
up to 30 minutes (Sanderson et al., 2007). Perfusions for these experiments were 
performed for either 10 or 30 minutes, as shown in Table 3-4. 
3.3.2.1C Co-formulated drug transport experiments 
As described in section 2.3.1.2 - In situ brain/choroid plexus perfusion, one of 
the main advantages of in situ brain perfusion is the control the investigator has over 
the contents of the artificial plasma (perfusate). In addition to the radiolabelled solute 
of interest, the artificial plasma contents can be adjusted to also include the solute of 
interest in non-radiolabelled form, potential competitors of transport, and specific 
inhibitors of transport. Furthermore, experimental design can be altered to vary the 
time of perfusion and thus obtain snapshots of uptake into the brain with respect to 
time. 
To examine the effect of co-formulating pentamidine with Pluronic® P85 on the uptake 
of pentamidine into the CNS, varying concentrations of Pluronic® P85 were added to 
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the artificial plasma, and their effects on the CNS uptake of [3H]-pentamidine 
measured. 
The CMC for Pluronic® P85 was previously found to be 0.03% m/v (Shaik et al., 2009) 
using the fluorescence probe 1, 6- diphenyl-1, 3, 5-hexatriene (DPH, Sigma Aldrich; 
Dorset, UK), and a different method to those used in this study and described in 
section 3.3.1.2 - Empirical measurement of critical micelle concentrations 
(CMC). Thus our initial in situ brain/choroid plexus perfusion experiments with 
Pluronic® P85 were designed based on a CMC of 0.03% m/v. However, further 
evaluation by us revealed that the CMC was ten-fold higher (approximately 0.3% m/v) 
in our hands, both theoretically and empirically (described later in section 3.4.2.1 - 
Critical micelle concentration). As such, and with an aim to measure [3H]-
pentamidine uptake into the CNS in the presence of Pluronic® P85 both below and 
above the CMC (i.e. in the absence and presence of micelles), co-formulations 
contained either 0.01% or 0.1% Pluronic® P85, respectively. 
Un-labelled pentamidine isethionate was also included in some experiments at a 
concentration of 10 µM to mimic the plasma concentrations usually achieved in human 
patients following treatment (Waalkes & DeVita, 1970; Sanderson et al., 2009). The 
poor water solubility of pentamidine required that it be dissolved in dimethyl sulfoxide 
(DMSO, Sigma Aldrich; Dorset, UK), so that the final DMSO concentration in the 
artificial plasma was 0.05% m/v. The inclusion of DMSO at this concentration has 
previously been shown not to affect blood-brain and blood-CSF barrier permeability 
(Sanderson et al., 2009). Perfusions were initially performed for 10 minutes, and then 
repeated with a perfusion time of 30 minutes. Since the rationale for co-formulating 
with Pluronic® P85 was to reduce efflux of pentamidine from the CNS by inhibiting 
efflux transporters, it was hypothesised that increasing the perfusion time to 30 
minutes would provide adequate time for any effects on efflux transport mechanisms to 
manifest. 
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A breakdown of the experimental conditions used for co-formulated drug transport 
experiments are shown in Table 3-4. After perfusion, the CNS was sampled and 
prepared for liquid scintillation counting as described earlier. 
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3.3.2.2 Isolated incubated choroid plexus technique 
The isolated incubated choroid plexus technique provides a means of measuring the 
movement of radiolabelled solutes of interest into the choroid plexus. The technique 
involves the removal of the fourth ventricle of the choroid plexus from the mouse brain, 
which is then transferred into artificial CSF containing the radiolabelled solute of 
interest - allowing the study of transport ex vivo. 
3.3.2.2A Experimental procedure 
Adult male BALB/c mice (23-25 g, Harlan; Oxon, UK) were anaesthetised and 
heparininsed perfused transcardially as described previously (section 2.3.1.2 - In 
situ brain/choroid plexus perfusion) for 4 minutes, with artificial plasma, but not 
containing any radiolabelled compounds. After 4 minutes mice were decapitated, and 
the IVth ventricle of the choroid plexus removed from under the cerebellum using 
micro-forceps and Leica S4E L2 stereo-microscope. The choroid plexus was then 
immediately transferred to 0.65 mL warm oxygenated artificial CSF solution (contents 
outlined in Appendix 1) and incubated at 37°C for 10 minutes in order to equilibrate 
ionic concentrations (equilibration incubation step). After 10 minutes the choroid 
plexus was removed and placed into a second 0.65 mL artificial CSF solution which 
also contained [3H]-pentamidine and [14C]-sucrose, and any other compound of interest 
(e.g. specific inhibitors of transport, or competitors for transport, solute incubation 
step, Table 3-5 and Table 3-6). The second artificial CSF solution was also 
oxygenated and the choroid plexus incubated at 37 °C for 10 minutes, before removing 
the choroid plexus, blotting to remove excess liquid, and weighing on a microbalance 
(Cahn C33). As a point of reference, 50 µL samples were taken in triplicate from the 
final incubation medium (containing [3H]-pentamidine and [14C]-sucrose) both before 
incubation and after incubation, and these values used to calculate accumulation of 
[3H]-pentamidine in the choroid plexus, as described below in section 2.3.1.2I - 
Expression of results. 
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It should be noted that all experiments were carried out by MF with the assistance of 
Ms Juanita Ravindran as part of summer lab project. N = 5 for all treatment groups. 
3.3.2.2B Expression of results 
Uptake in the incubated choroid plexus was calculated as the accumulation of 
radiolabelled solute of interest, corrected for extracellular space (marked by [14C]-
sucrose) and expressed as a tissue-to-incubation medium (artificial CSF) ratio: 
 
  [3.22] 
 
3.3.2.2C Experimental design 
Following a similar format to that described in section 2.3.1.2 - In situ 
brain/choroid plexus perfusion, the isolated incubated choroid plexus technique 
was used to measure: 
i. The effect on the movement of [3H]-pentamidine between the artificial CSF and 
choroid plexus when co-formulated with Pluronic® P85 
ii. The effect on the movement of [3H]-pentamidine between the artificial CSF and 
choroid plexus in combination with specific transport inhibitors.  
The details of these experiments are outlined below. 
Co-formulated drug transport experiments 
In order to measure the effect of Pluronic® P85 on the movement of pentamidine 
between the CSF and choroid plexus, [3H]-pentamidine (0.31 µM), [14C]-sucrose (0.93 
µM) and DMSO (0.05% m/v) were added to the artificial CSF before incubation. In 
addition, varying concentrations of Pluronic® P85 (0.01%, 0.1% or 0.5% m/v) were 
added to measure their effect on the movement of [3H]-pentamidine between the CSF 
and choroid plexus. An outline of the experimental plan for these experiments is shown 
in Table 3-5. After incubation for 10 minutes, samples were prepared and analysed by 
 
Accumulation (mL/g) = radioactivity (dpm) per g of choroid plexus tissueradioactivity (dpm) per mL of incubation medium
3. ‘NANOHAT’ 
- 296 - 
liquid scintillation counting as described in section 2.3.1.2H - Liquid scintillation 
analysis. 
 
Table 3-5: Summary of experimental conditions for experiments to explore [3H]-
pentamidine accumulation in isolated incubated choroid plexus. 
Added compound and concentration 
DMSO (0.05%) 
DMSO (0.05%), Pluronic® P85 (0.01% m/v) 
DMSO (0.05%), Pluronic® P85 (0.1% m/v) 
DMSO (0.05%), Pluronic® P85 (0.5% m/v) 
 
Transport inhibitor experiments 
With an aim to identify the transport system responsible for transporting pentamidine 
at the apical surface of the choroid plexus, specific transport inhibitors were added to 
the artificial CSF used in the second incubation (solute incubation step). It should 
however be noted that transport at the basolateral (blood-facing) membrane cannot be 
ruled out using this method. It is expected that any transport detected using this 
method is dominated by apical transport, as the surface area of the apical membrane is 
far greater than the surface area of the basolateral membrane. The inclusion of 
transport inhibitors can correlate with either an increase or decrease in the uptake of 
the radiolabelled solute of interest; which is respectively indicative of an efflux or influx 
transport system at the choroid plexus. 
All transport inhibitors used were readily soluble in the artificial plasma and required 
no extra steps for dissolution beyond standard mechanical stirring and heating to 
physiological temperature (37 °C). A breakdown of the experimental conditions used for 
transport inhibitor experiments are shown in Table 3-6. After incubation, samples 
were prepared and analysed by liquid scintillation counting as described above. 
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3.3.2.3 High Performance Liquid Chromatography (HPLC) and radiodetector 
analysis 
HPLC analysis was performed as a means of confirming that the [3H]-pentamidine used 
in in vivo experiments was intact and radiolabelled. The experimental setup for HPLC 
analysis was a Jasco HPLC system (HG-1580 high pressure, high performance gradient 
HPLC solvent delivery system, AS-1555-10 cooled autosampler, and UV-1575 UV/Vis 
detector, Jasco; Essex, UK), together with a Packard Radiodetector (Radiomatic 
525TR Analyser, Packard; Pangbourne, UK). 
The integrity of [3H]-pentamidine stock isotope was confirmed by HPLC analysis to 
ensure no degradation had occurred over time. Samples containing either unlabelled 
pentamidine or [3H]-pentamidine were injected onto a Zorbax RX-C8, 5 μm, 4.6 × 250-
mm column following a previously published protocol (Berger et al., 1991). Separation 
was carried out by gradient elution on the Jasco HPLC system described above. 
Samples were eluted using a gradient of 3.5 to 45% acetonitrile (Fisher Scientific; 
Leicestershire, UK) in water (1 mL/min flow rate) over a period of 30 minutes. 
Conditions were returned to 3.5% acetonitrile over 2 min and held to allow the column 
to equilibrate for 3 min (35-min total time) before running the next sample. The 
gradient was achieved by mixing solvents A (H2O) and B (50% acetonitrile), both of 
which contained 10 mM heptane sulfonate (Fisher Scientific; Leicestershire, UK), 10 
mM tetramethylammonium chloride (Sigma Aldrich; Dorset, UK), and 4.2 mM 
phosphoric acid (Sigma Aldrich; Dorset, UK). UV absorbance was measured at 265 nm, 
before passing the column eluant into a radioactive detector (Packard; Pangbourne, 
UK), where it was mixed 1:3 with scintillation fluid (Ultima-Flow® M, Perkin-Elmer; 
Boston, MA, USA) for real-time radioactive analysis. This was then repeated using 10 
µM pentamidine isethionate (un-labelled, Sigma Aldrich; Dorset, UK) as a reference. 
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3.3.3 Peripheral free fraction / pancreatic toxicity experiments 
It has been observed that up to 10% of patients receiving pentamidine treatment go on 
to develop hyperglycaemia and diabetes (Jha & Sharma, 1984; Thakur et al., 1991). A 
number of possible explanations for this have been proposed: 
i. Hyperglycaemia could be caused by the activation of hepatic glucose-6-
phosphatase in response to pentamidine treatment (Scott & Burchell, 1991). 
ii. Hyperinsulinaemia could result from irreversible damage to islet β-cells at sub-
stimulatory glucose concentrations, and impaired glucose-induced insulin 
release (Sai et al., 1983; Zhou & Ipp, 1989). 
With these considerations in mind, it was hypothesised that co-formulating 
pentamidine within Pluronic® P85 micelles could compartmentalise and shield islet β-
cells from the damaging effects of pentamidine in circulation following administration. 
In vitro experiments were designed to test this hypothesis in islet cell culture, and are 
described below. Experiments were performed with the assistance of Dr Bo Liu 
(Endocrinology and Reproduction Research Group, King's College London). 
3.3.3.1 Cell culture conditions 
Mouse insulinoma (MIN6) β-cells (kindly provided by Professor SJ Persaud, 
Endocrinology and Reproduction Research Group, King's College London) were 
maintained at 37 °C (95% O2/5% CO2) in Dulbecco's Modified Eagle's Medium 
(DMEM, Sigma Aldrich; Dorset, UK) supplemented with 15% v/v foetal calf serum, 2 
mM glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin (Gibco; Paisley, 
UK). Medium was changed every 3–4 days and cells were detached from the cell 
culture wells using 0.02% m/v EDTA when 80–90% confluence had been attained. 
MIN6 cells were then seeded into 96-well plates at a density of 30 000 cells/well and 
cultured overnight in DMEM at 37 °C to adhere. DMEM was then aspirated from each 
well and washed twice with DMEM containing glucose at 2 mM. DMEM containing 2 
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mM glucose (Sigma Aldrich; Dorset, UK) was then added to each well a third time, but 
also to include either 10 µM pentamidine isethionate, or 1.0% m/v Pluronic® P85, or 
both pentamidine isethionate and Pluronic® P85 together, as outlined in the plate plan 
in Table 3-7. The poor solubility of pentamidine in water required that it be first 
dissolved in DMSO, resulting in a final DMSO concentration of 0.05% v/v. DMSO was 
also added to all other culture media used for incubation at the same concentration of 
0.05% v/v. 
 
Table 3-7: Plate plan for measuring insulin secretion from MIN6 cells after pre-exposure 
to pentamidine and Pluronic® P85. 
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Plates were then incubated at 37 °C for either 3 hours, or 24 hours, before washing 
twice with a bicarbonate-buffered physiological salt solution (Gey & Gey buffer, (Gey 
& Gey, 1936)) containing 2 mM glucose, 2 mM CaCl2 and 0.5 mg/ml BSA (Sigma 
Aldrich; Dorset, UK) and incubated for 30 minutes at 37 °C. Following incubation, 100 
µL of medium from each well was transferred to 5 mL polystyrene FACS tubes (BD 
Biosciences; Oxford, UK) containing 900 µL borate buffer for analysis by 
radioimmunoassay. 
3.3.3.2 Insulin secretion as an indirect measure of cell viability 
The insulin content of the incubation medium was assessed by radioimmunoassay 
following a previously outlined protocol (Jones et al., 1988). The basic premise for this 
approach was that by adding known quantities of anti-insulin antibody and [125I]-insulin 
to samples containing insulin secreted by MIN6 β-cells, the un-labelled and 
radiolabelled insulin would compete for binding to the antibody and form complexes, as 
shown in Figure 3-15. 
 
 
Figure 3-15: Schematic diagram of insulin-antibody interactions in 
radioimmunoassay. Un-labelled and radiolabelled insulin form complexes with anti-insulin 
monoclonal antibodies, allowing for the quantification of total un-labelled insulin in the 
sample. High concentrations of un-labelled insulin in a sample correlates with a reduced 






+ insulin complexes 
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Anti-insulin monoclonal antibody was prepared at a dilution of 1:20 in borate buffer, 
and 100 µL added per sample. [125I]-insulin tracer was also prepared in a separate 
solution of borate buffer, at a dilution of 1:65, and 100 µL added per sample. Samples 
were then incubated at 4 °C for 48 hours, before adding 1 mL of precipitant buffer 
containing γ-globulin, poly(ethylene glycol) and Tween 20 to each sample in order to 
precipitate complexes from unbound insulin. Samples were then centrifuged at 3,000 
r.c.f for 15 minutes at 4 °C prior to gamma counting relative to a standard curve and 
corrected for non-specific binding. 
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3.3.4 Statistics 
Data from all experiments are presented as mean ± standard error of the mean (SEM). 
Due to the broad range of experimental design and methods, specific details of 
statistical analyses performed on individual data sets will be presented in the context of 
the data in results chapters. Statistical significance was taken as follows: not significant 
(ns) p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. All statistical analyses were 
performed using GraphPad Prism® v6.0b graphing and statistics package for Mac. 
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3.4 Results: Formulation development & 
characterisation 
As described in section 3.1.2 - Nanotechnology: Focus on Pluronic® P85, the 
macromolecular state (unimeric vs. micellic) of Pluronic® P85 appears to dictate its 
effects as a biological response modifier. Therefore, an understanding of the biophysical 
parameters that dictate the formation of micelles in solution and their interactions with 
the drug (pentamidine) in solution is particularly useful when designing a drug 
formulation. The results of experiments to determine these biophysical properties are 
described below. 
3.4.1 In silico characterisation 
3.4.1.1 Critical Micelle Concentration and Aggregation number 
Coarse-grained simulations containing Pluronic® P85 at seven different concentrations 
(0.03% - 1.00% m/v) were modelled in an implicit dH2O-like environment (Anderson et 
al., 2008), and the distribution of aggregates plotted relative to the probability of their 
existence (between 0 and 1) in the simulation box, shown in Figure 3-16. At 0.03% 
and 0.14% m/v, the majority of Pluronic exists in unimeric form (aggregation number 
= 1 for ≈ 90% and ≈ 50%) of Pluronic® in simulation. In the 0.29% m/v simulation one 
can detect the onset of micelle formation, with ≈ 75% of the simulation containing 
Pluronic® P85 in aggregates greater than or equal to two molecules of Pluronic® P85. 
Thus, these simulations give a predicted CMC of approximately 0.29% m/v in dH2O at 
37 °C. 
In addition to calculating CMC from these simulations, one can clearly observe that 
the aggregation number increases with increasing concentrations of Pluronic® P85, 
where Nagg = 10 at 1.00% m/v. This is also depicted in Figure 3-17, which shows four 
snapshots of these simulations taken at Pluronic® P85 concentrations of 0.29%, 0.65%, 
0.87% and 1.00% m/v. 
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Figure 3-16: Probability of aggregates in simulation as a function of aggregation 
number for coarse-grained simulations of seven concentrations of Pluronic® P85. 
Aggregates of greater than 2 molecules can be observed at Pluronic® P85 concentrations 
of 0.29% and above, implying a theoretical CMC of 0.29% m/v. The modal (most 
frequently observed) aggregation number is detected at 1.00% m/v Pluronic® P85, where 




Figure 3-17: Snapshots taken from coarse-grained simulations of Pluronic® P85 at 
varying concentrations. Red beads represent the hydrophobic blocks of the block co-
polymer and the blue beads the hydrophilic block. All simulations were run under dH2O-
like conditions at 37°C. As the concentration increases, the clusters of the hydrophobic 
(red) beads increase in size, which provides visual evidence of the increasing aggregation 
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3.4.1.2 Micelle diameter 
The data obtained from the coarse-grained simulations informed the design of atomistic 
simulations. Figure 3-18 shows a snapshot of a single micelle modelled atomistically 
to contain 10 molecules of Pluronic® P85. As shown in the image, the diameter of the 
micelle was found to be approximately 59 Å (5.9 nm) at 310 K (37 °C). 
 
Figure 3-18: Single Pluronic® P85 micelle modelled atomistically. 
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3.4.2 In vitro characterisation 
3.4.2.1 Critical micelle concentration 
3.4.2.1A Eosin Y methodology 
CMC measurements for Pluronic® P85 were first measured using the Eosin Y method 
(Patist et al., 2000), as described in section 3.3.1.2A. The method was first 
optimised with respect to the concentration range for Pluronic® P85 and its method for 
dissolution (whether by mechanical stirring, or sonication, data not shown). The 
optimised method, described in section 3.3.1.2A, was then taken forward to obtain 
the data described below. 
3. ‘NANOHAT’ 
- 308 - 
 
Figure 3-19: CMC measurements for Pluronic® P85 in dH2O at 25 °C and 37 °C 
using the Eosin Y method. Graphs show mean±SEM, n=3 for each data point (created 
by GraphPad Prism v6 for Mac). 
 
Figure 3-19 shows the CMC for Pluronic® P85 in dH2O as measured using Eosin Y 
dye at 25 °C and 37 °C, calculated as being 0.27% and 0.24% m/v respectively. 
 



























- 309 - 
 
Figure 3-20: CMC measurements for Pluronic® P85 in optimised plasma at 25 °C 
and 37 °C using the Eosin Y method. Graphs show mean±SEM, n=3 for each data 
point (created by GraphPad Prism v6 for Mac). 
 
Figure 3-20 shows the CMC for Pluronic® P85 in optimised plasma as measured 
using Eosin Y dye at 25 °C and 37 °C, calculated as being 0.33% and 0.30% m/v 
respectively. 
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Figure 3-21: CMC measurements for Pluronic® P85 in optimised plasma + 10 µM 
pentamidine at 25 °C and 37 °C using the Eosin Y method. Graphs show mean±SEM, 
n=3 for each data point (created by GraphPad Prism v6 for Mac). 
 
Figure 3-21 shows the CMC for Pluronic® P85 in optimised plasma as measured 
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3.4.2.1B Pyrene methodology 
Figure 3-22 shows representative fluorescence emission spectra for 500 nM 
pyrene:dH2O at 25°C, and an example of the analysis used to calculate CMC for 
Pluronic® P85. Identical analyses were also applied to data collected for Pluronic® P85 
in 500 nM pyrene:dH2O at 37 °C, in 500 nM pyrene:optimised plasma at 25 °C, and at 
37 °C. All experiments were performed on different days, and with different samples 
freshly prepared for each experimental condition. 
The CMC values calculated from these data are shown together in Table 3-8. 
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Figure 3-22: Example fluorescence emission spectra of 500 nM Pyrene in dH2O with 
varying concentrations of Pluronic® P85 at 25°C. Peak fluorescence intensity increases 
with increasing Pluronic® P85 concentration. For a full breakdown of concentrations used 
please refer to Table 3-3. Inset: Fluorescence intensities measured at the emission 
wavelength (λem) of 374 nm plotted vs. Pluronic® P85 concentration, used for the 
calculation of the CMC. 
 
 
Table 3-8: Collated CMC values for Pluronic® P85 in either dH2O or optimised plasma, 
at 25 °C or 37 °C. 
Solution Temperature CMC (% m/v ± SEM) n 
Pyrene:dH2O 
25 °C 0.234 ± 0.010 6 
37 °C 0.170 ± 0.008 6 
Pyrene:optimised plasma 
25 °C 0.338 ± 0.001 3 
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Figure 3-23: Comparison of CMC values for Pluronic® P85 calculated using pyrene 
in either dH2O or optimised plasma, and at 25 °C or 37 °C. Mean ± SEM for each 
experimental condition were analysed by two-way ANOVA with Sidak's multiple 
comparisons test. *p < 0.05, ***p < 0.001. 
 
As shown in Table 3-8 and Figure 3-23, the CMC of Pluronic® P85 decreases when 
the temperature is increased from 25 °C to 37 °C in both solutions. Interestingly, at 
both temperatures studied the CMC is higher in the optimised plasma than in water (p 
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3.4.2.2 Aggregation number 
Figure 3-24 shows representative fluorescence emission spectra for 500 nM 
pyrene:dH2O containing 1.0 % m/v Pluronic® P85 and varying concentrations of 
cetylpyridinium chloride at 25°C, and an example of the analysis used to calculate Nagg 
for Pluronic® P85. Identical analyses were also applied to data collected for Pluronic® 
P85 in 500 nM pyrene:dH2O at 37 °C, in 500 nM pyrene:optimised plasma at 25 °C, 
and at 37 °C. All experiments were performed on different days, and with different 
samples freshly prepared for each experimental condition. 
The Nagg values calculated from these data are shown together in Table 3-9. 
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Figure 3-24: Example of fluorescence emission spectra of 500 nM Pyrene in dH2O and 
1.0 % m/v Pluronic® P85 with varying concentrations of the quench cetylpyridinium 
chloride. Peak fluorescence intensity is inversely proportional to concentration of 
cetylpyridinium chloride. For a full breakdown of concentrations used please refer to 
Table 3-3. Inset: Fluorescence intensities measured at the emission wavelength (λem) of 
393.3 nm, used for the calculation of Nagg. 
 
 
Table 3-9: Collated Nagg values for Pluronic® P85 in either dH2O or optimised plasma, at 
25 °C or 37 °C. 
Solution Temperature Nagg ± SEM n 
Pyrene:dH2O 
25 °C 8.5 ± 0.1 6 
37 °C 4.2 ± 0.2 6 
Pyrene:optimised plasma 
25 °C 7.1 ± 0.1 6 
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Figure 3-25: Comparison of Nagg values for Pluronic® P85 calculated using pyrene 
and cetylpyridinium chloride in either dH2O or optimised plasma, and at 25 °C or 37 
°C. Mean ± SEM for each experimental condition were analysed by two-way ANOVA 
with Sidak's multiple comparisons test, ***p < 0.001. 
 
As shown in Table 3-9 and Figure 3-25, the aggregation number of Pluronic® P85 
micelles decreases when increasing the temperature from 25 °C to 37 °C in both 
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3.4.2.3 Partitioning of pentamidine into Pluronic® P85 
Figure 3-26 shows representative fluorescence emission spectra for 10 µM pentamidine 
in aqueous solutions of Pluronic® P85 at varying concentrations at 25°C, and an 
example of the analysis used to calculate P. Identical analyses were applied to data 
collected for 10 µM pentamidine and Pluronic® P85 in dH2O at 37 °C, and in optimised 
plasma at 25 °C, and at 37 °C. All experiments were performed on different days, and 
with different samples freshly prepared for each experimental condition. 
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Figure 3-26: Example of fluorescence emission spectra of 10 µM pentamidine in dH2O 
with varying concentrations of Pluronic® P85. Peak fluorescence intensity increases with 
increasing Pluronic® P85 concentration. For a full breakdown of concentrations used 
please refer to Table 3-3. Inset: Fluorescence intensities taken at the emission 
wavelength (λem) of 338.0 nm, used for the calculation of P. 
 
Table 3-10: Collated partition coefficient (P) values for pentamidine isethionate in 
Pluronic® P85 dissolved in either dH2O or optimised plasma, at 25 °C or 37 °C. 
Solution Temperature P ± SEM n 
dH2O 
25 °C 60.3 ± 3.2 8 
37 °C 60.7 ± 3.2 8 
Optimised plasma 
25 °C 9.2 ± 1.3 8 
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Figure 3-27: Comparison of the partition coefficient (P) values for pentamidine 
isethionate in Pluronic® P85 dissolved in either dH2O or optimised plasma, at 25 °C 
and 37 °C. Mean ± SEM for each experimental condition were analysed by two-way 
ANOVA with Sidak's multiple comparisons test, ***p < 0.001. NB: All partition 
coefficient values were calculated using the same calculated partial molar volume value (γ 
= 1.2059) of Pluronic® P85 in dH2O at 25 °C using pycnometry. 
 
As shown in Table 3-10 and Figure 3-27, pentamidine partition into Pluronic® P85 
micelles is substantially lower in optimised plasma relative to dH2O (***p < 0.001). 
This phenomenon appears to be completely independent of temperature, since there is 
no difference between the partition coefficient measured between 25 °C and 37 °C, in 
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3.4.2.4 Mean hydrodynamic diameter 
Figure 3-28 shows the mean hydrodynamic diameter of Pluronic® P85 micelles as 
measured by dynamic light scattering. No micelles were present at 0.001% m/v 
Pluronic® P85 dissolved either in dH2O or optimised plasma. However, above the 
CMC, a single monodisperse population of micelles were formed both in dH2O (18 nm) 
and artificial plasma (15 nm). 
 
 
Figure 3-28: Size (mean hydrodynamic diameter) distribution of Pluronic® P85 
micelles in dH2O and optimised plasma. Solutions containing either 0.001% m/v or 
1.0% m/v Pluronic® P85 were sized at 37°C using a Malvern NanoZS zetasizer. Solutions 
containing 0.001% m/v Pluronic® P85 displayed no observable peak, while both solutions 
containing 1.0% m/v Pluronic® P85 contain a single, monodisperse population of micelles 
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3.5 Results: Effect of formulation on CNS delivery 
of pentamidine to the CNS 
3.5.1 Radiolabelled pentamidine integrity 
Since both in vivo and ex vivo experimental techniques required the use of radiolabelled 
pentamidine for quantification by liquid scintillation counting, the integrity of [3H]-
pentamidine was first checked by HPLC, as described in section 3.3.2.3. 
 
 
Figure 3-29: HPLC traces for two batches of unlabelled pentamidine (100 µM, 
batch 1 & 2), and [3H]-pentamidine in 0.05% m/v DMSO(aq) compared to 0.05% 
m/v DMSO(aq) alone. Bottom trace shows radiodetector analysis of [3H]-pentamidine in 
0.05% m/v DMSO(aq). 
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A single peak, with a retention time of approximately 27 minutes (Figure 3-29) was 
detected in all three samples containing pentamidine (unlabelled or radiolabelled), in 
accordance with previously published data (Sanderson et al., 2009). Furthermore, the 
fact that the majority of radioactivity detected by radiodetector analysis eluted at 
approximately 27 minutes also shows that the [3H]-pentamidine is intact. 
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3.5.2 In situ brain/choroid plexus perfusion 
3.5.2.1 Sucrose baseline 
Since [14C]-Sucrose can only enter the brain and CSF by simple diffusion it is a useful 
molecule to use as an internal control for BBB and BCSFB integrity in each 
experiment. It can also provide an approximation of cerebrovascular space in brain 
regions, and extracellular space formed between choroid plexus capillary endothelium 
and epithelium, and thus is a measure of variation between animals (Sanderson et al., 
2009). [14C]-Sucrose values for all control experiments in all regions were concurrently 
compared to [14C]-sucrose values for treatment experiments (one-way ANOVA with 
Dunnett's post-hoc test comparing means for each region), and found to be not 
significant (data not shown). Thus, none of the experimental conditions affected 
vascular space. 
3.5.2.2 Pentamidine 
In situ brain perfusion experiments involving pentamidine were first performed with a 
ten-minute perfusion time, and each treatment group had N=5, unless otherwise stated. 
As a point of comparison to all other treatments, this group of experiments contained a 
‘control’ group containing only [3H]-pentamidine and [14C]-sucrose. Experiments were 
first performed with a 10-minute perfusion, the results of which are shown in Figure 
3-30, Figure 3-31 and Figure 3-32. These experiments were mirrored with a 30-
minute perfusion, and are shown in Figure 3-33, Figure 3-34 and Figure 3-35. 
Figure 3-30 shows the effect of 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine into all brain regions after 10 minutes of perfusion. 
These data indicate that [3H]-pentamidine distribution in the brain regions sampled 
after 10 minutes of perfusion is unaffected by the presence of Pluronic® P85 at either 
0.01% or 0.1% m/v (p > 0.05). 
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However, taking the capillary depletion analysis shown in Figure 3-31 into 
consideration, it would appear that the accumulation of [3H]-pentamidine in the brain 
capillary endothelial cell-enriched pellet is enhanced by the inclusion of 0.1% Pluronic® 
P85 in the artificial plasma (p < 0.01). 
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Figure 3-30: The effect 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine in the brain after 10 minutes of perfusion. Uptake is 
expressed as the percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for 
[14C]-sucrose (vascular space). Each bar represents the mean ± SEM of 5 animals. Mean 
± SEM for each experimental condition were analysed by two-way ANOVA with 

























































































































[3H]-Pentamidine + 0.01% P85 + 0.1% P85
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Figure 3-31: The effect 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine in capillary depletion samples after 10 minutes of 
perfusion. Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-1) 
and is corrected for [14C]-sucrose (vascular space). Each bar represents the mean ± SEM 
of 5 animals. Mean ± SEM for each experimental condition were analysed by two-way 
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Figure 3-32 shows the effect of Pluronic® P85 on the distribution of [3H]-pentamidine 
in the pineal gland, choroid plexus, and pituitary gland after 10 minutes of perfusion. 
These data indicate that [3H]-pentamidine accumulation in the pineal gland is 
unaffected by Pluronic® P85. However, [3H]-pentamidine accumulation in the choroid 
plexus is enhanced by both 0.01% m/v and 0.1% m/v Pluronic® P85, and is also 
enhanced in the pituitary gland, but only by 0.01% m/v Pluronic® P85. 
 
 
Figure 3-32: The effect 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine in pineal gland, choroid plexus and pituitary gland 
after 10 minutes of perfusion. Uptake is expressed as the percentage ratio of tissue to 
plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Each bar 
represents the mean ± SEM of 5 animals. Mean ± SEM for each experimental condition 
were analysed by two-way ANOVA with Dunnett’s multiple comparisons test, *p < 0.05, 
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Figure 3-33 shows the effect of 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine into all brain regions after 30 minutes of perfusion. 
These data indicate that [3H]-pentamidine distribution in the frontal cortex, occipital 
cortex, hippocampus, thalamus and cerebellum is reduced by the inclusion of 0.01% 
m/v Pluronic® P85 in the artificial plasma following 30 minutes of perfusion. 
Furthermore, the distribution of [3H]-pentamidine in the hippocampus and cerebellum 
is also reduced after 30 minutes by the inclusion of 0.1% m/v Pluronic® P85. 
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Figure 3-33: The effect 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine in the brain after 30 minutes of perfusion. Uptake is 
expressed as the percentage ratio of tissue to plasma (mL.100 g-1) and is corrected for 
[14C]-sucrose (vascular space). Each bar represents the mean ± SEM of 5 animals. Mean 
± SEM for each experimental condition were analysed by two-way ANOVA with 
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Taking the capillary depletion analysis shown in Figure 3-34 into consideration, it 
would appear that [3H]-pentamidine accumulation in the whole-brain homogenate and 
brain capillary endothelial cell-enriched pellet is unaffected by the presence of 
Pluronic® P85. However, the inclusion of 0.1% m/v Pluronic® P85 in artificial plasma 




Figure 3-34: The effect 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine in capillary depletion samples after 30 minutes of 
perfusion. Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-1) 
and is corrected for [14C]-sucrose (vascular space). Each bar represents the mean ± SEM 
of 5 animals. Mean ± SEM for each experimental condition were analysed by two-way 
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Figure 3-35 shows the effect of Pluronic® P85 on the distribution of [3H]-pentamidine 
in the pineal gland, choroid plexus, and pituitary gland after 30 minutes of perfusion. 
These data indicate that [3H]-pentamidine accumulation in all three samples is 
unaffected by inclusion of 0.01% m/v Pluronic® P85 in the artificial plasma following 
30 minutes of perfusion. However, [3H]-pentamidine accumulation in the choroid plexus 
and pituitary gland is enhanced by 0.1% m/v Pluronic® P85 (p < 0.01). 
 
 
Figure 3-35: The effect 0.01% m/v and 0.1% m/v Pluronic® P85 on the 
distribution of [3H]-pentamidine in pineal gland, choroid plexus and pituitary gland 
after 30 minutes of perfusion. Uptake is expressed as the percentage ratio of tissue to 
plasma (mL.100 g-1) and is corrected for [14C]-sucrose (vascular space). Each bar 
represents the mean ± SEM of 5 animals. Mean ± SEM for each experimental condition 
were analysed by two-way ANOVA with Dunnett’s multiple comparisons test, *p < 0.05, 
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3.5.3 Isolated incubated choroid plexus 
After observing the interactions of pentamidine and Pluronic® P85 with the choroid 
plexus using the in situ brain perfusion technique, these interactions were probed 
further using the isolated incubated choroid plexus technique. 
3.5.3.1 Effect of Pluronic® P85 and transport inhibitors on choroid plexus 
extracellular space 
[14C]-Sucrose was present in each of the isolated choroid plexus incubations described in 
this study as a marker of extracellular space within the tissue. After the control 
incubations (10 minute incubations in [3H]-pentamidine and [14C]-sucrose alone, with no 
Pluronic® P85 present), [14C]-sucrose accumulation was measured as 2.32 ± 0.30 mL g-1 
and this was used as an indicator of barrier integrity. [14C]-sucrose accumulation for 
incubations including Pluronic® P85 was also measured, and found not to be 
significantly different from the baseline accumulation measured in their absence (one-
way ANOVA, p > 0.05). The accumulation of [14C]-sucrose in these experiments is 
shown in Figure 3-36. 
 
 
Figure 3-36: [14C]-sucrose accumulation in the absence (control) and presence of 
Pluronic® P85 dissolved in artificial CSF and 0.05% m/v DMSO during [3H]-
pentamidine incubated isolated choroid plexus experiments (n=5). [14C]-sucrose 
accumulation did not change in the presence of Pluronic® P85 at any of the 
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The effect of transport inhibitors on the accumulation of [14C]-sucrose in isolated 
incubated choroid plexus was also measured, and found to not be significantly altered 
in the presence of any of the inhibitors used (Figure 3-37). 
 
 
Figure 3-37: [14C]-sucrose accumulation in the absence (control) and presence of 
transport inhibitors dissolved in artificial CSF and 0.05% m/v DMSO during [3H]-
pentamidine incubated isolated choroid plexus experiments (n=5). [14C]-sucrose 
accumulation did not change in the presence of any of the inhibitors used (one-way 
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3.5.3.2 Effect of Pluronic® P85 on the accumulation of pentamidine in the 
choroid plexus 
The effect of Pluronic® P85 on the accumulation of [3H]-pentamidine in the isolated 
incubated choroid plexus is shown in Figure 3-38. Accumulation of [3H]-pentamidine 
is significantly reduced when co-formulating with 0.01% and 0.1% m/v Pluronic® P85, 
but not with 0.5% m/v Pluronic® P85. 
 
Figure 3-38: [3H]-pentamidine accumulation (corrected for [14C]-sucrose) in the 
absence (control) and presence of Pluronic® P85 dissolved in artificial CSF and 
0.05% m/v DMSO during incubated isolated choroid plexus experiments (n=5). 
[3H]-pentamidine accumulation corrected for extracellular space was decreased by the 
inclusion of Pluronic® P85 in the artificial CSF incubation medium, but only at 
concentrations of 0.01% and 0.1% m/v (one-way ANOVA with Dunnett's multiple 
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3.5.3.3 Effect of efflux transporter inhibitors on the accumulation of 
pentamidine in the choroid plexus 
The effect of specific inhibitors of efflux transporters on the accumulation of [3H]-
pentamidine in the isolated incubated choroid plexus is shown in Figure 3-39. 
Accumulation of [3H]-pentamidine is significantly reduced by the inclusion of 35 µM 
MK-571 (MRP inhibitor), but is unaffected by the inclusion of 500 µM PAH or 200 µM 
TCA (OAT and OATP inhibitors, respectively). 
 
 
Figure 3-39: [3H]-pentamidine accumulation (corrected for [14C]-sucrose) in the 
absence (control) and presence of either MK-571 (35 µM), PAH (500 µM) or TCA 
(200 µM) dissolved in artificial CSF and 0.05% m/v DMSO during incubated 
isolated choroid plexus experiments (n=5). [3H]-pentamidine accumulation corrected 
for extracellular space was decreased only by the inclusion of MK-571 (35 µM) in the 
artificial CSF incubation medium (one-way ANOVA with Dunnett's multiple comparisons 
test of means±SEM to control, p < 0.05). 
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3.6 Results: Effect of formulation on pentamidine-
related pancreas toxicity 
Figure 3-40 shows the inhibition of insulin release from MIN6 β-cells following pre-
exposure to 10 µM pentamidine for either 3 or 24 hours (56.9% and 41.4% inhibition, 
respectively). The inhibition of insulin release was not observed when pre-exposing β-
cells to 1% m/v Pluronic® P85 alone (p > 0.05), and was also restored to control (2 
mM glucose) conditions when co-exposing β-cells to both Pluronic® P85 (1% m/v) and 
10 µM pentamidine. 
 
 
Figure 3-40: Pluronic® P85 blocks pentamidine inhibition of insulin secretion in 
vitro. Exposure of MIN6 β-cells to 10 µM pentamidine for 3 hours (left panel) or 24 
hours (right panel) significantly (p < 0.001 or 0.01 respectively) inhibited acute insulin 
secretion, measured over 30 minutes. This inhibitory effect of pentamidine on β-cell 
exocytosis was prevented by co-exposure with 1% m/v Pluronic® P85 (one-way ANOVA 
with Dunnett’s multiple comparisons post-hoc test relative to 2 mM glucose control). 
































Glucose (2 mM) + + + + + + + +
Pluronic® P85 (1% m/v) - - + + - - + +
Pentamidine (10 µM) - + - + - + - +
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3.7 Discussion 
This chapter has examined the biophysical properties of the tri-block co-polymer 
Pluronic® P85 using both computational and experimental techniques. The results from 
both in silico and in vitro experiments were then used to inform the design of in vivo 
and ex vivo experiments to determine the suitability of Pluronic® P85 as a means of 
improving the delivery of pentamidine to the CNS through co-formulation. This multi-
disciplinary approach allows for iterative improvements in formulation design assessed 
by in silico, in vitro and in vivo techniques that all feed back into a cyclical 
development pathway. Furthermore, the information obtained from in silico and in 
vitro methods facilitate a better informed strategic design of formulation parameters to 
be tested in vivo; reducing the number of animals that would otherwise be used 
following a purely empirical (trial & error) in vivo approach. 
Results indicate that the molecular interactions of Pluronic® P85 molecules with each 
other and with pentamidine are sensitive to solvent and temperature, as shown by the 
observed changes in critical micelle concentration, aggregation number and partition 
coefficient both in silico and in vitro. Attempts were made to determine the biological 
effects of Pluronic® P85 on the blood-CNS barriers and the impact co-formulation has 
with the interactions of the drug pentamidine with these barriers in vivo and ex vivo. 
These findings will be discussed in greater details in the sections that follow. 
3.7.1 Formulation characterisation 
3.7.1.1 CMC 
Coarse-grained molecular dynamics simulations containing Pluronic® P85 modelled in 
an implicit dH2O-like environment for the present study predicted that polymolecular 
aggregates (greater than or equal to two molecules of Pluronic® P85) were detectable 
at concentrations above 0.29% m/v (Figure 3-16). 
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While the CMC for Pluronic® P85 has been reported to be as high as 0.8% m/v in 
dH2O at 30 °C (Ohashi et al., 2009), previously published values are more typically 
found at between 0.006 – 0.03% (Kabanov et al., 1995; Batrakova et al., 1999a). In 
contrast to these published values, but in agreement with the theoretical values 
predicted by the coarse-grained molecular dynamics simulations, the CMC values for 
Pluronic® P85 in dH2O measured using eosin Y were 0.27% m/v at 25 °C and 0.24% 
m/v at 37 °C (Figure 3-19). The CMC of Pluronic® P85 was found to decrease when 
increasing temperature from 25 °C to 37 °C (Figure 3-19 and Figure 3-20) regardless 
of the solvent (water or optimised plasma), in accordance with previously published 
data (Kabanov et al., 1995). 
Interestingly, Pluronic® P85 CMC measured using the eosin Y methodology increased 
in optimised plasma relative to dH2O – 0.33% m/v at 25 °C (vs. 0.27% m/v in water) 
and 0.30% m/v at 37 °C (vs. 0.24% m/v), shown in Figure 3-20. Previously published 
data for Pluronic® P85 found the CMC to decrease with increasing inorganic salt 
concentration (Ohashi et al., 2009). Other tri-block co-polymers with PEO-PPO-PEO 
structures (such as L64, P65) have been shown to display lower CMCs in solutions 
containing inorganic salts (Jain et al., 1999; Mata et al., 2005). While it is not clear 
why the present study found the CMC in optimised plasma to increase relative to the 
CMC in dH2O, it should be noted that previously published studies did not determine 
the effect that a mixture of different salts present in the solution had on the CMC.  
The CMC of Pluronic® P85 in optimised plasma containing 10 µM pentamidine, as 
measured by the eosin Y methodology, was found to increase – reaching 1.09% m/v at 
25 °C. The CMC of Pluronic® P85 in optimised plasma containing 10 µM pentamidine 
was lower (0.24% m/v) at 37 °C, and thus the CMC of Pluronic® P85 remains constant 
37 °C. Understanding the effect of pentamidine on the CMC of Pluronic® P85 is crucial 
as it will ultimately relate to micelle stability and circulation time. The large increase 
of the CMC observed at 25°C is not clear, and further measurements at higher loadings 
of pentamidine would be needed to validate these measurements. 
3. ‘NANOHAT’ 
- 339 - 
In accordance with both the theoretical CMC predicted by coarse-grained molecular 
dynamics simulations and the empirical values determined by the eosin Y method 
described in section 3.4.2.1A - Eosin Y methodology, Pluronic® P85 CMC in 
dH2O was measured using the pyrene method as 0.17 and 0.23 % m/v, at 25 °C and 37 
°C, respectively (Table 3-8). As with the eosin Y method, the CMC for Pluronic® P85 
in optimised plasma was higher than in dH2O, at both temperatures measured (Figure 
3-23). 
The CMC of Pluronic® P85 in both optimised plasma and dH2O calculated using the 
pyrene method also decreased with increasing temperature (from 25 °C to 37 °C, 
Figure 3-23), as found previously with the eosin Y method. Table 3-11 shows that 
the CMC values for Pluronic® P85 obtained from both the Eosin Y and Pyrene method 
were very similar in all conditions tested. 
 
Table 3-11: Collated CMC values for Pluronic® P85 in either dH2O or optimised plasma, 
at 25 °C or 37 °C. 
Solution Temperature CMC (% m/v) n 
Eosin Y:dH2O 
25 °C 0.27 3 
37 °C 0.24 3 
Eosin Y:optimised 
plasma 
25 °C 0.33 3 
37 °C 0.30 3 
Pyrene:dH2O 
25 °C 0.234 ± 0.010 6 
37 °C 0.170 ± 0.008 6 
Pyrene:optimised plasma 
25 °C 0.338 ± 0.001 3 
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3.7.1.2 Nagg 
Coarse-grained molecular dynamics simulations containing 1% m/v Pluronic® P85 
modelled in an implicit dH2O-like environment at approximately 37 °C for the present 
study predicted the aggregation number to be 10 molecules per micelle (Figure 3-16). 
By comparison, the mean aggregation number for 1% m/v Pluronic® P85 in dH2O was 
measured by fluorescence spectroscopy to be 8.5±0.1 at 25 °C, and decreased to 
4.2±0.2 at 37 °C. Furthermore, the mean aggregation number for 1% m/v Pluronic® 
P85 in optimised plasma was calculated to be 7.1±0.1 at 25 °C, and decreased to 
4.2±0.1 at 37 °C. Thus the aggregation number of Pluronic® P85 decreases with 
increasing temperature. 
The aggregation number for Pluronic® P85 has previously been found using data-fitting 
of small-angle neutron scattering (SANS) data to increase with increasing temperature 
(from 20 °C to 40 °C, (Mortensen & Pedersen, 1993)). In the case of the data obtained 
from the present study using quenching of pyrene with cetylpyridinium chloride 
monohydrate, the opposite was found (Figure 3-25). This result is surprising, since at 
higher temperature, the dehydration of both PPO and PEO blocks is expected to 
increase micellisation and aggregation number. Further experiments would be needed to 
clarify this point. 
3.7.1.3 Partition 
Partition coefficient for pentamidine in Pluronic® P85 micelles was not found to be 
affected by temperature, with no significant difference between values obtained at 25 
°C and 37 °C (whether in dH2O or optimised plasma, Figure 3-27). However, the 
partition of pentamidine into Pluronic® P85 micelles appears to be greatly reduced in 
optimised plasma, relative to values observed for pentamidine in Pluronic® P85 
micelles in dH2O. 
For simple ionic surfactants with polar head groups and hydrophobic tails, the 
solubilisation of drugs within micelles typically increases with increasing temperature 
(Alkhamis et al., 2003), an observation attributed to an increase in molecular agitation 
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resulting from increasing the temperature that would increase micelle size and thus the 
space available for solubilisation within micelles (Alkhamis et al., 2003). For non-ionic 
surfactants such as Pluronics® the effect of temperature on the partition of drug within 
micelles depends on whether the drug partitions exclusively into the hydrophobic core, 
or is distributed at the interface between the core and hydrophilic coronal/palisade 
layer. If aggregation number increases with increasing temperature, one would expect 
highly hydrophobic drugs to partition into the hydrophobic core more efficiently, 
however the opposite can also be true (lower partition, (Barry & El Eini, 1976)). Since 
aggregation number in the present study decreased with increasing temperature, and 
the precise location of pentamidine in the micelle structure is unknown, it is difficult to 
determine the significance of these findings based on the data obtained in this study 
alone. 
A caveat from this study that further complicates the interpretation of these data is 
that the partial molar volume (γ) used in the calculation of these values was obtained 
through pycnometry performed only with Pluronic® P85 in dH2O at 22.3 °C. The use 
of this value for the calculation of pentamidine partition in Pluronic® P85 micelles in 
dH2O at 37 °C, but also in optimised plasma at both concentrations is an 
approximation. One would expect the partial molar volume of Pluronic® P85 micelles 
in both dH2O and optimised plasma to decrease with increasing temperature, since 
individual Pluronic® P85 molecules would have a lower volume and could therefore 
pack more tightly (leading to a higher density, (Artzner et al., 2007)). 
3.7.1.4 Micelle size 
Atomistic simulations of a single Pluronic® P85 micelle based on a theoretical 
aggregation number of 10 predicted a micelle diameter of approximately 5.9 nm 
(Figure 3-18). The mean hydrodynamic diameter of Pluronic® P85 micelles was 
measured at 37 °C as approximately 18 nm in dH2O, and 16 nm in optimised plasma 
(Figure 3-28) from dynamic light scattering. Both predicted and measured values for 
micelle size are similar to previously published values of approximately 20 nm 
(Batrakova et al., 2004a). 
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3.7.1.5 Summary 
Both coarse-grained and atomistic in silico simulations provided useful information on 
the CMC, Nagg and micelle size. These results were further validated by spectroscopic 
techniques. 
The data obtained from in silico and in vitro biophysical characterisation experiments 
presented here constitute both information that was taken forward for in vivo 
experiments (discussed below), but also a benchmark to compare to other Pluronics®, 
or even mixtures of multiple Pluronics® in the future.  
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3.7.2 Pentamidine transport across the blood-CNS barriers following 
co-formulation with Pluronic® P85 
3.7.2.1 Radiolabelled pentamidine integrity 
The integrity of radiolabelled pentamidine used in this study is of great importance. 
Should the radiolabel dissociate from the drug it would easily pass across the blood-
CNS barriers to accumulate in the CNS and give an over-estimation of CNS uptake. 
Comparison of HPLC and radiodetector analyses of solutions containing 0.05% m/v 
DMSO and either unlabelled 10 µM pentamidine or [3H]-pentamidine clearly 
demonstrated that the [3H]-pentamidine used in this study was intact and radiolabelled 
(Figure 3-29). 
3.7.2.2 Pentamidine transport across the BBB 
The motivations behind the study presented here stemmed from the initial observations 
of saturable influx of [3H]-pentamidine into the CNS across the blood-CNS barriers, but 
also efflux of [3H]-pentamidine from the CNS mediated by P-gp (Sanderson et al., 
2009). The co-formulation of [3H]-pentamidine with Pluronic® P85 was hypothesised to 
improve the delivery of [3H]-pentamidine to the brain by inhibiting the efflux 
transporters responsible for its removal. However, after perfusing for 10 minutes with 
[3H]-pentamidine co-formulated either with 0.01% or 0.1% m/v Pluronic® P85 no 
significant difference in the distribution of [3H]-pentamidine was observed in any of the 
brain regions relative to optimised plasma containing [3H]-pentamidine alone (Figure 
3-30). 
However, capillary depletion analysis on whole-brain following a 10-minute perfusion 
suggests that [3H]-pentamidine may be sequestered in BCECs following co-formulation 
with 0.1% Pluronic® P85 (Figure 3-31). The previously described limitations of the 
capillary depletion analysis technique mean that further analyses would be required to 
confirm this, but if it were found to be true it would imply that 0.1% m/v Pluronic® 
P85 inhibits the efflux of [3H]-pentamidine from BCECs, although it is interesting that 
3. ‘NANOHAT’ 
- 344 - 
this does not translate to an increase in brain distribution in the eight brain regions 
sampled. 
Extending the perfusion time to 30 minutes produced similar results, with brain 
distribution of [3H]-pentamidine in the frontal cortex, occipital cortex, hippocampus, 
thalamus and cerebellum actually decreasing when co-formulated with Pluronic® P85 
(Figure 3-33). Capillary depletion analysis of these samples revealed the enhanced 
delivery of [3H]-pentamidine to BCECs following co-formulation with 0.1% Pluronic® 
P85 seen following 10-minute perfusions is lost after 30 minutes (Figure 3-34). 
The concentrations of Pluronic® P85 used in these experiments (0.01% and 0.1% m/v) 
were initially selected on the basis that previously published CMC values for Pluronic® 
P85 were in the range of 0.03% m/v (Kabanov et al., 1995; Batrakova et al., 1999a; 
Shaik et al., 2009). The concentrations of 0.01% and 0.1% m/v would therefore 
represent Pluronic® P85 concentrations respectively below the CMC (only unimers 
present) and above the CMC (micelles and unimers present). However, on the basis of 
our data obtained from coarse-grained molecular dynamics simulations and biophysical 
characterisation experiments using pyrene and eosin Y presented in this study, both 
concentrations would be below the CMC. 
Un-published in vitro BBB (hCMEC/D3) data obtained from experiments performed 
by members of our group show that an increase in the accumulation of [3H]-
pentamidine co-formulated with 0.01% and 0.1% m/v Pluronic® P85 (relative to [3H]-
pentamidine alone is only observed after incubation for 60 minutes and 120 minutes 
(Brown, 2012). No significant differences in the accumulation of [3H]-pentamidine were 
found by co-formulating [3H]-pentamidine with 0.01% and 0.1% m/v Pluronic® P85 
and incubating for 5 or 20 minutes (Brown, 2012). It would therefore appear that 
Pluronic® P85 must first accumulate within BCECs before having any effect on the 
efflux of [3H]-pentamidine. While one would ideally want to extend the perfusion time 
to mirror these in vitro BBB studies, the upper limit of in situ brain/choroid plexus 
perfusion time is 30 minutes before loss of BBB integrity (personal observations). It 
should be noted however, that co-formulation of [3H]-pentamidine with 0.5% m/v 
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Pluronic® P85 did not alter the accumulation of [3H]-pentamidine in hCMEC/D3 cells 
(relative to [3H]-pentamidine alone) at any time point (Brown, 2012). A possible 
explanation for this may be that trapping of [3H]-pentamidine within micelles prevents 
its interactions with influx transporters expressed in the membrane of the BCECs in 
vitro. This observation, combined with the cost of [3H]-pentamidine (custom 
synthesised) and the quantities required for 10 and 30 minute in situ brain/choroid 
plexus perfusions meant that we were unable to perform these experiments in vivo with 
0.5% m/v Pluronic® P85. 
3.7.2.3 Pentamidine transport across the BCSFB 
3.7.2.3A In situ brain/choroid plexus perfusion 
[3H]-Pentamidine accumulation in the pineal gland after 10 minutes was not affected by 
Pluronic® P85 at either 0.01% or 0.1% m/v (Figure 3-32). However, co-formulation of 
[3H]-pentamidine with 0.01% Pluronic® P85 improved its accumulation in both the 
choroid plexus and the pituitary gland (Figure 3-32). Interestingly, co-formulating 
[3H]-pentamidine with 0.1% m/v Pluronic® P85 improved its accumulation in the 
choroid plexus further, while accumulation of [3H]-pentamidine when co-formulated 
with 0.1% m/v Pluronic® P85 returned to control levels in the pituitary gland (Figure 
3-32).  
It is not entirely obvious why this might happen. Should the CMC for Pluronic® P85 
indeed fall between 0.01% and 0.1% m/v one could potentially theorise that micelles 
would be present at 0.1% m/v and that encapsulation of [3H]-pentamidine within the 
micelles could prevent the interaction of [3H]-pentamidine with influx transporters 
present in the pituitary gland. However, both in silico and in vitro characterisation of 
Pluronic® P85 in the present study would suggest that micelles would not be present at 
0.1% m/v. However, even if the CMC value of approximately 0.3% m/v calculated in 
the studies presented in this chapter are true, it is somewhat difficult to explain why 
the enhancement of [3H]-pentamidine accumulation following a 10-minute perfusion is 
additive in the case of the choroid plexus, but not in the case of the pituitary gland. 
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Data obtained following a 30-minute perfusion are shown in Figure 3-35, and present 
an additional opportunity to dissect the intricacies of the interactions of [3H]-
pentamidine and Pluronic® P85 and the BCSFB. As was observed after 10 minutes, 
Pluronic® P85 appears to have no effect on the accumulation of [3H]-pentamidine in the 
pineal gland. In the cases of both the choroid plexus and pituitary gland, [3H]-
pentamidine accumulation after 30 minutes was only enhanced when co-formulated 
with 0.1% (Figure 3-35). Figure 3-41 shows a time-dependent increase in the 
distribution of [3H]-pentamidine in the pineal gland and choroid plexus. It is clear from 
presenting the data in this way that the same time-dependent increase in [3H]-
pentamidine distribution in the choroid plexus is also present when co-formulating with 
0.1% m/v Pluronic® P85, albeit enhanced at both time-points. Interestingly, 0.01% 
m/v Pluronic® P85 appears to prevent the time-dependent increase in [3H]-pentamidine 
accumulation in the choroid plexus, despite initially enhancing its accumulation after 
10 minutes.  
In the case of the pituitary gland, [3H]-pentamidine distribution appears to decrease 
from 10 minutes to 30 minutes in the absence of Pluronic® P85, a phenomenon that is 
also true with 0.01% m/v Pluronic® P85. The co-formulation of [3H]-pentamidine with 
0.1% m/v Pluronic® P85 appears to reverse this effect, and facilitates a time-dependent 
increase in [3H]-pentamidine distribution in the pituitary gland (Figure 3-41). 
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Figure 3-41: Distribution of [3H]-pentamidine in the pineal gland, choroid plexus and 
pituitary gland in the absence or presence of Pluronic® P85 as a function of time. 
Uptake is expressed as the percentage ratio of tissue to plasma (mL.100 g-1) and is 
corrected for [14C]-sucrose (vascular space). Each point represents the mean+SEM of 5 
animals. 
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3.7.2.3B Incubated choroid plexus 
The inclusion of [14C]-sucrose in all incubated choroid plexus experiments confirmed 
that extracellular space was unaffected by Pluronic® P85 at 0.01%, 0.1% and 0.5% m/v 
(Figure 3-36), or indeed any of the specific transport inhibitors (Figure 3-37). 
Figure 3-38 shows that Pluronic® P85 at 0.01% and 0.1% m/v, but not 0.5% m/v 
inhibits the accumulation of [3H]-pentamidine in the isolated incubated choroid plexus. 
The isolated incubated choroid plexus technique predominantly measures the 
movement of molecules from the CSF across the apical (CSF-facing) membrane of the 
choroid plexus. On the basis of the biological effects of Pluronic® P85 on efflux 
transporters described in section 3.1.2.2 - Inhibitory effect of unimers on 
efflux transporters, it was hypothesised that the accumulation of [3H]-pentamidine 
would be increased when co-formulated with Pluronic® P85, since both BCRP and P-
gp are expressed at the apical membrane of the choroid plexus and serve to remove 
substrates from the choroid plexus epithelium into the CSF (Redzic, 2011). While 
pentamidine has been shown to be a substrate of P-gp at the murine blood-CNS 
barriers (Sanderson et al., 2009), it would not be unreasonable to predict that 
pentamidine may also interact with BCRP, since there is a strong overlap in the 
substrate specificities of these transporters (Giacomini et al., 2010). However, these 
data not only suggest that Pluronic® P85 does not inhibit the efflux of pentamidine 
from the choroid plexus by either of these transporters, but that some influx 
transporter for pentamidine into the choroid plexus is inhibited. 
Following the observations discussed in the previous section that Pluronic® P85 may 
need to be exposed to cells for 60 minutes or more to affect [3H]-pentamidine 
distribution, it may be that 10 minute incubation time utilised in these experiments 
was not sufficiently long enough a period of time to allow Pluronic® P85 to accumulate 
in the choroid plexus. A simple experiment to test this hypothesis would be to extend 
the incubation time to 30 or even 60 minutes. 
Following the observations that Pluronic® P85 may inhibit the influx of [3H]-
pentamidine into the choroid plexus via the apical membrane, isolated incubated 
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choroid plexus experiments were also designed to determine the effect of specific 
transport inhibitors on [3H]-pentamidine accumulation, and are shown in Figure 3-39. 
From the lack of inhibition by either 500 µM PAH or 200 µM TCA it would appear 
that pentamidine does not interact in any way with OAT-1, OAT-3, or OATP-3, which 
are influx transporters known to be expressed at the apical membrane of the choroid 
plexus. It would also suggest that pentamidine does not interact with the bi-directional 
transporters OATP-2 or -14 expressed at the basolateral membrane. An interesting 
observation was that [3H]-pentamidine accumulation in the isolated choroid plexus was 
inhibited by the MRP-specific inhibitor MK-571 at 35 µM (Figure 3-39). Since MRPs 
are transporters that typically mediate the efflux of substrates from cells, it was 
hypothesised that the inclusion of MK-571 in the artificial CSF would result in reduced 
efflux of [3H]-pentamidine from the choroid plexus and thus, greater detected 
accumulation. The fact that the opposite was observed here suggests that a currently 
unknown MRP transporter is expressed at the choroid plexus in an opposite orientation 
to that which is typically observed for MRP transporters, or any other transporters 
belonging to the ABC superfamily. Another possible explanation is that MK-571 may 
not be completely specific to MRP transporters alone, and may be inhibiting another 
transporter with [3H]-pentamidine specificity. 
In any case the studies presented here are insufficient to completely describe the 
interaction of pentamidine, or indeed Pluronic® P85 with transporters at the blood-
CNS barriers. Future experiments to address these gaps in the current knowledge are 
described in section 3.7.5 - Future work. 
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3.7.3 Reduced pancreatic toxicity 
Pentamidine is known to cause hyperglycaemia and diabetes mellitus in approximately 
10% of patients following treatment (Jha & Sharma, 1984; Waskin et al., 1988; Thakur 
et al., 1991). It was therefore hypothesised that encapsulation of pentamidine within 
Pluronic® P85 micelles may protect pancreatic β-cells from pentamidine-mediated 
cytotoxicity. An experiment was designed to investigate any possible benefits to co-
formulating pentamidine with Pluronic® P85 that used insulin release was as a 
surrogate marker of pancreatic β-cell health, the results of which are shown in Figure 
3-40. 
As expected, insulin release from MIN6 β-cells was significantly reduced following both 
3- and 24-hour pre-exposure to 10 µM pentamidine (Figure 3-40), relative to control 
conditions where only 2 mM glucose was present in the incubation medium. The 
presence of 1% m/v Pluronic® P85 and 2 mM glucose alone in the incubation medium 
had no effect on the release of insulin from MIN6 cells following both 3- and 24-hour 
pre-exposure. Most interestingly, the inhibition of insulin release mediated by 
pentamidine alone was prevented by co-formulating pentamidine with Pluronic® P85, 
which restored insulin release to control levels. It would therefore appear that 
encapsulation of pentamidine within Pluronic® P85 micelles does indeed protect 
pancreatic β-cells from damage by ‘free’ pentamidine in vitro. 
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3.7.4 Conclusions 
The data presented in this chapter represent the beginnings of establishing a cyclical 
formulation development pathway, whereby the suitability of different Pluronic® block 
co-polymers for use in vivo can be predicted by both in silico and in vitro approaches. 
Having an understanding of the biophysical properties of the co-polymers allows for 
better initial design of experiments to measure the effect of co-formulation on 
pentamidine transport across the blood-CNS barriers in vivo, but also any subsequent 
optimisation of the co-formulation.  
The data obtained from these experiments would suggest that a tension exists between 
improving delivery to brain by not having micelles present in the co-formulation, and 
protecting the pancreas from pentamidine by encapsulating it in micelles. Clearly there 
is no intermediate in this situation – micelles by definition are not present below the 
CMC, and are present at concentrations above the CMC. If a co-formulation of 
pentamidine and Pluronic® P85 was to be taken forward at sub-CMC concentrations 
one may consider reducing the dose of pentamidine in the co-formulation with the 
hopes of reducing the side-effects on the pancreas, however this is far from ideal. 
While Pluronic® P85 may not be the optimal choice for improving the delivery of 
pentamidine to the brain a large number of alternative Pluronics® exist for 
consideration and use in further experiments, which are described in the section below. 
The co-formulation of Pluronic® P85 with pentamidine is a starting point and will form 
a comparison to any future work, which itself will be informed by the lessons learned in 
the generation of data presented in this chapter. It should also be noted that while 
pentamidine was selected as a model drug for the purposes of this study, it is 
conceivable that the same theory could be applied to any drug found to be a substrate 
for efflux from the CNS. Indeed, it would be expected that different drugs would 
interact differently with micelles, which could feasibly improve the efficacy of Pluronic® 
P85 as a drug vehicle. 
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In summary, the key findings of this study are: 
1. The CMC of Pluronic® P85 was predicted to be approximately 0.29% m/v 
using coarse-grained molecular dynamics simulation. This was found to be 
highly predictive of the empirical CMC, which was calculated by two different 
techniques to be approximately 0.30% m/v. 
2. CMC decreased with increasing temperature, but had the net effect of 
increasing slightly in optimised plasma relative to dH2O. 
3. Aggregation number of Pluronic® P85 micelles at 1.0% m/v was predicted using 
coarse-grained molecular dynamics simulations to be 10, confirmed empirically 
to be between 4 and 9. Aggregation number decreased with increasing 
temperature, contrary to previously published data, in both dH2O and 
optimised plasma. 
4. Partitioning of pentamidine into Pluronic® P85 micelles was found to be 
independent of temperature, but greatly reduced in optimised plasma relative to 
dH2O. 
5. Atomistic simulations of a single Pluronic® P85 micelle predicted a diameter of 
approximately 6 nm. The true diameter was found by dynamic light scattering 
to be approximately 19 nm, in accordance with previously published data for 
Pluronic® P85. 
6. Co-formulation of pentamidine with Pluronic® P85 at sub-CMC concentrations 
(according to our calculation of CMC) did not enhance the delivery of 
pentamidine to any of the brain regions sampled, contrary to our hypothesis. 
7. Pluronic® P85 may be transiently enhancing the accumulation of pentamidine 
in BCECs as shown by capillary depletion analysis following a 10-minute in situ 
brain/choroid plexus perfusion, but this effect is lost after 30 minutes. 
8. Unpublished in vitro data using the human BBB cell line hCMEC/D3 suggests 
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that a greater exposure time may be needed to allow Pluronic® P85 to 
accumulate within BCECs, and that the encapsulation of pentamidine within 
micelles may actually negatively impact on the ability of pentamidine to 
interact with influx transporters at the BBB. 
9. Pluronic® P85 enhances the delivery of pentamidine to the choroid plexus and 
pituitary gland at sub-CMC concentrations, but not to the pineal gland. 
10. Pluronic® P85 at sub-CMC concentrations inhibits the transport of pentamidine 
into isolated incubated choroid plexus (presumably inhibiting an influx 
transporter at the apical membrane that is also sensitive to inhibition by the 
MRP-specific inhibitor MK-571). 
The precise mechanism by which Pluronic® P85 enhances the transport of pentamidine 
from the blood into the choroid plexus and pituitary gland cannot be elucidated from 
the evidence presented in this study alone. It is possible that P-gp expressed sub-apical 
membrane epithelium for these tissues and/or MRP expressed at the basolateral 
membrane (Rao et al., 1999) are inhibited by P85 unimers, as per the hypothesis 
proposed in section 3.2 - Rationale and aims. That being said, an entirely 
different mechanism could equally be responsible for the enhanced delivery of [3H]-
pentamidine when combined with Pluronic® P85 at sub-CMC concentrations. 
The interactions of [3H]-pentamidine and Pluronic® P85 with the apical membrane of 
the choroid plexus were determined using the incubated isolated choroid technique. The 
data from these studies suggest that the movement of [3H]-pentamidine back from the 
CSF into the choroid plexus is mediated by a transporter that is sensitive both to the 
MRP inhibitor MK-571, but also sub-CMC concentrations of Pluronic® P85. Since the 
choroid plexus is a likely major site of entry for the trypanosome parasite into the brain 
(Wolburg et al., 2012) it might be expected that the co-formulation of pentamidine 
with Pluronic® P85 may be an effective treatment for early-stage 2 HAT.  
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A diagrammatic summary of the predicted role of Pluronic® P85 in enhancing 
pentamidine delivery to the choroid plexus based on the data in this study is shown in 
Figure 3-42. 
 
Figure 3-42: Theoretical interactions of Pluronic® P85 at sub-CMC concentrations 
and pentamidine with the choroid plexus epithelium. The mechanism for the 
movement of pentamidine across the choroid plexus epithelium cannot be elucidated from 
the data presented in the current study. However, it appears that removal of pentamidine 
from the epithelium is inhibited by Pluronic® P85, enhancing accumulation of 
pentamidine. Based on the isolated incubated choroid plexus data, Pluronic® P85 also 
inhibits the removal of pentamidine from the CSF back into the epithelium, possibly via a 















Pluronic® P85 unimer 
3. ‘NANOHAT’ 
- 355 - 
3.7.5 Future work 
The data presented in this chapter formed the basis for a successful Biomedical 
Catalyst grant application jointly awarded by Technology Strategy Board (TSB) and 
Medical Research Council (MRC) in November 2012 in order to enable further 
evaluation of the suitability of Pluronic® block co-copolymers to enhance drug delivery 
to the CNS. While the application contained an extensive breakdown of a critical path 
for formulation evaluation and development based on milestones, a summary of future 
experiments to complete the present study is outlined below. 
3.7.5.1 General strategy 
As has already been alluded to, a number of the more than 50 Pluronic® block co-
polymers could be evaluated in the same way that Pluronic® P85 was for the present 
study. Furthermore, it has been shown that combining different Pluronics® could 
enhance drug/micelle interactions and drug loading (Oh et al., 2004), and thus 
mixtures of multiple co-polymers could also be considered. One of the most promising 
alternatives to Pluronic® P85 that could be considered are Pluronic® L61 and F127, 
which recently were combined as a blend with doxorubicin to form the drug candidate 
SP1049C in a phase 2 clinical trial for the treatment of oesophageal cancer (Valle et al., 
2011). 
3.7.5.2 In silico experiments 
Probing the effect of pentamidine and temperature on micelle size and morphology 
using atomistic simulations would help explain the unexpected decrease in aggregation 
number with increasing temperature in vitro, but also could help explain why the 
partition of pentamidine into Pluronic® P85 was found to decrease so steeply in 
optimised plasma. Understanding the precise location of pentamidine within the micelle 
structure (whether merely absorbed to the surface, or at the interface between the 
hydrophilic palisade layer or within the hydrophobic core itself) could help inform 
future optimisation to improve encapsulation. In addition to modelling where in the 
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micelle structure pentamidine exists, atomistic simulations could also be expected to 
demonstrate how many molecules of pentamidine are associated with each micelle. 
The complex structure of proteins such as P-gp makes atomistic simulations unsuitable 
for modelling over any biologically relevant periods of time. Therefore coarse-grained 
molecular simulations to model how Pluronics® interact with P-gp or indeed any other 
ABC transporters in plasma membrane could be used to inform but also test future 
optimisation with different co-polymers and even blends of multiple co-polymers. 
3.7.5.3 Animal experiments 
While 0.5% m/v Pluronic® P85 was found not to enhance the accumulation of [3H]-
pentamidine into hCMEC/D3 cells in vitro, and this experiment was not replicated 
using in situ choroid plexus/brain perfusion due to time and financial constraints, it 
would be interesting to determine how the encapsulation of [3H]-pentamidine within 
Pluronic® P85 micelles affects its transport across blood-CNS barriers in vivo. 
An additional extension to the in situ perfusion experiments shown here would be to 
include specific transport inhibitors such as MK-571 in the artificial plasma to better 
understand the observed increase in [3H]-pentamidine in BCECs following capillary 
depletion analysis of whole-brain following 10 minutes of perfusion. In carrying out 
these experiments one would have to be conscious of the fact that any transport 
inhibitors included in the artificial plasma are likely to also interact with Pluronic® 
P85 and this could alter the interactions of each with transporters. 
In light of the un-published observations in hCMEC/D3 cells that between 60 and 120 
minutes were required before any enhancements on [3H]-pentamidine accumulation were 
detected, a natural extension to the isolated incubated choroid plexus experiments 
presented in this thesis would be to extend the incubation time from 10 minutes to 30 
minutes, or more. 
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Appendices 
Appendix 1 – Solutions 
Modified Krebs-Henseleit Mammalian Ringer (artificial plasma, pH 7.4) 
solution contents: 
 





NaCl 6.8375 - 117.0 
KCl 0.3504 - 4.7 
MgSO4.7H2O 6.7781 - 27.5 
NaHCO3 2.0834 - 24.8 
KH2PO4 0.1633 - 1.2 
Dextran (60,000 – 90,000)* 39.0000 - - 
CaCl2(aq) (1M) - 2.5 2.5 
dH2O - 997.5 - 
Added on day of expt.    
Glucose 1.8016 - 10.0 
Bovine Serum Albumin* 1.0000 - - 
Evan's Blue* 0.0551 - 57.3 
Total  1000  
*= Removed to produce optimised plasma. 
 
Artificial plasma (pH 7.4) was prepared to include clinical grade 60-90 kDa dextran (39 
g/L) purchased from MP Biomedicals; CA, USA, NaCl (117.0 mM), KCl (4.7 mM), 
NaHCO3 (24.8 mM), and KH2PO4 (1.2 mM) from BDH/VWR International; 
Leicestershire, UK, CaCl2 (2.5 mM) (from a 1M stock solution, Sigma Aldrich; Dorset, 
UK), and MgSO4.7H2O (27.5 mM, Sigma Aldrich; Dorset, UK). 
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Then, glucose (10 mM, purchased from BDH/VWR International; Leicestershire, UK), 
bovine serum albumin (BSA, 0.1% w/v, purchased from Sigma Aldrich; Dorset, UK) 
and Evan’s Blue dye (57.4 µM) were added on the day of the experiment to ensure the 
solution remained free of bacterial and fungal growth. Glucose is included to maintain 
cerebral glucose metabolism and ATP production, BSA for maintenance of oncotic 
pressure, and to bind to Evan’s Blue dye, and Evan's blue was added as a qualitative 
measure of BBB integrity. All reagents were freely soluble in water following gentle 
mechanical stirring.   
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Capillary depletion buffer contents (pH 7.4): 
 





NaCl 8.2400 - 141.0 
KCl 0.2982 - 4.0 
MgSO4.7H2O 0.2465 - 1.0 
HEPES 2.6030 - 10.9 
NaH2PO4.2H2O 0.1560 - 1.0 
CaCl2(aq) (1M) - 2.8 2.8 
dH2O  997.2  
    
Added on day of expt.    
Glucose 1.8016 - 10.0 
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Artificial CSF contents (pH 7.4): 
 





NaCl 0.0076 - 0.13 
KCl 0.2237 - 3.00 
NaHO3 2.2178 - 26.4 
NaH2PO4.2H2O 0.0343 - 0.22 
MgCl2 0.3647 - 3.83 
CaCl2(aq) (1M) - 2.50 2.50 
dH2O  997.50  
    
Added on day of expt.    
Glucose 0.9855 - 5.47 
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Appendix 2 – Calculating drug partition coefficient in 
micelles 







I − I 0
I∞ − I 0
  [2.1] 
Fluorescence intensity is proportional to the concentration of pentamidine (the emitting 
substance) and can be defined as follows: 
  I 0 =C 0k0   [2.2] 
Where I0 is fluorescence intensity of pentamidine, C0 is the concentration of 
pentamidine, and k0 is the fluorescence proportionality constant, all in the absence of 
micelles (0 subscript). 
For partition coefficient experiments the concentration of pentamidine was constant at 
10 µM, and the concentration of Pluronic® P85 altered in samples. Since fluorescence 
intensity is typically additive (total fluorescence intensity is the summation of 
fluorescence emitted from pentamidine both inside and outside micelles), fluorescence 
intensity measured in these samples becomes: 
  I = (C 0 −Cmicelle)k0 +Cmicellek∞   [2.3] 
Where k∞ is the proportionality constant when all drug present is inside micelles, and 
Cmicelle is the concentration of drug when all drug is present inside micelles. 
Thus, equation [2.3] can be re-written as follows: 
  I =C 0k0 −Cmicellek0 +Cmicellek∞   [2.4] 
And then I0 from equation [2.2] substituted for C0k0: 
  I = I 0 +Cmicelle(k∞ − k0)  [2.5] 
 
Subtracting I0 from both sides: 
  I − I 0 =Cmicelle(k∞ − k0)  [2.6] 
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Then, in the theoretical instance of pentamidine being 100% solubilised inside micelles: 
  I∞ − I 0 =C 0(k∞ − k0)   [2.7] 
Thus, fluorescence intensity for a full range of samples containing varying 




I − I 0
I∞ − I 0
=
Cmicelle (k∞ − k0)







  [2.8] 
 
 
